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Summary	
Advanced	 breast	 cancer	 is	 frequently	 associated	 with	 skeletal	 metastases.	 During	
dissemination	 to	bone,	breast	 cancer	 cells	 locate	 in	 a	putative	 ‘metastatic	niche’.	 Its	
components	 are	 not	 fully	 elucidated,	 however	 there	 is	 evidence	 of	 at	 least	 partial	
overlap	 between	 the	 hematopoietic	 stem	 cell	 (HSC),	 endosteal,	 metastatic	 and	
perivascular	niches	in	bone.		
Two-photon	microscopy	was	used	to	detect	single	tumour	cells	and	map	their	location	
within	 the	 bone	microenvironment.	 Irrespective	 of	 ER	 status,	 route	 of	 injection	 and	
animal	 age,	 breast	 cancer	 cells	 preferentially	 located	 in	 the	 trabecular	 region	 of	 the	
bone	 adjacent	 to	 the	 bone	 surface.	 Animals	 pre-treated	with	 AMD3100	 to	mobilise	
HSCs	prior	 injection	of	 tumour	cells	displayed	a	higher	number	of	breast	cancer	cells	
homing	to	bone,	indicating	that	HSCs	and	breast	cancer	cells	compete	for	space	within	
the	niche.	
The	 microenvironment	 of	 tumour	 growth-promoting	 (6-week	 old)	 and	 dormancy-
supporting	 (12-week	old)	 animal	models	were	 investigated.	 In	mature	animals,	bone	
volume,	 length	 and	 number	 of	 H-vessels	 and	 expression	 of	 CD31+	 and	 CD34+	
vasculature	 were	 reduced,	 while	 TSP-1	 expression	 was	 increased,	 compared	 to	 the	
young	model.	
To	investigate	the	effect	of	Zoledronic	acid	(ZOL)	on	the	bone	microvasculature,	young	
and	mature	animal	model	were	treated	with	a	single	dose	of	ZOL	and	changes	in	the	
vasculature	 visualised	 with	 immunofluorescent	 protocols.	 In	 young	 animals	 ZOL	 did	
not	 change	 the	 microvasculature,	 while	 mature	 animals	 showed	 shorter	 and	 more	
numerous	vessels.	
Alteration	 of	 microvascular	 activity,	 decreased	 with	 cediranib	 and	 increased	 with	
Deferoxamine	mesylate,	was	 investigated.	 Preliminary	data	did	not	 show	 substantial	
changes	 in	either	the	bone	or	the	microvasculature	structure	and	further	studies	are	
required.		
Overall,	 my	 work	 supports	 that	 the	 bone	 metastatic	 niche	 consists	 of	 several	
overlapping	 and	 interconnected	 niches.	 My	 data	 suggest	 that	 new	 approaches	 for	
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treatment	of	bone	metastasis	should	evaluate	the	effect	on	several	components	of	the	
bone	microenvironment.	
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1.1	Metastatic	breast	cancer	
Breast	 cancer	 is	 the	 most	 common	 cancer	 worldwide	 in	 females	 and	 the	 second	
commonest	 cancer	 overall.	 In	 the	 UK,	 1	 in	 8	 women	 will	 be	 diagnosed	 with	 breast	
cancer	 during	 their	 life	 time,	 Cancer	Research	UK	 (CRUK)	 reports	 almost	 55000	new	
cases	of	breast	cancer	every	year,	with	a	20%	increase	of	the	incidences	rates	in	the	UK	
since	 the	 early	 1990	 and	 a	 4%	 increase	 in	 the	 past	 decade	 (cruk.org/cancerstats).	
Improvement	 of	 the	 screening	 and	 diagnosis	 allow	 an	 early	 detection	 of	 the	
malignancy	with	79-87%	of	breast	cancer	diagnosed	at	stage	I-II.	Unfortunately,	6-7%	
of	patients		are	diagnosed	at	stage	IV	and	already	have	metastatic	disease.	Secondary	
disease,	particularly	skeletal	metastasis,	can	develop	decades	after	the	detection	and	
treatment	 of	 the	 primary	 tumour.	 Recent	 studies	 show	 that	 the	 risk	 of	 distant	
recurrence	progress	at	a	steady	rate	for	at	least	20	years	[1].	The	organs	that	are	most	
frequently	colonised	by	breast	cancer	cells	are	bone,	lungs	and	brain	and	post-mortem	
exams	of	patients	with	advanced	breast	cancer	shown	evidence	of	metastasis	in	bone	
in	 the	 majority	 (≈70%)	 of	 cases	 [2]–[4].	 Even	 though	 the	 bone	 metastases	 can	 be	
asymptomatic,	 pain,	 hypercalcemia,	 pathological	 fractures	 and	 spinal	 instability	with	
compression	of	the	spinal	cord	may	occur	[5].		One	of	the	major	issues	of	treating	the	
metastatic	disease	is	that	it	is	not	known	which	patient	will	develop	secondary	cancer	
or	when	this	will	happen.	The	lack	of	available	biopsies	hamper	the	investigation	of	the	
disease	in	humans,	therefore	pre-clinical	models	play	a	big	role	in	the	search	for	new	
therapeutic	targets.		
1.1.1	The	early	steps	of	the	metastatic	process	
The	development	of	 the	malignancy	 in	a	secondary	organ	 is	a	multistep	process	that	
begins	 with	 the	 detachment	 of	 the	 tumour	 cells	 from	 the	 primary	 site.	 The	
mechanism(s)	 that	 trigger	 cancer	 cells	 to	 alter	 their	 interaction	 with	 the	 matrix	
surrounding	 the	 tumour	 and	 enter	 in	 the	 lymphatic	 or	 blood	 stream	 is	 not	 fully	
understood.	It	known	that	tumour	cells	undergo	an	epithelial-mesenchymal	transition	
(EMT)	that	allows	cells	to	increase	their	migration,	invasion	and	resistance	to	apoptosis	
due	 to	 biochemical	 changes	 towards	 the	 mesenchymal	 phenotype	 [6].	 After	 this	
transformation,	 the	 EMT	 cells	 with	 their	 enhanced	 tumourogenity,	 enter	 the	 blood	
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stream	and	travel	through	the	circulation	to	reach	the	secondary	organ.	However,	only	
a	 small	 proportion	 of	 the	 cells	 detached	 from	 the	 primary	 sites	 will	 successfully	
colonise	 a	 distant	 organ	 as	 the	 majority	 of	 circulating	 tumour	 cells	 (CTCs)	 are	
recognised	and	eliminated	by	the	immune	system,	undergo	spontaneous	apoptosis	or	
re-enter	 the	 blood	 stream	 and	 potentially	 colonise	 other	 organ(s)	 [7]–[10].	 The	 few	
CTCs	that	survive	 in	the	circulation	and	reach	the	bone	can	remain	dormant	for	 long	
periods	 of	 time.	At	 the	 end	of	 the	 19th	 century,	 Paget	 formulated	 the	 theory	 of	 the	
‘seed	and	soil’,	stating	that	the	interaction	between	disseminated	tumour	cells	(DTCs)	
and	microenvironment	 is	 necessary	 for	 the	 survival	 of	 cancer	 cells	 in	 distant	 organs	
and	 fundamental	 for	 the	 progression	 of	 the	 secondary	 disease	 [11].	 The	 cross-talk	
between	 breast	 cancer	 cells	 and	 the	 components	 of	 the	 bone	 microenvironment	
determine	 the	 fate	 of	 the	 tumour	 cells.	 As	 the	metastatic	 foci	 develop,	 interactions	
between	the	tumour	cells	and	bone	cell	populations	create	a	cascade	of	events,	known	
as	the	‘vicious	cycle’.	Cancer	cells	that	locate	in	the	bone	microenvironment	interact	in	
particular	 with	 the	 bone	 resorbing	 cells	 (osteoclasts,	 OCs),	 resulting	 in	 release	 of	
cytokines	and	growth	factors	that	stimulate	the	growth	of	the	secondary	tumour	[9],	
[12]–[16]	(Figure	1.1).		
While	 the	 interaction	 between	 cancer	 cells	 and	 the	 surrounding	 microenvironment	
that	 promotes	 tumour	 growth	 when	 metastases	 are	 already	 established	 has	 been	
extensively	 investigated	 [14]–[16],	 the	 mechanism(s)	 that	 initiates	 this	 process,	
triggering	 the	DTCs	 to	 escape	 the	 quiescent	 state	 and	 start	 proliferating,	 have	 been	
less	well	studied.	
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The	development	of	breast	cancer	bone	metastasis	 is	a	multistep	process	 in	which	the	principal	steps	
are:	 detachment	 from	 the	 primary	 tumour,	 entry	 in	 the	 circulation,	 colonisation	 of	 the	 bone	
microenvironment,	dormant	state	of	the	cells,	proliferation	and	destruction	of	the	bone.	
1.1.2	Dormant	cells	
Malignancies	 such	 as	 prostate	 and	 breast	 cancer	 are	 able	 to	 develop	 secondary	
tumours	 long	 after	 the	 initial	 diagnosis	 and	 treatment	 due	 to	 the	 presence	 of	 DTCs	
that	stay	dormant	in	the	secondary	site	[7].	The	mechanism(s)	that	allows	tumour	cells	
to	 acquire	 the	 dormant	 phenotype	 is	 still	 unclear,	 likewise	 a	 comprehensive	
characterisation	of	the	quiescent	state	has	not	been	clarified	yet,	is	the	focus	of	many	
investigations.	DTCs	presents	 stem	 cells	 (e.g.	 CD44highCD24low)	 and	 EMT	 (e.g.	 EpCAM	
and	cytokeratins)	phenotypes	[17],	[18].	Current	anti-cancer	treatments	usually	target	
cells	with	high	proliferation	rate	and	therefore	they	are	not	efficient	against	dormant	
cells	 which,	 due	 to	 their	 quiescent	 phenotypes,	 do	 not	 undergo	 proliferation	 or	
apoptosis	[19]–[21].		Being	in	a	non-proliferative	state,	dormant	cells	are	negative	for	
proliferation	markers	such	as	Ki67	and	they	have	a	high	capability	to	retain	membrane	
Figure	1.1	Schematic	illustration	of	the	metastatic	colonisation	of	bone	
	 26	
dyes	 that	 would	 be	 lost	 during	 cellular	 division	 [22]–[24].	 This	 ability	 to	 retain	
membrane	 dyes	 has	 been	 used	 to	 track	 single	 tumour	 cells	 in	 the	 bone	
microenvironment	in	the	early	stages	of	bone	colonization	[24]–[26].	The	mechanism(s)	
that	dormant	cells	use	to	maintain	a	quiescent	state	have	not	been	fully	clarified,	but	it	
has	 been	 suggested	 that	 these	 are	 similar	 to	 the	 ones	 used	 by	 hematopoietic	 stem	
cells	 (HSCs)	 in	 the	 bone	 marrow,	 such	 as	 CXCR4/CXCl12	 and	 angiopoietin-1/Tie-2	
interactions	[10],	[27]–[33].	Moreover,	to	acquire	their	quiescent	state	and	to	gain	self-
renewal	ability,	HSCs	have	to	engage	with	components	of	the	bone	microenvironment	
[34].	 Data	 from	 model	 systems	 have	 suggested	 that	 dormant	 prostate	 cancer	 cells	
locate	in	the	same	region(s)	occupied	by	the	HSCs,	highlighting	the	importance	of	the	
microenvironment	 in	 the	maintenance	of	 the	quiescent	 state	 for	both	of	 these	non-
proliferating	cells	[16],	[28],	[35],	[36],	however	this	has	not	been	shown	yet	for	breast	
cancer.		
1.2	The	Metastatic	niche(s)	
Bone	 is	 a	 particular	 organ	 in	 that	 it	 supports	 both	 active	 cell	 proliferation,	 e.g.	
haematopoiesis,	 as	well	 as	 supporting	 the	 quiescent	 state	 of	 the	HSCs.	 Bone	 is	 also	
subject	to	a	constant	remodelling	process	with	the	action	of	osteoblasts	forming	new	
bone	and	osteoclasts	resorbing	it,	in	particularly	during	physiological	bone	growth	and	
in	 order	 to	 repair	 microdamage	 [37].	 The	 balance	 of	 these	 dynamic	 processes	 is	
obtained	 due	 to	 an	 intricate	 network	 of	 signalling	 between	 the	many	 different	 cell	
populations	of	the	bone	marrow,	a	balance	that	can	be	altered	by	the	action	of	tumour	
cells	[38].		It	has	been	suggested	that	dormant	tumour	cells,	in	particular	prostate	and	
breast	cancer	cells,	colonise	specialized	region	of	bone	in	which	the	microenvironment	
supports	their	quiescent	state:	the	metastatic	niche(s)	[16].	In	these	areas	of	bone,	the	
dormant	 cells	 interact	 with	 the	 surrounding	 microenvironment	 and	 this	 cross-talk	
supports	either	tumour	cell	dormancy	or	promotes	the	proliferation	of	the	cancer	cells,	
resulting	 in	 the	 development	 of	 bone	 metastasis.	 The	 exact	 composition	 of	 the	
metastatic	niche	has	not	yet	been	elucidated,	but	there	are	evidences	indicating	that	
tumour	 cells	 locate	 in	 regions	 of	 bone	 where	 the	 HSCs	 niche,	 endosteal	 niche	 and	
perivascular	 niche	overlap	 [34],	 [39]–[41].	 	 This	 region	of	 bone	 is	 characterized	by	 a	
complex	microenvironment,	the	presence	of	cytokines,	hormones	and	soluble	factors	
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produced	 by	 all	 the	 different	 components	 of	 the	 surrounding	 niches,	 creating	 a	
particularly	rich	soil	for	the	seeding	of	the	tumour	cells	reaching	the	bone	marrow	and	
influencing	their	fate	towards	dormancy	or	proliferation	[31].	
Besides	 osteoblasts	 (OBs)	 and	 osteoclasts	 (OCs),	 various	 components	 of	 the	 bone	
marrow	affect	the	growth	of	metastatic	disease,	for	example	an	emerging	player	in	the	
bone	colonization	is	the	adipose	tissue.	It	has	been	shown	both	in	vitro	and	in	vivo	that	
adipose	tissue	promotes	the	colonisation	of	bone	and	tumour	growth	of	both	breast	
cancer	 and	myeloma	 [29],	 [42],	 [43].	 In	 vitro	 co-culture	 of	MDA-MB-231	 and	MCF-7	
breast	cancer	cell	lines	with	human	femoral	head	discs	indicated	an	infiltration	of	the	
cancer	 cells	 in	 the	 bone	 marrow	 and	 displayed	 extensive	 contact	 with	 adipocytes,	
moreover	 it	 has	 been	 suggested	 that	 the	 recruitment	 of	 tumour	 cells	 towards	 the	
adipose	niche	was	mediated	by	secretion	of	 leptin	and	IL-1β	 [42].	 	The	bone	marrow	
also	 contains	 several	 components	 of	 the	 immune	 system,	 monocytes	 and	
macrophages	 in	 particular,	 that	 have	 been	 shown	 to	 be	 involved	 in	 initiation	 and	
development	 of	 secondary	 disease	 by	 secreting	 chemokines	 and	 Matrix	
metalloproteinases	 (MMPs)	 [44],	 [45].	 As	well	 as	 the	 immune	 system,	mesenchymal	
derived	 cells,	 like	 fibroblasts,	 have	been	 recognised	 to	play	 a	 role	 in	 tumourigenesis	
promoting	 the	 expression	 of	 inflammatory	 cytokines,	 recruiting	 macrophages	 and	
stimulating	angiogenesis	 [46].	Overall,	 the	complexity	of	 the	bone	microenvironment	
with	its	numerous	interacting	cellular	and	molecular	components	makes	it	difficult	to	
pinpoint	the	precise	role	of	each	individual	cell	type	in	regulating	tumour	cell	homing.	
As	well	as	the	fertile	soil	produced	by	resident	cell	populations	of	the	metastatic	niche,	
Kaplan	 and	 colleagues	 stated	 that	 hematopoietic	 progenitor	 cells	 derived	 from	 the	
bone	marrow	are	 implicated	 in	 the	 creation	of	 a	 pre-metastatic	 niche	 [38].	 Cox	 and	
colleagues	have	also	investigated	the	concept	of	pre-metastatic	niche,	demonstrating	
that	the	homing	of	breast	cancer	cells	to	bone	is	influenced	by	factors	secreted	by	the	
primary	tumour.	High	levels	of	lysyl	oxidase	(LOX)	in	the	primary	tumour	in	particular,	
alter	the	microenvironment	of	bone	resulting	in	the	creation	of	a	pre-metastatic	niche	
which	attracts	the	homing	of	CTCs	[47].		
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It	 is	not	 fully	understood	whether	 the	metastatic	niche(s)	 is	 a	precisely	defined,	 size	
limited	physical	area	of	the	bone	marrow	that	can	be	saturated	or	whether	there	are	
multiple	distinct	niches	available	for	colonization	by	tumour	cells.	What	it	is	known	is	
that	 the	 altered	 balance	 between	 the	 activities	 of	 the	 cellular	 components	 of	 the	
overlapping	 niches	 (osteoblastic,	 hematopoietic	 stem	 cells	 and	 perivascular	 niches)	
influence	the	development	of	bone	metastasis	in	in	vivo	models	[30],	[48].	
1.2.1	The	HSC	niche	
The	presence	of	the	HSCs	niche,	located	in	the	endosteal	region	of	the	bone	marrow,	
was	 defined	 in	 the	 1970’s	 by	 Trentin	 and	 Schofield	 as	 a	 region	 of	 bone	 where	 the	
microenvironment	 signals	 regulate	 the	 balance	 between	 quiescent	 state	 and	
proliferation	 of	 the	 HSCs	 [49],	 [50].	 The	mechanism(s)	 involved	 in	 the	 attraction	 of	
HSCs	 to	 the	 niche(s),	 the	 maintenance	 of	 the	 quiescent	 phenotype	 and	 the	 signals	
promoting	 proliferation	 and	 differentiation	 have	 not	 been	 fully	 elucidated.	 Likewise	
the	metastatic	 niche,	 the	 region	 of	 bone	 hosting	 HSCs	 is	 a	 complex	 heterogeneous	
microenvironment	 composed	by	different	 cell	populations.	 It	 is	well	 established	 that	
the	HSC	niche	is	composed	by	two	different	regions:	an	endosteal	(or	osteoblastic)	and	
a	 perivascular	 niche	 [51].	 	 The	 close	 association	 between	 OBs	 and	 HSCs	 has	 been	
extensively	studied	and	 it	has	been	shown	that	OBs	or	osteoblastic	cell	 lines	support	
HSCs	in	 in	vitro	and	ex	vivo	culture	producing	cytokines	that	regulate	haematopoiesis	
[52]–[54].	Moreover,	it	has	been	shown	in	vivo	that	OBs	can	regulate	the	HSCs	number	
through	 production	 of	 Notch	 ligand	 Jagged-1	 [55],	 [56],	 molecules	 that	 are	 also	
overexpressed	in	several	cancer	types	and	thought	to	be	implicated	in	cell	proliferation	
and	 metastasis	 [57].	 OBs	 can	 also	 influence	 the	 quiescent	 state	 and	 self-renewal	
properties	of	HSCs	 through	 thrombopoietin	 signalling	 [58],	 [59],	 the	 inhibition	of	 the	
Wnt	signalling	through	expression	of	Dkk1	[60]	and	the	production	of	osteopontin	[61].	
CXCL12/CXCR4	is	another	important	interaction	between	HSCs	and	OBs,	known	to	be	
implicated	 in	 recruitment	 and	 preservation	 of	 HSCs	 in	 the	 bone	 marrow	 [62]–[64].	
Inhibition	of	the	interaction	between	the	CXCR4	expressed	by	the	HSCs	and	its	ligand	
CXCL12	 (abundantly	 expressed	 by	 the	OBs)	 results	 in	 an	 increase	 level	 of	 circulating	
HSCs	[64],	[65].	CXCR4/CXCL12	has	been	particularly	useful	in	target	therapies	and	it	is	
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of	 interest	 to	 researchers	 focusing	 investigating	 the	metastatic	 processes,	 as	 it	 also	
influences	the	homing	of	prostate	cancer	cells	in	the	bone	marrow	[66].		
In	 addition	 to	 OBs,	 other	 cell	 types	 also	 influence	 the	 HSCs	 regulation	 in	 the	 bone	
marrow.	 Several	 studies	 reported	 that	 the	 osteoblastic	 and	 the	 perivascular	
compartments	 are	not	 to	be	 considered	as	distinct,	 but	 rather	 as	overlapping	areas,	
and	the	HSCs	niche	is	therefore	most	commonly	described	as	a	vascularized	endosteal	
region	 [67].	 	 In	 support	 of	 the	 theory	 of	 an	 overlap	 between	 osteoblastic	 and	
perivascular	 niches,	 extensive	 cross-talk	 between	 the	 two	 different	 cell	 populations	
has	been	demonstrated.	An	example	of	the	interaction	between	OBs	and	endothelial	
cells	is	the	support	of	the	quiescent	state	and	enhanced	survival	of	HSCs	in	the	niche	
and	the	increase	in	angiogenesis	due	to	the	activation	of	Tie-2	on	endothelial	cells	by	
angiopoietin-1,	 produced	 by	 the	 OBs	 [34],	 [68]–[72].	 Likewise,	 OBs	 secrete	 vascular	
endothelial	 growth	 factor	 (VEGF)	 that	 is	 known	 to	 regulate	vascularization	and	bone	
morphogenesis	[73]–[75].	
It	 is	 clear	 that	 multiple	 cell	 populations	 are	 involved	 in	 the	 HSCs	 recruitment	 and	
maintenance	 in	 the	 niche(s),	 but	 it	 has	 not	 yet	 been	 established	whether	 the	 bone	
marrow	 holds	 distinct,	 topologically	 separated,	 highly	 specialised	 niches	 and	 how	
exactly	the	HSCs	gain	space	in	these	regions	of	bone.		
1.2.1.1	How	is	access	to	the	HSCs	niche	regulated?	
The	involvement	of	the	microenvironment	 in	the	regulation	of	the	HSCs	function	has	
been	widely	investigated,	however	the	mechanism(s)	required	to	regulate	the	foothold	
of	HSCs	in	the	niche(s)	remain	to	be	identified.	Experiments	using	transplantation	and	
modification	 of	 the	 cellular	 composition	 of	 the	 HSCs	 niche	 showed	 that	 the	 space	
within	it	is	limited	and	can	therefore	only	host	a	certain	number	of	HSCs	[39],	[51].	To	
explain	the	recruitment	of	HSCs	in	the	niche(s),	different	theories	have	been	proposed	
[41]	 (figure	1.2).	The	 first	 theory	describes	 the	niche	as	 ‘specialized’,	 suggesting	 that	
the	bone	marrow	presents	several	distinct	niches	and	that	each	of	them	is	specialized	
to	 hold	 a	 specific	 type	 of	 HSCs.	 The	 distinction	 between	 niches	 for	 quiescent	 and	
activated	 HSCs	 suggest	 that	 the	 cellular	 composition	 of	 these	 areas	 is	 different	
depending	on	the	function	of	the	niche	[76],	[77].	The	regions	holding	quiescent	HSCs	
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have	been	proposed	to	be	rich	in	OBs,	the	interaction	of	the	bone	cells	with	the	HSCs	
via	N-cadherin,	Angiopoietin-1	and	thrombopoietin	sustain	the	quiescent	state	of	the	
HSC,	while	the	activated	HSCs	are	thought	be	in	close	association	with	the	perivascular	
niche	[71].			
The	alternative	model	assumes	the	presence	of	an	‘equivalent’	niche,	able	to	host	both	
quiescent	 HSCs	 and	 their	 proliferating	 progenitors	 [41].	 This	 theory	 introduces	 the	
concept	of	competition	for	limited	sites	available	in	the	niche,	since	the	HSCs	have	to	
compete	 with	 other	 cells	 that	 are	 compatible	 with	 this	 microenvironment	 to	 gain	
access.	 The	 concept	of	 an	equivalent	niche	 is	 consistent	with	 the	effect	of	 therapies	
such	 as	 chemotherapy	 or	 irradiation	 have	 on	 the	 cells	 located	 in	 the	 niche.	 These	
treatments	 affect	 the	 highly	 proliferating	 HSCs	 progenitors	 but	 do	 not	 disturb	 the	
quiescent	HSCs	 population	 [41].	Moreover,	 this	model	 suggests	 that	when	HSCs	 are	
mobilized	 into	 the	 circulation	 they	 leave	 vacant	 space	 in	 the	 niche	 that	 can	 be	
occupied	by	other	type	of	cells,	including	tumour	cells	[16],	[26],	[36],	[78],	[79].		
It	is	not	clear	whether	the	‘specialised’	or	the	‘equivalent’	niche	model	is	correct,	but	
the	second	theory	has	been	used	in	several	studies	to	explain	the	competitive	process	
that	 tumour	 cells	 undergo	 to	 home	 in	 areas	 of	 the	 bone	marrow	 supposed	 to	 hold	
HSCs.	
		
(A)	 In	 this	 model	 the	 niche	 can	 hold	 different	 type	 of	 cells.	 This	 ‘equivalent	 niche’	 supports	 the	
hypothesis	of	competition	between	DTC	and	HSC	for	gaining	the	space	in	the	niche.	(B)	The	‘specialized	
niche’	 (indicated	 with	 yellow	 OB)	 theory	 suggests	 that	 HSC	 have	 their	 own	 niche	 that	 cannot	 be	
occupied	by	other	type	of	cells.	
Figure	1.2	Schematic	models	of	competition	for	the	space	in	the	niche	
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1.2.1.2	Competition	for	the	limited	space	in	the	HSCs	niche	
It	 is	 evident	 that	 the	HSCs	niche	 represents	 a	 fertile	 soil	 for	 the	early	 stage	of	 bone	
colonization	of	tumour	cells,	particularly	breast	and	prostate	cancer	cells.	Furthermore,	
it	has	been	shown	that	these	are	the	same	areas	of	bone	that	have	the	capability	to	
keep	 cells	 in	 a	 quiescent	 state.	 Tumour	 cells	 may	 therefore	 use	 utilise	 the	 same	
signalling	pathways	 in	used	by	the	HSCs	for	the	homing	to	bone,	maintenance	of	the	
dormant	 state	 and	 switch	 to	 active	 proliferation.	 One	 of	 the	 most	 studied	 is	 the	
interaction	between	CXCR4	expressed	by	stem	cells	and	CXCL12	expressed	in	the	bone	
marrow,	 thought	 to	be	crucial	 in	 the	homing	 to	bone	 [76],	 [80].	Several	 competition	
studies	demonstrate	that	tumour	cells	and	HSCs	not	only	home	to	the	same	niche(s)	
but	they	also	compete	to	establish	foothold	in	the	bone	marrow.	Using	in	vivo	models	
of	prostate	cancer,	Shiozawa	and	colleagues	elegantly	showed	how	the	mobilization	of	
HSC	 from	 their	 niche	 created	 more	 space	 available	 for	 the	 subsequent	 homing	 of	
prostate	cancer	cells	[28],	[36].	 In	this	study,	an	antagonist	of	CXCR4	(AMD3100)	was	
used	to	mobilise	the	HSC	from	the	niche.	AMD3100	disrupts	the	interaction	between	
the	ligand	(CXCR4)	and	the	receptor	(CXCL12),	resulting	in	the	detachment	of	the	HSCs	
from	the	bone	marrow	niche	making	them	re-enter	the	circulation.	The	recruitment	of	
the	HSCs	 in	 the	 circulation	 therefore	modified	 the	 cellular	 composition	 in	 the	niche,	
making	 the	 site	 available	 for	 other	 cells	 to	 colonise.	 This	 alteration	 of	 the	 cellular	
population	in	the	niche	resulted	in	an	increase	of	the	number	of	prostate	cancer	cells	
(detected	 by	 qPCR)	 that	 were	 able	 to	 home	 and	 locate	 in	 this	 region	 of	 the	 bone	
marrow,	 confirming	 that	 the	 tumour	 cell	 co-locate	with	 the	HSCs	 in	 particular	 niche	
situated	in	the	highly	vascularised	endosteal	surface	of	the	bone.	Moreover,	confocal	
microscopy	 was	 used	 to	 localise	 labelled	 prostate	 cancer	 cells	 and	 HSCs	 after	
transplant	showing	that	these	cells	locate	in	close	proximity	to	each	other	[36].		
It	has	been	reported	that	breast	cancer	cell	lines	express	high	level	of	CXCR4,	while	in	
normal	mammary	gland	 tissue	 this	 receptor	was	not	detected	 [81],	 [82].	 It	has	been	
shown	 in	 vivo	 that	 limited	 expression	 of	 CXCR4	 reduced	 the	 growth	 of	 orthotropic	
breast	 cancer	 cells	 and	 prevented	 the	 development	 of	 metastasis	 from	 primary	
tumour	 to	 lungs	 [82].	Moreover,	 the	migratory	 response	 to	 condition	media	derived	
from	organs	commonly	colonised	by	breast	cancer	cells,	such	as	lungs,	liver	and	bone	
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marrow,	was	significantly	reduced	after	blocking	the	CXCR4	cascade	using	AMD3100	or	
CXCR4	RNAi	[81].	CXCR4	has	been	suggested	to	promote	the	growth	of	primary	breast	
cancer	 by	 increasing	 angiogenesis	 in	 the	 primary	 site,	 stimulate	 proliferation	 and	
recruiting	 immune	 cells	 that	 supress	 anti-tumour	 immunity	 [83].	 Due	 to	 the	
involvement	of	CXCR4	 in	multiple	processes	associated	with	 tumour	progression	and	
metastatic	 spread,	 this	 marker	 has	 been	 considered	 as	 a	 potential	 molecule	 of	
prognosis	and	therapeutic	target	for	breast	cancer	[83]–[85].		
1.2.2	The	osteoblastic	niche	
The	endosteal	 surface	of	 the	bone	 is	 a	dynamic	 region	 in	which	bone	 remodelling	 is	
taking	place,	due	to	the	action	of	osteoblasts	and	osteoclasts,	and	this	area	also	acts	as	
a	 reservoir	 of	 HSCs.	 The	 principal	 components	 of	 this	 niche	 are	 the	 osteoblasts	 and	
their	main	function	is	bone	deposition.	This	population	of	cells	can	be	divided	in	two	
distinct	 categories:	 1)	 the	 active	 osteoblasts;	 cuboidal	 cells	 that	 are	 positive	 for	
markers	of	bone	formation	(alkaline	phosphatase,	ALP,	and	collagen-1,	Col-1),	and	2)	
the	inactive	bone	lining	cells;	flattened	cells	that	stretch	over	the	bone	surface	forming	
a	 protection	 layer	 for	 the	 metabolically	 inert	 bone	 [34].	 As	 previously	 mentioned,	
these	bone	cells	play	a	key	role	in	the	attraction,	retention	and	function	of	the	HSCs.	
Osteoblasts	express	several	adhesion	molecules	that	form	adherent	junctions	with	the	
HSCs	 through	 the	 surface	 molecules	 N-cadherin	 (N-cad)/	 β-catenin	 (β-cat)	 and	 Tie-
2/angiopoietin-1	 [39],	 [86],	 [87].	 Once	 the	 contact	 with	 the	 osteoblastic	 cells	 is	
interrupted,	HSC	 lose	 their	 self-renewal	ability	and	start	 to	differentiate,	highlighting	
the	 importance	 on	 the	 interaction	 between	 these	 cell	 types	 to	 keep	 the	 HSC	 in	 a	
quiescent	state	[39].		
This	 region	of	bone	has	a	 characteristic	plasticity	due	 to	 the	 continuous	 remodelling	
mediated	by	actions	of	the	bone-forming	osteoblasts	and	bone-resorbing	osteoclasts.	
Osteoblasts	activity	lasts	as	long	as	the	bone	apposition	is	required	to	replace	resorbed	
bone,	after	which	this	type	of	cells	face	two	types	of	destiny:	to	die	or	turn	into	cells	
not	 functionally	 active	 in	 the	 bone	 deposition,	 like	 osteocytes	 or	 bone-lining	 cells.	
Because	of	this	transient	aspect	of	the	osteoblasts	it	is	not	likely	that	this	type	of	cells	
are	the	only	ones	implicated	in	the	HSC	osteoblastic	niche	[55],	[88].	In	addition	to	the	
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cell	types	mentioned	above,	other	components	of	the	bone	microenvironment	of	also	
play	a	role	in	the	maintenance	of	the	HSC;	for	example	megakaryocytes	secrete	factors,	
including	TGF-β,	that	increase	the	population	of	osteoblasts	and	therefore	the	size	of	
the	 niche.	 Likewise,	 macrophages	 are	 important	 for	 niche	 maintenance	 as	 their	
depletion	causes	 the	release	of	 the	HSC	 from	their	niche	 [89],	 [90].	The	number	and	
function	of	osteoblasts	can	also	be	modulated	by	 the	endocrine	system,	one	striking	
example	 is	 the	 interaction	 of	 parathyroid	 hormone	 (PTH)	 with	 its	 receptor	 (PPR)	
expressed	on	osteoblastic	cells	or	mesenchymal	stem	cells.	This	interaction	causes	an	
increase	 in	 the	pool	of	 the	bone-forming	 cells	 and	 it	 also	enhances	 their	 function	 in	
vitro	and	in	vivo	[55].	PTH	treatment	increases	the	number	of	HSC	niches	and	thereby	
the	number	of	HSCs	recruited	in	the	bone	marrow	[36].	Moreover,	unpublished	data	of	
our	 lab	 showed	 that	 pre-treatment	 with	 PTH	 results	 in	 increased	 number	 of	 breast	
cancer	 skeletal	 metastasis,	 associating	 once	 again	 osteoblastic	 action	 with	 tumour	
growth	in	bone.	
1.2.2.1	Osteoblasts	and	their	interaction	with	cancer	cells	
In	addition	to	their	function	in	retaining	HSC	in	the	niche,	osteoblasts	may	have	a	role	
in	the	attraction	and	 interaction	with	cancer	cells	that	colonise	the	bone	marrow.	As	
mentioned	above,	breast	cancer	cells	act	 in	a	way	similar	to	the	HSC	when	they	gain	
access	 in	 the	metastatic	 niche,	 due	 to	 the	 similarity	 of	 the	molecules	 expressed	 on	
both	 types	 of	 cells.	 Osteoblast	 and	 cancer	 cells	 interact	 through	 several	 pathways	
stimulated	by	secreted	factors	or	direct	cell-cell	interactions	(table	1.1).		
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Table	 1.1	 Common	molecules	 involved	 in	 pathways	 of	 interaction	 between	 osteoblasts	 and	 cancer	
cells		
Molecules	 Function	 References	
IL-6/	IL-8	
Modulation	 of	 the	 osteoblasts	 differentiation;	 regulation	 of	
angiogenesis	
[91],	[92]	
TGF-β	 Regulation	of	proliferation	 [93]	
CXCR4/CXCL12	 Chemotaxis	towards	bone;	retention	in	the	niche	 [36]	
E-/N-Cadherin	 Cell-cell	adhesion	 [87]	
VEGF	 Stimulation	of	angiogenesis	 [73]	
IGFs	 Cell	proliferation	 [94]	
ET-1	 Osteoblast	proliferation	 [94]	
RANK/	RANKL	 Bone	remodelling	 [91]	
IL-6/IL-8=interleukin-6/8;	 TGF-β=transforming	 growth	 factor	 beta;	 CXCR4=C-X-C	 chemokine	 receptor	
type	 4;	 CXCL12=C-X-C	 motif	 chemokine	 12	 (also	 know	 as	 stromal	 cell-derived	 factor	 1,	 SDF-1);	
VEGF=vascular	 endothelial	 growth	 factor;	 IGFs=insulin-like	 growth	 factors;	 ET-1=endothelin	 1;	
RANK/RANKL=receptor	activator	of	nuclear	factor	kappa-B/ligand.	
	
The	 interleukin-6	 (IL-6)	 pathway	 is	 one	 of	 the	 most	 studied	 in	 HSC-osteoblast	
interactions	that	is	also	commonly	used	by	breast	cancer	cells.	IL-6	is	an	inflammatory	
cytokine	secreted	by	osteoblasts	and	macrophages	during	the	remodelling	of	bone	and	
it	is	involved	in	the	regulation	of	cell	proliferation,	apoptosis	angiogenesis	and	positive	
modulation	 of	 the	 osteoblasts	 differentiation	 [95].	 This	 cytokine	 is	 needed	 for	 the	
engraftment	 of	 the	 HSC	 and	 these	 cells	 in	 turn	 modulate	 its	 secretion	 from	 the	
osteoblasts.	The	group	of	Mundy	et	al.	elegantly	described	the	function	of	the	‘vicious	
cycle’	 or	 rather	 the	 complex	 interconnection	 between	 the	 metastatic	 cells	 and	 the	
bone	microenvironment	in	the	late	stage	of	disease	[9],	and	IL-6	is	known	to	have	an	
active	 role	 in	 this	 process.	 The	 cytokine	 increases	 the	 expression	 of	 RANKL	 by	
osteoblastic	cells	that	binds	to	RANK	on	osteoclasts,	stimulating	bone	resorption.	The	
destruption	of	the	bone	matrix	allows	the	release	of	matrix-bound	growth	factors	that	
stimulate	 further	 tumour	 cell	 growth.	Moreover,	 it	 has	 been	 demonstrated	 both	 in	
vitro	and	in	vivo	that	RANKL	stimulates	IL-6	expression	in	breast	cancer	cells,	which	in	
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turn	stimulates	the	expression	of	RANK	on	cancer	cells	themselves	to	make	them	more	
sensitive	to	RANKL	[91],	[96].	Furthermore,	Rajski	and	colleagues	reported	that	the	IL-6	
pathway	mediates	interactions	between	breast	cancer	cells	and	osteoblasts	in	vitro.	In	
their	 study,	 several	 breast	 cancer	 cell	 lines	 were	 co-cultured	 with	 bone-forming	
osteoblasts	(NHOst)	and	analysis	of	the	gene	expression	of	both	type	of	cells	in	the	co-
culture	were	performed.	Interestingly,	the	gene	expression	pattern	in	the	two	cell	lines	
was	modified	 in	 the	 co-culture	 compared	with	 the	 pattern	 in	 the	 single	 cultures.	 In	
particular,	two	sets	of	genes	were	highly	increased,	the	first	was	genes	involved	in	the	
DNA	replication	while	the	second	was	the	IL-6	signature	genes	[93].		
The	ultimate	effect	of	the	‘vicious	cycle’	and	the	changes	in	the	gene	expression	is	the	
stimulation	 of	 tumour	 growth,	 and	 high	 levels	 of	 serum	 IL-6	 are	 linked	with	 a	 poor	
prognosis	in	breast	cancer	patients	[93].	
It	 has	 been	 proposed	 that	 direct	 contact	 between	 osteoblasts	 and	 cancer	 cells	 is	
needed	 for	 the	proliferation	of	 the	malignant	 cells	 in	 the	bone	microenvironment	 in	
the	early	stages	of	the	metastatic	colonization.	To	investigate	this	hypothesis,	Wang	et	
al.	 studied	 the	 interactions	 between	 breast	 cancer	 cells	 and	 osteoblasts,	 with	
particular	 focus	 on	 the	 formation	 of	 adherent	 junctions	 between	 these	 cells	 [87].	
Cancer	 cells	 were	 shown	 to	 express	 E-cadherin	 (E-cad)	 and	 this	 transmembrane	
protein	 binds	 through	 adherent	 junctions	 with	 N-cadherin	 (N-cad),	 expressed	 on	
osteoblasts,	resulting	in	activation	of	the	mTOR	pathway	that	is	associated	with	cancer	
progression.		
The	 importance	 of	 interactions	 between	 osteoblasts	 and	 tumour	 cells	 suggest	 that	
combining	 agents	 that	 interfere	 with	 these	 could	 be	 a	 potential	 approach	 in	 anti-
cancer	treatment.		
1.2.3	The	perivascular	niche	
The	area	of	bone	marrow	where	the	HSCs	niche	and	the	osteoblastic	niche	are	located	
is	a	highly	vascularised	region	of	red-marrow-containing	long	bone.	The	organisation	of	
the	 bone	 microvasculature	 has	 not	 yet	 been	 fully	 elucidated	 due	 to	 technical	
difficulties	 in	 the	 visualisation	of	 the	 three-dimensional	 structure	of	 the	 vasculature.	
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Arteries	 enter	 the	 bone	 marrow	 cavity	 through	 the	 cortical	 bone	 and	 a	 few	
unbranched	arteries	are	found	in	the	bone	diaphysis,	while	towards	the	growth	plate	
these	vessels	are	highly	branched	and	arterioles	connecting	with	capillaries	in	the	bone	
metaphysis.	 In	 the	 bone	 diaphysis	 the	 capillary	 network	 is	 joined	 to	 the	 venular	
component	 that	 is	 located	 in	 the	 central	 part	 of	 the	 bone	 and	 this	 exits	 the	 bone	
marrow	 cavity	 through	 the	 cortical	 bone	 [97](figure	 1.3).	 Therefore,	 because	 the	
majority	of	blood	vessels	within	the	bone	marrow	are	 in	fact	capillaries	these	will	be	
referred	to	as	bone	vessels	in	all	subsequent	sections	of	this	thesis.		
Schematic	illustration	of	the	bone	microvasculature.	A	small	number	of	arteries	enter	the	bone	marrow	
cavity	 through	 the	 cortical	 bone,	 in	 the	 bone	 diaphysis	 this	 structure	 are	 unbranched	 while	 in	 the	
metaphysis	they	branch	and	subsequently	connect	with	an	extensive	capillary	network	that	occupies	the	
majority	of	the	bone	marrow.		This	capillary	network	typically	drains	into	a	large	central	vein	that	exits	
the	 bone	 cavity	 through	 the	 cortical	 bone.	Grey=bone,	 blue=capillary,	 yellow=vein	 and	 red=artery.
The	principal	role	of	the	microvasculature	is	the	transport	of	oxygen	and	nutrients	as	
well	as	waste	products,	it	also	plays	a	key	role	in	the	homing	of	HSCs	and	DTCs.	In	vivo	
studies	reported	that	transplanted	hematopoietic	stem	cells	progenitors	locate	in	the	
trabecular	 region	 of	 bone,	 where	 vasculature	 and	 endosteal	 niches	 are	 overlapping	
[98],	[99].			
As	has	been	described	above	for	bone,	the	vasculature	 is	a	dynamic	structure	that	 is	
balanced	 between	 growth	 and	 regression	 and	 the	 main	 factors	 that	 control	 these	
Figure	1.3	Schematic	illustration	of	the	vessel	architecture	in	bone	
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processes	are	vascular	endothelial	growth	factor	(VEGF)	and	pigment	epithelial	derived	
factor	 (PEDF)	 [100].	 Intriguingly,	 the	 inhibitor	 of	 angiogenesis	 PEDF	 and	 the	
proangiogenic	VEGF	are	expressed	 in	 area	of	 active	bone	 remodelling.	 Expression	of	
PEDF	was	 detected	 by	 immunohistochemistry	 and	 real	 time	 PCR	 in	 cultured	murine	
osteoblasts	and	marginally	in	murine	osteoclasts,	moreover	Western	Blot	analyses	on	
condition	 media	 from	 osteoblasts	 indicated	 that	 they	 secret	 high	 levels	 of	 PEDF.	
Furthermore,	both	osteoblasts	and	osteoclasts	cultures	expressed	high	levels	of	VEGF-
A	 and	 its	 receptor	 VEGF-R1	 and	 -R2	 [74].	 This	 data	 indicate	 that	 the	 inhibitory	 and	
stimulating	signals	 for	 the	angiogenic	process	 in	bone	are	tightly	coupled	with	active	
bone	remodelling.		
The	theory	of	an	overlap	between	perivascular	and	endosteal	niches,	 including	cross-
talk	between	 the	components	of	 these	niches,	 is	 supported	by	 the	discovery	of	new	
vessel	 sub-type	 that	 couple	 angiogenesis	 and	 osteogenesis.	 Using	 an	 innovative	
technique	for	the	visualisation	of	the	bone	microvasculature,	Kusumbe	and	colleagues	
detect	 this	 novel	 capillary	 (H-vessel,	 CD31hiEndomucinhi)	 that	 express	 high	 levels	 of	
both	the	endothelial	markers	Endomucin	and	platelet	endothelial	cell	adhesion	marker	
(PECAM1)	or	cluster	of	differentiation	31	(CD31).	The	H-vessel	sub-type	have	a	specific	
column-like	shape	and	it	is	located	in	the	metaphysis	region,	while	another	sub-type	of	
vessels	expressing	low	level	of	the	endothelial	markers	(L-vessel,	CD31lowEndomucinlow)	
presents	a	highly	branched	sinusoidal	structure	and	is	localized	in	the	diaphysis	[97].	H-
vessels	 have	 been	 shown	 to	 be	 surrounded	 by	 osteoprogenitors	 in	 young	 murine	
models.	In	aged	mice,	where	bone	turnover	is	reduced	the	presence	of	this	vessel	sub-
type	 was	 limited	 and	 only	 few	 osteoprogenitors	 were	 detected	 in	 the	 surrounding	
microenvironment	 [97].	 Using	 transgenic	 murine	 system	 or	 a	 pharmacological	
approach,	alterations	of	 the	microvascular	 component	were	demonstrated	 to	 reflect	
changes	 in	 the	 bone	 structure	 and	 cell	 populations,	 indicating	 a	 close	 relationship	
between	 these	 two	 compartments	 of	 the	mice	 [97].	 The	 bone	microvasculature	 is	 a	
highly	changeable	component	that	stabilises	 in	adulthood,	similar	to	what	 is	seen	for	
bone	 remodelling.	 The	 alteration	 of	 both	 these	 niches	 could	 be	 therefore	 an	
explanation	 on	 the	 reduced	 level	 of	 tumour	 uptake	 in	 mature	 animal	 models	
compared	with	young	animals	[101].	
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1.2.3.1	Regulation	of	dormancy	
As	previously	stated,	breast	cancer	cells	behave	like	the	HSCs	and	their	progenitors	in	
many	aspects	of	process	of	homing	to	bone.	It	is	known	that	microenviromental	signals	
determine	 the	 fate	 of	 HSCs	 by	 supporting	 the	 quiescent	 state	 or	 promoting	
proliferation	 and	 differentiation	 [102].	 Rafii	 and	 colleagues	 observed	 that	 human	
endothelial	 cells	 from	 the	 bone	 marrow	 co-cultured	 in	 vitro	 with	 HSCs	 progenitors	
promoted	 their	proliferation	and	differentiation	by	production	of	 interleukin-6	 (IL-6),	
Kit-ligand,	granulocyte	colony-stimulating	factor	(G-CSF),	and	granulocyte	macrophage	
colony-stimulating	factor	(GM-CSF)	[103].	The	importance	of	the	chemokine	signalling	
between	vasculature	and	HSCs	has	also	been	studied	using	 in	vivo	models.	Heissig	et	
al.	demonstrated	that	the	mobilisation	of	HSCs	from	a	niche	supporting	the	quiescent	
state	 to	 an	 active	 vascular	 niche	 in	 the	 bone	 marrow	 where	 proliferation	 and	
differentiation	 was	 taken	 place	 was	 influenced	 by	 expression	 of	 matrix	
metalloproteinase-9	(MMP-9)	and	release	of	soluble	c-kit	ligand	[104].	Furthermore,	in	
vivo	studies	have	demonstrated	that	the	regeneration	of	the	bone	marrow	vasculature	
after	chemotherapy	is	necessary	to	re-establish	thrombopoiesis	[105].		
As	 well	 as	 HSCs,	 disseminated	 tumour	 cells	 (DTCs)	 require	 environmental	 signals	 to	
maintain	 their	 dormancy	 or	 start	 the	 proliferation	 process	 that	 result	 in	 overt	
metastasis.	Even	though	the	precise	mechanism(s)	determining	the	fate	of	DTCs	is	not	
fully	elucidated,	it	has	been	shown	that	the	vasculature	has	a	key	role	in	the	regulation	
of	 the	 growth	 stimulating	 or	 inhibiting	 signals	 [78],	 [106].	 Recently,	 it	 has	 been	
reported	that	the	microvasculature	has	a	key	role	 in	the	maintenance	of	 tumour	cell	
dormancy	 via	 expression	 of	 Thrombospondin-1	 (TSP-1)	 [35],	 [107].	 Ghajar	 and	
colleagues	observed	that	in	vivo	breast	cancer	cells,	when	colonising	secondary	organs	
such	as	lungs	and	bone,	locate	in	close	proximity	to	microvasculature.	Furthermore,	in	
these	 studies	 the	 researchers	 co-cultured	 HUVEC	 cells	 with	 mesenchymal	 cells	 or	
fibroblasts	and	several	breast	cancer	cell	lines	and	noticed	that	tumour	cells	seeded	in	
proximity	 of	 sprouting	 vasculature	 had	 a	 higher	 rate	 of	 growth	 than	 tumour	 cells	
located	 next	 to	 established	 quiescent	 microvasculature.	 These	 observations	 led	 to	
proteomic	 and	 mass	 spectrometry	 analyses	 that	 revealed	 that	 different	 states	 of	
microvasculature	development	influence	the	expression	of	inhibitory	(TSP-1)	or	growth	
promoting	(periostin	and	TGF-β1)	molecules	[35]	(figure	1.4).	 Interestingly,	as	well	as	
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being	 soluble	 in	 the	 bone	 microenvironment,	 high	 level	 of	 TSP-1	 are	 expressed	 by	
myeloid	cells	and	 in	particular	by	megakaryocytes.	This	particular	cell	population	has	
been	 shown	 to	 maintain	 HSCs	 population	 in	 a	 quiescent	 state	 in	 vivo	 [108].	
Furthermore,	 in	 vivo	 studies	 underlined	 the	 importance	 of	 megakaryocytes	 in	 the	
inhibition	of	metastasis	development	in	both	prostate	[109]	and	breast	cancer		[109],	
[110]	through	expression	of	TSP-1.		
Metastatic	process	steps	are	illustrated	in	(a-e).	Once	the	DTC	reach	the	secondary	organ,	their	fate	is	
regulated	 by	 the	 vascular	 niche;	 expression	 of	 TSP-1	 by	 established	 vasculature	 maintain	 the	 DTC	
dormant	while	 production	 of	 TGF-1	 and	 periostin	 (POSTN)	 by	 sprouting	 vessels	 stimulate	 the	 DTC	 to	
proliferate.	Reprinted	by	permission	from	SpringerNature:	Nature	Cell	Biology	[107].		
	
1.3	Therapeutic	modification	of	the	metastatic	niche	
As	 previously	 discussed,	 the	 interaction	 between	 cancer	 cells	 and	 bone	
microenvironment	are	required	from	the	early	stages	of	the	metastatic	process.	These	
interactions	in	turn	influence	the	homing	of	tumour	cells	 in	the	secondary	organ,	the	
maintenance	of	dormancy,	the	initiation	of	the	proliferative	state	and	later	the	tumour	
growth	 progression	 and	 consequent	 osteoclast-mediated	 bone	 destruction.	
Unfortunately,	 the	 treatments	 currently	 available	 for	 bone	 metastasis	 are	 palliative	
rather	 than	 curative,	 aiming	 in	 improving	 the	 quality	 of	 life	 of	 the	 patients,	 and	 the	
disease-free	 and	 overall	 survival	 in	 combination	 with	 surgery,	 radiotherapy	 or	
Figure	1.4	Regulation	of	dormancy	by	the	perivascular	niche	
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chemotherapy	[30],	[111].	The	microenvironment	plays	a	key	role	in	the	progression	of	
the	metastatic	disease	and	therefore	it	is	essential	to	not	only	target	the	tumour	cells	
but	also	the	components	of	the	bone	that	promote	tumour	development	[111]	(figure	
1.5).		
	
Several	treatment	approaches	targeting	the	cancer	cells	(a)	can	also	affect	the	components	of	the	bone	
microenvironment	 (b)	 enhancing	 the	 anti-tumour	 effect.	 MMP=	 matrix	 metalloproteinase;	 XRT=	
radiotherapy;	 RTK=receptor	 tyrosine	 kinase;	 TGFβ=transforming	 growth	 factor-β;	 BMPs=bone	
morphogenetic	proteins.	Reprinted	by	permission	from	SpringerNature:	Nature	Reviews	Cancer	[32].	
		 	
Figure	1.5	Benefits	of	targeting	both	cancer	cells	and	microenvironment	
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1.3.1	Targeting	the	bone	cell	population	of	the	niche	
Once	 tumour	 cells	 are	 seeded	 in	 the	 bone	 microenvironment	 they	 promote	 the	
activation	and	differentiation	of	bone-resorbing	osteoclasts,	 this	 leads	to	the	starting	
of	a	vicious	cycle	in	which	osteoclasts	resorb	bone	releasing	growth	factors	embedded	
in	 the	 bone	matrix	 which	 stimulate	 tumour	 growth	 that	 increase	 osteoclast	 activity	
and	 inhibit	 osteoblasts	 causing	 bone	 destruction	 [15].	 To	 limit	 the	 skeletal	 lesions	
caused	 by	 the	 bone	 metastasis,	 current	 therapies	 are	 focused	 in	 the	 inhibition	 of	
osteoclast	 activity	 using	 different	 approaches,	 such	 as	 cathepsin	 K,	 mTOR	 or	 c-Scr	
inhibitors,	the	standard	of	care	anti-resorptive	drugs	(bisphosphonates)	or	anti-RANKL	
antibody	(Denosumab)	[111].	The	use	of	bisphosphonates,	in	particular	Zoledronic	acid,	
will	be	discussed	in	greater	detail	as	it	was	used	for	the	in	vivo	experiment	of	Chapter	5	
of	this	thesis.	
1.3.1.1	Bisphosphonates	
Bisphosphonates	 (BPs)	 are	 the	 standard	 of	 care	 for	 skeletal	 disorders,	 such	 as	
osteoporosis	 and	 cancer-induced	 bone	 disease,	 and	 their	 anti-resorptive	 activity	
results	in	pain	relief	and	reduction	of	bone	lesion	incidence	[112],	[113].	BPs	have	high	
affinity	for	the	bone	matrix	due	to	their	stable	P-C-P	motif	that	bind	to	divalent	cations	
such	as	Ca2+,	Mg2+	and	Fe2+	[114].	The	anti-resorptive	activity	and	potency	of	the	BPs	is	
determined	 by	 their	 chemical	 structure,	 dividing	 this	 class	 of	 drugs	 in	 two	 groups:	
simple	BPs	and	nitrogen-containing	BPs.	With	 its	complex	structure	containing	a	 ring	
structure	with	nitrogen,	Zoledronic	acid	(ZOL)	is	the	most	potent	of	the	BPs	presenting	
a	 10,000	 fold	 higher	 anti-resorptive	 activity	 than	 the	 simpler	 BPs	 [115].	 	 Nitrogen	
containing	BPs,	such	as	ZOL,	 inhibit	the	mevalonate	pathway	which	is	responsible	for	
the	 production	 of	 isoprenoid	 and	 cholesterol	 required	 for	 cell	 proliferation.	 In	more	
detail,	 the	 inhibitory	 action	 of	 BPs	 is	 carried	 out	 on	 the	 key	 enzyme	 farnesyl	
diphosphate	 (FPP)	 synthase,	 which	 is	 responsible	 for	 conversion	 of	 isopentenyl	
diphosphate	(IPP)	to	FPP.	This	results	in	a	lack	of	prenylation	of	GTPases,	such	as	Ras,	
Rab,	Rho	and	Rac	that	are	essential	for	osteoclast	activity	and	viability	[116],	[117].	BPs	
bind	to	the	bone	surface	 in	regions	of	active	bone	remodeling	and	this	could	explain	
the	 high	 selectivity	 on	 osteoclasts,	 however	 it	 has	 been	 shown	 that	 repeated	
administration	of	BPs	results	in	the	internalization	of	the	drugs	by	other	cells,	such	as	
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macrophages,	osteoblasts,	vascular	endothelial	cells	and	tumour	cells	[44],	[117]–[119].	
1.3.1.1.1	Anti-tumour	effects	of	BPs	
In	 addition	 to	 their	 anti-resorption	 action,	 the	 anti-tumour	 effect	 of	 BPs	 has	 been	
extensively	 studied	 in	 vitro	 and	 in	 vivo.	 As	 indicated	 in	 figure	 1.6,	 this	 anti-tumour	
effect	 is	 both	direct	 to	 tumour	 cells	 and	 indirect	 acting	on	 the	microenvironment	 in	
which	the	tumour	develops.			
	
	
Nitrogen-containing	 BPs	 (chemical	 structure	 on	 the	 top	 panel)	 can	 have	 a	 direct	 anti-tumour	 effect	
interfering	with	cell	 adhesion,	 invasion,	proliferation	and	 survival	and	an	 indirect	one,	 inhibiting	bone	
resorption,	angiogenesis	and	stimulating	T	cells.	Reprinted	by	permission	from	American	Association	for	
Cancer	Research:	Cancer	Research	[120].	
Figure	1.6	Chemical	structure	and	anti-tumour	effects	of	nitrogen-containing	bisphoshonates	
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In	vitro	studies	performed	on	several	cancer	cell	lines,	including	breast	cancer,	indicate	
that	 BPs	 induce	 apoptosis,	 inhibition	 of	 proliferation,	 invasion	 and	 adhesion	 [121]–
[123].	However,	these	 in	vitro	studies	used	prolonged	exposure	and/or	high	doses	of	
BPs	that	are	not	achievable	in	vivo.	In	clinical	settings	ZOL	is	administered	at	a	dose	of	
4mg	 infusion	every	 3-4weeks	 and	 it	 has	been	 shown	 to	have	 a	 short	 serum	half-life	
(approximately	1	hour),	however	in	bone	ZOL	is	stored	for	years	and	bone	resorption	
caused	by	osteoclasts	releases	the	drug	stored	in	the	matrix	and	that	could	in	theory	
induce	cytotoxic	effects	in	DTC	in	bone	[124],	[125].	In	addition	to	the	cytotoxic	effect	
of	ZOL	on	tumour	cells,	BPs	also	have	an	indirect	anti-tumour	effect	via	disruption	of	
the	vicious	cycle	of	bone	metastasis.	The	majority	of	the	preclinical	studies	performed	
in	vivo	identify	the	inhibition	of	the	osteoclast-mediated	bone	resorption	as	the	major	
cause	for	the	reduction	of	tumour	burden	in	animal	models	treated	with	ZOL	[30],	[32],	
[126]–[128]	 and	 reduction	 of	 the	 tumour	 relapse	 incidence	 in	 animal	models	 [129],	
[130].	 Even	 though	 treatment	 with	 ZOL	 caused	 a	 change	 in	 the	 bone	
microenvironment	 resulting	 in	 reduced	 development	 of	 overt	 metastasis,	 a	
combination	therapy	with	repeated	dosing	of	cytotoxic	drug	such	as	doxorubicin	(DOX)	
and	ZOL	had	a	more	potent	 anti-tumour	effect	 in	 tumour	bearing	mice	 [120],	 [126],	
[127],	 [131],	 [132].	 Furthermore,	 it	 has	 been	 shown	 that	 in	 mice,	 a	 single	
administration	of	ZOL	affects	the	metastatic	process	from	the	early	steps,	altering	the	
pattern	of	homing	of	breast	cancer	cells	in	the	bone	microenvironment,	probably	due	
to	 the	modification	 of	 the	 bone	 resident	 cells	 number	 and	 activity	 [118].	 The	 bone	
microenvironment	 is	 complex,	with	multiple	components	 that	 interact	 to	 regulate	of	
each	others	 functions,	 it	 is	 therefore	surprising	 that	 the	 information	on	 the	effect	of	
ZOL	on	other	cell	 type	residing	 in	bones	 is	 limited.	 In	the	 literature	there	are	reports	
indicating	 that	 ZOL	 increases	 level	 of	 apoptosis	 in	macrophages	 both	 in	 vivo	 and	 in	
vitro	 [44],	 [133].	 Additionally,	 ZOL	 has	 been	 shown	 to	 have	 an	 effect	 on	
haematopoiesis	 and	 on	 the	 generation	 of	 tumour-suppressing	 bone	marrow	 cells.	 A	
single	 dose	 of	 ZOL	 (100µg/kg)	 administered	 to	 both	 immunocompromised	 and	
immunocompetent	mice	 increased	the	number	of	progenitors	of	HSCs,	myeloid	cells,	
megakaryocytes	and	macrophages	in	the	bone	marrow.	Moreover,	when	bone	marrow	
cells	 isolated	 from	 animals	 treated	with	 ZOL	were	 added	 to	MDA-MD-231	 cells	 that	
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were	 subsequently	 injected	 subcutaneously	 in	 recipient	 mice,	 researchers	 observed	
that	tumour	incidence	in	animals	injected	with	bone	marrow	cells	deriving	from	mice	
treated	with	 ZOL	was	 reduced,	 indicating	 that	 ZOL	 contributed	 to	 the	 generation	 of	
tumour-suppressing	bone	marrow	cells	[134].	
Furthermore,	 emerging	 data	 indicated	 that	 anti-tumour	 effect	 of	 ZOL	 is	 partially	
mediated	 by	 its	 anti-angiogenic	 properties.	 In	 vitro	 and	 in	 vivo	 studies	 reported	 a	
reduction	of	angiogenesis	and	proliferation,	migration	and	tubule	formation	of	HUVEC	
cells	 (0.31-160µM	ZOL	 for	 24,	 48	 or	 72h)[135],	 [136].	Moreover,	 it	 has	 been	 shown	
that	ZOL	inhibits	proliferation	of	endothelial	progenitors	and	causes	their	apoptosis	a	
in	 a	 dose-dependent	manner	 [137].	 In	 agreement	with	 this,	 cancer	 patients	 treated	
with	 BPs	 show	 a	 reduced	 level	 of	 the	 angiogenic	 factor	 VEGF	 after	 intermittent	
treatment	with	low-doses	of	ZOL	[138].	
1.3.1.1.2	Clinical	use	of	BPs	
Bone	metastasis	can	cause	hypercalcemia,	bone	pain,	pathological	fractures	and	spinal	
cord	 compression	 and	 usually	 bisphosphonates	 are	 use	 to	 treat	 these	 skeletal	
morbidities	in	metastatic	breast	and	prostate	cancer	and	advanced	multiple	myeloma	
[139].	 The	 efficacy	 of	 BPs	 in	 treating	 the	 skeletal	 disease	 suggested	 that	 BPs	 could	
potentially	 be	 used	 in	 adjuvant	 setting	 to	 prevent	 bone	 metastasis.	 Early	 clinical	
studies	 reported	 improved	disease-free	 survival	 as	well	 as	 overall	 survival	 of	 patient	
presenting	breast	cancer	(stage	I-III)	following	treatment	with	clodronate	[140].	These	
promising	 results	 obtained	 with	 one	 of	 the	 weakest	 BPs,	 led	 to	 several	 clinical	
investigation	on	the	potential	of	more	potent	BPs,	such	as	ZOL.	Clinical	trials,	including	
the	ABSCSG-12,	AZURE	and	 ZO-FAST,	 investigated	 the	beneficial	 effect	 of	 ZOL	 in	 the	
adjuvant	 setting	 in	 combination	 with	 endocrine	 therapy,	 aromatase	 inhibitors	 and	
chemotherapy	[139],	[141]–[144].	In	the	ABSCSG-12	trial,	premenopausal	patients	who	
had	 received	 ovarian	 function	 suppression	 (and	 thus	 should	 be	 considered	
postmenopausal,	n=1,803),	with	endocrine	responsive	breast	cancer	were	treated	with	
the	aromatase	 inhibitor	anastrazole	+/-	ZOL.	The	addition	of	the	BP	to	the	endocrine	
treatment	 resulted	 in	 an	 increase	 disease-free	 survival.	 Furthermore,	 the	
administration	 of	 ZOL	 decreased	 the	 development	 of	 metastases	 both	 inside	 and	
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outside	 bone,	 as	 well	 as	 regional	 recurrence	 and	 eliminated	 the	 cancer-treatment	
induced	bone	loss	[144].	Comparable	studies	were	performed	in	the	ZO-FAST	trial,	 in	
which	 postmenopausal	 women	 with	 hormone-receptor	 positive	 breast	 cancer	
(n=1,065)	were	treated	with	the	aromatase	inhibitor	 letrozole	+/-	ZOL	[144].	Patients	
treated	with	ZOL	had	an	increase	in	the	bone	mineral	density	and,	in	agreement	with	
the	 ABSCSG-12	 trial,	 they	 had	 a	 prolonged	 disease-free	 survival	 and	 reduction	 of	
distant	disease	both	inside	and	outside	bone	[143],	[144].	The	design	of	the	AZURE	trial	
was	slightly	different	from	the	studies	discussed	above,	in	this	trial	women	with	both	
hormone-receptor	positive	and	negative	breast	cancer	were	included	regardless	their	
menopausal	 status	 (n=3,360);	 patient	 were	 treated	 with	 standard	 therapy	 	 +/-	 ZOL	
[142].		In	contrast	with	the	previous	studies,	the	AZURE	trial	did	not	show	a	difference	
in	 the	 overall	 disease-free	 survival	 between	 the	 treatment	 groups.	 However,	 sub-
groups	 analyses	 demonstrated	 that	 postmenopausal	 patients	 had	 a	 beneficial	 effect	
with	 the	 adjuvant	 ZOL	 by	 preventing	 or	 delay	 cancer	 recurrence	 and	 develop	 of	
skeletal	metastases	[141],	[142].		
The	Early	Breast	Cancer	Trial	Collaborative	Group	(EBCTCG)	performed	a	meta-analysis	
of	 results	 from	26	 randomised	 trials	on	 treatment	with	BPs	 involving	18,766	women	
describing	 that	 clinical	 outcomes,	 such	 as	 the	 time	 till	 the	 first	 overall	 recurrence,	
recurrence	 in	 bone,	 distant	 recurrence	 in	 any	 site	 and	 breast	 cancer	mortality,	 was	
improved	only	for	postmenopausal	women	[145]–[147].	Furthermore,	the	differential	
effect	 of	 menopausal	 status	 has	 also	 been	 demonstrated	 in	 vivo,	 showing	 the	
effectiveness	 of	 ZOL	 in	 preventing	 the	 development	 of	 overt	 tumour	 from	
disseminated	tumour	cells	varies	between	animal	models	mimicking	the	pre-	and	post-
menopausal	status	 [148],	 [149].	These	data	suggest	that	the	bone	microenvironment	
plays	a	key	role	 in	the	progression	of	the	metastatic	disease,	however	the	reason	for	
this	 differential	 effect	 in	 pre-	 and	 post-menopausal	 women	 is	 unknown	 and	 the	
mechanism(s)	behind	it	remains	to	be	identified.		
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1.3.2	Targeting	the	microvasculature	
The	 importance	 of	 angiogenesis	 for	 tumour	 development	 and	 progression	 is	 a	well-
known	concept.	In	the	1970s,	Folkman	observed	that	in	the	absence	of	vascularisation,	
tumour	growth	was	arrested	and	that	pro-angiogenic	factor	were	released	not	only	by	
the	 microenvironment	 but	 also	 by	 the	 neoplastic	 cells,	 suggesting	 that	 the	 tumour	
vasculature	could	be	a	potential	target	in	the	treatment	of	cancers	[150].	Stromal	and	
tumour	 cells	 produce	 pro-	 and	 anti-angiogenic	 factors	 that	 modulate	 the	
vascularisation	required	for	tumour	growth;	the	key	regulator	factors	include	vascular-
endothelial	 growth	 factor	 (VEGF),	 platelet-derived	 growth	 factor	 (PDGF),	 epidermal	
growth	factor	(EGF)	and	fibroblast	growth	factor	(FGF)	[151].	
VEGF	 is	 one	 of	 the	most	 important	 pro-angiogenic	 signals	 in	 tumour	 vascularisation	
from	the	early	stages	of	the	tumour	development	and	high	tumour	expression	of	VEGF	
is	considered	a	marker	 for	a	poor	prognosis	 [152],	 [153].	Thus,	VEGF	was	one	of	 the	
first	 targets	 for	 the	 development	 of	 anti-angiogenic	 therapies	 in	 the	 treatment	 of	
cancer.	Bevacizumab	is	a	recombinant	humanised	VEGF-neutralising	antibody	that	has	
been	 shown	 to	 reduce	 tumour	 growth	 in	 several	 human	 cell	 lines,	 such	 as	 ovarian,	
prostate,	 colon	 and	 breast	 cancer,	 in	 animal	 models	 and	 inhibit	 metastasis	
development;	 combination	 with	 chemotherapy	 or	 radiotherapy	 resulted	 in	 additive	
and	 synergistic	 effects	 [154],	 [155].	 Bevacizumab	 received	 FDA	 approval	 for	 the	
treatment	of	several	cancers,	 including	cervical,	colorectal,	glioblastoma,	ovarian	and	
renal	cancer	[156],	but	the	approval	for	breast	cancer	has	been	controversial.	Clinical	
trials	 show	modest	effects	of	bevacizumab	treatment	 that	could	not	compensate	 for	
the	 risk	 of	 life-threatening	 side	 effects	 including	 hypertension,	 proteinuria,	
haemorrhage,	 wound	 healing	 complications,	 arterial	 thromboembolism	 and	
gastrointestinal	 perforation.	As	 a	 result	 of	 these	widespread	 toxicities,	 FDA	approval	
has	been	 revoked	 for	 the	use	of	 bevacizumab	 in	 the	 treatment	of	metastatic	 breast	
cancer	[157]–[159].	
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1.3.2.1	Cediranib	
Over	recent	years,	additional	agents	targeting	the	VEGF	pathway	have	been	developed,	
including	 tyrosine	 kinase	 inhibitors	 (sunitib	 and	 sorafenib)	 that	 have	 shown	
therapeutic	benefit	in	the	treatment	of	several	tumours	[160],	[161].	Receptor	tyrosine	
kinase	 consists	 of	 an	 extracellular	 N-domain	 binding	 the	 ligand,	 a	 transmembrane	
domain,	an	intracellular	C-terminal	domain,	with	a	kinase	domain	with	binding	cleft	for	
ATP	between	the	C-	and	the	N-terminal.	Binding	of	ligand	to	the	extracellular	domain	
results	 in	dimerization	of	the	receptor	and	stimulation	of	the	tyrosine	kinase	activity,	
leading	to	activation	of	(multiple)	signal	pathways	involved	in	biological	responses	such	
as	 cell	 activation,	 proliferation,	 differentiation,	 migration,	 survival,	 and	 vascular	
permeability	[162].		
Cediranib	 (AZD2171)	 is	 a	 highly	 potent,	 orally	 available	 novel	 pan-VEGF	 receptor	
tyrosine	 kinase	 inhibitor	 (TKI)	 developed	 by	 AstraZeneca	 (chemical	 structure	 and	
mechanism	of	action	illustrated	in	figure	1.7).	The	key	target	of	this	drug	 is	VEGFR-2,	
but	cediranib	has	been	shown	to	be	active	against	VEGFR-1	and	3,	c-KIT	and	with	lower	
potency	 also	 inhibits	 PDGFR-α	 and	 PDGFR-β	 [163],	 [164].	 Effective	 towards	multiple	
targets,	 cediranib	 inhibits	 both	 angiogenesis	 and	 lymphangiogenesis	 and	 could	
therefore	 be	 potentially	 beneficial	 for	 the	 prevention	 of	 tumour	 growth.	Moreover,	
the	orally	available	 formulation	and	the	short	half-life	 (12.5-35.4	hours)	allow	a	daily	
dosing	that	could	be	performed	autonomously	by	the	patients.		
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Chemical	 structure	 of	 the	 TKI	 cediranib	 is	 illustrated	 in	 the	 bottom	 panel.	 Cediranib	 is	 pan-VEGFR	
tyrosine	 kinase	 inhibitor;	 by	blocking	 the	 action	of	VEGFR-1	 and	2	 the	 TKI	 inhibits	 angiogenesis	while	
lymphangiogenesis	is	blocked	by	the	inhibition	of	VEGFR-3.	Flt-1=fms-like	tyrosine	kinase	1;	KDR=kinase	
insert	 domain	 protein	 receptor;	 PIGF=placental	 growth	 factor;	 TK=tyrosine	 kinase.	 Adapted	 and	
reprinted	by	permission	from	Elsevier:	Clinical	Breast	Cancer	[165].	
	
	
	
	
	
	
Figure	1.7	Chemical	structure	and	mechanism	of	action	of	Cediranib	
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1.3.2.1.1	Anti-tumour	effects	of	Cediranib	
In	addition	to	the	anti-angiogenic	activity	of	this	TKI,	the	efficacy	in	several	cancers	has	
also	been	 tested	extensively	 in	vitro,	 in	vivo	and	 in	clinical	 studies,	with	multiple	on-
going	trials.		
In	 vitro	 studies	 were	 performed	 to	 compare	 the	 efficacy	 of	 three	 TKIs,	 Cediranib,	
Sunitinib,	 and	 Imatinib,	 on	 viability,	 cell	 cycle,	 apoptosis,	migration,	 and	 invasion	 on	
eight	 glioblastoma	cell	 lines.	Cediranib	was	 found	 to	be	 the	most	potent	of	 the	TKIs	
tested	with	a	half-maximal	inhibitory	concentration	(IC50)	of	1.71	±	0.97μM	compared	
to	Sunitinib	(IC50	2.92	±	1.59μM)	and	Imatinib	(IC50	13.01	±	6.09μM)[166].	Furthermore,	
the	viability,	migration,	 invasion	and	cell	death	was	also	investigated	for	three	breast	
cancer	 cell	 lines,	 Hs578T	 (ER-),	MDA-MB-231	 (triple-negative)	 and	 T47D	 (ER+,	 PR+/-,	
HER2-)	 treated	with	Cediranib.	Cediranib	 IC50	were	measured	at	24,	48	and	72	hours	
and	 the	 values	 at	 72h	 for	 the	 first	 two	 cell	 lines	 were	 comparable	 with	 the	 IC50	
observed	for	glioblastoma	cell	lines	(2.08±0.77μM	Hs578T	and	2.52±0.81μM	MDA-MB-
231)	 while	 the	 concentration	 needed	 to	 inhibit	 T47D	 was	 considerably	 higher	 (IC50	
18.85±3.21μM).	 Cytotoxic	 effects	 were	 measured	 analysing	 the	 poly(ADP	 ribose)	
polymerase	(PARP)	cleavage	and	the	results	 indicated	that	Hs578T	and	MDA-MB-231	
exhibit	 greater	 level	 of	 cleaved	 PARP	 than	 T47D	 cells	 following	 cediranib	 treatment,	
suggesting	a	resistant	profile	in	this	cell	line.	Wound-healing	assays	were	performed	to	
determine	the	migration	of	these	cell	 lines	after	treatment	with	can	results	 indicated	
Hs578T	 (80%	 inhibition)	 to	 be	 the	 most	 sensitive	 of	 the	 breast	 cancer	 cell	 lines	
analysed,	 followed	 by	 T47D	 (70%)	 and	 MDA-MB-231	 (54%).	 Cediranib	 treatment	
significantly	 inhibited	cell	 invasion	 in	all	breast	cancer	cell	 lines	 [T47D	 (70%),	Hs578T	
(60%)	and	MDA-MB-231	(30%)]	compared	to	control.	Cediranib-induced	modulation	of	
miRNA	expression	showed	that	Hs578T	is	the	most	sensitive	cell	line	used	in	this	study,	
however	targets	shared	with	the	MDA-MB-231	cell	lines,	including	VEGFA,	VEGFC,	and	
PDGFRA,	 were	 implicated	 in	 important	 biological	 processes	 such	 development,	
metabolic	processes,	cell	motility	and	homeostasis	[167].		
In	 addition	 to	 the	 in	 vitro	 studies	 indicating	 the	 potential	 of	 Cediranib	 as	 an	 anti-
tumour	drug,	 several	 investigations	were	performed	 in	 vivo	 to	detect	 the	efficacy	of	
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the	TKI	in	animal	models	across		a	number	of	cancer	cell	types.	Wedge	et	al.	described	
the	 broad-spectrum	 anti-tumour	 activity	 of	 Cediranib	 on	 growth	 of	 several	
subcutaneous	tumours,	including	colon,	lung,	ovary,	prostate	and	breast	cancer.	In	this	
in	vivo	study	nude	mice	were	treated	daily	for	28	days	(24	days	 in	the	case	of	breast	
cancer	 cell	 line	 MDA-MB-231)	 with	 a	 range	 of	 doses	 of	 TKI	 (0.75-6	 mg/kg/daily)	
resulting	 in	 significant	 inhibition	 of	 tumour	 growth	 [168].	 	 Several	 groups	 confirmed	
the	 anti-tumour	 efficacy	 of	 Cediranib	 in	 different	 animal	 cancers	 models,	 such	 as	
primary	 renal	 carcinoma	 [169],	 colorectal	 carcinoma	 [170],	 prostate	 cancer	 [171],		
glioblastoma	 [166],	 [172],	ovarian	 carcinoma	 [173],	 thyroid	 cancer	 [174]	and	ovarian	
cancer	[175].					
Cediranib	was	associated	with	a	reduction	of	tumour	angiogenesis,	but	the	effect	that	
the	 administration	 of	 this	 drug	 has	 on	 the	 bone	 microenvironment,	 was	 only	
marginally	 investigated.	Wedge	 and	 colleagues	 reported	 a	 severe	 epiphyseal	 growth	
plate	dysplasia	 in	 rats	 treated	with	Cediranib	 for	28	days,	 that	was	 reversed	28	days	
after	stopping	the	treatment	with	the	TKI	[168].	Yin	observed	that	metastatic	growth	
in	 bone	was	 reduced	with	 the	 administration	 of	 Cediranib	 in	 both	 the	 treatment	 as	
well	 as	 in	 preventative	 settings,	 but	 any	 effects	 that	 the	 drug	 had	 on	 the	 bone	
microenvironment	were	not	 reported	 [171].	 Thus,	 the	aim	of	Chapter	6	of	 the	work	
presented	 in	 this	 thesis	 was	 to	 fill	 the	 gap	 in	 the	 knowledge	 about	 the	 potential	
changes	 of	 the	 bone	 structure	 and	 microvasculature	 caused	 by	 treatment	 with	
Cediranib.		
1.3.2.1.2	Clinical	use	of	Cediranib	
After	 obtaining	 promising	 data	 in	 pre-clinical	 models,	 the	 efficacy	 of	 Cediranib	 in	
various	cancer	 types	has	been	 tested	 in	clinical	 studies.	Currently	 several	 trials	using	
Cediranib	 as	monotherapy	 or	 in	 combination	with	 other	 compounds	 are	 ongoing,	 a	
summary	of	the	clinical	trials	involving	breast	cancer	can	be	found	in	table	1.2.	
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Table	1.2	Currently	ongoing	and	completed	clinical	trials	using	cediranib	for	the	treatment	of	breast	
cancer	
Name	 Phase	 Patients/tumour	type	 ClinicalTrials.gov	
identifier	
AZD2171	 in	 addition	 to	
Fulvestrant	 in	 patients	 with	
advanced	breast	cancer	
II	
Advanced	 breast	 cancer	 (hormone	 sensitive	
breast	 cancer	 with	 histological	 evidence	 of	
metastatic	disease)	
NCT00454805	
A	 phase	 II	 study	 of	 AZD2171	 in	
breast	cancer	stage	IV	
II	 • Male	breast	cancer	
• Recurrent	breast	cancer	
• Stage	IV	breast	cancer	
NCT00244881	
AZD2171	 and	 combination	
chemotherapy	 in	 treating	
women	 with	 locally	 advanced	
breast	cancer	
N/A	 Locally	advanced	breast	cancer	(stage	IIIA-C)	 NCT00310089	
Cediranib	maleate	 and	Olaparib	
in	 treating	 patients	 with	
recurrent	 ovarian,	 fallopian	
tube,	 peritoneal	 cancer	 or	
recurrent	 triple-negative	 breast	
cancer	
I/II	
• Deleterious	BRCA1/2	Gene	Mutation	
• Estrogen	Receptor	Negative	
• HER2/Neu	Negative	
• Ovarian	Endometrioid	Adenocarcinoma	
• Ovarian	 Serous	 Surface	 Papillary	
Adenocarcinoma	
• Progesterone	Receptor	Negative	
• Recurrent	Breast	Carcinoma		
• Recurrent	Fallopian	Tube	Carcinoma	
• Recurrent	Ovarian	Carcinoma	
• Recurrent	Primary	Peritoneal	Carcinoma	
• Triple-Negative	Breast	Carcinoma		
NCT01116648	
Phase	 I/II	 study	 of	 the	 anti-
programmed	 death	 ligand-1	
antibody	 MEDI4736	 in	
combination	 with	 Olaparib	 and	
or	 cediranib	 for	 advanced	 solid	
tumours		
I/II	
• Lung	cancer	
• Breast	cancer	
• Ovarian	cancer	
• Colorectal	cancer	
• Prostate	cancer	
• Triple	negative	breast	cancer	
NCT02484404	
Gamma-secretase	 inhibitor	
RO4929097	 and	 cediranib	
maleate	 in	 treating	 patients	
with	advanced	solid	tumors	
I	
• Adult	 anaplastic	
Astrocytoma/Ependymoma/	
Oligodendroglioma	
• Adult	Glioblastoma/Giant	cell	Glioblastoma/	
Brain	 stem	 Glioma/mixed	
Glioma/Gliosarcoma	
• Male	breast	carcinoma	
• Colorectal	 carcinoma	 (recurrent	 and	 stage	
III/IV)	
• Skin	melanoma	(recurrent	and	stage	III/IV)	
• Ovarian	cancer	(recurrent	and	stage	III/IV)	
• Breast	cancer	(recurrent	and	stage	III/IV)	
• Pancreatic	cancer	(recurrent	and	stage	III/IV)	
• Renal	cancer	(recurrent	and	stage	III/IV)	
• Non-small	 cell	 lung	 cancer	 (recurrent	 and	
stage	III/IV)	
NCT01131234	
A	phase	 II	 study	 of	 cediranib	 in	
combination	 with	 Olaparib	 in	
advanced	solid	tumours	
II	
• Pancreatic	cancer	stage	III/IV	
• Non-small	 cell	 and	 small	 cell	 lung	 cancer	
stage	III/IV	
• Oestrogen	receptor	negative,	HER2	negative	
and	triple-negative	breast	cancer	stage	III/IV	
NCT02498613	
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Hyams	 and	 colleagues	 investigated	 the	 effect	 of	 Cediranib	 in	 combination	 with	 the	
oestrogen	 receptor	 antagonist	 Fulvestrant	 for	 the	 treatment	 of	 post-menopausal	
women	with	metastatic	hormone-sensitive	breast	cancer	(n=75)	[176].	Cediranib	was	
administered	 at	 an	 initial	 dose	 of	 45mg	 in	 combination	 with	 Fulvestrant,	 but	 this	
caused	 several	 side	 effects,	 such	 as	 diarrhoea,	 fatigue	 and	 hypertension,	 therefore	
doses	were	reduced.	The	results	showed	a	trend	 in	the	progression-free	survival	and	
decrease	 of	 tumour	 size	 in	 the	 combination	 treatment	 but	 the	 data	 did	 not	 reach	
statistically	 significance.	 This	 indicates	 a	 potential	 beneficial	 effect	 of	 Cediranib	 in	
combination	 with	 hormonal	 agents	 or	 chemotherapy,	 possibly	 at	 a	 lower	 dose	
(30mg/day)	 [176].	 Similar	 indication	 for	 the	 reduction	 of	 the	 dose	 of	 Cediranib	was	
obtained	 in	a	 small	 clinical	 trial	 (n=39)	 investigating	 the	 safety/tolerability	of	 the	TKI	
with	Saracatinib	 (inhibitor	of	 the	proto-oncogene	Src)	 for	 the	treatment	of	advanced	
solid	 tumours,	 such	 as	 colorectal,	 pancreas,	 ovary,	 liver	 and	 breast	 cancer	 [177].	 	 A	
30mg/daily	dose	was	used	also	 in	combination	with	the	PARP-inhibitor	Olaparib,	and	
even	 though	 75%	of	 the	 patients	 experienced	 a	 grade	 3	 or	 higher	 toxicity,	 suffering	
from	diarrhoea,	fatigue,	nausea,	decreased	neutrophil	count	and	hypertension;	these	
events	were	anticipated	and	manageable.	This	regime	was	used	for	the	treatment	of	
recurrent	 epithelial	 ovarian	 cancer	 and	 metastatic	 triple	 negative	 breast	 cancer.	
Ovarian	cancer	patients	responded	well	to	the	treatment	with	a	clinical	benefit	rate	of	
61%,	the	two	patients	with	BRCA	mutation	carriers	in	metastatic	triple	negative	breast	
cancer	patients	showed	a	reduction	of	approximately	27%	of	tumour	size	however	due	
to	the	limited	sample	size	it	was	not	possible	to	draw	conclusion	on	the	effect	of	the	
combination	therapy	in	this	cancer	type	[178].	
Even	 though	 several	 clinical	 trials	did	not	meet	 their	primary	end	point	 [179],	 [180],	
the	investigation	of	the	potential	beneficial	effects	of	treatment	with	the	TKI	as	part	as	
combination	therapies	continues	to	be	evaluated.	
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1.3.3.1	Deferroxamine	mesylate		
One	 other	 important	 pathway	 target	 in	 anti-angiogenic	 treatment	 is	 the	 hypoxia	
inducible	 factor-1α	 (HIF-1α).	When	 tumour	 cells	 proliferate	quickly	 to	 generate	 solid	
masses,	blood	vessels	get	obstructed	 leading	 to	poor	oxygen	supply	 to	 the	centre	of	
the	tumour,	creating	a	hypoxic	region.	To	survive	in	this	restrictive	microenvironment,	
tumour	 cells	 activate	 the	 HIF-1	 transcription	 factor	 which	 led	 to	 the	 activation	 of	
downstream	 genes	 required	 for	 the	 regulation	 of	 tumour	 survival	 in	 low	 oxygen	
condition,	such	as	glucose	metabolism,	cell	proliferation,	migration	and	angiogenesis.	
Considering	 its	 function	 in	 tumour	 progression	 and	metastasis,	 developing	 inhibitors	
targeting	the	HIF-1α	pathway	has	been	of	great	interests.	However,	HIF-1α	pathway	is	
involved	 in	 several	 physiological	 processes	 (e.g.	 angiogenesis,	 cell	 proliferation,	
metabolisms	 of	 iron	 and	 glucose),	 cell	 therefore	 targeting	 off	 only	 hypoxic	 tumours	
without	disrupting	normal	homeostasis	remains	a	considerable	challenge	[181].		
In	the	work	presented	in	Chapter	6	of	this	thesis,	the	HIF-1α	pathway	was	targeted	to	
increase	 the	 microvascular	 activity	 to	 detect	 potential	 changes	 in	 the	 homing	 of	
tumour	cells	in	an	altered	microenvironment,	rather	than	trying	to	inhibit	the	pathway	
to	 obtain	 an	 anti-angiogenic	 and	 consequently	 an	 anti-tumour	 effect.	 Deferoxamine	
mesylate	 (DFM)	 was	 used	 to	 enhance	 HIF-1α.	 This	 iron	 chelator	 inhibits	 the	 prolyl	
hydroxylase	domain	 (PHD)	 resulting	 in	stabilization	of	HIF-1α	which	can	then	bind	to	
HIF-1β,	 translocation	of	 the	complex	to	the	nucleus	and	 induction	of	 transcription	of	
several	hypoxia	inducible	genes	[182],	[183].	DFM	has	been	shown	to	increase	tubule	
formation	 by	 endothelial	 cells	 in	 vitro	 and	 to	 enhance	 angiogenesis	 in	 response	 to	
acute	hindlimb	ischemia	in	vivo	[184],	[185].	As	discussed	previously,	angiogenesis	and	
osteogenesis	are	tightly	connected,	therefore	it	is	not	surprisingly	that	several	studies	
indicated	that	the	pro-angiogenic	effect	of	DFM	is	accompanied	by	an	increase	of	bone	
mass	 in	 various	 animal	 models	 [97],	 [186]–[193].	 Kusumbe	 and	 colleagues	 treated	
aged	mice	(60-65	weeks	old)	with	DFM	(15mg/ml	per	mouse	every	other	day	for	4-6	
weeks)	 and	 they	 observed	 a	 significant	 increase	 in	 the	 trabecular	 bone,	 number	 of	
osteoprogenitors	 and	 presence	 of	 H-vessels	 in	 treated	 animals	 [97].	 In	 vivo	 studies	
demonstrated	the	efficacy	of	this	treatment	to	repair	bone	injuries.	A	rat	model	of	was	
used	 to	 observe	 the	 effect	 of	 DFM	 on	 bone	 repair	 in	 combination	 with	 hindlimb	
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suspension.	Hindlimb	suspension-induced	a	reduction	in	the	bone	repair,	however	this	
effect	was	mitigated	with	the	treatment	with	DFM	(2	or	5	doses	of	20µl	of	200µmol/L	
on	 alternate	 days)	 that	 increased	 both	 the	 angiogenesis	 and	 osteogenesis	 [187].	
Similar	 results	 were	 also	 obtained	 in	 a	 mouse	model	 of	 hindlimb	 unloading,	 where	
animals	 receiving	 10mg	of	DFM	once	 a	week	 for	 3weeks	 showed	 an	 increase	 in	 the	
bone	mass	reverting	the	bone	loss	caused	by	the	tail	suspension	[188].	Deferoxamine	
treatment	in	rat	presenting	mandibular	distraction	enhanced	the	angiogenesis	and	the	
osteogenesis	 [193];	 furthermore,	 this	 results	 were	 obtained	 also	 when	 the	 animal	
models	were	exposed	to	radiation	[190].	
In	addition	to	the	investigation	of	the	effect	of	DFM	treatment	on	bone	structure	and	
microvasculature,	 a	 few	 studies	 examined	 whether	 DFM	 caused	 a	 change	 in	 the	
behaviour	 of	 cancer	 cells	 displaying	 a	 pro-tumorigenic	 effect	 in	 vitro.	 In	 vitro	 assays	
indicated	that	treatment	with	DFM	increased	migration	and	invasion	of	MDA-MB-231	
without	affecting	their	viability	(dose	range	30-300µM)	[194].	The	treatment	 induced	
an	increase	in	intracellular	level	of	iron	in	aggressive	MDA-MB-231	cells,	while	this	was	
deplete	 in	MCF-7	 cell	 line.	Moreover,	 the	MDA-MB-231	 cells	 showed	 increased	 cell	
migration	and	higher	level	of	mesenchymal	markers	after	administration	of	DFM	[195].	
To	support	the	theory	that	DFM	should	be	carefully	used	in	patients	with	breast	cancer,	
Duarte	and	colleagues	reported	that	HSCs	homing	to	bone	marrow	is	 increased	after	
administration	with	DFM	[196].	Since	HSCs	and	breast	cancer	cells	are	thought	to	use	
similar	 mechanism	 to	 home	 to	 the	 bone	 marrow,	 in	 chapter	 6	 of	 this	 thesis	 I	
investigated	 whether	 the	 treatment	 with	 DFM	 altered	 the	 components	 of	 the	
metastatic	niche	and	 if	 this	modification	of	 the	microenvironment	was	 reflected	 in	a	
change	in	the	number	of	tumour	cells	seeding	to	bone.	
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1.4	Summary,	conclusion	and	outstanding	questions	
In	 summary,	 breast	 cancer	 cells	 colonise	 an	 area	 of	 bone	 marrow,	 known	 as	 the	
metastatic	 niche,	 where	 the	 HSC,	 osteoblastic	 and	 perivascular	 niche	 are	 at	 least	
partially	 overlapping.	 	 The	 components	 of	 the	 complex	 microenvironment	 that	
comprise	 the	 metastatic	 niche	 are	 key	 players	 that	 regulate	 multiple	 steps	 of	 the	
metastatic	process,	 including	the	homing	of	cancer	cells	to	bone,	 in	the	maintenance	
of	 dormancy,	 in	 the	 proliferation	of	 tumour	 cells	 and	 finally	 in	 the	 creation	of	 bone	
lesions.	 Moreover,	 the	 different	 cellular	 components	 of	 the	 metastatic	 niche	 are	
intimately	 interconnected	 and	 they	 can	 influence	 the	 activity	 of	 each	 other,	 both	
through	direct	cell	contact	and	through	release	of	soluble	factors.	
Currently	 there	are	no	curative	 treatments	available	 for	metastatic	disease,	but	only	
palliative	measures	that	treat	the	symptoms	of	the	secondary	disease,	such	as	slowing	
down	the	cancer-induced	bone	resorption.	It	has	been	demonstrated	that	alterations	
in	the	microenvironment	cause	changes	in	the	growth	of	metastasis	in	bone,	but	it	 is	
still	not	fully	understood	to	what	degree	modification	of	one	component	of	the	niche	
also	influences	the	overlapping	niches,	or	how	this	affects	disseminated	tumour	cells.	
To	 date,	 most	 of	 the	 therapeutic	 approaches	 are	 focused	 on	 targeting	 bone	 cells	
(mainly	osteoclasts)	and	tumour	cells,	but	targeting	only	one	of	the	key	players	of	the	
progression	 of	 the	 secondary	 tumour	 is	 not	 sufficient	 to	 arrest	 the	 metastatic	
development.	 Little	 is	 known	 about	 the	 role	 of	 the	 bone	 microvsculature	 in	 bone	
metastasis	 and	 response	 to	 therapy.	 Additional	 information	 on	 the	 mechanism	 of	
response	 to	 therapies	 by	 the	microenvironment	 are	 needed	 to	 eventually	 find	 new	
potential	therapeutic	targets.	
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1.5	Hypothesis,	aims	and	objectives	
The	 principal	 aim	of	 this	work	was	 to	 increase	 the	 understanding	 of	 the	 role	 of	 the	
bone	 microvasculature	 in	 the	 early	 stages	 of	 breast	 cancer	 bone	 metastasis.	 To	
address	this	aim	the	following	hypothesis	will	be	tested:	
Breast	 cancer	 cells	 located	 in	 a	 region	 of	 bone	 in	 which	 HSC,	 osteoblastic	 and	
perivascular	niches	 (partially)	overlap	and	the	tightly	connected	components	of	 the	
niche	mediate	the	response	to	therapeutic	agents.	
	
The	main	aims	of	this	thesis	were	as	follows:	
• To	 assess	 the	 pattern	 of	 homing	 of	 breast	 cancer	 cells	 in	 bone	 in	 vivo	 using	
several	cell	lines	and	routes	of	administration	
• To	characterize	the	microenvironment	of	tumour	promoting	(young	mice)	and	
of	dormancy	supporting	(mature	mice)	animal	models	
• To	determine	whether	 the	modification	of	 the	bone	 component	of	 the	niche	
was	reflected	 in	modification	of	 the	perivascular	component	of	 the	niche	and	
the	homing	of	breast	cancer	cells	to	bone	
• To	 investigate	 the	 effect	 of	 changes	 of	 the	 microvasculature	 on	 the	 bone	
component	of	the	niche	and	the	homing	of	breast	cancer	cells	to	bone								
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Chapter	2 	
Materials	and	Methods	
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Materials	
	
Table	2.	1	Laboratory	reagents	or	kits		
Reagent	or	Kit	 Supplier	
Acetic	Acid	 AnalaR	VWR	
AMD3100	 Sigma-Aldrich	
Cediranib	 Selleckchem.com	
Cryo-M-Bed	 Bright	
DAPI	 Invitrogen,	Thermo	Fisher	Scientific	
Deferoxamine	mesylate	 Sigma-Aldrich	
DMEM	culture	medium	 Gibco	
DMSO	 Sigma-ALdrich	
DPX	mountant	 VWR	
EDTA	 Sigma-Aldrich	
Eosin	 Atom	Scientific	LDT	
Gelatine	for	porcine	skin	 Sigma-Aldrich	
Gill’s	haematoxylin	solution	 Merck	
Isoflourane,	IsoFlo	 Abbott	
Luciferin	 Perkin	Elmer	
Masson-Goldner	trichrome	staining	kit		 Merck		
Naphthol	AS-BI	phosphate	(sodium	salt)	 Sigma-Aldrich	
Paraformaldehyde	 Sigma-Aldrich	
PBS	for	in	vivo	studies	and	tissue	culture	 Gibco,		
PBS	tablets	 Oxoid	
ProLong	Gold	antifade	reagent	 Invitrogen,	Thermo	Fisher	Scientific	
PVP	 Sigma-Aldrich	
RPMI	culture	medium	 Gibco	
Sodium	Hydroxide	pellet	(NaOH)	 Fisher	Scientific	
Streptavidin/Biotin	Blocking	Kit		 Vector	Laboratories	SP-2002	
Sucrose	 Fisher	Scientific	
Toluidine	Blue	O	 Sigma-Aldrich	
Triton-X	100	 Sigma-Aldrich	
Tween-80	 Sigma-Aldrich	
Vibrant-CM-DiI	Cell-Labeling	Solution	 Life	Technologies	
Vibrant-DiD	Cell-Labeling	Solution	 Life	Technologies	
Zoledronic	Acid	 Novatris	
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Table	2.2	Plastic	and	disposable	equipment	
Cell	strainer	70μm	 BD	Biosciences	
Cover	slips	(22x22	and	22x40mm)	 Menzel-Gläser	
Cryovials	(1ml)	 Thermo	Scientific	
Filter	tips	(10,	20,	200	and	1000μl)	 STARLAB	
Glass	bottomed	dish	12mm	 Thermo	Scientific	
Insulin	syringe	(0.5	and	1ml)	with	needle	(27G)	 Terumo	Europe	N.V.	
Microcentrifuge	tubes	(0.6	and	1.5ml)	 STARLAB	
Needle	(25G)	 Becton	Dickinson	UK	Ltd.	
Pipette	tips	(10,	20,	200	and	1000μl)	 Costar	
Strippets	(5,	10	and	25ml)	 Costar		
SuperFrost	PLUS	microscope	slides	 Thermo	Scientific	
Syringe	(1ml)	 Terumo	Europe	N.V.	
Tissue	culture	flasks	(T75)	 Nalgene	Nunc	Ltd.	
Universal	containers,	Bijoux	tubes	 Starstedt	
	
Table	2.3	Software	used	for	data	analysis	
Aperio	ImageScope	 Leica	Biosystems	
CTAnalyser	software	 SkyScan,	Burker	microCT,	CT-Analyser	
version	
FiJi	(ImageJ)	 ImageJ,	version		
GraphPad	Prism	software	 Prism,	version	
LAS	AF	 Leica	
Living	Image	4.0	software	 Caliper	Life	Science	
Nrecon	 OsteoMetrics	
Volocity	software	 Improvision,	version	4.3.2	
NIS-Element	Confocal	 Nikon	
ZEN	software	 Zeiss	
	
Table	2.4	Laboratory	equipment	
Benchtop	Centrifuges	 MSE	Mistral	2000	
Centrifuge	 Beckman	
Confocal	microscope	 Zeiss	LSM880	AiryScan	and	Nikon	A1	
Cryostat	 5030	Microtome,	Bright	
Cryostat	 MICROM	HM560	
Desktop	X-ray	microtomograph	 SkyScan	1272,	Bruker	microCT	
IVIS	Lumina	II	 Perkin	Elmer	
Multiphoton	Confocal	Microscope	 Zeiss	LSM510	NLO	Inverted	
Olympus	BX53	microscope	 Olympus	BX53	
pH	meter	SevenEasy	 Mettler	Toledo	
Superfrost	Plus	Slides	 Thermo	Scientific,	J1800AMNZ	
Vortexer	 Rotamixer,	Hook&/tucker	Instruments	
Water	bath	 Grant	JB	Series	
Widefield	fluorescence	microscope	 Leica	AF6000	
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Methods	
In	vitro	experiments	
2.1	Cell	Lines	
All	 the	 human	 breast	 cancer	 cell	 line	 were	 handled	 in	 aseptic	 conditions	 under	
laboratory	 containment	 level	 2,	 as	 recommended	by	 the	European	Collection	of	Cell	
Cultures	 (ECACC)	 and	 the	 American	 Type	 Culture	 Collection	 (ATCC)	 (table	 2.5).	 DNA	
fingerprinting	was	used	to	confirm	cell	lines	authenticity.			
	
Table	2.5	Molecular	classification	of	breast	cancer	cell	lines	used	in	this	thesis	
Cell	line	 Classification	 Immunoprofile	 Other	characteristic	
MCF-7	 Luminal	A	 ER+,	PR+/-,	HER2-	
Ki67	low,	endocrine	responsive,	
often	chemotherapy	responsive	
T47D	 Luminal	A	 ER+,	PR+/-,	HER2-	
Ki67	low,	endocrine	responsive,	
often	chemotherapy	responsive	
MDA-MB-231	 Claudin-low	 ER-,	PR-,	HER2-	
Ki67,	E-cadherin,	claudin-3/4/7	
low,	intermediate	response	to	
chemotherapy	
ER=oestrogen	receptor,	PR=progesterone	receptor,	HER2=human	epidermal	growth	factor	receptor	
	
2.1.1	MDA-MB-231-GFP-IV	bone	homing	
MDA-MB-231	 cell	 line	 was	 first	 isolated	 from	 the	 pleural	 effusion	 of	 a	 51-year	 old	
Caucasian	woman	presenting	with	breast	adenocarcinoma.	The	characteristics	of	this	
cell	line	is	that	it	does	not	express	the	receptors	for	oestrogen	(ER),	progesterone	(PR)	
or	human	epidermal	growth	factor	receptor-2	(HER-2)	[197].	This	triple	negative	breast	
cancer	 cell	 line	 is	 tumorigenic	 in	 a	murine	model	 and,	when	 administered	 via	 intra-
cardiac	injection	the	animals	develop	bone	metastasis,	in	particular	in	the	metaphysis	
areas	 of	 the	 hind	 limbs.	 Tumour	 growth	 in	 non-bone	 sites	 is	 rarely	 seen	 using	 this	
injection	route.	
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The	cell	line	used	to	determine	the	homing	pattern	of	tumour	cells	in	the	early	stages	
of	 bone	metastasis	was	 a	 highly	 bone-seeking	 clone	 derived	 from	 the	MDA-MB-231	
cell	 line.	 MDA-MB-231	 cells	 were	 previously	 transfected	 with	 enhanced	 green	
fluorescent	 protein	 (eGFP)	 [131]	 and	 subsequently	 the	 GFP	 positive	 clones	 were	
injected	 in	vivo	to	obtain	the	bone-homing	cell	 line.	MDA-MB-231-GFP-IV.	These	cells	
were	injected	in	the	left	cardiac	ventricle	and	tail	vein	of	immunocompromised	mice,	
tumour	 colonies	 obtained	 were	 isolated	 from	 the	 bone	 marrow	 based	 on	 GFP	
expression	 and	 subsequently	 re-injected	 seven	 times	 [198].	 	 These	 seven	 cycle	 of	
injections	were	required	to	generate	a	cell	line	that	homes	to	bone	following	injection	
into	the	tail	vein	of	animal	models.	
2.1.2	MDA-MB-231-B02		
To	compare	the	pattern	of	homing	of	breast	cancer	cells	within	the	bone	marrow,	the	
MDA-MB-231-B02	 cell	 line	 was	 used.	 The	 B02	 clone	 was	 also	 generated	 following	
transfection	with	GFP	to	obtain	a	traceable	cell	line	and	the	highly	bone	homing	clone	
developed	through	repeated	in	vivo	passages	[129].		
2.1.3	MDA-MB-231-NW1-Luc2		
Tumour	 growth	 studies	 were	 performed	 with	 the	MDA-MB-231-NW1-Luc2	 cell	 line.	
This	clone	had	been	transfected	with	a	luciferase	vector	by	Dr.	Ning	Wang	(University	
of	 Sheffield,	 UK),	 producing	 a	 cell	 line	 that	 can	 generate	 tumour	 colonies	 traceable	
with	 the	 In	Vivo	 Imaging	 System	 (IVIS)	 following	prior	 subcutaneous	 injection	of	 the	
substrate	 luciferin.	 	Mice	administered	via	 intra-cardiac	 injection	(i.c.)	with	this	clone	
develop	 detectable	 hind	 limb	 micro-metastasis	 as	 early	 as	 3-5	 days	 post	 injection,	
highlighting	the	aggressiveness	of	the	cell	line.	
2.1.4	MCF-7		
MCF-7,	 acronym	 of	 Michigan	 Cancer	 foundation-7,	 is	 a	 breast	 cancer	 cell	 line	
established	in	1970	from	the	pleural	effusion	of	a	69-year-old	Caucasian	patient	with	
invasive	breast	adenocarcinoma	[199].		In	contrast	to	the	MDA-MB-231	cell	line,	these	
breast	cancer	cells	express	both	oestrogen	and	progesterone	receptors,	but	 they	are	
HER-2	 negative.	 MCF-7	 cells	 are	 tumorigenic	 in	 mice	 when	 injected	 i.c.	 or	 in	 the	
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mammary	 fat	 pad	 even	 though	 they	 are	 slowly	 growing	 in	 vivo	 without	 estrogen	
supplementation.	 	 This	 clone	of	 cells	was	used	 to	determine	 the	 location	within	 the	
bone	marrow	of	ER	+ve	breast	cancer	cell	followed	i.c.	injection.		
2.1.5	T47D		
Similar	 to	 the	 MCF-7	 cell	 line,	 the	 T47D	 cell	 line	 is	 positive	 for	 both	 estrogen	 and	
progesterone	receptors.	This	cell	 line	was	first	 isolated	from	the	pleural	effusion	of	a	
54	year	old	patient	presenting	with	ductal	carcinoma	[200].		
The	cell	 line	was	used	 to	determine	 the	homing	pattern	of	a	 second	ER	+ve	cell	 line	
after	i.c.	injection	in	immunocompromised	mice.	
2.2	Cell	line	subculture	
Subcultures	 of	 cells	 were	 prepared	 by	 defrosting	 cells	 from	 a	 fresh	 batch	 of	 low	
passage	number	stored	in	liquid	nitrogen,	each	experiment	was	performed	using	cells	
of	 similar	 passage	 number	 (passage	 12-14).	 The	 previously	 described	 cell	 lines	were	
grown	 in	 T75	 flasks	 in	 RPMI-1640	 medium	 supplemented	 with	 10%	 foetal	 bovine	
serum	 at	 37°C	 and	 5%CO2,	 or	 DMEM	 +	 Pyruvate	 medium	 enriched	 with	 1%	
penicillin/streptomycin	and	10%	foetal	bovine	serum	for	the	MDA-MB-231-NW1-Luc2	
clone.	Prior	the	addition	in	the	culture	medium,	serum	was	heat	inactivated	in	a	water	
bath	 at	 56°C	 for	 45min.	 Cells	 were	 subcultured	 approximately	 trice	 a	 week	 under	
sterile	 condition	 in	 a	 tissue	 culture	 hood.	 Overcrowding	 of	 cells	 should	 be	 avoided,	
therefore	cells	were	subcultured	when	reaching	a	confluence	of	about	80%.	 	Culture	
medium	was	 removed	 from	 the	 flask	 and	 cells	were	washed	 twice	with	 sterile	 PBS.	
Cells	were	trypsinised	with	0.15%	Trypsin-EDTA	and	incubated	for	2-3	min	at	37°C	and	
5%CO2.	After	the	incubation,	cells	were	harvested	using	5ml	of	sterile	RPMI-1640	10%	
FBS	 and	 pelleted	 in	 a	 sterile	 medium	 by	 centrifuging	 at	 150g	 for	 5	 min.	 The	
supernatant	 was	 discarded	 and	 cells	 were	 resuspended	 in	 10ml	 of	 fresh	 culture	
medium	prior	the	seeding	into	a	sterile	culture	flask	at	the	desired	concentration	and	
placed	 in	 the	 incubator	 at	 37°C	 and	 5%CO2.	 Routinely	 tests	were	 performed	 once	 a	
month	in	all	cell	cultures	to	check	for	mycoplasma	contamination.	
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2.2.1	Counting	cell	number	by	haemocytometer	
A	 Haemocytometer	 was	 used	 to	 determine	 the	 cell	 number	 of	 the	 cell	 suspension	
obtained	after	trypsinising	the	monolayer	of	adherent	cells	from	the	culturing	flask.	An	
aliquot	 of	 cell	 suspension	 (typically	 50μl)	 was	mixed	 with	 a	 0.4%	 (w/v)	 trypan	 blue	
solution	 (1:1)	 to	 discriminate	 between	 viable	 and	 non-viable	 cells.	 10μl	 of	 the	 cell-
trypan	blue	suspension	were	loaded	in	the	counting	chamber	of	the	haemocytometer.	
The	number	of	cells	located	on	the	four	main	squares	of	both	grids	was	counted	using	
an	 inverted	 light	microscope	as	 shown	 in	 figure	2.1.	The	average	mean	of	 the	viable	
cells	 (unstained)	counted	 in	 the	main	 four	squares	was	used	 to	calculate	 the	cellular	
concentration	(cells/ml)	of	the	suspension	of	origin.		
	
Cells	are	counted	in	the	four	principal	squares,	but	in	the	event	that	cells	are	located	on	the	borders	of	
the	square	only	two	of	its	sides	are	included	in	the	counting.	
	
2.2.2		 Storage	and	thawing	of	cells	
Cell	 lines	 were	 stored	 in	 liquid	 nitrogen	 at	 a	 temperature	 of	 -196°C	 for	 long-period	
storage	 and	 in	 a	 -80°C	 freezer	 for	 short-term	 storage.	 Prior	 to	 freezing,	 cells	 were	
quickly	washed	twice	with	PBS,	trypsinised	with	0.15%	Trypsin-EDTA	and	incubated	at	
37°C	and	5%CO2	to	allow	detachment	from	the	bottom	of	the	flask.	Cells	were	counted	
Figure	2.1	Schematic	illustration	of	Haemocytometer	
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using	 a	 haemocytometer	 and	 pelleted	 at	 150g	 for	 5	min.	 Supernatant	was	 removed	
and	a	suspension	of	1x10
6
cells/ml	was	made	in	10%	FBS	medium	supplemented	with	
10%	DMSO.	Aliquots	of	1ml	were	 transferred	 in	 cryovials,	 stored	over	night	at	 -80°C	
and	finally	placed	into	liquid	nitrogen	for	long-term	storage.		
To	 revive	 frozen	 cells,	 the	 cryovials	were	 quickly	 defrosted	 in	 a	water	 bath	 at	 37°C,	
suspended	 in	9ml	of	pre-warmed	medium	enriched	with	10%	FBS	and	centrifuged	at	
150g	 for	 5	min.	 The	 supernatant	was	 discarded	 and	 the	 cells	 pellet	 resuspended	 in	
10ml	of	fresh	medium	and	seeded	into	a	T75	flask	at	the	desired	concentration.		
2.3	Staining	of	cells	with	lipophilic	membrane	dyes		
To	trace	single	tumour	cells	within	the	bone	microenvironment	in	histological	sections	
or	 cryo-sections	of	 tissue	derived	 from	 the	 in	 vivo	 experiments	using	 two-photon	or	
fluorescence	 microscopy,	 the	 breast	 cancer	 cells	 were	 stained	 with	 the	 lipophilic	
membrane	dyes	Vybrant	DiD	and	Vybrant	CM-DiI	 (Life	Technologies	Ldt,	Paisley,	UK)	
according	to	the	supplier’s	instructions.	The	characteristic	orange	and	red	fluorescence	
labels	are	retained	in	the	lipid	bilayer	of	the	membrane	of	non-dividing	cells	cells	[24],	
[201]–[204],	while	in	dividing	cells	the	dye	is	evenly	distributed	between	the	daughter	
cells	 and	 the	 intensity	 decreases	 progressively.	 Breast	 cancer	 cells	were	 trypsinized,	
counted	and	resuspended	at	a	concentration	of	1x106	cells/ml	of	serum	free	medium	
for	Vybrant-DiD	labelling	or	Hanksʼ	balanced	salt	solution	(HBSS)	for	Vybrant-CM-DiI.	A	
volume	of	5μM	of	 labelling	dye	per	millilitre	of	cells	 suspension	was	added.	Samples	
were	protected	from	light	and	incubated	at	37°C	degree	for	20	min	(Vybrant	DiD)	or	5	
min	 followed	by	15	min	on	 ice	 (Vybrant	CM-DiI).	Cell	 suspensions	were	then	spun	at	
150g	for	5min,	the	supernatant	discarded	and	the	resulting	pellet	of	cells	resuspended	
in	PBS.	The	serial	centrifugations	and	resuspensions	were	repeated	trice.	Vybrant	DiD	
stains	the	membrane	of	the	cells	more	evenly	compared	to	Vybrant-CM-DiI	and	it	can	
be	detected	by	multiphoton	microscopy	for	100μm	depth	in	the	tissue	while	the	laser	
used	to	detect	Vybrant-CM-DiI	could	be	used	only	 for	70μm	depth.	The	drawback	of	
using	 Vybrant-DiD	 is	 that	 its	 fluorescent	 properties	 are	 lost	 during	 tissue	 fixation,	
therefore	 Vybrant-CM-DiI	 is	 recommended	 if	 the	 samples	 will	 undergo	 subsequent	
analyses	which	require	fixation	agents	such	as	PFA.		
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In	vivo	work	
2.4	Home	Office	approval		
The	Research	Ethics	Committee	of	the	University	of	Sheffield	(Sheffield,	UK)	reviewed	
and	approved	all	the	in	vivo	experiments	that	were	performed	in	conformity	with	the	
UK	 Animals	 (Scientific	 Procedures)	 Act	 1986	 under	 the	 Home	 Office	 regulations	
(Project	license	70/8964	of	Professor	Nicola	Brown	and	70/8799	of	Doctor	Colby	Eaton	
and	Personal	license	40/10823).		
2.5	Animals	
Young	 (6-week	old)	and	adult	 (12-week	old)	 female	BALB/c	nude	mice	were	ordered	
from	 Charles	 Rives	 (UK)	 and	 Envigo	 RSM	 (UK).	 Mice	 were	 housed	 in	 individually	
ventilated	cages	in	a	controlled	environment	with	a	12hrs	light/dark	cycle	at	22	°C.	
2.6	Tumour	cell	injection	
2.6.1	Intravenous	injection	
On	 the	 day	 of	 the	 injection,	 MDA-MB-231-GFP-IV	 cells	 were	 harvested	 and	 stained	
with	Vybrant-DiD	or	Vybrant-CM-DiI	as	described	in	section	2.3.		A	suspension	of	1x106	
labeled	 cells/ml	was	 prepared	 in	 PBS.	 Prior	 to	 the	 injection	 the	 cell	 suspension	was	
filtered	 using	 a	 cell	 strainer	 (70μm	 pores)	 to	 ensure	 the	 breast	 cancer	 cells	 were	
suspended	as	single	cells	and	not	clumps	that	could	cause	emboli	in	the	animal.		
Warming	the	animal	 in	 the	 incubator	prior	 to	the	 injection	facilitated	visualisation	of	
the	 tail	 veins.	 The	 mouse	 was	 placed	 in	 the	 mouse	 restrainer	 holding	 the	 tail	 in	
position	 and	 the	 injection	was	 performed	 keeping	 the	 tail	 under	 slight	 tension.	 	 An	
insulin	syringe	 (27	gauge	needle)	was	 inserted,	with	 the	bevelled	edge	of	 the	needle	
facing	up,	superficially	under	the	skin	and	horizontally	across	the	vein.	Once	the	needle	
was	placed	 in	 the	 correct	position,	 the	plunger	of	 the	 syringe	was	pressed	 slowly	 to	
inject	the	cell	suspension	(100μl).	After	the	injection,	the	needle	was	removed	slowly	
and	pressure	was	applied	to	the	area	to	ensure	haemostasis.			 	
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2.6.2	Intracardiac	injection	
Breast	 cancer	 cells	 were	 prepared	 as	 described	 for	 the	 intravenous	 injection	 (see	
section	 2.6.1).	 This	 procedure	 was	 performed	 with	 the	 mouse	 under	 general	
anaesthesia.	Isoflurane	was	vaporized	in	the	chamber	to	provide	a	5%	concentration	of	
anaesthetic	 vapour	 that	 was	 reduced	 to	 2.5-3%	 to	 maintain	 the	 animal	 asleep,	
complete	anaesthesia	was	assessed	by	the	pinch	reflex.		The	animal	was	placed	supine	
and	pressure	on	the	chest	was	applied	to	tighten	the	skin	and	allow	visualization	of	the	
bottom	of	the	sternum.	An	insulin	syringe	was	inserted	through	the	abdomen	(slightly	
lateral	 to	 the	 bottom	 extremity	 of	 the	 sternum)	 directly	 in	 the	 left	 heart	 ventricle.	
Gentle	aspiration	was	recommended	to	verify	the	correct	location	of	the	needle	in	the	
heart	 of	 the	mouse,	 bright	 red	oxygenated	blood	 is	 indication	of	 it,	 prior	 the	 slowly	
injection	of	the	cells	suspension	(100μl).	After	the	 injection,	animals	were	monitored	
closely	to	ensure	a	complete	recovery.	Animals	that	experienced	hind	 limbs	paralysis	
were	 culled	 by	 cervical	 dislocation.	 This	 technique	was	 used	 to	 inject	MDA-MB-231-
GFP-IV	 and	 MDA-MB-231-B02	 (to	 investigate	 cell	 location	 using	 different	 injection	
routes),	MDA-MB-231-NW1-Luc2,	MCF-7	and	T47D	cell	lines.		
2.6.3	Intraarterial	injection	
Breast	 cancer	 cells	 were	 prepared	 as	 described	 in	 section	 2.6.1	 and	 animals	 were	
maintained	under	general	anaesthesia	as	per	the	intracardiac	injections	(section	2.6.2).	
Dr.	Hannah	Brown	kindly	performed	the	intraarterial	injection	in	the	tail	by	restrain	the	
animal	 in	supine	position	to	better	visualise	the	arterial	vein	and	slowly	 injecting	the	
cell	 suspension	 (100μl)	 into	 the	 circulation.	 After	 the	 injection,	 animals	 were	
monitored	closely	to	ensure	a	complete	recovery	and	pressure	was	applied	to	the	area	
to	ensure	haemostasis.			 	
	 67	
2.7	Administration	of	drugs	and	other	solutions		
2.7.1	Preparation	of	drugs	
2.7.1.1	Luciferin	
D-Luciferin	 solution	 (Perkin	 Elmer,	 #	122796),	 was	 kindly	 provided	 and	 prepared	 by	
Anne	Fowles	and	Diane	Lefley	(University	of	Sheffield,	UK).	1g	of	luciferin	powder	was	
hydrated	 in	 160ml	 of	 distillated	water	 to	make	 a	 6.25mg/ml	 stock	 solution	 and	 5ml	
aliquots	were	 stored	at	 -20°C.	 Prior	 to	 the	 injection,	 the	 solution	was	defrosted	and	
100μl	 of	 the	 stock	 solution	was	 administrated	 subcutaneously	 at	 a	 concentration	 of	
30mg/kg.	
2.7.1.2	AMD3100	octahydrochloride	hydrate	
The	CXCR4	inhibitor	AMD3100	octahydrochloride	hydrate	was	supplied	as	a	white	solid	
(Sigma-Aldrich,	#155148-31-5).	The	powder	was	hydrated	with	PBS	to	prepare	a	stock	
solution	of	1mg/ml,	aliquots	were	 stored	at	 -20°C.	A	5mg/kg	AMD3100	solution	was	
prepared	from	its	stock	solution,	prior	to	intraperitoneal	injection	(i.p.)	of	a	volume	of	
100μl	PBS.	
2.7.1.3	Zoledronic	acid	(ZOL)	
The	 anti-resorptive	 Bisphosonate	 Zoledronic	 acid	 was	 provided	 as	 a	 disodium	 salt	
(Novartis).	Stock	solution	was	prepared	in	PBS	by	Alyson	Evans	(University	of	Sheffield,	
UK)	 to	 hydrate	 and	 prepare	 10mg/ml	 stock	 that	was	 aliquoted	 and	 stored	 at	 -20°C.	
Prior	to	i.p.	injection,	a	fresh	100μg/kg	solution	was	prepared	in	PBS.	
2.7.1.4	Cediranib	(AZD2171)	
The	 VEGF	 tyrosine-kinase	 inhibitor	 Cediranib	 (AZD2171)	 was	 supplied	 as	 powder	
(Selleckchem.com,	 #	 S1017),	 1%	 Tween-80	 was	 used	 to	 hydrate	 and	 prepare	 a	
50mg/ml	 stock	 solution.	 Aliquots	 were	 stored	 at	 -80°C	 and	 a	 working	 solution	 of	
3mg/kg	in	1%	Tween-80	were	prepared	for	the	daily	(5-days/week)	oral	administration	
of	the	drug.	
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2.7.1.5	Deferoxamine	mesylate	(DFM)	
Deferoxamine	mesylate	(DFM)	was	provided	as	salt	powder	(Sigma).	PBS	was	used	to	
prepare	a	50mg/ml	stock	solution,	then	aliquoted	and	stored		at	-20°C.	Daily,	prior	to	
the	i.p.	administration,	a	working	solution	of	15mg/ml	were	prepared.	
2.7.1.6	Phosphate	buffered	saline	
Phosphate	 buffered	 saline	 (PBS)	 was	 used	 in	 all	 the	 in	 vivo	 studies	 except	 for	 the	
Cediranib	study	in	which	1%	Tween-80	was	used.	Volume	(typically	100μl)	and	route	of	
injection	was	the	same	as	used	for	the	experimental	drug	in	use.		
2.7.2	Route	of	administration	
2.7.2.1	Subcutaneous	injection	
A	sterile	1ml	syringe	with	a	25-gauge	needle	was	used	to	 inject	the	 luciferin	solution	
subcutaneously	 (typically	 100μl).	 The	most	 common	 sites	 for	 s.c.	 injections	 are	 over	
the	 shoulders,	 into	 the	 loose	 skin	of	 the	neck,	 and	over	 the	 flank.	No	anaesthesia	 is	
required.				
2.7.2.2	Intraperitoneal	injection	
Mice	were	 restrained	manually	 to	 expose	 the	 abdomen	 and	 100μl	 of	 solution	were	
injected	cranial	and	slightly	medial	 to	 the	 last	nipple	of	 the	animals	with	an	angle	of	
entry	of	approximately	30	degree	using	a	25-gauge	needle.	No	anaesthesia	is	required.			
	2.7.2.3	Oral	gavage	
Mr.	 Matthew	 Fisher	 (University	 of	 Sheffield,	 UK)	 kindly	 performed	 the	 oral	 gavage	
gently	 restraining	 the	 animals	 and	 injecting	 the	 liquid	 compounds	 (typically	 200μl),	
Cediranib	or	the	control	solution,	using	a	rigid	gavage	needle.	Particular	attention	must	
be	paid	to	not	damaging	the	trachea	or	perforating	the	oesophagus	but	no	anaesthesia	
is	required.				 	
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2.8	In	vivo	detection	of	tumour	growth	
Development	 of	 tumour	 was	 monitored	 weekly	 or	 twice	 a	 week	 using	 the	 In	 vivo	
imaging	system	(IVIS)	Lumina	II	in	combination	with	the	Living	Image	software.	Animals	
were	anaesthetised	with	Isoflurane,	as	described	in	section	2.6.2,	 injected	with	100μl	
of	30mg/ml	Luciferin	solution	in	PBS	subcutaneously,	placed	into	the	imaging	chamber	
and	 the	non-invasive	 in	 vivo	 imaging	was	performed	with	animals	both	 in	 the	prone	
and	 supine	 position.	 	 The	 bioluminescent	 signal	 visualized,	 was	 overlaid	 on	 the	
photographs	of	the	animals	to	detect	the	location	of	the	growing	tumours.		
Ex	vivo	work	
2.9	Collection	of	bone	samples	
Animals	 were	 culled	 by	 i.p.	 injection	 of	 pentobarbital	 (50μl)	 followed	 by	 cervical	
disclocation.	Hind	 limbs	were	 collected,	muscle	 tissue	was	 removed	 from	 the	 bones	
and	tibias	and	femurs	were	separated.	Care	was	taken	not	to	damage	the	joint.	
2.9.1	Preparation	of	bone	samples	for	histological	analysis	
4%	(w/v)	PFA	was	prepared	dissolving	paraformaldehyde		(Sigma-Aldrich,	#	30525-89-4)	
in	pre	warmed	(55°C)	PBS	on	a	stirring	hotplate,	cooled	on	ice	and	stored	at	4°C.	Bones	
used	 for	 histology	 were	 fixed	 in	 4%	 PFA	 for	 72hrs	 followed	 by	 2	 weeks	 of	
decalcification	 in	 a	 0.5M	 EDTA/	 0.5%	 PFA	 solution	 prior	 to	 processing,	 paraffin	
embedding	 and	 cutting	 sections	 of	 3μm	 thickness.	 The	 decalcification	 solution	 was	
prepared	 by	 dissolving	 the	 EDTA	 in	 PBS,	 pH	 was	 adjusted	 with	 pellets	 of	 sodium	
hydroxile	(NaOH)	until	reach	pH8,	PFA	added	to	the	pre-warmed	(55°C)	EDTA	solution.	
The	 decal	 solution	 was	 changed	 trice	 per	 week	 and	 samples	 were	 kept	 at	 4°C	 in	
constant	 shaking	 to	 allow	 a	 uniform	 decalcification.	 	 Decalcified	 tissue	 were	 then	
embedded	 in	 paraffin	 and	 kindly	 sectioned	 by	 Alyson	 Evans	 (University	 of	 Sheffield)	
with	a	rotary	microtome	(Leica	RM2265)	at	a	thickness	of	3μm.			 	
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2.9.2	Preparation	of	bones	for	fluorescent	immunohistochemistry	
Hind	 limbs	 used	 for	 immunohistochemistry	 were	 fixed	 in	 4%	 ice-cold	 PFA	 for	 4hrs,	
incubated	 at	 4°C	 for	 24hrs	 in	 0.5M	 EDTA	 in	 PBS.	 After	 the	 incubation	 bones	 were	
immersed	 in	 ice-	 cold	 CPT	 solution	 (20%	 Sucrose	 and	 2%	 Polyvinylpyrrolidone	 (PVP)	
prepared	 in	 PBS)	 for	 at	 least	 24hrs	 at	 4°C	under	 constant	 shaking.	 Bones	were	 then	
placed	 in	 molds	 filled	 with	 embedding	 solution	 (8%	 gelatin	 from	 porcine	 skin,	 20%	
sucrose	and	2%	PVP	prepared	in	PBS)	prior	to	warming	up	at	60°C	in	a	water	bath	for	
45	min,	and	set	at	ambient	temperature	for	30	min.	The	embedded	samples	were	then	
stored	 at	 -80°C	 and	 cut	 with	 a	 cryostat	 (Microm	 HM	 560,	 ThermoScientific)	 with	 a	
thickness	of	30μm.	
2.10	Two-photon	microscopy	
2.10.1	Preparation	of	the	bone	specimen	
For	 two-photon	microscopy	analysis,	hind	 limbs	were	collected,	 snap	 frozen	 in	 liquid	
nitrogen,	 tibias	 and	 femurs	 were	 embedded	 into	 the	 embedding	 medium	 for	
cryopreservation	Bright	Cryo-M-Bed	(Bright	Instrument,	#	B1056),	left	fibula	facing	the	
left	side	of	the	modules	and	the	opposite	direction	for	the	right	limb,	and	stored	at	-
80°C.		
After	complete	freezing	of	the	embedded	tissue	blocks,	the	bone	marrow	was	exposed	
using	 a	 Bright	 OTF	 Cryostat	 with	 a	 3020	 microtome	 (Bright	 Instrument	 Co.	 Ltd,	
Huntingdon,	UK).	 The	 blade	 of	 the	 cryostat	was	 regularly	 sharpened	 at	 a	 45	 degree	
angle	with	 a	 Shandon	Autosharp	5	 knife	 sharpener	 (Labequip)	 and	 the	 cutting	 angle	
was	adjusted	at	22	degrees	to	obtain	an	even	surface,	necessary	for	optimal	imaging	of	
the	specimen.		
The	exposed	surface	of	the	bone	was	placed	onto	a	glass	bottomed	dish	and	to	avoid	
the	tissue	moving	during	the	scan	a	cover	slip	was	applied.	The	dish	was	subsequently	
placed	 upside	 down	 onto	 a	 microscope	 slide	 presenting	 the	 bone	 surface	 upwards	
towards	the	upright	two-photon	microscope	(Zeiss	LSM510	NLO,	Carl	Zeiss,	Cambridge,	
UK),	see	figure	2.2.	
	 71	
2.10.2	Imaging	the	bone	
A	Chameleon	 laser	 at	 900nm	 (Coherent,	 Santa	Clara,	 CA.)	was	used	 to	 generate	 the	
second	 harmonic	 generation	 to	 detect	 the	 calcified	 bone	 structure.	 To	 visualize	 the	
breast	 cancer	 cells	 homing	 in	 the	 bone	marrow	 HeNe	 lasers	 were	 used,	 633nm	 for	
Vybrant-DiD	 labeled	 cells	 and	 543nm	 for	 Vybrant-CM-DiL	 labeled	 cells.	 The	 filters	
detecting	the	signal	from	the	900nm,	633nm	and	543nm	lasers	were	BP390-465	(blue),	
BP	650–710	(far	red)	and	BP	565–615	(orange/red)	respectively.		
The	 specimen	 was	 visualized	 and	 focused	 using	 transmitted	 light,	 prior	 to	 scanning	
with	 the	 two-photon	 microscope.	 For	 the	 preliminary	 visualisation	 of	 the	 bone	
structure	using	the	Chameleon	laser	at	maximum	speed,	the	frame	size	was	set	at	256	
with	a	mean	pixel	depth	of	1.	The	brightest	level	was	set	as	the	middle	of	the	z	stack	
and	the	focus	was	then	moved	upwards	and	downwards	to	find	the	upper	and	bottom	
layer	of	the	tissue	to	scan.	The	depth	of	the	scan	was	70μm	with	an	 interval	of	2μm	
between	different	levels	and	it	was	determined	by	the	weaker	laser	used,	the	543nm	
HeNe	laser.	To	image	the	exposed	bone	marrow	area,	the	growth	plate	and	trabecular	
region,	a	stack	area	of	2104μm	x	2525μm	was	set	and	the	frame	was	changed	to	512,	
mean	 pixel	 depth	 to	 4	 and	 the	 scan	 was	 performed	 using	Multi	 Time	 Series	 (MTS)	
software	[25].	
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(A)	Tibia	embedded	in	Bright	Cryo-M-Bed	and	bone	marrow	exposed	using	a	Bright	OTF	Cryostat	with	a	
3020	microtome.	 (B)	 Specimen	with	 the	exposed	marrow	 surface	 facing	downwards	placed	 in	 a	 glass	
bottom	dish	held	in	place	with	a	cover	slip	as	indicated	in	the	schematic	illustration.	(C)	Using	an	upright	
miscroscope	 the	 dish	 is	 placed	 facing	 upwards	 and	 onto	 a	 microscopy	 slide	 which	 positions	 the	
specimen.	Reprinted	with	permission	of	SpringerNature:	BoneKey	[25].	 	
Figure	2.2	Preparation	of	the	specimen	for	two-photon	microscopy	
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2.10.3	3D	reconstruction	and	analysis	of	the	location	of	tumour	cells	within	bone		
Volocity	 3D	 Image	 Analysis	 Software	 (PerkinElmer,	 Cambridge,	 UK)	 was	 used	 to	
reconstruct	 a	 three-dimensional	 image	 of	 the	 tissue	 scanned	 with	 the	 two-photon	
microscope.	 The	 bone	 signal	 was	 pseudo-coloured	 in	 white	 to	 accentuate	 the	 3D	
structure	and	 the	 signal	 from	 the	HeNe	543nm	 laser	was	pseudocoloured	 in	blue	 to	
enhance	the	contrast	with	the	signal	produced	by	the	633nm	laser.		
A	threshold	of	250μm3	was	fixed	to	discriminate	between	objectives	detected	with	the	
633nm	and	543	HeNe	laser	considered	to	be	Vybrant-DiD	and	Vybrant-CM-DiI	labelled	
breast	 cancer	 cells	 and	 background	 noise.	 The	 number	 of	 positive	 events	 detected	
from	both	lasers	were	counted	and	their	distance	to	the	nearest	bone	surface	and	the	
nearest	 tumour	 cell	 was	 measured	 in	 two	 different	 regions	 of	 interest	 (ROI),	 the	
growth	plate	and	the	trabecular	region	of	the	bone	marrow	(figure	2.3).		 	
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The	ROIs	taken	into	consideration	are	shown	in	(A),	ROI1	is	the	trabecular	region	of	bone	while	ROI2	is	
the	growth	plate	area.	Cortical	bone	was	excluded	by	the	analysis.	 (B)	Distance	of	 tumour	cells	 to	the	
nearest	bone	surface	and	(C)	nearest	tumour	cell.	
Figure	2.3	Schematic	illustration	of	the	analysis	of	the	location	of	tumour	cells	within	the	bone	marrow	
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2.11	Micro	computed	tomography	(μCT)	
To	 detect	 changes	 in	 the	 calcified	 bone	 structure	 such	 as	 the	 ratio	 of	 bone	
volume/trabecular	 volume	 (BV/TV),	 trabecular	 thickness	 (Tb.	 Th.)	 and	 trabecular	
number	 (Tb.	 N.),	 tibias	 were	 scanned	 within	 the	 fixation	 time	 in	 4%	 PFA	 prior	 to	
decalcification	 (48hr	 time	frame	for	samples	 to	be	embedded	 in	paraffin	and	4hr	 for	
tissue	 to	 be	 embedded	 in	 gelatin).	 Bones	 were	 scanned	 using	 the	 SkyScan	 1272	
(Bruker),	200mA	currency,	51kV,	a	0.5	aluminium	filter,	a	medium	resolution	camera	of	
2016	x	1344	and	the	pixels	size	was	set	at	4.3μm.	Images	obtained	from	the	SkyScan	
were	reconstructed	with	NRecon	software.	CTAn	software	was	used	to	determine	the	
volume	of	 interest	 (VOI)	by	manually	drawing	on	 the	 two-dimensional	 reconstructed	
images.	A	 reference	 line	was	set	at	 the	 lower	part	of	 the	growth	plate	and	 from	the	
reference	 point	 an	 offset	 of	 0.5mm	was	 fixed.	 For	 each	 bone	 a	 length	 of	 1mm	was	
analyzed	 for	 different	 bone	 parameters:	 trabecular	 bone	 volume	 (express	 as	 bone	
volume	 per	 tissue	 volume,	 BV/TV	 in	 %),	 trabecular	 number	 (Tb.N	 in	 mm-1)	 and	
trabecular	thickness	(Tb.	Th.	in	mm)(figure	2.4).	
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Example	µCT	 image	(A).	Panel	B	represents	the	reference	point	 (red	 line)	and	respective	cross	section	
showing	the	break	of	the	growth	plate	bridge	(white	arrow	in	A),	offset	of	0.5mm	(red	vertical	line)	and	
area	of	analysis	of	1mm	(vertical	black	line).	
Figure	2.4	Illustration	of	the	μCT	reference	point	
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2.12	Staining	of	bone	components	
A	 variety	 of	 staining	 procedures	 were	 used	 to	 determine	 different	 cell	 types	 and	
structures	 on	 the	 histological	 sections	 (3μm)	 of	 paraffin	 embedded	 bones.	 All	 these	
techniques	 were	 performed	 accordingly	 to	 the	 standard	 operating	 procedures	
developed	by	the	Bone	Analysis	Laboratory,	University	of	Sheffield.	
2.12.1	Dewaxing	and	dehydrating	of	paraffin	embedded	bones	
The	histological	sections	of	paraffin	embedded	bones	were	dewaxed	in	xylene	(2x5min)	
and	rehydrated	through	decreasing	concentration	of	alcohols	 (99%,	95%,	70%,	3	min	
each)	 to	 tap	 water.	 Prior	 to	 mounting	 and	 cover	 slipping	 with	 DPX	 [(distryrene),	
plasticiser	 (tricresyl	 phosphate)	 and	 xylene]	 mounting	 medium,	 the	 slides	 were	
dehydrated	through	70%,	95%	and	99%	alcohol	to	xylene.		
2.12.2	Haematoxylin	and	Eosin	(H&E)	staining					
This	 protocol	 was	 used	 to	 visualize	 different	 structures,	 by	 the	 staining	 of	 the	 cell	
nuclei	 in	 blue	 (haemotoxylin)	 and	 pink	 coloration	 (eosin)	 of	 the	 cytoplasm	 and	
connective	tissue.		
Rehydrated	 slides	 were	 incubated	 in	 Gill’s	 Haematoxylin	 solution	 (VWR)	 for	 2	 min	
followed	by	a	washing	step	in	running	water	for	5	min.	Samples	were	then	incubated	in	
1%	 eosin	 solution	 for	 5	min	 prior	 to	washing	 in	 running	 tap	water	 until	 completely	
clear.	Histological	sections	were	next	dehydrated	and	the	cover	slip	was	mounted	as	
described	in	section	2.12	(figure	2.5).	
2.12.3	Masson-Goldner	trichrome	staining	
Masson-Goldner	 trichrome	 staining	 is	 a	 histological	 technique	 that	 allows	 clear	
discrimination	between	different	tissue	components.	Tissue	stained	with	this	particular	
method	 show	 nuclei	 stained	 in	 dark	 brown,	 cytoplasm	 and	 muscle	 in	 brick	 red,	
connective	tissue	and	bone	matrix	in	green	and	erythrocytes	in	bright	orange.		
The	 Masson	 Goldner	 staining	 kit	 (Merck	 KGaA,	 Darmstadt,	 Germany)	 was	 used	
according	 to	 the	manufacturer’s	 instruction.	 Briefly,	 rehydrated	 bone	 sections	 were	
incubated	at	ambient	temperature	for	5	min	with	Weigert’s	hematoxylin	(Solution	A:		1%	
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Heatoxylin	in	95%	alcohol,	Solution	B:		29%	Ferric	chloride	in	dH2O/concentrated	HCl;	
1:1),	washed	 for	 5	min	under	 running	 tap	water	 and	 rinsed	 in	 1%	acetic	 acid	 for	 30	
seconds.	Azophloxine	solution		was	added	onto	the	tissue	slides	for	10	min	followed	by	
another	 30	 seconds	 rinse	 in	 1%	 acetic	 acid.	 Prior	 to	 a	 third	 rinse	 in	 1%	 acetic	 acid,	
samples	were	 incubated	for	1	min	 in	Tungstophosphoric	acid	Orange	G	solution.	The	
final	 solution	 added	 to	 the	 samples	was	 Light	 green	 solution,	 and	 following	 a	 2	min	
incubation,	1%	acetic	acid	was	used	to	rinse.	Specimens	were	finally	dehydrated	and	
mounted	(figure	2.5).	
2.12.4	Toluidine	Blue	staining	
Toluidine	 Blue	 is	 a	 metachromatic	 dye	 that	 is	 highly	 acidophilic,	 used	 to	 stain	 acid	
proteoglycan,	 and	 to	 identify	 changes	 in	 the	 growth	 plate	 cartilage	 of	 tibiae	
histological	sections.	
Dewaxed	and	hydrated	bone	slides	were	incubated	for	3min	at	ambient	temperature	
in	 toluidine	 blue	 solution	 (Toluidine	 Blue	 O,	 Sigma	 Aldrich:	 1%	 NaCl	 pH	 2.0-2.5),	
followed	by	rinsing	under	running	water,	dehydration	and	cover	slipping	(figure	2.5).	
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Histological	 sections	of	 tibia	were	 stained	with	H&E	 staining	 (A),	Glodner’s	 trichrome	 staining	 (B)	 and	
Toluidine	Blue	staining	(C).	The	top	panel	shows	images	took	with	a	4x	objective	(scale	bar	200μm)	while	
in	the	bottom	panel	are	images	took	with	a	20x	objective	(scale	bar	50μm).	GP=growth	plate,	BM=bone	
marrow.		
	 	
Figure	2.5	Histological	sections	showing	tibial	structures		
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2.13	Immunoflourescence	
Immunofluorescence	 staining	 protocols	 to	 identify	 components	 of	 the	 perivascular	
niche	were	performed	on	30μm	thick	frozen	section	of	tibiae	and	femurs	embedded	in	
gelatin.	The	tissues	were	prepared	using	the	protocol	described	by	Dr.	A	Kusumbe	[97]	
and	briefly	summarized	in	section	2.9.3.	
2.13.1	Visualization	of	bone	microvasculature	on	gelatin	embedded	sections	
To	visualize	the	bone	marrow	vasculature,	with	the	help	of	Dr.	R	Hughes	(University	of	
Sheffield,	 UK)	 I	 adapted	 the	 protocol	 kindly	 provided	 by	 Dr.	 A	 Kusumbe,	 Kennedy	
Institute	of	Rheumatology,	University	of	Oxford	(Oxford,	UK).	Protocols	optimisations	
consisted	 in	testing	different	concentrations	(1:300,	1:200,	1:100,	1:50	and	1:25)	and	
incubation	 times	 (1h,	2h	or	overnight	at	 room	 temperature	and	overnight	at	4°C)	of	
several	 clones	of	 antibodies,	 antibodies	 selected	 for	 these	protocols	 are	 in	 table	 2.6	
and	2.7.		
The	 immunofluorescence	 staining	 was	 performed	 on	 30μm	 thick	 sections	 of	 frozen	
tibiae	and	femurs.	The	slides	were	left	to	defrost	at	ambient	temperature	followed	by	
permeabilisation	 in	 0.3%	 Triton	 X-100	 for	 20	min.	 After	 the	 incubation,	 tissue	were	
rinsed	3	 times	 in	PBS	 followed	by	 incubation	with	 the	primary	antibody	 (prepared	 in	
PBS,	 table	 2.6)	 against	 endothelial	 marker	 Endomucin	 and	 α-SMA	 for	 1h	 at	 room	
temperature	or	overnight	at	4°C.	For	markers	against	CD31,	CD34,	TSP-1	and	Osterix	
the	 incubation	 was	 performed	 either	 overnight	 at	 ambient	 temperature	 or	
amplification	of	the	signal	blocking	for	15	min	at	room	temperature	with	Streptavidin	
solution	 (Streptavidin/Biotin	Blocking	Kit	 –	Vector	 Laboratories	 SP-2002)	 followed	by	
15	 min	 at	 ambient	 temperature	 with	 Biotin	 solution,	 preceded	 by	 1h	 at	 ambient	
temperature.		
Three	washes	with	PBS	were	performed	and	the	bone	slides	were	then	incubated	with	
the	appropriate	secondary	antibody	for	1h	at	ambient	temperature.	Samples	treated	
with	 the	Avidin/Biotin	 Blocking	 Kit	were	 incubated	with	 biotinylated	 secondary	 	 	 for	
40min	 at	 ambient	 temperature	 followed	 by	 three	washes	 in	 PBS	 and	 incubation	 for	
30min	 with	 the	 fluorophore-conjugated	 streptavidin	 (table2.7).	 Incubation	 with	 the	
secondary	 antibody	 was	 followed	 by	 3	 washes	 with	 PBS	 and	 nuclei	 were	
	 81	
counterstained	with	DAPI		(Prolong	Gold	antifade	reagent	with	DAPI,	Life	Technologies	
P36935)	and	coverslips	were	mounted.	
	
Table	2.6	Primary	antibodies	used	for	staining	components	of	the	perivascular	niche	
MOLECULE	 SUPPLIER	(CAT.	NUMBER)	 DILUTION	
CD31	(rat	anti-mouse)	 DIA-310	(Clone:	SZ31)	 1:100	
CD34	(rat	anti-mouse)	 BioRad	(MCA1825)	 1:100	
ENDOMUCIN	(rat	anti-mouse)	 Santa	Cruz	(Sc65495)	 1:100	
α-SMA	(rabbit	anti-mouse)	 Abcam	(Ab5694)	 1:100	
TSP-1	(rabbit	anti-mouse)	 Abcam	(Ab85762)	 1:100	
OSTERIX	(rabbit	anti-mouse)	 Abcam	(Ab22552)	 1:300	
	
	
Table	2.7	Secondary	antibodies	used	used	for	staining	components	of	the	perivascular	niche	
MOLECULE	 SUPPLIER	(CAT.	NUMBER)	 DILUTION	
Alexa	fluor	488	(goat	anti-rat)	 ThermoFisher	(A11006)	 1:200	
Alexa	fluor	555	(goat	anti-rat)	 ThermoFisher	(A21434)	 1:200	
Alexa	fluor	647	(goat	anti-rat)	 ThermoFisher	(A21247)	 1:200	
Alexa	fluor	488	(goat	anti-rabbit)		 ThermoFisher	(A11034)	 1:200	
Alexa	fluor	555	(goat	anti-rabbit)	 ThermoFisher	(A21245)	 1:200	
*Biotinylated	goat	anti-rabbit	 Vector	Laboratories	(BA1000)	 1:200	
*Biotinylated	goat	anti-rat	 Vector	Laboratories	(BA9401)	 1:200	
*Streptavidin	Alexa	fluor	647	 ThermoFisher	(AF647)	 1:200	
*Antibodies	used	when	the	samples	were	treated	with	the	Streptavidin/Biotin	Blocking	Kit	
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2.14	Scoring	of	histological	slides	
Bone	 histomorphometric	 analyses	 were	 performed	 on	 two	 non-serial	 3μm	 paraffin	
sections	 and	 cortical	 bone	 was	 excluded	 from	 any	 analysis.	 Quantification	 of	 the	
immunofluorescent	 staining	 was	 carried	 out	 on	 three	 non-serial	 30μm	 gelatin	
embedded	bone	slides.	
2.14.1	Quantification	of	extracellular	matrix	composition	
To	 identify	 any	 changes	 in	 the	 epiphysis	 of	 the	 bone,	 a	 proteoglycan-rich	 area,	
histological	slides	were	stained	with	Toluidine	blue	as	described	in	section	2.12.5.	The	
area	of	 interest	(AOI)	 included	the	proteoglycan-rich	growth	plate	and	the	trabecular	
bone	 surface	 connected	 with	 the	 epiphysis,	 and	 manually	 identified	 using	 Aperio	
ImageScope	software	(figure	2.6).	
	
	
The	extracellular	matrix	 rich	 in	proteoglycan	 included	using	Aperio	 ImageScope	 software.	 The	area	of	
interest	(green	line)	covered	the	growth	plate	area	and	the	trabecular	bone	connected	to	it.	All	cortical	
bone	and	trabecular	bone	not	in	contact	with	the	proteoglycan-rich	area	(black	arrows)	were	excluded	
from	the	analysis.	
Figure	2.6	Area	of	interest	quantified	with	Toluidine	Blue	staining	
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2.14.2	Quantification	of	Endomucin	positive	vessels	
Images	 of	 the	 immunofluorescent	 staining	 were	 captured	 using	 an	 inverted	
fluorescence	 microscope	 (Leica	 AF6000).	 Aperio	 ImageScope	 software	 was	 used	 to	
manually	 track	Endomucin	positive	microvessels	and	determine	their	 length,	number	
and	 area	 of	 bone	 marrow	 occupied.	 The	 structure	 of	 the	 vessels	 was	 used	 to	
discriminate	between	H-	and	L-vessels	(figure	2.7).	
	
Image	of	the	stained	30μm	thick	gelatin	embedded	bones	were	captured	with	a	Leica	AF	6000	and	a	5x	
objective	 (left	 picture).	 Using	 Aperio	 ImageScope	 software	 the	 Endomucin	 positive	 vessels	 were	
manually	 identified.	 The	 parameters	 quantified	 included:	 (i)	 bone	marrow	 area	 analysed	 (green),	 (ii)	
area	 of	 bone	 marrow	 covered	 by	 H-vessels,	 (iii)	 their	 length	 and	 (iv)	 number	 (yellow)	 and	 (v)	 bone	
marrow	 area	 occupied	 by	 L-vessels	 as	 well	 as	 their	 number	 and	 length	 (blue).	 GP=growth	 plate	 and	
BM=bone	marrow.	
	 	
Figure	2.7	Endomucin	positive	vessel	quantification	
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2.14.3	Quantification	of	CD31	and	CD34	positive	vessels	
Images	of	the	immunofluorescent	staining	were	captured	using	Zeiss	LSM880	AiryScan	
Confocal	 microscope	 and	 ImageJ	 software	 was	 used	 to	 measure	 the	 expression	 of	
CD31	 and	 CD34	markers.	 The	 region	 of	 interest	 of	 the	 bone	marrow	was	manually	
identified	 and	 the	 signal	 outside	 of	 this	 ROI	 was	 removed.	 The	 vessel	 channel	 was	
transformed	 into	 a	 grey	 scale	 colour	 and	 a	 look-up-table	 (LUT)	 that	 transforms	
brightness	into	number	value	was	applied.	The	LUT	values	were	then	inverted	and	the	
threshold	was	set	so	only	the	pixels	with	the	maximum	signal	were	count	(figure	2.8).	
The	results	were	expressed	as	percentage	of	area	expressing	the	specific	marker.	Since	
CD31	 and	 CD34	 are	 also	 expressed	 also	 on	 Endomucin	 positive	 vessels,	 also	 the	
percentage	of	Endomucin+/CD31+	or	CD34+	were	measured	
Aperio	 ImageScope	 software	 was	 used	 to	 manually	 track	 CD31/CD34	 positive	
microvessels	and	determine	their	length,	number	and	area	of	bone	marrow	occupied,	
as	described	for	the	Endomucin	vessels.		
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(A)	ROI	was	manually	drawn	around	the	bone	marrow	(red	line)	and	the	outside	signal	was	removed	(B).	
The	vessel	channel	(C)	was	transformed	in	LUT	value	using	ImageJ	software	(D)	and	the	inverted	LUT	(E)	
were	quantified.	The	vessels	were	then	manually	drawn	with	Aperio	ImageScope	software	to	measure	
their	number	and	length.	
Figure	2.8	Schematic	illustration	of	quantification	of	CD31/CD34	positive	vessels	
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2.14.4	 Quantification	 of	 α-SMA,	 TSP-1	 and	 Osterix	 expression	 in	 the	 bone	
microenvironment	
Zeiss	LSM880	AiryScan	confocal	microscope	was	used	to	capture	the	images	of	30µm	
thick	gelatin	 sections	of	 tibiae	 stained	against	Osterix,	α-SMA	or	TSP-1.	As	described	
for	 the	CD31/CD34	vessels,	 the	quantification	was	performed	using	 ImageJ	software.	
ROIs	were	drawn,	outside	signal	removed	and	inverted	LUT	were	quantified	following	
the	setting	of	a	threshold.		
The	 ‘cell	 counter’	 function	 of	 the	 software	 was	 also	 used	 to	 manually	 count	 the	
number	of	α-SMA	positive	vessels	or	TSP-1	positive	megakaryocytes.	
For	 the	 much	 more	 abundant	 Osterix	 positive	 cells,	 the	 function	 ‘cell	 counter’	 was	
used	to	manually	quantify	a	few	slides	and	the	numbers	obtained	were	then	compared	
with	the	ones	produced	by	the	automatic	function	‘3D	object	counter’,	since	there	was	
a	 high	 correlation	 between	 the	 two	 values	 obtain	 all	 the	 other	 tissue	 sections	were	
analysed	using	the	automatic	function.	
2.15	Statistical	analysis	
GraphPad	 Prism	 software	 (Version	 7.0)	 was	 used	 to	 perform	 statistical	 analysis.	
Student	 T-tests	 and	 Two-way	 ANOVA	 were	 used	 as	 indicated	 in	 the	 Materials	 and	
Methods	section	of	each	results	chapter	as	well	as	in	each	figure	legend.	A	p-value	of	
p<0.5	was	considered	significant.	
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Chapter	3 	
Homing	of	breast	cancer	cells	in	the	bone	
microenvironment	
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3.1	Summary	
Bone	metastasis	is	one	of	the	most	common	complications	of	advanced	breast	cancer	
and	 is	 associated	with	 a	 considerable	 reduction	 in	 the	 quality	 of	 life	 of	 the	 patient.	
During	the	dissemination	to	the	skeleton,	breast	cancer	cells	detach	from	the	primary	
site,	enter	the	circulation	and	home	to	a	putative	metastatic	niche	in	the	bone	marrow	
where	 they	 can	 remain	 dormant	 for	 a	 considerable	 length	 of	 time.	 The	 cellular	
composition	 of	 this	 niche	 is	 not	 clearly	 defined,	 but	 there	 is	 evidence	 showing	 an	
overlap	 between	 the	 bone	 metastatic,	 perivascular	 and	 haematopoietic	 stem	 cell	
niches.	 The	 interaction	 and	 the	 signals	 from	 the	 bone	 microenvironment	 to	 the	
tumour	cells	and	vice-versa	are	crucial	 for	 the	progression	of	secondary	disease.	 It	 is	
known	that	the	components	of	 the	niche	have	a	key	role	 in	homing,	maintenance	of	
the	quiescence	state	and	progression	of	tumour	growth	in	bone,	but	the	mechanisms	
that	 enable	 tumour	 cells	 to	 undergo	 these	 processes	 and	 develop	 overt	metastases	
have	 not	 been	 fully	 elucidated.	 The	 identification	 of	 the	 specific	 components	 of	 the	
niche	 would	 give	 a	 better	 understanding	 of	 the	 cellular	 types	 involved	 in	 the	
metastatic	 process	 at	 its	 early	 stages	 and	 consequently	 improve	 the	 therapeutic	
approaches	for	patients	with	a	poor	prognosis.		
The	aim	of	the	work	described	in	chapter	3	to	identify	the	pattern	of	location	of	breast	
cancer	cells	within	the	microenvironment	in	the	early	stage	of	bone	colonisation,	and	
investigate	the	effect	of	modification	of	the	bone	niche	on	the	homing	of	tumour	cells	
using	an	in	vivo	model.	
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3.2	Introduction	
Bone	metastasis	is	one	of	the	most	common	complications	of	advanced	breast	cancer	
and	 is	 associated	with	 a	 considerable	 reduction	 in	 the	 quality	 of	 life	 of	 the	 patient.	
Moreover,	 despite	 the	 improvement	 in	 the	 therapy	 it	 remains	 the	 major	 cause	 of	
female	 cancer	 related	 death	 [2],	 [205],	 [206].	 Hypercalcemia,	 pathological	 fractures,	
spinal	 cord	 compression	 and	 pain	 are	 some	 of	 the	 complications	 related	 to	 skeletal	
metastasis	[5].			
The	development	of	metastasis	in	secondary	organs	is	a	multistep	process	that	begins	
with	the	detachment	of	the	cancer	cells	 from	the	primary	tumour	and	entry	 into	the	
blood	 stream,	 cells	 traveling	 through	 the	 circulation	 to	 reach	 bone	 where	 they	
integrate	 into	specific	niches	and	may	remain	dormant	 for	 long	periods	of	 time	[14],	
[205],	 [207],[208].	 Not	 all	 cells	 detached	 from	 the	 primary	 tumour	 will	 successfully	
seed	 in	 the	 distant	 organ	 resulting	 in	 overt	 metastasis,	 in	 fact	 these	 disseminated	
tumour	cells	(DTCs)	can	face	several	fates,	including	death	by	apoptosis	or	elimination	
by	the	immune	system,	return	to	the	circulation	or	entering	a	quiescent	state	[7]–[10],	
[20],	[209],	[210].		When	the	malignant	cells	switch	to	a	proliferative	state	they	start	to	
grow	quickly,	generating	the	metastases	and	eventually	cause	bone	destruction	[16].	
The	mechanism/s	triggering	breast	cancer	cells	to	leave	the	dormant	state	is	not	fully	
understood,	 but	 the	 role	 of	 the	 bone	microenvironment	malignant	 progression	 is	 a	
well-recognized	concept	firstly	proposed	in	the	‘seed-and-soil’	hypothesis	by	Stephen	
Paget	 in	 1889	 [11].	Another	 example	of	 how	breast	 cancer	 cells	 and	 various	 cellular	
components	 of	 the	 bone	 microenvironment	 interact	 is	 the	 ‘vicious	 cycle’	 created	
between	osteoclasts	 and	 tumour	 cells	which	 describes	 how	 the	 release	 of	 cytokines	
and	growth	factors	aid	the	progression	of	the	bone	metastasis	[9],	[12],	[13],	[15].	Not	
only	 does	 the	 microenvironment	 influence	 the	 growth	 of	 tumour	 cells,	 Cox	 et	 al.	
recently	 described	 how	 cancer	 cells	 secrete	 factors	 that	 can	 create	 pre-metastatic	
lesions	which	will	support	the	colonisation	of	this	niche	by	DTCs	[47].	Even	thought	it	is	
a	well-accepted	concept	that	the	microenvironment	plays	an	important	role	in	all	the	
stages	of	bone	metastasis,	the	precise	nature	and	composition	of	the	metastatic	niche	
is	not	well	defined.	
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The	 bone	 microenvironment	 where	 the	 metastatic	 process	 takes	 place,	 is	
characterized	 by	 the	 presence	 of	 cytokines,	 hormones	 and	 other	 soluble	 factors	
produced	by	the	different	sub-populations	of	the	bone	marrow,	which	all	influence	the	
development	 of	 the	 metastasis	 in	 this	 fertile	 soil.	 Numerous	 cell	 types,	 including	
osteoclasts,	 osteoblasts,	 endothelial	 cells	 and	 hematopoietic	 cells,	 contribute	 to	 the	
complexity	of	this	rich	microenvironment	which	forms	the	bone	metastatic	niche	[15],	
[40],	[211].	It	has	been	suggested	that	this	rich	soil	where	tumour	cells	seed,	is	located	
in	 regions	 of	 the	 bone	marrow	 in	which	 components	 of	 the	HSC	 niche,	 osteoblastic	
niche	and	perivascular	niche	are	overlapping	[34],	[39]–[41].	Supporting	the	hypothesis	
of	 an	 overlap	 between	 niches,	 Shiozawa	 and	 colleagues	 described	 a	 competition	
between	HSCs	and	prostate	cancer	cells,	for	the	space	in	bone,	suggesting	that	tumour	
cells	home	to	the	HSC	niche	[28],	[36].	Although	it	is	believed	that	prostate	and	breast	
cancer	 cells	 locate	 in	 the	 same	 niches,	 it	 remains	 to	 be	 established	whether	 breast	
cancer	 cells	 compete	 for	 the	 space	 in	 the	niche	as	previously	described	 for	prostate	
cancer.	 The	 interrelationship	 between	 niches	 and	 the	 role	 played	 by	 multiple	
components	of	the	bone	microenvironment	is	also	highlighted	by	the	fact	that	the	HCS	
niche	is	located	in	close	proximity	to	the	endosteal	surface	of	the	trabecular	bone,	an	
area	 that	 is	 highly	 vascularized	 [34],	 [55],	 [97],	 [212],	 [213].	 In	 vivo	 model	 studies	
showed	that	tumour	cells,	in	particular	breast	and	prostate	cancer	cells,	locate	into	the	
endosteal	region	of	bone,	the	area	in	which	HSC	are	also	located	[26],	[36],	[48],	[118],	
[148],	 additional	 validation	 that	 this	 rich	 microenvironment	 	 accommodates	 the	
putative	metastatic	niche.		
To	date,	most	studies	have	focused	on	advanced	stages	of	disease	where	the	micro-	or	
macro-metastases	 are	 already	 established,	 with	 only	 little	 information	 on	 the	 early	
stages	of	the	breast	cancer	bone	colonisation	when	tumour	cells	are	still	in	a	dormant	
state	 within	 the	 bone	 marrow.	 Although	 the	 focus	 of	 intensive	 research,	 the	
mechanisms	 initiating	 the	 metastatic	 process	 are	 not	 fully	 understood	 [214],	 and	
cannot	be	studied	 in	patients.	This	highlights	 the	need	for	 in	vivo	models	 that	mimic	
the	 early	 steps	 of	 cancer	 cell	 dissemination	 in	 bone.	 The	 introduction	 of	 novel	
technologies	 such	 as	 two-photon	microscopy	 and	 the	 use	 of	 lipophilic	 dyes	 that	 are	
retained	in	non-proliferating	(tumour)	cells,	it	has	made	research	on	the	initial	stages	
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of	 the	 metastatic	 process	 possible.	 Combining	 these	 approaches	 has	 allowed	 the	
mapping	of	the	location	of	single	breast	cancer	cells	(or	small	colonies)	within	the	bone,	
investigate	their	interaction	within	the	calcified	structure	and	observe	how	changes	in	
the	bone	cell	population,	affects	the	homing	of	tumour	cells	to	bone	[25],	[215].		
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3.3	Aims	
All	 work	 described	 in	 this	 chapter	 was	 carried	 out	 in	 in	 vivo	 models	 to	 test	 the	
following	hypothesis:	
Breast	 cancer	 cells	 home	 to	 a	 specific	 region	of	 bone	 in	which	HSC,	 osteoblastic	 and	
perivascular	niche	overlap.	
The	main	aims	were	as	follows:	
• To	map	the	location	of	breast	cancer	cells	within	the	bone	microenvironment	in	
the	early	stages	of	bone	colonisation	
• To	 assess	 whether	 there	 were	 difference	 in	 the	 homing	 of	 different	 breast	
cancer	cell-lines,	both	ER	positive	and	ER	negative	
• To	 investigate	 whether	 the	 seeding	 of	 tumour	 cells	 in	 the	 bone	
microenvironment	was	influenced	by	the	route	of	injection	
• To	 compare	 the	 homing	 of	 breast	 cancer	 cells	 to	 bone	 in	 young	 and	mature	
murine	models	
• To	 determine	 how	 modification	 of	 the	 bone	 microenvironment	 affects	 the	
seeding	of	breast	cancer	cells.			
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3.4	Materials	and	Methods	
Detailed	information	can	be	found	in	the	main	Materials	and	Methods	Chapter	2.	
3.4.1	Breast	cancer	cell-lines	
Triple	negative	breast	cancer	cells	MDA-MB-231-GFP-IV	[198]	and	MDA-MB-231/B02-
GFP	cells	 [129]	[kindly	provided	by	Dr.	Philippe	Clezardin	(INSERM,	UFR	de	Médecine	
Lyon-Est,	Lyon,	France	and	University	of	Sheffield,	UK)]	and	ER+ve	breast	cancer	cell-
lines	 MCF-7	 and	 T47D	 were	 cultured	 in	 RPMI	 1640	 enriched	 with	 10%	 FCS	 (Life	
Technologies/Invitrogen)	 at	 37°C	 5%CO2.	 Prior	 to	 the	 injections,	 tumour	 cells	 were	
labeled	either	with	the	 lipophilic	membrane	dye	Vybrant-CM-DiI	or	Vybrant-DiD	(Life	
Technologies	Ldt,	Paisley,	UK)	according	to	the	manufacturer’s	instructions.		
3.4.2	In	vivo	studies	
All	 the	 in	vivo	experiment	were	approved	and	carried	out	 in	accordance	with	the	UK	
Animals	 (Scientific	 Procedures)	Act	 1986	under	 the	Home	Office	 regulations	 (Project	
license	40/35319	held	by	Professor	Nicola	Brown	and	70/8799	held	by	Doctor	Colby	
Eaton	and	Personal	license	40/10823).		
3.4.2.1	Homing	of	breast	cancer	cells	in	mature	animal	models	
To	 evaluate	 the	 homing	 of	 the	 bone-seeking	 breast	 cancer	 cell-line,	 12-week	 old	
female	BALB/c	nude	mice	were	 injected	with	 i.v.	100μl	of	PBS	and	on	day	7	with	 i.v.	
1x105	MDA-MB-231-GFP-IV	 cells	 labeled	either	with	 the	membrane	dye	Vybrant-CM-
DiI	 (n=6)	 or	 Vybrant-DiD	 (n=3,	 due	 to	 technical	 problems	 in	 the	 processing	 of	 the	
samples	 the	 size	 of	 the	 group	 was	 reduced	 to	 n=2).	 Animals	 were	 culled	 and	 long	
bones	collected	on	day	12	(figure	3.1	A).		
To	determine	whether	different	bone-seeking	breast	 cancer	cell-lines	have	 the	 same	
pattern	of	homing,	12-week	old	 female	BALB/c	nude	mice	were	 injected	on	day	one	
with	either	1x105	MDA-MB-231-GFP-IV	cells	(n=3)	or	MDA-MB-231/B02-GFP	cells	(n=2	
due	to	an	animal	not	recovery	after	the	anaesthesia)	labeled	with	the	membrane	dye	
Vybrant-DiD	and	culled	on	day	5	when	long	bones	were	collected	(figure	3.1	B).	
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Experimental	outline.	A)	12-week	old	female	BALB/c	nude	female	mice	were	injected	intravenously	(i.v.)	
with	PBS	on	day	0	and	on	day	7	with	1x105	MDA-MB-231-GFP-IV	cells	labeled	with	Vybrant-CM-DiI	(n=6)	
or	Vybrant-DiI	(n=2).	Animals	were	culled	on	day	12	and	tibiae	and	femora	were	collected	for	analysis	by	
two-photon	microscopy.	B)	12-week	old	 female	BALB/c	nude	 female	mice	were	 injected	on	day	1	 i.v.	
with	 1x105	MDA-MB-231-GFP-IV	 cells	 labeled	with	Vybrant-DiD	 (n=3)	 or	 i.a.	with	Vybrant-DiD	 labeled	
1x105	MDA-MB-231-B02	cells	 (n=2).	 Five	days	after	 tumour	 cells	 inoculation,	animals	were	 culled	and	
long	bones	collected	for	ex-vivo	two-photon	analysis.		 	
Figure	3.1	Outline	for	the	in	vivo	studies	evaluating	homing	of	bone-seeking	MDA-MB-231	cell-lines	
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To	investigate	whether	the	route	of	 injection	could	affect	the	 location	of	the	tumour	
cells	 in	 the	 bone	 microenvironment,	 12-week	 old	 female	 BALB/c	 nude	 mice	 were	
injected	 either	 i.v.	 (n=1)	 or	 i.c.	 (n=5)	 with	 1x105	 Vybrant-DiD	 labeled	MDA-MB-231-
GFP-IV	and		culled	on	day	5	(figure	3.2	A).	Long	bones	were	collected	for	two-photon	
microscopy.		
To	establish	whether	ER+ve	cell-lines	colonised	the	same	area	of	bone	compared	with	
the	 triple	 negative	 MDA-MB-231-GFP-IV	 cells,	 1x105	 Vybrant-DiD	 labeled	 MCF-7	 or	
T47D	 cell-lines	 were	 injected	 i.c.	 (performed	 under	 general	 anaesthesia	 with	
Isofluorane	 tested	 by	 pinch	 reflex)	 in	 12-week	 old	 female	 BALB/c	 nude	 mice	
(n=5/group).	Long	bones	were	collected	5	days	after	cell	injection	(figure	3.2	B).	
	
	
A)	12-week	old	female	BALB/c	nude	female	mice	were	injected	either	i.v.	(n=1)	or	i.c.	with	1x105	MDA-
MB-231-GFP-IV	cells	 labeled	with	Vybrant-DiD	(n=5)	to	compare	the	pattern	of	homing	using	different	
route	of	injection.	B)	12-week	old	female	BALB/c	nude	mice	were	injected	on	day	1	i.v.	with	1x105	T47D	
or	MCF7	Vybrant-DiD		labeled	cells	(n=5/group)	to	compare	the	homing	pattern	of	ER+ve	cell-lines	with	
the	triple	negative	MDA-MB-231..	Five	days	later,	animals	were	culled	and	long	bones	collected	for	ex-
vivo	multiphoton	analysis.		
Figure	3.2	Homing	after	different	routes	of	injection	and	both	ER+ve	and	ER-ve	cell-lines	
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3.4.2.2	Hematopoietic	stem	cell	(HSCs)	niche	modification	
To	 assess	whether	 the	mobilisation	 of	 hematopoietic	 stem	 cells	 (HSCs)	would	 affect	
subsequent	homing	of	breast	 cancer	 cells	 in	bone,	12-week	old	 female	BALB/c	nude	
were	injected	i.p.	with	the	CXCR4	antagonist	AMD3100	(Sigma-Aldrich)	5	mg/kg	(100	μl)	
or	PBS	daily	for	5	days.	24	hours	after	the	last	injection,	animals	were	injected	i.v	with	
1x105	MDA-MB-231-GFP-IV	Vybrant-DiD	-labeled	cells	and	culled	at	day	10	(figure	3.3).	
3.4.2.3	Comparison	between	young	and	mature	animal	models	
To	compare	the	seeding	of	breast	cancer	cells	in	the	bone	microenvironment	of	young	
and	mature	animal	models,	6-	and	12-week	old	female	BALB/c	nude	mice	(n=8/group)	
were	 injected	 i.v.	 with	 1x105	MDA-MB-231-GFP-IV	 cells	 labeled	 with	 the	membrane	
dye	 Vybrant-CM-DiI.	 Animals	 were	 culled	 5	 days	 after	 tumour	 cells	 injection	 (figure	
3.3).	
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	(A)	 12-week	 old	 BALB/c	 nude	 female	mice	were	 injected	 daily	 for	 5	 days	 i.p.	 with	 PBS	 or	 AMD3100	
(5mg/kg)	(n=5/group).	On	day	5,	animals	were	injected	i.v.	with	1x105	DiD	labelled	MDA-MB-231-GFP-IV	
cells	 and	 culled	 on	 day	 10,	 tibias	 were	 collected	 for	 multiphoton	microscopy	 B)	 6-	 and	 12-week	 old	
female	 BALB/c	 nude	 female	mice	 (n=8/group)	were	 injected	 on	 day	 1	 i.v.	 with	 1x105	CM-DiI	 labelled	
MDA-MB-231-GFP-IV	 cells.	 Five	 days	 later,	 animals	 were	 culled	 and	 long	 bones	 collected	 for	 ex-vivo	
multiphoton	analysis.		
	
3.4.2.4	Collection	and	preparation	of	the	samples	
Animals	were	culled	by	an	overdose	of	anaesthetic	(i.p.	50μl	Pentobarbital)	and	death	
was	 confirmed	 by	 cervical	 dislocation.	 Hind	 limbs	 were	 dissected,	 muscles	 were	
removed,	 femora	 and	 tibiae	 were	 separated	 and	 collected	 snap	 frozen	 in	 liquid	
nitrogen	 and	 stored	 at	 -80°C.	 For	 the	 in	 vivo	 study	 investigating	 the	 competition	
between	 HSCs	 and	 breast	 cancer	 cells,	 right	 tibiae	 were	 collected	 in	 4%	 PFA	 and	
processed	for	fluorescent	immunohistochemistry,	as	described	in	section	2.9.3.		
	 	
Figure	3.3	Modification	of	HSCs	niche	and	comparison	between	young	and	mature	mice	
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3.4.3	Two-photon	microscopy	
Snap	 frozen	 long	 bones	 were	 embedded	 into	 Cryo-M-Bed	 (Instrument	 Co.	 Ltd,	
Huntingdon,	UK)	and	a	Bright	OTF	Cryostat	and	3020	microtome	(Bright	Instrument	Co.	
Ltd,	 Huntingdon,	 UK)	 was	 used	 to	 expose	 the	 bone	 marrow.	 The	 specimen	 was	
mounted	 on	 a	 glass	 bottom	 dish	 as	 described	 in	 section	 2.10.1,	 with	 the	 exposed	
surface	upwards	towards	the	upright	Zeiss	LSM510	NLO	two-photon	microscope	(Carl	
Zeiss,	 Cambridge,	UK).	An	 area	of	 2104	μm	×	2525	μm	at	 70	μm	depth	was	 captured	
using	a	Chameleon	two-photon	laser	at	900nm	(Coherent,	Santa	Clara,	CA)	to	visualize	
the	 bone	 structure,	 a	 HeNe	 633nm	 laser	 for	 Vybrant-DiD	 labeled	 cancer	 cells	 and	 a	
HeNe	 543nm	 laser	 for	 Vybrant-CM-DiI	 dye.	 The	 tile	 scan	 of	 2104μm	 x	 2525μm	 for	
70μm	 depth	 using	 two	 lasers	 (HeNe	 633/543nm	 and	 Chameleon	 laser	 900nm)	 took	
approximately	3	hours	and	30	minutes	per	sample.	
3.4.3.1	Mapping	the	location	of	breast	cancer	cells	
Three-dimensional	reconstruction	of	the	image	was	performed	with	Volocity	3D	Image	
Analysis	software	6.01	(PerkinElmer,	Cambridge,	UK).		To	distinguish	between	positive	
events	detected	with	 the	543nm	and	633nm	HeNe	(Vybrant-CM-DiI	and	Vybrant-DiD	
labeled	 breast	 cancer	 cells	 respectively)	 and	 the	 background	 noise,	 a	 threshold	 of	
250μm3	 was	 fixed.	 The	 positive	 events	 were	 counted	 and	 their	 distance	 from	 their	
edge	 to	 the	nearest	bone	surface	and	 the	nearest	 cancer	 cell	was	measured.	All	 the	
quantifications	were	performed	in	two	different	regions	of	interest	(ROI)	in	which	the	
cortical	bone	was	excluded.	Femora	and	tibiae	were	both	analysed.	The	variability	 in	
the	 number	 of	 cells	 seeding	 in	 the	 bone	 microenvironment	 (0-97)	 influenced	 the	
length	of	the	analysis,	from	few	minutes	up	to	more	than	24h.	
3.4.4	Statistical	analysis	
Statistical	 analyses	 were	 executed	 using	 GraphPad	 Prism	 software	 (Version	 6.0	 and	
7.0).		Student	T-tests	and	Two-way	ANOVA	and	Tukey		post	test	were	used	as	indicated	
in	each	figure	legend.	A	p-value	of	<0.5	was	considered	significant.	
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3.5	Results	
During	the	metastatic	process,	breast	cancer	cells	home	to	a	putative	metastatic	niche	
in	the	bone	marrow	cavity.	 In	our	 in	vivo	models	of	bone	metastasis,	 the	majority	of	
tumours	 develop	 in	 the	 metaphysis	 of	 long	 bones,	 tibia	 and	 femora	 (figure	 3.4).	
Therefore	 these	 bones	 were	 analysed	 to	 assess	 the	 location	 of	 breast	 cancer	 cells	
within	the	bone	microenvironment	in	the	early	stages	of	bone	colonisation.	
	
	(A)	Representative	image	of	an	animal	model	used	in	our	laboratory.	The	mouse	was	injected	i.c.	with		
MDA-MB-231-GFP	cells	transfected	with	luciferase,	in	vivo	tumour	growth	was	detected	over	time	using	
an	 in	vivo	 imaging	system	(IVIS).	 (B)	Goldner’s	trichrome	staining	of	a	femur	slide	of	a	tumour	bearing	
mouse.	Yellow	circle=tumour,	BM=bone	marrow,	GP=growth	plate.	
	
	 	
Figure	3.4	In	vivo	tumour	model	
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3.5.1	The	MDA-MB-231-GFP-IV	cell-line	homes	to	the	trabecular	region	of	bone		
Previous	studies	performed	by	our	group	demonstrated	that	injection	in	the	tail	vein	of	
the	 bone-seeking	 cell-line	 MDA-MB-231-GFP-IV	 resulted	 in	 tumour	 growth	 in	 long	
bones	of	young	(6-week	old)	animals	two	weeks	after	inoculation	[198].	As	the	focus	of	
my	PhD	project	is	on	the	early	stages	of	the	metastatic	process,	to	investigate	the	bone	
colonisation	I	used	mature	mice	(12-week	old)	known	to	have	a	low	bone	turnover	and	
therefore	be	supportive	of	tumour	cell	dormancy	[216].	As	shown	in	figure	3.1,	animals	
were	culled	5	days	after	injection	of	the	bone-seeking	breast	cancer	cell-line	MDA-MB-
231-GFP-IV	labeled	with	either	Vybrant-DiD	or	Vybrant-CM-DiI.	As	explained	in	section	
2.3	of	the	Materials	and	Methods	Chapter,	Vybrant-DiD	is	distributed	more	evenly	on	
the	 lipophilic	 membranes	 and	 can	 be	 detected	 deeper	 in	 the	 specimen	 but	 the	
fluorescent	 properties	 do	 not	 resist	 fixation	 of	 tissue.	 In	 contrast,	 Vybrant-CM-DiI	 is	
not	the	most	appropriate	dye	for	two-photon	microscopy	but	it	is	recommended	if	the	
samples	 require	 fixation	 such	 using	 e.g.	 PFA.	 In	 current	 in	 vivo	 studies	 I	 wanted	 to	
compare	 the	 reliability	 of	 the	 two	 dyes	 for	 two-photon	 analysis,	 since	 in	 future	
experiments	the	plan	was	to	use	Vybrant-CM-DiI	would	be	used	to	detect	tumour	cells	
in	fixed	tissue.	
Time	 point	 of	 five	 days	was	 chosen	 to	 allow	 the	 tumour	 cells	 to	 localise	within	 the	
bone	marrow	without	starting	to	proliferate,	and	lose	the	fluorescent	membrane	dye.		
Moreover,	at	this	time	point	cells	that	do	not	reach	a	niche	have	died	and	therefore	I	
was	able	to	quantify	the	cells	in	bone	that	most	likely	contain	the	metastasis-initiating	
population.	 In	 our	 in	 vivo	 models	 of	 bone	 metastasis,	 the	 majority	 of	 tumours	
developed	 on	 the	 metaphysis	 of	 long	 bones,	 predominantly	 tibia	 and	 femora,	 so	 I	
focused	my	analysis	on	these	bones.		On	the	day	of	cull,	 long	bones	where	collected,	
snap	frozen	in	liquid	nitrogen,	embedded	in	Cryo-M-Bed	and	stored	at	-80°	until	they	
were	 used	 for	 the	 two-photon	 scan.	 To	 assess	 whether	 this	 cell-line	 colonise	
preferentially	 to	 specific	 regions	 of	 the	 bone	 marrow,	 Volocity	 3D	 Image	 Analysis	
software	was	used	to	count	the	number	of	events	recorded	using	633	and	543	HeNe	
lasers	in	two	different	ROIs:	the	growth	plate	area	(ROI1)	and	the	trabecular	region	of	
the	bone	(ROI2)	(figure	3.5).		
	 101	
MDA-MB-231-GFP-IV	cells	localised	preferentially	in	the	trabecular	region	of	the	bone	
marrow	 (ROI1)	 rather	 than	 in	 the	 growth	plate	 area	 (ROI2).	 In	 fact,	 the	events/mm3	
recorded	 in	ROI1	were	 significantly	 higher	 compared	 to	 those	 in	ROI2	 (p=0.0047	 for	
cells	 labeled	with	Vybrant-CM-DiI,	p<0.0001	 for	Vybrant-DiD	and	p=0.0031	when	 the	
studies	 are	 merged)	 (figure	 3.5).	 As	 described	 in	 section	 2.3	 of	 the	 Material	 and	
Methods	Chapter,	the	fluorescent	dye	Vybrant-CM-DiI	intercalate	non-uniformly	in	the	
membrane	of	cells.	Therefore	a	proportion	of	the	cells	partially	 labeled	with	this	dye	
may	have	been	excluded	from	the	analysis,	as	they	could	not	be	distinguished	from	the	
background	 noise.	 This	 perhaps,	 explain	 why	 the	 overall	 number	 of	 Vybrant-CM-DiI	
was	lower	compared	to	the	Vybrant-DiD	positive	events.	Despite	this	dissimilarity,	the	
pattern	of	tumour	cell	homing	was	identical	regardless	of	the	membrane	dye	used.		
These	results	demonstrate	that	 in	this	model,	the	bone-seeking	triple	negative	MDA-
MB-231-GFP-IV	breast	cancer	cell-line,	 localise	preferentially	 to	 the	trabecular	 region	
of	the	bone	metaphysis.	
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A)	Schematic	representation	of	the	regions	of	 interest	(ROIs)	of	two-photon	bone	scan	analyzed:	ROI1	
consists	of	the	trabecular	bone	region	and	ROI2	the	growth	plate.	Cortical	bone	was	excluded.	(B)	Shows	
the	 results	 when	 the	 two	 studies	 are	 combined.	 (C)	 Graph	 showing	 the	 number	 of	 Vybrant-CM-DiI+	
events/mm3	 (n=6	 animals,	 11	 bones	 analysed),	 Vybrant-DiD+	 (n=2	 animals,	 3	 bones	 analysed)	 events	
shown	in	(D).	(E)	and	(F)	are	examples	of	two-photon	scan	showing	bone	(white),	Vybrant-CM-DiI+		cells	
(blue	 and	 blue	 arrows)	 and	 Vybrant-DID+	 cells	 (red	 and	 red	 arrows).	 Scale	 bars	 100µm	 and	 10µm.	
**p≤0.005	and	****p<0.0001	student’s	t-test,	graphs	show	mean	±	SEM.	 	
Homing	of	MDA-MD-231-GFP-IV	cells	
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3.5.1.1	MDA-MB-231-GFP-IV	cells	locate	close	to	the	bone	surface	
In	 order	 to	 determine	 the	 location	 of	 this	 breast	 cancer	 cell-line	 within	 the	
microenvironment	more	accurately,	the	distance	from	the	edge	of	the	tumour	cells	to	
the	 nearest	 bone	 surface,	 as	 well	 as	 the	 closest	 tumour	 cell,	 was	 measured	 using	
Volocity	3D	Image	Analysis	software.	In	ROI1	the	mean	distance	between	tumour	cells	
labeled	with	Vybrant-CM-DiI	and	the	nearest	bone	surface	was	71.90±11.82μm	(range	
between	23-144μm),	for	Vybrant-DiD	cells	was	108.27±42.19μm		(63-192μm)	while	the	
overall	 mean	 was	 79.70±12.66μm.	 Compared	 to	 ROI1,	 Vybrant-CM-DiI	 labeled	 cells	
were	 located	 significantly	 (p=0.0373)	 closer	 to	 the	 bone	 surface	 in	 ROI2	 where	 the	
mean	 distance	 was	 24.93±4.85μm	 (figure	 3.6).	 In	 contrast,	 the	 distance	 between	
tumour	 cells	 was	 significantly	 greater	 384.30±	 129.80µm	 in	 the	 growth	 plate	 area	
compared	 to	 the	 trabecular	 bone	 region	 with	 mean	 values	 of	 174.9±26.07µm	
respectively	(p=0.0239).	 In	both	ROIs,	the	bone-seeking	cell-line	MDA-MB-231-GFP-IV	
was	homing	significantly	(p=0.0015	in	ROI1	and	p=0.0214	in	ROI2)	closer	to	the	bone	
surface	 than	 to	 the	 nearest	 tumour	 cell	 (figure	 3.6).	 For	 Vybrant-DiD	 it	 was	 not	
possible	to	perform	statistical	analysis	due	to	the	low	number	of	sample	available	for	
analysis.	
Taken	together,	 in	both	 the	ROIs	analysed	this	cell-line	 located	significantly	closer	 to	
the	nearest	bone	surface	than	to	other	tumour	cells.	
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	(A)	Schematic	 illustration	of	 the	distances	measurement	 from	the	edge	of	 tumour	cell	 to	 the	nearest	
bone	surface	and	(B)	to	the	closest	breast	cancer	cell.	Graphs	showing	the	distance	of	Vybrant-CM-DiI	
cells	 to	 the	 bone	 surface	 (C)	 and	 to	 other	 tumour	 cells	 (D)	 (n=6	 animals,	 11	 bones	 analysed).	 The	
comparison	between	the	distance	to	the	bone	and	the	distance	to	other	tumour	cells	in	the	two	ROI1	is	
shown	in	(E)	and	 in	ROI2	 is	shown	in	(F).	*p≤0.05	and	**p≤0.01,	student’s	t-test,	graphs	show	mean	±	
SEM.	
	 	
Figure	3.5	Location	of	MDA-MB-231-GFP-IV	cells	in	the	bone	microenvironment	
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3.5.2	Comparison	between	the	pattern	of	homing	of	MDA-MB-231-GFP-IV	and	MDA-
MB-231/B02-GFP	cells	
To	assess	whether	the	pattern	of	homing	obtained	with	the	MDA-MB-231-GFP-IV	cells	
was	characteristic	of	 this	particular	cell-line	 (generated	by	Dr.	Ottewell,	University	of	
Sheffield,	UK	[198])	I	performed	an	in	vivo	study	comparing	this	cell-line	with	the	bone-
seeking	MDA-MB-231/B02-GFP	cell-line	(created	by	the	team	of	Dr.	Clezardin	INSERM,	
UFR	 de	Médecine	 Lyon-Est,	 Lyon,	 France	 and	University	 of	 Sheffield,	 UK)[129].	 Both	
bone-seeking	 cell-lines	 form	metastasis	 in	 the	metaphysis	 of	 young	 animals	 and	 are	
associated	 with	 lytic	 lesions,	 therefore	 a	 similar	 pattern	 of	 seeding	 was	 expected.	
Female	12-week	old	immunocompromised	mice	were	injected	with	either	Vybrant-DiD	
labeled	MDA-MB-231-GFP-IV	 cells	 (i.v.)	or	MDA-MB-231/B02-GFP	 (i.a.),	 culled	5	days	
later	 and	 long	 bones	 were	 analyzed	 using	 two-photon	 microscopy.	 Although	 in	 the	
literature	it	has	been	reported	that	MDA-MB-231/B02-GFP	colonise	to	bone	following	
intravenous	 injection,	previous	studies	 in	Prof.	Holen’s	team	have	demonstrated	that	
this	cell-line	predominantly	localised	to	bone	when	injected	via	the	intra-arterial	route.	
Therefore	this	route	of	administration	was	used	in	the	animal	model	with	the	kind	help	
of	Dr.	Hannah	Brown	(University	of	Sheffield,	UK).	
MDA-MB-231-GFP-IV	 cells	 homed	 as	 previously	 described,	with	 the	majority	 of	 cells	
being	located	in	the	trabecular	region	of	the	bone	even	though	in	this	study	statistical	
significance	was	not	reached	(p=0.2616).	In	contrast,	MDA-MB-231/B02-GFP	cells	were	
evenly	distributed	between	the	two	regions	of	interest	(p=0.9896)	(figure	3.7).		
Although	 the	 dissemination	 of	 the	 bone-seeking	 cell-lines	 in	 the	 bone	
microenvironment	demonstrate	differences,	 in	both	ROIs,	 the	distance	of	 the	breast	
cancer	 cells	 to	 the	 nearest	 bone	 surface	 was	 comparable	 with	 mean	 value	 of	
91.55±21.27μm	 and	 86.67±30.72μm	 in	 ROI1	 for	MDA-MB-231-GFP-IV	 and	MDA-MB-
231/B02-GFP	 respectively	 (p=0.9004)	 and	 16.62±4.32μm	 and	 14.01±4.92μm	 in	 ROI2	
(p=0.7293)	(figure	3.7).		
The	 data	 show	 that,	 despite	 a	 different	 distribution	 between	 different	 areas	 of	 the	
bone	 for	 the	 two	 triple	 negative	 bone-seeking	 MDA-MB-231	 clones,	 both	 cell-lines	
maintain	a	close	connection	with	the	nearest	bone	surface.	
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A)	Graph	 showing	 the	number	of	MDA-MB-231-GFP-IV	 (n=3	animals,	 6	bones	analysed)	 vs.	MDA-MB-
231/B02-GFP	cells	(n=2	animals,	4	bones	analysed)	labeled	with	Vybrant-DiD+,	graph	show	events/mm3	
mean	 ±	 SEM.	 (B)	 Distance	 of	 the	 bone-seeking	 breast	 cancer	 cell-lines	 to	 the	 nearest	 bone	 surface.	
Examples	of	two-photon	scan	showing	bone	(white),	MDA-MB-231-GFP-IV	cells	(C,	in	red)	and	MDA-MB-
231/B02-GFP	cells	(D,	in	red),	scale	bars	100μm.	
	 	
Figure	3.6	Comparison	between	homing	of	MDA-MB-231-GFP-IV	cells	and	MDA-MB-231/B02-GFP	cells	
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3.5.3	The	route	of	injection	does	not	affect	the	homing	of	MDA-MB-231-GFP-IV	cells	
to	the	bone	microenvironment	
Due	to	their	characteristic	bone	tropism,	MDA-MB-231-GFP-IV	cells	home	to	the	bone	
marrow	following	tail	vein	injection.	In	contrast,	most	of	the	xenograft	animal	models	
of	bone	metastasis	are	obtained	by	administration	of	tumour	cells	via	the	intracardiac	
route,	allowing	the	cells	to	reach	the	bone	through	the	arterial	network,	as	previously	
described	in	section	3.5.2.		
To	 understand	whether	 the	 route	 of	 injection	 could	 affect	 breast	 cancer	 cells	 bone	
colonisation,	12-week	old	BALB/c	nude	mice	were	injected	with	MDA-MB-231-GFP-IV	
Vybrant-DiD	 labeled	 cells	 either	 i.v.	 (n=1,	 just	 to	 confirm	 the	 pattern	 previously	
described	in	section	3.5.1)	or	i.c.	(n=5)	and	after	5	days	long	bones	were	collected	and	
tumour	 cells	 were	 visualized	 in	 the	 bone	 microenvironment	 using	 two-photon	
microscopy.	
When	 injected	 via	 the	 tail	 vein,	MDA-MB-231-GFP-IV	 cells	 displayed	 the	preferential	
pattern	of	homing	as	previously	described	 (ROI1>ROI2),	 but	did	not	 show	significant	
difference,	between	events	recorded	in	the	trabecular	region	of	the	bone	compared	to	
the	 growth	 plate	 area.	 This	 was	 probably	 due	 to	 the	 reduced	 number	 of	 samples	
(p=0.4480)	(figure	3.8).		
As	expected,	the	route	of	injection	did	not	affect	the	seeding	of	the	breast	cancer	cells	
within	the	bone	microenvironment.	In	fact,	the	majority	of	MDA-MB-231-GFP-IV	cells	
located	to	ROI1	compared	to	ROI2	(p=0.0464)	when	injected	in	the	left	ventricle	of	the	
heart	(figure	3.7).	Moreover,	the	breast	cancer	cells	colonised	areas	in	close	proximity	
with	the	bone	surface	with	a	mean	value	of	56.99±11.55μm	in	ROI1	and	10.30±4.04μm	
in	ROI2	(p=0.0053),	while	they	located	further	away	from	other	tumour,	mean	value	of	
253.50±110.40μm	 in	 ROI1	 and	 174.90±53.36μm	 in	 ROI2	 (p=0.1225	 and	 p=0.0096	 in	
ROI1	and	ROI2	respectively)(figure	3.8).	
Taken	together,	these	results	show	that	the	route	of	injection	does	not	affect	the	way	
breast	 cancer	 cells	 colonised	 the	 bone	 microenvironment	 and	 confirm	 that	 triple	
negative	breast	cancer	cells	generally	seed	in	the	trabecular	region	of	the	metaphysis	
in	close	proximity	with	the	bone	surface.	 	
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A)	Graph	showing	the	number	of	MDA-MB-231-GFP-IV	cells	localised	in	two	ROIs	when	injected	i.v.	(n=1	
animal,	 3	 bones	 analysed)	 and	 B)	 following	 i.c.	 injection	 (n=5	 animals,	 10	 bones	 analysed).	 (C)	Graph	
representing	the	direct	comparison	between	the	homing	of	MDA-MB-231-GFP-IV	cells	after	i.v	(squares)	
and	 i.c	 injection	 (circles).	 Comparison	 between	 the	 distance	 to	 the	 nearest	 bone	 surface	 and	 to	 the	
closest	tumour	cells	after	i.c.	injection	is	show	in	(D)	*p≤0.05	and	**p≤0.01	student’s	t-test	and	two-way	
ANOVA	and	Tukey		post	test.	
	 	
Figure	3.7	Comparison	between	different	routes	of	injection	
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3.5.4	 ER+ve	 breast	 cancer	 cell-lines	 display	 the	 same	 pattern	 of	 seeding	 as	 triple	
negative	cell-lines	
The	 majority	 of	 breast	 cancers	 are	 oestrogen	 receptor	 positive	 (ER+ve)	 tumours,	
respond	well	to	hormonal	therapies	and	are	commonly	diagnosed	before	the	tumour	
metastasizse	 to	 bone.	 However,	 the	 majority	 of	 bone	 metastasis	 studies	 use	 triple	
negative	breast	cancer	cell-line	e.g.	MDA-MB-231.	To	have	a	more	comprehensive	idea	
of	whether	tumour	cells	prefer	to	colonise	particular	areas	of	the	bone	marrow,	an	in	
vivo	 study	 to	 map	 the	 location	 of	 ER+ve	 cells	 within	 the	 bone	 was	 performed	 by	
injecting	T47D	and	MCF-7	cells	labeled	with	Vybrant-DiD	i.c.	into	12-week	old	mice.	
Similar	 to	 the	 triple	 negative	 breast	 cancer	 cell-lines,	 the	 ER+ve	 cell-lines	 injected	 in	
the	mature	animal	model	also	display	a	predilection	 for	 the	 trabecular	 region	of	 the	
bone	compared	to	the	area	adjacent	to	the	growth	plate,	though	the	p-value	did	not	
reach	 statistical	 significance	 (p=	 0.3481	 for	 T47D	 and	 p=	 0.2457	 for	MCF7	 cell-line).	
Interestingly,	 the	 number	 of	 T47D	 cells	 reaching	 the	 bone	 microenvironment	 was	
lower	than	for	the	MCF7	cells,	the	difference	in	Vybrant-DiD	positive	events	detected	
in	ROI1	was	statistically	significant	(p=0.0472)	(figure	3.9).		
MCF7	 cells	 appear	 to	 home	 slightly	 further	 away	 from	 the	 bone	 surface	 in	 ROI1	
compared	 to	all	 the	other	cell-lines	analysed,	with	a	mean	value	of	118.50±48.44μm	
(42-257μm)	while	in	ROI2	the	mean	value	of	6.09±2.21μm	(0-10μm)	is	comparable	to	
both	the	triple	negative	cell-lines	and	the	ER+ve	clone	T47D	(figure	3.9).	
Of	all	cell-lines	investigated	the	T47D	were	the	cells	located	in	the	closest	proximity	to	
the	bone	surface,	exhibiting	a	mean	distance	of	 just	27μm	(0-71μm)	in	ROI1	showing	
that	there	may	be	some	cell-specific	differences	in	location	in	the	niche.	
Additionally	to	the	data	discussed	in	the	previous	sections,	these	results	confirm	that	
breast	cancer	cells,	both	ER	positive	and	negative,	colonise	some	region	of	 the	bone	
microenvironment,	 regardless	 of	 the	 route	 of	 administration.	 Furthermore,	 all	 cell-
lines	except	the	bone-seeking	MDA-MB-231/B02-GFP	present	some	degrees	of	affinity	
for	the	trabecular	area	of	the	bone	marrow	compared	to	the	growth	plate	region.			
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(A)	 Graph	 representing	 the	 direct	 comparison	 between	 the	 homing	 of	 T47D	 cells	 vs	MCF7	 cells	 (n=5	
animals	 and	 5	 bones/group	 analysed).	 (B)	 Comparison	 between	 the	 distances	 to	 the	 nearest	 bone	
surface	of	the	two	cell-lines	injected.	*p≤0.05	two-way	ANOVA	and	Tukey		post	test.	Examples	of	two-
photon	scan	showing	the	proximity	to	the	bone	surface	of	T47D	(C)	and	MCF7	(D),	position	of	the	cells	is	
highlighted	by	the	yellow	arrows	and	scale	bar	are	100μm	(right	panel)	and	50μm	(left	panel).	
	
	 	
Figure	3.	8	T47D	and	MCF7	cell-lines	colonisation	of	bone	
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3.5.5	Modification	of	the	HSCs	niche	changes	the	homing	of	breast	cancer	cells	
It	 has	 been	 suggested	 that	 the	 metastatic	 niche	 broadly	 overlaps	 with	 the	
hematopoietic	 stem	 cell	 niche	 that	 can	 be	 found	 in	 the	 trabecular	 region	 of	 the	
metaphysis	of	long	bones.	Shiozawa	et	al.	elegantly	showed	how	prostate	cancer	cells	
and	HSCs	locate	within	the	same	niche	[28],	[36]	using	a	CXCR4	antagonist	to	mobilize	
the	 HSCs.	 In	 the	 following	 study	 I	 used	 the	 same	 compound,	 AMD3100,	 with	 daily	
dosing	for	5	days	to	“empty”	the	HSCs	niche.	Subsequently	MDA-MB-231-GFP-IV	cells	
labeled	with	Vybrant-CM-DiI	were	injected	into	the	tail	vein	of	the	12-week	old	mice.	
Animals	were	culled	after	5	days	and	two-photon	microscopy	was	used	to	count	 the	
number	of	 cells	 able	 to	 colonise	 the	bone	marrow	 in	 control	or	 treated	animals	and	
also	to	establish	whether	the	location	was	affected.	
As	anticipated,	the	mobilization	of	the	HSCs	cells	from	their	niche	created	more	space	
available	 for	 the	 homing	 of	 breast	 cancer	 cells,	 resulting	 in	 a	 significantly	 greater	
number	 of	 tumour	 cells	 colonizing	 the	 trabecular	 region	 of	 the	 bone	 (p=0.0409).	 In	
contrast,	no	difference	in	tumour	cell	number	was	observed	in	the	growth	plate	area	
of	 the	 bone	 (p=0.7303)	 which	 is	 usually	 less	 colonised	 and	 does	 not	 contain	 HSCs	
niches	(figure	3.10).	
These	data	showed	how	alteration	of	the	HSCs	population	resulted	in	a	modification	of	
the	number	of	breast	cancer	cell	detected	with	two-photon	microscopy.	Modification	
of	 a	 component	of	 the	bone	microenvironment	 changes	 the	homing	of	 tumour	 cells	
which	 indicates	 that	 the	 different	 cellular	 components	 of	 the	 metastatic	 niche	
influences	 the	 metastatic	 progression,	 from	 the	 early	 stages	 of	 breast	 cancer	 cell	
colonisation	of	bone.	
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Graph	representing	the	homing	of	MDA-MB-231-GFP-IV	cells	after	treatment	with	the	CXCR4	antagonist	
AMD3100	(n=5	animals,	9	bones	analysed)	or	with	PBS	(n=5	animals,	10	bones	analysed).	Significantly	
greater	number	of	tumour	cells	was	detected	in	ROI1	after	the	mobilization	of	the	HSCs	cells	outside	the	
niche.	*p≤0.05	two-way	ANOVA	and	Tukey		post	test.	
	
3.5.6	Breast	cancer	cells	show	no	difference	in	the	colonisation	of	young	or	mature	
animals	
The	animal	model	described	earlier	 in	this	chapter	(sections	3.5.1-5)	 involved	mature	
mice	(12-week	old)	with	a	low	bone	turnover	that	has	been	shown	to	support	tumour	
cell	dormancy	[128],	[216].	However,	the	majority	of	published	in	vivo	studies	evaluate	
the	 efficacy	 of	 therapeutic	 agents	 on	 tumour	 growth,	 therefore	 young	 animals	 (≈6-
week	 old)	 are	 usually	 utilized.	 To	 assess	 whether	 there	 were	 changes	 in	 the	 breast	
cancer	 bone	 colonisation	 in	 young	 compared	 to	 mature	 mice,	 6-	 and	 12-week	 old	
BALB/c	 nude	 (n=8/group)	 were	 injected	 i.v.	 with	 Vybrant-CM-DiI	 labeled	 MDA-MB-
231-GFP-IV	cells,	long	bones	were	collected	and	analyzed	by	multiphoton	microscopy.	
It	is	important	to	note	that	human	cells	were	only	detected	in	50%	(4	bones	out	of	8)	
of	the	long	bones	of	young	animals	and	their	number	was	highly	variable	with	a	range	
of	9-2142	cells/mm3.	In	contrast,	tumour	cells	were	identified	in	70%	(7	out	of	10)	of	
mature	mice	and	there	was	less	variability	in	the	number	of	cells	homing	to	the	bone	
marrow	 (5-58	 cells/mm3)	 (figure	 3.11).	 In	 vitro	 studies	 investigating	 this	 further	
Figure	3.9	Modification	of	the	HSCs	niche	
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detected	 a	 small	 cytotoxic	 effect	 of	 the	 new	batch	 of	 Vybrant-CM-DiI	 dye	 used	 that	
could	have	caused	the	reduced	number	of	breast	cancer	cells	homing	within	the	bone	
microenvironment,	in	subsequent	studies	the	concentration	of	this	dye	was	therefore	
reduced	from	5μM	to	2μM.	
The	pattern	of	homing	of	MDA-MB-231-GFP-IV	cells	was	maintained	both	in	young	(6-
week	old)	and	mature	(12-week	old)	animals,	although	the	preferential	localization	of	
the	tumour	cells	 in	ROI1	compared	to	ROI2	was	not	statistically	significant,	p=0.4312	
and	p=0.1213	for	young	and	mature	respectively	(n=8/group).	
In	both	 the	ages	breast	 cancer	cells	homed	 really	 close	 to	 the	nearest	bone	surface,	
with	 the	 mean	 value	 measure	 in	 ROI1	 was	 29.01±9.97μm	 in	 6-week	 old	 and	
59.13±17.14μm	 in	 12-week	 old	 animals	 while	 in	 ROI2	 this	 value	 were	 reduced	 to	
3.72±3.00μm	and	2.24±1.56μm	respectively.	As	described	earlier	 in	 this	 chapter,	 the	
breast	cancer	cells	appear	to	locate	closer	to	the	bone	surface	in	the	growth	plate	area	
compared	to	the	trabecular	region	of	the	bone,	but	this	trend	was	not	of	significant,	
p=0.0902	and	p=0.0691	for	young	mice	vs	mature	animals	(figure	3.11).	
Another	similarity	between	the	colonisation	of	bone	in	young	and	mature	animals	was	
that	tumour	cells	located	closer	to	the	nearest	bone	surface	than	to	the	nearest	cancer	
cell.	 Despite	 the	 clear	 trend,	 this	 preferential	 spatial	 location	 was	 not	 statistically	
significant	in	neither	ages	nor	ROIs.	
These	results	demonstrate	that	 there	 is	no	significant	difference	between	young	and	
mature	animals	in	breast	cancer	cell	colonisation	of	bone,	not	in	the	overall	number	of	
cells	homing	or	in	the	location	of	these	cells	in	relation	to	the	bone	surface	and	other	
tumour	 cells.	 Furthermore,	 the	 similarity	 in	 the	pattern	of	 homing	 suggests	 that	 the	
increased	outgrowth	of	tumours	in	bones	of	young	animals	compared	to	mature	ones	
is	 most	 likely	 due	 to	 differences	 in	 the	 dynamic	 process	 as	 in	 the	 bone	
microenvironment	and	associated	with	accelerated	turnover.	
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A)	Graph	shows	the	number	of	MDA-MB-231-GFP-IV	cells	detected	 in	6-	and	12-week	old	mice	5	days	
after	 tumour	 cells	 i.v.	 injection	 (n=8	 animals	 and	 bones	 analysed/group),	 graph	 shows	mean	 ±	 SEM.	
Distances	 of	 the	 tumour	 cells	 to	 the	 nearest	 bone	 surface	 and	 to	 the	 closest	 breast	 cancer	 cells	 are	
shown	 respectively	 in	 (B)	 and	 (C).	 No	 significant	 difference	 was	 observed	 between	 the	 homing	 of	
tumour	 cells	 in	animal	models	of	different	ages,	 as	assessed	using	a	 two-way	ANOVA	and	Tukey	post	
test.	
	 	
Figure	3.10	Homing	of	breast	cancer	cells	 in	the	young	(6-week	old)	vs	mature	(12-week	old)	animal	
model	
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Taken	 together,	 the	 studies	 described	 in	 this	 chapter	 show	 that	 using	 different	
membrane	dyes,	differences	 in	 the	overall	 number	of	 tumour	 cells	 are	detected	but	
their	 pattern	 of	 homing	 is	 not	 altered.	 Moreover	 there	 is	 a	 high	 similarity	 in	 the	
seeding	of	subtypes	of	breast	cancer	cell-lines,	both	ER+ve	and	ER-ve,	regardless	of	the	
route	 of	 injection	 used	 or	 the	 age	 of	 the	 animal	model	 used.	 The	 cell-lines	 utilised	
displayed	 an	 affinity	 for	 the	 trabecular	 region	 of	 bone	metaphysis	 compared	 to	 the	
growth	plate	area,	and	they	locate	in	close	proximity	to	the	bone	surface.	Modification	
of	 the	microenvironment	 results	 in	modulation	of	 the	 total	number	of	breast	 cancer	
cells	detected	 in	bone,	 supporting	 the	 theory	of	an	overlap	between	 the	HSCs	niche	
and	the	metastatic	niche.	
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3.6	Discussion	
The	 main	 aim	 of	 this	 chapter	 was	 to	 determine	 whether	 breast	 cancer	 cells,	 both	
ER+ve	 and	 triple	 negative,	 colonise	 the	 bone	 following	 a	 specific	 homing	 pattern.		
Investigating	 the	 location	of	breast	 cancer	 cells	 in	 the	early	events	of	 the	metastatic	
process	 to	 bone	 in	 in	 vivo	 models	 was	 made	 possible	 by	 the	 recent	 technological	
advances	 both	 in	 cell	 labelling	 and	 imaging.	 I	 have	 used	 these	 techniques	 to	
characterize	 the	 homing	 of	 tumour	 cells	 to	 long	 bones,	 tibiae	 and	 femora,	 and	
demonstrate	that	breast	cancer	cells	locate	to	specific	areas	of	the	bone	irrespective	of	
whether	 they	are	ER+ve	or	ER-ve.	The	 trabecular	 region	of	 the	bone,	which	was	 the	
preferential	location	for	seeding	of	breast	cancer	cells	colonizing	the	secondary	organ,	
contains	 the	 HSCs	 niche,	 high	 numbers	 of	 osteoblasts	 as	 well	 as	 cells	 of	 the	
microvasculature.	Intriguingly,	all	of	these	cellular	populations	thought	to	compose	the	
metastatic	niche,	and	are	suggested	to	play	a	role	in	the	maintenance	of	the	quiescent	
state	 and	 subsequently	 in	 the	 progression	 of	 metastatic	 disease.	 Moreover,	 I	
established	 that,	 by	 changing	 the	microenvironment	 and	 the	 space	 available	 in	 the	
metastatic	 niche,	 the	 number	 of	 breast	 cancer	 cells	 detected	 in	 the	 bone	
microenvironment	 increased.	 These	 findings	 emphasize	 the	 importance	 of	 cell	
populations	resident	in	bone,	in	the	homing	to	and	maintenance	of	tumour	cells	in	the	
putative	metastatic	niche,	and	not	only	during	the	late	stages	of	the	metastatic	process.		
Despite	the	large	number	of	breast	cancer	cells		(1x105/mouse)	that	were	successfully	
injected	into	the	circulation	of	the	animal	models,	only	a	small	portion	(with	a	range	of	
0-97	cells/bone)	colonised	the	long	bones	in	the	region	analysed.	Within	five	days,	the	
majority	 of	 tumour	 cells	 have	 died,	 most	 likely	 due	 to	 an	 inability	 to	 locate	 to	 an	
appropriate	niche.	Furthermore,	as	in	human	disease,	our	in	vivo	model	demonstrates	
that	simply	arriving	 in	bone	 is	not	sufficient	to	cause	the	secondary	tumour	[2],	 [16],	
[205],	 [206],	 [214],	 [217].	 Malignant	 cells	 must	 be	 able	 to	 interact	 with	 the	
microenvironment	in	order	to	receive	and	respond	to	signals	to	survive	and	proliferate	
[87],	[218].		
Although	identification	of	these	regulatory	signals	is	a	subject	of	intensive	research,	to	
date	only	little	is	known	about	their	nature,	and	particularly	in	the	early	stages	of	bone	
colonisation.	Moreover,	while	the	function	of	osteoblasts	and	osteoclasts	as	players	in	
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the	vicious	cycle	that	drives	the	late	stages	of	bone	metastasis	is	well	established,	their	
roles	 in	 the	 initial	 step	of	 the	metastatic	process	such	as	homing	and/or	 initiation	of	
the	proliferation	of	DTCs	 in	bone	 is	still	unclear	 [12],	 [14]–[16],	 [118].	Recent	studies	
carried	out	in	our	laboratory	provided	evidence	that	increasing	osteoclast	activity,	as	a	
result	 of	 ovariectomy	 or	 castration,	 triggers	 the	 growth	 of	 disseminated	 breast	 and	
prostate	cancer	cells	to	form	tumours	in	bone	[128],	[148].	It	was	established	that	this	
was	an	osteoclast-mediated	effect	 the	 tumour	growth	was	prevented	using	 the	anti-
resorptive	agent	zoledronic	acid	or	OPG-fc	[149].	To	further	support	that	an	alteration	
of	 the	 bone	microenvironment	 results	 in	 changes	 in	 the	 homing	 of	 tumour	 cells,	 Dr	
Hannah	Brown	elegantly	described	that	a	reduction	in	the	number	of	osteoblasts	prior	
to	breast	cancer	cell	injection	resulted	in	modification	of	the	distribution	of	the	tumour	
cells	 within	 the	 bone	 microenvironment	 attenuating	 the	 preferential	 pattern	 of	
location	 to	 the	 trabecular	 region,	 but	with	 no	 effect	 on	 overall	 total	 number	 [118].	
These	 data	 suggest	 that	 the	 location	 of	 the	 tumour	 cells	 influences	 their	 ability	 to	
proliferate	 and	 develop	 overt	 metastasis	 and	 data	 presented	 in	 this	 chapter	
demonstrate	 that	 breast	 cancer	 cells	 locate	 in	 vivo	 preferentially	 in	 the	 trabecular	
region	 of	 the	 bone,	 areas	 rich	 in	 cells	 of	 the	 osteoblastic	 linage	 and	 vessels.	 It	 is	
important	to	note	that,	although	the	bone	cell	population,	HSCs	and	microvasculature	
are	 the	 major	 focus	 of	 this	 thesis,	 they	 are	 not	 the	 only	 components	 of	 the	 bone	
microenvironment	to	play	a	role	in	the	metastatic	process.	For	example,	a	study	from	
the	Edwards	 group	 recently	underlined	 the	 strong	 impact	of	 bone	adipose	 tissue	on	
tumour	 growth	 [43]	 and	 others	 have	 reported	 that	 the	 innate	 immune	 system,	 in	
particular	macrophages,	has	a	role	in	the	initiation	and	cancer	progression	[45].	
As	well	as	being	rich	in	osteoblast	and	osteoclasts,	the	HSCs	niche	is	located	in	the	area	
of	bone	preferentially	occupied	by	the	breast	cancer	cells.	 It	has	been	proposed	that	
the	space	in	the	HSCs	niche	is	limited	and	therefore	only	a	certain	number	of	HSCs	can	
reside	 in	 the	 bone	 marrow	 [39],	 [51],	 [219],	 [220].	 The	 mechanism	 behind	 the	
competitive	 access	 of	 the	 HSCs	 to	 this	 limited	 space	 in	 the	 niche	 remains	 to	 be	
identified.	One	possible	alternative	is	that	different	‘specialized	niches’	are	present	in	
the	bone	marrow	that	allow	entry	and/or	survival	of	only	certain	types	of	cells	[41].	An	
opposing	 theory	 describes	 the	 space	 available	 as	 ‘equivalent	 niches’,	 in	 which	 the	
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number	of	HSCs	that	reside	in	the	niche	is	limited	by	the	competition	with	other	cells	
that	 can	 seed	 in	 the	 same	microenvironment	 [41].	 The	 theory	of	 ‘equivalent	 niches’	
could	explain	the	competition	between	prostate	cancer	cells	and	HSCs	competing	for	
spaces	in	the	niche	and	the	hypothesis	of	an	overlap	between	the	metastatic	and	the	
HSCs	niche	 [36].	 In	 their	manuscript	 Shiozawa’s	 group	observed	 that	modification	of	
the	HSCs	population	altered	the	number	of	prostate	cancer	able	to	seed	in	the	partially	
emptied	microenvironment.	 The	 experimental	 data	 described	 earlier	 in	 this	 chapter	
detailed	that	 the	same	result	was	obtained	using	breast	cancer	cells.	Shiozawa	at	al.	
monitored	 changes	 in	 the	 prostate	 cancer	 cell	 number	 by	 qPCR	while	 in	my	ex-vivo	
analysis	 I	 utilized	 two-photon	 microscopy,	 that	 made	 it	 possible	 to	 investigate	 any	
potential	alteration	of	the	location	of	the	tumour	cells	as	well	as	their	number.	Here	it	
is	 demonstrated	 for	 the	 first	 time	 for	 breast	 cancer	 that	 modification	 of	 the	 HSCs	
population	 results	 in	 an	 alteration	 of	 the	 overall	 number	 of	 breast	 tumour	 cells	
detected	in	the	bone	microenvironment.	After	the	treatment	with	the	CXCR4	inhibitor	
AMD3100,	 increased	 numbers	 of	 breast	 cancer	 cells	 were	 detected	 in	 the	 bone	
microenvironment,	suggesting	that	liberating	space	in	the	HSCs	niche	allowed	tumour	
cells	to	colonise	this.	
The	 trabecular	 region	of	 the	bone	where	breast	 cancer	 cells	 prefer	 to	 seed	 is	 highly	
vascularized	 [97],	 [106],	 [221].	 The	 microvascular	 component	 of	 the	 bone	
microenvironment	 and	 understanding	 the	 importance	 of	 the	 perivascular	 niche	 is	
increasingly	becoming	a	 field	of	 considerably	 interest	 in	 cancer	 research.	The	Adams	
group	 described	 the	 complexity	 of	 the	 microvascular	 structure	 in	 the	 metaphysis	
region	 in	 the	 bone,	moreover	 this	 publication	 described	 a	 novel	 structurally	 distinct	
capillary	subtype	(H	vessels)	which	mediates	bone	microvascular	growth	and	maintains	
perivascular	 osteoprogenitors,	 coupling	 angiogenesis	 with	 osteogenesis	 [97].		
Furthermore,	 it	 has	 recently	 been	 proposed	 that	 the	 microvasculature	 plays	 an	
important	 role	 in	 the	 maintenance	 of	 the	 quiescent	 state	 of	 breast	 cancer	 cells.	
Ghajar’s	 group	has	 demonstrated	 that	 expression	of	 thrombospondin	 (TSP-1)	 by	 the	
stable	 microvasculature	 support	 dormancy,	 in	 contrast	 pro-tumourigenic	 molecules	
like	 periostin	 and	 TGF-β1	 production	 during	 vessels	 sprouting	 stimulate	 tumour	 cell	
proliferation	[35].		
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In	 conjunction	 with	 the	 number	 of	 tumour	 cells	 seeding	 within	 the	 bone	
microenvironment,	I	also	investigated	their	location	with	respect	to	the	bone	structure	
of	the	metaphysis.	I	found	that	breast	cancer	cell	locate	in	closer	proximity	to	the	bone	
surface,	rather	than	next	to	other	tumour	cells	and	this	particular	pattern	of	homing	
has	 been	 confirmed	 in	 several	 cell-lines	 and	 animals	 of	 different	 ages.	 This	 suggests	
that	 the	 composition	 of	 the	microenvironment	 is	 key	 to	 tumour	 cell	 colonisation	 of	
bone,	 rather	 than	 the	 presence	 of	 “pioneering	 “	 DTCs	 that	 signal	 to	 attract	 further	
tumour	 cells.	 The	 proximity	 to	 the	 bone	 surface	was	 particularly	 accentuated	 in	 the	
T47D	 cell-line.	 Moreover,	 T47D	 seeded	 more	 evenly	 between	 the	 ROIs	 analysed	
compared	to	the	other	cell-lines	 investigated.	The	difference	recorded	 in	the	homing	
of	 the	 two	 ER+ve	 cell-line	 was	 surprising	 since	 MCF7	 and	 T47D	 share	 the	 same	
classification	and	immunoprofile	(luminal	A,	ER+ve,	PR+ve/-ve	and	HER2-ve)	but	it	has	
been	reported	that	these	cell-lines	present	differential	expression	of	a	high	number	of	
protein	involved	in	various	biological	functions	including	carcinogenesis	[222].	
In	 summary,	 my	 data	 demonstrate	 that	 breast	 cancer	 cells	 present	 a	 preferential	
pattern	of	seeding	to	bone	in	 in	vivo	models,	regardless	of	the	route	of	injection,	the	
characteristic	 of	 the	 cell-line	 used	 or	 the	 age	 of	 the	 animals.	 Moreover,	 I	 have	
demonstrated	that	alteration	of	the	bone	cell	population	is	reflected	in	a	modification	
in	the	number	of	cancer	cells	homing	to	bone.	Taken	together,	 the	data	validate	the	
theory	 that	 several	 components	 of	 the	 microenvironment,	 above	 all	 osteoblast,	
osteoclast,	 HSCs	 and	microvasculature,	 influence	 the	metastatic	 process	 not	 only	 in	
late	stages	of	metastasis	formation	but	also	in	the	earlier	steps	of	colonisation.	Further	
characterization	of	 the	 components	of	 this	 niche	 and	 their	 interactions	with	 tumour	
cells	is	required	to	create	a	better	understanding	of	the	early	stages	of	the	metastatic	
process	 and	 consequently	 improve	 the	 therapeutic	 approaches	 for	 patients	 with	 a	
poor	prognosis.	
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Chapter	4 	
Characterisation	of	the	metastatic	niche	in	
young	and	mature	mice	
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4.1	Summary		
During	 dissemination	 to	 distant	 organs,	 breast	 cancer	 cells	 detach	 from	 the	 primary	
site,	enter	 the	circulation	and	 finally	 reach	the	bone	marrow	where	they	can	remain	
dormant	for	extended	periods	of	time.	Despite	the	large	number	of	breast	cancer	cells	
that	successfully	locate	in	the	bone	microenvironment,	only	a	very	limited	number	of	
colonies	develop	 to	 form	overt	 tumours.	The	bone	microenvironment	plays	a	 crucial	
role	in	the	homing	of	cancer	cells	to	the	metastatic	site	and	in	the	maintenance	of	the	
dormant	 state	 and/or	 progression	of	 tumour	 growth,	 but	 the	 cellular	 and	molecular	
components	that	enable	tumour	cells	to	undergo	these	processes	have	not	been	fully	
elucidated.		
The	 aim	 of	 this	 study	 was	 to	 characterise	 in	 vivo	 models	 of	 breast	 cancer	 bone	
metastasis	 in	 young	 animals	 (6-week	 old)	 with	 high	 bone	 turnover	 that	 promotes	
tumour	growth	and	in	mature	animals	(12-week	old)	in	which	dormancy	is	supported.	
Different	aspects	of	the	bone	microenvironment	were	 investigated	using	two-photon	
microscopy	 to	 map	 the	 location	 of	 single	 tumour	 cells	 within	 the	 bone	
microenvironment,	 μCT	 to	 visualise	 the	 bone	 structure	 and	 immunofluorescent	
protocols	 to	 investigate	 variation	 in	 the	 bone	 microvasculature	 of	 the	 two	 animal	
models	used.	
Young	animals	appear	 to	have	a	denser	bone	structure	and	the	organisation	of	 their	
microvasculature	 network	 shows	 an	 expansion	 of	 different	 vessel	 sub-types	 in	 the	
metaphysis	 in	 long	 bones	 when	 compared	 to	 mature	 animal.	 Intriguingly,	 the	 only	
marker	expressed	in	higher	levels	in	the	12-week	old	animal	is	TSP-1,	which	is	known	
to	 support	 tumour	 dormancy.	 The	 results	 described	 here	 highlight	 the	 close	
association	between	 the	different	 components	of	 the	bone	microenvironment,	bone	
turnover	and	the	microvasculature,	and	breast	cancer	cell	dormancy.		
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4.2	Introduction	
The	metastatic	 niche(s)	 is	 the	 region	 of	 bone	where	 breast	 cancer	 cells	 seed.	 These	
regions	of	bone	present	a	complex	microenvironment	in	which	components	of	the	HSC	
niche,	osteoblastic	niche	and	perivascular	niche	are	overlapping	[34],	[39]–[41].	Once	
in	 bone,	 tumour	 cells	 interact	 with	 the	 microenvironment	 receiving	 signals	 that	
influence	 either	 the	 development	 of	 the	 metastasis	 in	 the	 fertile	 soil	 or	 the	
maintenance	of	a	dormant	state	[10],	[16],	[48],	[118],	[211],	[223].	The	importance	of	
the	 extensive	 cross-talk	 between	 tumour	 cells	 and	 the	 microenvironment	 for	 the	
progression	of	disease	explains	why,	despite	hundreds	of	breast	cancer	cells	reaching	
the	 bone	 marrow	 only	 a	 limited	 number	 develop	 to	 form	 secondary	 tumours	 [87],	
[217],	[218],	[224],	[225].	
The	 well-recognised	 concept	 of	 the	 ‘vicious	 cycle’	 between	 osteoclasts	 and	 tumour	
cells	 is	 just	one	example	of	how	the	progression	of	bone	metastasis	 is	 influenced	by	
the	presence	of	cytokines	and	growth	factors	[9],	[12],	[13],	[15].	However	the	specific	
mechanism(s)	 that	 triggers	 DTCs	 to	 escape	 quiescence	 and	 proliferate	 is	 less	 well	
understood.	One	of	 the	major	 issues	 in	 treating	metastatic	breast	 cancer	 is	 that	 it	 is	
not	 known	 which	 patients	 will	 develop	 metastasis	 and	 when	 this	 will	 occur.	 The	
metastases	can	form	decades	after	the	initial	diagnosis,	long	after	the	primary	tumour	
is	removed	or	successfully	treated.	This	is	caused	by	the	presence	of	dormant	tumour	
cells	 in	 the	microenvironment.	 This	 type	 of	 cell	 remains	 quiescent	 in	 the	 secondary	
organ,	neither	proliferating	nor	undergoing	apoptosis	[20],	[209],	[210].		
The	engagement	with	 the	bone	microenvironment	 regulates	 the	preservation	of	 the	
dormant	 state	 or	 the	 transition	 to	 a	 proliferative	 phenotype	 [34].	 It	 is	 a	 well-
recognised	concept	that	the	mechanisms	tumour	cells	use	to	retain	the	quiescent	state	
is	similar	to	the	ones	used	by	the	HSCs	[211].	Even	though	the	exact	mechanism	that	
attract	 these	 cells	 to	 the	 niches,	 keep	 them	 in	 a	 quiescent	 state	 and	 guide	 their	
proliferation	 and	 differentiation	 in	 not	 fully	 understood.	 It	 is	 clear	 that	 both	 the	
endosteal	 and	 the	 perivascular	 component	 of	 the	 HSC	 niches	 contribute	 to	 the	
recruitment	and	preservation	of	HSCs	[34],	[39],	[87],	[226],	[49]–[51],	[62],	[65],	[73],	
[74],	 [86].	 Several	 studies	 have	 reported	 cross-talk	 between	 the	 osteoblastic	 and	
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perivascular	 populations,	 emphasising	 the	 theory	 of	 overlapping	 niches	 rather	 than	
distinct	compartments.	The	HSC	niche	is	in	fact	most	commonly	described	as	a	highly	
vascularised	endosteal	region	[67].	In	addition	to	their	function	in	retaining	HSCs	in	the	
niche,	osteoblasts	have	a	role	 in	 the	attraction	and	 interaction	with	cancer	cells	 that	
colonise	the	marrow	cavity	[87],	[91]–[94],	[227],	[228]	and	it	has	been	proposed	that	
direct	 contact	 between	 osteoblasts	 and	 cancer	 cells	 is	 needed	 for	 tumour	 cell	
proliferation	 in	 the	 bone	 microenvironment,	 in	 the	 early	 stages	 of	 the	 metastatic	
colonisation	[87].	
Less	 well	 understood	 is	 the	 interaction	 between	 tumour	 cells	 and	 the	 perivascular	
niche	 components.	 It	 has	 been	 proposed	 that	 the	 microvasculature	 may	 support	
tumour	 cell	 dormancy	 through	 secretion	 of	 Thrombospondin	 [8],	 [31],	 [35],	 [107],	
[109].	 In	 vitro	 and	 ex	 vivo	 studies	 described	 that	 this	 angiogenesis	 inhibitor	 is	
expressed	 by	 the	 stable	 microvasculature,	 while	 it	 is	 reduced	 in	 the	 presence	 of	
sprouting	 vessels	 where	 its	 expression	 is	 replaced	 by	 the	 tumour-promoting	 factors	
Periostin	and	TGF-β1	[35].			
The	trabecular	region	of	bone	where	the	metastatic	niche(s)	reside	has	a	characteristic	
plasticity	due	to	the	continuous	remodelling	mediated	by	action	of	the	bone	forming	
osteoblasts	 and	 bone-resorbing	 osteoclasts.	 Moreover,	 the	 plasticity	 of	 this	
microenvironment	it	is	also	reflected	in	the	changes	detected	in	the	microvasculature	
of	aging	mice.	Kusumbe	et	al.	described	a	novel	capillary	subtype	(CD31	hi	Endomucinhi,	
H-vessels)	 that	 is	 localised	 in	 the	metaphisys	 of	 the	 bone,	 couples	 angiogenesis	 and	
osteogenesis	and	decreases	with	age	[97],	[221].	In	experimental	models,	tumour	take	
is	reduced	in	ageing	when	compared	to	young	mice	and	changes	in	both	bone	turnover	
and	in	the	perivascular	niche	may	explain	this	observation;	young	animals	represents	a	
tumour	 growth	 promoting	 microenvironment	 while	 the	 bone	 microenvironment	 of	
mature	animals	supports	dormancy.	
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4.3	Aims	
The	 aim	 of	 the	 work	 presented	 in	 this	 chapter	 is	 to	 characterize	 the	 bone	
microenvironment	and	the	perivascular	niche	in	two	in	vivo	murine	models	to	test	the	
following	hypothesis:	
	
The	 differential	 growth	 rate	 of	 breast	 cancer	 bone	metastases	 in	 young	 and	mature	
animal	models	is	caused	by	differences	in	the	bone	microenvironment.	
	
The	main	goals	of	the	work	are	to	use	young	and	mature	mice	to	performed	as	follows:	
• To	assess	the	bone	structure	of	the	in	vivo	models	
• To	compare	the	pattern	of	the	Endomucin	positive	vessel	network	in	young	and	
mature	murine	models	
• To	 determine	 the	 presence	 of	 CD31	 and	 CD34	 positive	 vessels	 and	 relative	
expression	compared	to	Endomucin	vessels	
• To	 investigate	 whether	 there	 are	 difference	 in	 the	 abundance	 of	
Thrombospondin-1	 (TSP-1)	expression	and	TSP-1+ve	cell	populations	between	
the	two	murine	models	analysed		
• To	evaluate	the	changes	in	the	presence	of	Osterix	positive	cell	population	with	
age		
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4.4	Materials	and	Methods	
Detailed	information	can	be	found	in	the	main	Material	and	Methods	Chapter	2.	
4.4.1	Breast	cancer	cell	lines	
The	triple	negative	MDA-MB-231-GFP-IV	breast	cancer	cell	 line	was	cultured	 in	RPMI	
1640	 medium	 enriched	 with	 10%FCS	 while	 MDA-MB-231-NW1-Luc2	 cells	 were	
cultured	 in	DMEM	+	Pyruvate	medium	enriched	with	1%	penicillin/streptomycin	and	
10%FCS	 and	 at	 37°C	 5%CO2.	 Once	 reaching	 confluence,	 breast	 cancer	 cells	 were	
labelled	with	the	lipophilic	dye	Vybrant-CM-DiI	as	explained	in	detail	in	section	2.3.	
4.4.2	In	vivo	study	
The	in	vivo	study	was	carried	out	accordingly	to	local	guidelines	and	with	Home	Office	
approval	under	project	licence	PPL	70/8964	held	by	Professor	Nicola	Brown,	University	
of	Sheffield,	UK.			
To	 assess	 the	differences	 in	 the	microenvironment	of	 young	and	mature	 animals,	 6-	
and	 12-week	 old	 BALB/c	 nude	 mice	 (n=5/age	 group)	 were	 injected	 i.v.	 with	 1x105	
MDA-MB-231-GFP-IV	cells	labelled	with	the	membrane	dye	Vybrant-CM-DiI.	Five	days	
after	 the	 injection,	 animals	 were	 culled	 and	 hind	 limbs	 were	 collected	 for	 ex	 vivo	
analysis	(Figure	4.1).		
To	 visualise	 the	microenvironment	 components	 in	 tumour	 bearing	mice,	 6-week	 old	
BALB/c	nude	mice	(n=24)	were	injected	i.v.	with	0.75x105	MDA-MB-231-NW-Luc2	cells	
labelled	with	the	membrane	dye	Vybrant-CM-DiI.	Tumour	growth	was	monitored	twice	
weekly	using	In	Vivo	Imaging	System	(IVIS).	Animals	were	culled	after	the	detection	of	
a	small	(4	days	after	first	detection),	medium	(7-11	days)	and	large	sized	tumour	(14-17	
days)	and	hind	limbs	were	collected	for	fluorescent	immunohistochemistry	(Figure	4.1).	
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Experimental	outline.	A)	6-	and	12-week	old	female	BALB/c	nude	mice	were	injected	intravenously	(i.v.)	
with	1x105	MDA-MB-231-GFP-IV	cells	 labeled	with	Vybrant-CM-DiI	 (n=5	animals/group).	Animals	were	
culled	five	days	after	the	injection	and	tibiae	and	femora	were	collected	for	ex-vivo	analysis.	B)	6-week	
old	 female	 BALB/c	 nude	mice	 were	 injected	 i.c.	 with	 0.75x105	MDA-MB-231-NW1-Luc2	 cells	 labelled	
with	Vybrant-DiD	 (n=24).	Animals	were	monitored	 twice	weekly	with	 IVIS	and	mice	were	culled	when	
tumour	colonies	were	 formed,	 colonies	grown	 for	0-4	days	were	considered	a	 small	 tumour,	medium	
size	 after	 growth	 of	 7-11	 days	 and	 large	 tumour	 within	 14-17	 days	 after	 the	 first	 detection.	 White	
arrow=tumour	cells	injection	and	black	arrow=culling	time	point.	
4.4.2.1	Collection	and	preparation	of	the	bones	for	two-photon	microscopy	
Animals	 were	 overdosed	 with	 an	 i.p.	 injection	 of	 Pentobarbital	 (50μl)	 and	 cervical	
dislocation	was	used	to	confirm	death.	Hind	 limbs	were	dissected	carefully	removing	
the	tissue	surrounding	the	bones	and	tibiae	and	femora	were	separated.	Femora	were	
wrapped	 in	 aluminium	 foil	 and	 collected	 snap	 frozen	 in	 liquid	 nitrogen.	 Snap	 frozen	
bones	were	placed	 into	 freezing	blocks,	 embedded	with	Cryo-M-Bed	and	 stored	at	 -
80°C.			
Snap	 frozen	 femora	were	 cut	 longitudinally	 using	 a	 Bright	 OTF	 Cryostat	 and	 a	 3020	
microtome	 and	 the	 bones	 were	 then	 placed	 onto	 a	 glass-bottomed	 dish	 with	 the	
exposed	bone	marrow	facing	downwards,	as	described	in	section	2.10.1.		 	
Figure	4.1	Outline	of	the	in	vivo	studies	evaluating	homing	of	bone-seeking	MDA-MB-231	cell-lines	
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4.4.2.2	Collection	and	preparation	of	the	bones	for	micro	computed	tomography	
(µCT)	and	fluorescent	immunohistochemistry	
On	the	day	of	cull,	femora	were	collected	for	two-photon	microscopy	while	were	tibiae	
processed	 for	 micro	 computed	 tomography	 and	 fluorescent	 immunohistochemistry.	
After	 dissection	 tibia	 were	 placed	 in	 4%	 PFA	 for	 up	 to	 6h,	 during	 which	 they	 were	
analysed	 by	 μCT,	 and	 afterwards	 were	 processed	 for	 fluorescent	
immunohistochemistry.	4%	PFA	was	replaced	by	0.5M	EDTA	for	48h	and	bones	were	
then	immersed	in	CPT	solution	and	subsequently	embedded	in	gelatine	as	explained	in	
section	2.9.3.	Gelatine	blocks	were	stored	at	-80°C	until	they	were	cut	into	30μm	thick	
sections	with	the	Microm	HM	560	cryostat.	
4.4.3	Two-photon	microscopy	and	location	of	cancer	cells	within	the	bone	structure	
A	 glass	 bottomed	dish	 containing	 the	 specimen	was	mounted	on	 a	 histological	 slide	
with	the	exposed	bone	marrow	facing	upwards	as	described	in	section	2.10.1.	A	Zeiss	
LSM510	NLO	upright	two-photon	microscope	was	used	to	scan	the	growth	plate	and	
the	metaphysis	area	of	the	bone	(2104μm	×	2525μm	field	of	view	and	70	μm	depth)	a	
Chameleon	two-photon	 laser	at	900nm	was	used	to	visualise	the	bone	structure	and	
HeNe	543nm	to	visualize	Vybrant-CM-DiI	labelled	breast	cancer	cells.	
Volocity	3D	Image	Analysis	software	6.01	was	used	to	analyse	the	reconstructed	three-
dimensional	 image	 acquired	 with	 the	 two-photon	microscope.	 Quantifications	 were	
performed	in	two	different	ROIs,	the	first	one	consisting	of	the	growth	plate	area	and	
the	 second	 one	 of	 the	 trabecular	 region	 of	 the	 bone	marrow.	 Objects	 of	 a	 volume	
larger	than	250μm3	detected	by	the	HeNe	543nm	laser	were	considered	breast	cancer	
cells	and	their	number,	distance	to	the	nearest	bone	surface	and	to	the	closest	cancer	
cell	were	calculated,	as	described	in	section	2.10.3.		
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4.4.4	Micro	computed	tomography	(μCT)	
Micro	 computed	 tomography	 was	 used	 to	 determine	 the	 difference	 in	 the	 bone	
structure	 of	 young	 and	 mature	 animal	 models.	 As	 described	 in	 section	 2.11,	 tibiae	
were	 scanned	 with	 SkyScan	 1272	 during	 the	 incubation	 time	 in	 4%	 PFA	 and	 the	
reconstructed	 images	 were	 analysed	 with	 CTAn	 software	 to	 determine	 the	 VOI.	
Trabecular	 bone	 volume,	 trabecular	 number	 and	 thickness	 were	 the	 parameters	
considered	in	the	analyses	of	the	bone	structure.	
4.4.5	 Immunofluorescence	 protocols	 for	 the	 staining	 of	 the	 perivascular	 niche	
components	
Perivascular	 niche	 components	 were	 stained	 using	 immunofluorescence	 protocols	
using	30μm	 thick	 sections	of	 gelatine	embedded	 tibiae	as	described	 in	 the	 following	
sections.		
4.4.5.1	Visualisation	of	Endomucin	positive	vessels	
Tibiae	frozen	sections	were	incubated	with	an	antibody	against	Endomucin		for	1h	at	
ambient	temperature	or	overnight	at	4°C	after	a	permeabilisation	step	in	0.3%	Triton	
X-100	(30min	ambient	temperature)	and	a	quick	wash	in	PBS.	After	the	incubation	with	
the	 primary	 antibody	 and	 three	washes	 in	 PBS,	 the	 slides	were	 incubated	 for	 1h	 at	
room	temperature	with	a	secondary	antibody	conjugated	with	a	fluorophore.	The	last	
step	 of	 the	 staining	 consisted	 of	 counterstaining	 the	 nuclei	 with	 DAPI	 (Vectashield	
mounting	 medium	 with	 DAPI,	 Vector	 Laboratories	 H-1200;	 Prolong	 Gold	 antifade	
reagent	with	DAPI,	Life	Technologies	P36935)	and	mounting	of	the	coverslips.	
4.4.5.2	Staining	of	CD31	or	CD34	and	Endomucin	positive	vessels	
The	30μm	thick	tissue	section	were	permeabilised	with	0.3%	Triton	X-100	for	30min	at	
ambient	temperature	 followed	by	blocking	 for	15min	with	Streptavidin	and	15min	 in	
Biotin	 (Streptavidin/Biotin	 Blocking	 Kit	 –	 Vector	 Laboratories	 SP-2002).	 Bone	 slides	
were	 then	 incubated	 with	 the	 primary	 antibody	 against	 CD31	 or	 CD34	 for	 1h	 at	
ambient	 temperature.	 The	 sections	 were	 then	 incubated	 for	 40min	 at	 ambient	
temperature	with	a	biotinylated	secondary	antibody	prior	 to	 incubation	 for	30min	at	
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ambient	 temperature	 with	 polyclonal	 rat-IgG.	 Tissue	 sections	 were	 then	 carefully	
washed	 in	 PBS	 and	 staining	 with	 the	 antibody	 against	 Endomucin	 (1h,	 ambient	
temperature)	 followed	by	an	 incubation	 for	40min	at	ambient	 temperature	with	 the	
appropriate	 secondary	 antibody.	 The	 final	 steps	of	 this	 double	 staining,	 consisted	of	
incubation	 for	 20min	 at	 ambient	 temperature	 with	 fluorophore-conjugated	
streptavidin,	 nuclei	 counterstaining	 with	 DAPI	 (Vectashield	 mounting	 medium	 with	
DAPI,	 Vector	 Laboratories	 H-1200;	 Prolong	 Gold	 antifade	 reagent	 with	 DAPI,	 Life	
Technologies	P36935)	and	mounting	of	coverslips.	
4.4.5.3	Visualisation	of	Osterix,	α-SMA	or	Thrombospondin		
Permeabilisation	 of	 the	 frozen	 sections	 was	 performed	 using	 0.3%	 Triton	 X-100	 for	
30min	 at	 ambient	 temperature	 followed	 by	 a	 blocking	 step	 the	 with	
Streptavidin/Biotin	 Blocking	 Kit,	 15min	 incubation	 at	 ambient	 temperature	 for	 each	
reagent.	The	blocking	step	was	followed	by	incubation	with	primary	antibodies	Osterix,	
α-SMA	 or	 TSP-1	 and	 Endomucin	 for	 1h	 at	 ambient	 temperature.	 Prior	 to	 incubation	
with	 fluorophore-conjugated	 streptavidin,	 bone	 sections	 were	 incubated	 with	 the	
appropriate	 secondary	 antibodies.	After	 the	 incubation	with	 streptavidin	 and	 careful	
washing	in	PBS,	nuclei	were	counterstained	with	DAPI	and	coverslips	were	mounted.	
4.4.6	Scoring	of	immunofluorescence	stainings	
Analyses	of	gelatine	embedded	tibiae	were	performed	on	three	non-serial	30μm	thick	
sections	stained	against	different	components	of	the	perivascular	niche.	
4.4.6.1	Quantification	of	Endomucin	positive	vessels	
A	Leica	AF6000	 inverted	fluorescence	microscope	was	used	to	capture	the	 images	of	
the	 immunofluorescent	 staining	 against	 the	 endothelial	 marker	 Endomucin.	 The	
distinctive	 structure	 of	 H-	 and	 L-vessels	 was	 manually	 tracked	 using	 the	 Aperio	
ImageScope	software	and	the	 length,	number	and	area	of	bone	marrow	occupied	by	
the	different	microvessels	were	determined.	
	 130	
4.4.6.2	Quantification	of	vessels	positive	for	both	Endomucin	and	CD31	or	CD34	
Immunofluorescent	stained	tissue	sections	were	imaged	using	a	Zeiss	LSM880	AiryScan	
Confocal	microscope	and	ImageJ	software	was	used	to	quantify	the	amount	of	vessels	
positive	for	both	the	markers	CD31/CD34	and	Endomucin.	The	region	of	 interest	was	
manually	drawn	around	the	metaphysis	area	of	the	bone	marrow	and	the	expression	
of	 CD31	 or	 CD34	 was	 calculated	 as	 a	 percentage	 of	 the	 microvasculature	 stained	
positive	for	the	endothelial	marker	Endomucin.		
4.4.6.3	Quantification	of	Osterix,	α-SMA	or	Thrombospondin	expression		
Similar	 to	 the	 CD31/CD34	 staining,	 images	 were	 captured	 with	 the	 confocal	
microscope	Zeiss	LSM880	AiryScan	and	the	expression	of	Osterix,	α-SMA	or	TSP-1	was	
measured	within	the	desired	ROI	using	ImageJ	software.	The	function	‘cell	counter’	of	
the	 software	was	also	used	 to	count	 the	number	of	α-SMA	positive	vessels	or	TSP-1	
positive	megakaryocytes.	 For	 Osterix	 positive	 cells	 the	 function	 of	 the	 ‘cell	 counter’	
was	 used	 to	manually	 quantify	 a	 few	 slides	 and	 the	 numbers	 obtained	 where	 then	
compared	with	 the	 values	 produced	 by	 the	 automatic	 function	 ‘3D	 object	 counter’.	
Since	 there	was	 a	 high	 correlation	between	 the	 two	 values	 obtain,	 all	 further	 tissue	
sections	were	analysed	using	the	automatic	function.	
4.4.7	Statistical	analysis	
GraphPad	 Prism	 software	 (versions	 6.0	 and	 7.0)	 was	 used	 to	 perform	 statistical	
analyses,	as	stated	 in	each	figure	 legend.	A	student	T-test	and	Two-way	ANOVA	with	
Tukey	post	test	were	used	and	a	p-value	of	p	<0.05	was	considered	significant.	
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4.5	Results	
It	is	a	broadly	accepted	concept	that	homing	to	bone	is	necessary	but	not	sufficient	for	
breast	 cancer	 cells	 to	develop	over	 tumour,	 cancer	 cells	 in	 fact	need	a	 fertile	 soil	 to	
allow	their	growth.	The	exact	mechanisms	that	enable	the	establishment	of	secondary	
colonies	 have	 not	 been	 fully	 elucidated	 but	 it	 has	 been	 reported	 that	 high	 bone	
turnover	promotes	 this	process	 [101](Figure	4.2).	The	present	 study	 investigated	 the	
differences	in	the	bone	microenvironment	of	young	(6-week	old)	and	mature	(12-week	
old)	 animal	models	 to	 identify	 components	playing	a	 role	 in	 the	maintenance	of	 the	
dormant	state	and/or	progression	of	tumour	growth.	
	
Representative	image	of	the	animal	model	used	in	our	laboratory.	Mice	were	injected	i.c.	with	MDA-MB-
231	 cells	 transfected	 with	 luciferase	 (MDA-MB-231-NW1-Luc2),	 in	 vivo	 tumour	 growth	 was	 detected	
over	 time	using	an	 in	 vivo	 imaging	 system	 (IVIS).	 Images	 show	 tumour	growth	14	days	post	 injection,	
young	animals	develop	tumour	quicker	than	mature	animals	in	which	no	colonies	was	detected	at	this	
time	point.					 	
Figure	4.	2	In	vivo	tumour	model	
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4.5.1	Breast	cancer	cell	bone	colonisation	in	young	and	mature	animal	models	
As	shown	in	figure	4.1,	when	tumour	cells	(1x105	cells)	are	injected	in	young	mice	they	
develop	 tumour	 faster	 than	when	 the	 same	 number	 of	 cells	 are	 injected	 in	mature	
animal	model.	To	verify	that	this	difference	in	the	growth	of	metastasis	was	not	due	to	
the	number	of	cells	reaching	the	tumour	microenvironment,	1x105	MDA-MB-231-GFP-
IV	cells	 labelled	with	Vybrant-CM-DiI	were	 injected	 i.v.	 in	6-	and	12-week	old	BALB/c	
nude	 (n=5/group).	 	 Five	days	after	 injection	 the	animals	were	 culled	and	 long	bones	
were	 collected	 for	 two-photon	 microscopy	 (femora)	 and	 for	 fluorescent	
immunohistochemistry	 (tibiae).	 	 As	 described	 in	 section	 3.5.6,	 the	 previous	 in	 vivo	
study	 performed	 to	 map	 the	 location	 of	 single	 tumour	 cells	 in	 the	 bone	
microenvironment	of	young	and	mature	animals	showed	a	slight	cytotoxic	effect	due	
to	the	concentration	of	the	membrane	dye	used.	In	this	case	a	concentration	of	2μM	
of	Vybrant-CM-DiI	(instead	of	5μM)	was	used,	resulting	in	a	considerable	reduction	of	
bones	 in	 which	 no	 cells	 were	 detected	 (1	 out	 of	 5	 femora	 from	 young	 mice).	 The	
preferential	 pattern	 of	 homing	 of	 this	 breast	 cancer	 cell	 line	 was	 maintained	 with	
fewer	 cells	 homing	 to	 ROI2	 compared	 to	 ROI1,	 even	 though	 this	 did	 not	 reach	 the	
significance	level	in	the	young	animal	group	(p=0.1654	in	6-week	old	mice,	p=0.0119	in	
12-week	 old	 mice).	 The	 variability	 between	 cells	 counted	 was	 also	 reduced	 with	 a	
range	of	39-390	(112.60±70.86)	and	46-101	(85.81±13.30)	cells/mm3	in	ROI1	and	0-21	
(4.25±4.25)	and	0-55	 (22.64±11.74)	cells/mm3	 in	ROI2	 for	young	and	mature	animals	
respectively	(figure	4.3A).	
Irrespective	of	age,	breast	cancer	cells	 locate	close	 to	 the	bone	surface	with	a	mean	
value	of	42.76±15.55μm	(18-66μm	range)	in	6-week	old	and	33.95±7.77μm	(21-56μm	
range)	 in	12-week	old	mice	 in	the	trabecular	region	of	the	bone.	 In	the	growth	plate	
region,	 these	 values	 were	 significantly	 reduced	 in	 the	 mature	 group	 (mean	 value	
7.38±4.80μm,	 range	0-16μm,	p=0.0456)	while	 in	 young	animals	 this	 comparison	was	
not	possible	since	only	one	bone	contained	cells	in	this	ROI	(figure	4.3B).	As	described	
in	 the	previous	chapter,	 tumour	cells	prefer	 to	home	significantly	closer	 to	 the	bone	
surface	than	to	other	tumour	cells	 (167.60±34.63μm,	p=0.0137	 in	young	animals	and	
144.50±10.29μm,	 p=0.0001	 in	mature	 animals).	 This	 analysis	was	 carried	out	 only	 in	
ROI1	because	of	the	low	number	of	bones	in	which	tumour	cells	were	detected	in	ROI2.		
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Figure	4.3	Homing	of	MDA-MD-231-GFP-IV	cells	in	young	and	mature	animals	
A)	Graph	shows	the	number	of	MDA-MB-231-GFP-IV	cells	detected	 in	6-	and	12-week	old	mice	5	days	
after	 tumour	 cell	 injection	 (n=5	 animals,	 4	 bones	 analysed/group),	 represented	 as	 mean	 ±	 SEM.	 (B)	
Distances	of	 the	tumour	cells	 to	the	nearest	bone	surface	 in	ROI1.	 (C)	and	(D)	are	examples	of	a	two-
photon	scan	of	6-	and	12-week	old	animals	showing	bone	(white),	Vybrant-CM-DiI+		cells	(pink	and	pink	
arrows)	and	Vybrant-CM-DiI+	cells	(pink	and	pink	arrows).	Scale	bars	100μm.	Two-way	ANOVA	and	Tukey	
post	test,	graphs	show	mean±SEM,	**p≤0.005	and	ns	is	not	significant.	 	
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Taken	 together,	 these	 results	 confirm	 the	 pattern	 of	 breast	 cancer	 to	 bone	
colonisation	with	a	significantly	higher	number	of	events	encounter	in	ROI1	compared	
to	ROI2,	a	 real	close	proximity	 to	 the	nearest	bone	surface	and	a	significantly	higher	
distance	to	the	nearest	tumour	cell.	Moreover,	the	data	showed	in	this	section	confirm	
that	 there	 is	 no	 significant	 difference	 in	 the	 early	 steps	 of	 the	 breast	 cancer	 bone	
metastasis,	neither	in	the	number	of	cells	homing	to	bone	nor	in	their	location	within	
the	bone	microenvironment,	suggesting	that	the	differences	in	outgrowth	is	due	to	the	
microenvironmental	signal	that	the	tumour	cells	receive	once	arrived	in	the	bone.	
4.5.2	Trabecular	bone	of	young	animals	is	more	dense	than	bone	of	mature	animals	
To	 investigate	 the	 differences	 between	 the	 bone	 structure	 of	 young	 and	 mature	
animals,	micro-Computed	 Tomography	 (µCT)	was	 performed	 as	 explained	 in	 section	
2.11	comparing	tibiae	of	6-	and	12-week	old	BALB/c	nude	female	mice	(n=7/group).		
µCT	analysis	 revealed	that	 there	was	no	difference	 in	 the	trabecular	bone	volume	at	
the	two	different	ages	(p=0.1023)	while	a	significant	difference	was	found	both	in	the	
number	and	in	the	thickness	of	the	trabeculae.	As	shown	in	figure	4.4,	the	trabeculae	
of	 young	 animals	 were	 significantly	 thinner	 (p<0.0001)	 and	 their	 number	 was	
significantly	higher	(p=0.0034)	when	compared	with	mature	animals	(table	4.1).		
	
Table	4.1	Summary	of	µCT	analysis	
Analysis	 Age	of	animals	 Mean	±	SEM	 Student	t-test	
Trabecular	volume	
(BV/TV	%)	
6-week	old	 14.84±0.73	
NS	
12-week	old	 13.04±0.71	
Trabecular	thickness	
(Tb.	Th.)	
6-week	old	 0.03±0.00	
****	
12-week	old	 0.04±0.00	
Trabecular	number	
(Tb.	N.)	
6-week	old	 4.86±0.33	
**	
12-week	old	 3.44±0.21	
NS=	not	significant	p>0.05,	**	is	p≤0.01,	****	is	p≤0.0001	
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Figure	4.	4	Quantification	of	trabecular	bone	volume,	thickness	and	number	
A)	Quantification	of	trabecular	bone	volume	(BV/TV),	(B)	trabecular	thickness	and	(C)	number	of	tibiae	
of	 6-	 and	 12-week	 old	 animals	 (n=5	 animals,	 7	 bones	 analysed/group).	 Student	 t-test,	
**p<0.01,***p<0.0001	and	ns	is	not	significant.	
	
This	bone	micro	architecture	is	shown	in	figure	4.5	and	4.6	where	it	is	highlighted	how	
the	trabecular	bone	of	young	animal	consists	in	a	much	more	dense	spongy	structure	
compared	to	the	mature	animals.	
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4.5.3	Differences	in	the	metastatic	niche	between	young	and	mature	mice	
By	developing	an	innovative	protocol	for	the	cryopreservation	and	immunofluorescent	
staining	 against	 endothelial	 cells,	 Kusumbe	 et	 al.	 made	 it	 possible	 to	 visualise	 the	
microvasculature	of	 the	bone	marrow	 [25],	 [97].	With	 the	help	of	Dr	Russell	Hughes	
and	 Dr	 Hannah	 Brown	 (University	 of	 Sheffield,	 UK)	 we	 modified	 this	 protocol	 to	
visualise	the	bone	marrow	microvasculature	and	other	components	of	the	perivascular	
niche	using	the	equipment	available	in	our	department.		
4.5.3.1	Young	animals	have	more	osteoprogenitors	cells	than	mature	animals	
To	visualise	the	osteoprogenitor	component	of	the	bone	microenvironment	of	young	
and	mature	animals,	tibia	sections	were	stained	with	an	antibody	against	Osterix	using	
the	 immunofluorescent	 protocol	 described	 in	 section	 2.14.3	 (figure	 4.7).	 Images	 of	
three	non-consecutive	30µm	section	of	tibia	(n=3/ages)	were	captured	using	the	Zeiss	
LSM880	 AiryScan	 Confocal	 microscope.	 The	 area	 of	 bone	 marrow	 analysed	 was	
2.50±0.25mm2	 for	 the	 6-week	 old	 animals	 and	 2.30±0.99mm2	 for	 the	 12-week	 old	
animals	 (p=0.5059)(figure	4.8).	Osterix+	cells	were	 found	mostly	 in	 the	metaphysis	of	
the	bone	section	in	close	proximity	to	the	Endomucin+	vessels	(figure	4.7)	and	Osterix	
expression	overall	was	 higher	 in	 young	 animals	 compared	 to	mature	mice,	 although	
this	 was	 not	 significant	 (p=0.1241)(figure	 4.8).	 The	 size	 of	 the	 objects	 detected	was	
measured	 to	 verify	 that	 only	 cells	 of	 the	 same	 size	 were	 stained	 with	 Osterix,	
90.28±0.66µm3	 and	 88.64±2.93µm3	 for	 6-	 and	 12-week	 old	 animals	 respectively	
(p=0.6147)	 (figure	 4.8).	 Three	 slides	 were	 chosen	 at	 random	 and	 the	 number	 of	
Osterix+	cells	were	counted	both	manually,	using	the	‘cell	counter’	function	of	ImageJ,	
and	automatically,	the	‘3D	object	counter’.	The	value	obtained	were	compared	using	a	
paired	 Student’s	 t-test	 and	 no	 significant	 difference	 was	 detected	 (p=0.5503);	
moreover	a	very	strong	positive	correlation	was	observed	when	a	Pearson	correlation	
test	 was	 performed	 (r=0.9713)(figure	 4.8).	 Following	 confirmation	 of	 the	 high	
reliability	of	the	automatic	quantification,	this	system	was	used	to	count	the	number	
of	Osterix+	 cells	 of	 the	 entire	 dataset.	 As	 expected,	 a	 significantly	 higher	 number	 of	
osteoprogenitors/mm2	 of	 the	 bone	 marrow	 area	 analysed	 was	 observed	 in	 young	
animals	compared	to	the	mature	animals	(273.80±4.43	vs	230.40±6.30;	p=0.0049).	
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Figure	4.8	Quantification	of	immunofluorescent	staining	against	Osterix	
A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	Osterix.	(C)	average	
size	of	cells	stained	with	Osterix.	(D)	and	(E)	are	comparisons	between	Osterix+	cells	counted	manually	
vs	 automatically	 analysed	 with	 Pearson	 comparisons	 and	 paired	 t-test	 respectively.	 (F)	 Number	 of	
Osterix+	 cells	 detected/mm2	 using	 the	 automatic	 function	 of	 ImageJ.	 Graphs	 show	mean	 ±	 SEM	 (n=5	
animals,	3	bones	analysed/group),	**p<0.01.	
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4.5.3.2	Endomucin	expression	is	higher	in	mature	mice	than	in	young	mice	
Endomucin	is	a	marker	expressed	both	in	the	metaphysis	and	in	the	diaphysis	of	long	
bones,	 therefore	 this	 marker	 was	 used	 to	 visualise	 the	 intricate	 microvasculature	
network	within	 the	 bone	marrow.	 Gelatine	 embedded	 frozen	 sections	 of	 tibia	were	
stained	 using	 the	 immunofluorescent	 protocol	 against	 the	 endothelial	 marker	
Endomucin	described	 in	section	2.14.3.	Three	non-consecutive	sections	were	stained	
for	each	bone	(n=9	and	n=10	for	6-	and	12-week	old	animals	respectively)	and	images	
were	 taken	 with	 an	 inverted	 widefield	 fluorescence	 microscope	 Leica	 AF6000.	 As	
shown	 in	 figure	 4.9B,	 a	 surface	 area	 of	 bone	marrow	of	 approximately	 2.5mm2	was	
analysed	 for	 both	 ages	 (2.67±0.13	 and	 2.34±0.14	 for	 6-	 and	 12-week	 old	 animals	
respectively;	 p=0.1163).	 The	 overall	 expression	 of	 the	 Endomucin	 marker	 was	
significantly	 higher	 (p=0.0123)	 in	 the	 mature	 group	 (16.16±0.70)	 compared	 to	 the	
young	mice	(12.99±0.90)	(figure	4.9C).	
	 	
	 142	
	
Figure	4.9	Immunofluorescent	staining	against	Endomucin	
A)	Immunofluorescent	staining	of	vessels	was	performed	on	gelatin	embedded	tibiae	(30	µm)	of	6-	and	
12-week	old	female	BALB/c	nude	mice	(Endomucin	1:100,	goat	anti-rat	Alexa	flour	555	1:200,	DAPI	to	
counterstain	nuclei).	 (B)	Area	of	bone	marrow	analysed	 for	both	ages.	 (C)	Percentage	of	area	of	bone	
marrow	 analysed	 expressing	 Endomucin.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals/group,	 9	 bones	
analysed	 6-week	 old	 and	 10	 bones	 analysed	 12	 week-old),	 Student	 t-test,	 *p<0.05	 and	 ns	 is	 not	
significant.	Scale	bar	250	µm.		 	
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4.5.3.2.1	Area	occupied	by	different	vessels	sub-types	
As	 elegantly	 explained	 by	 Kusumbe	 et	 al.	 [97],	 the	 bone	 vascular	 bed	 contains	 of	 a	
newly	 identified	 vessel	 subtypes	 that	 couple	 angiogenesis	 and	 osteogenesis.	 This	
consists	 of	 straight	 column	 like	 vessels	 interconnected	 by	 loops	 (H-vessels)	 in	 the	
metaphysis	 of	 bones,	 while	 in	 the	 diaphysis	 the	 microvasculature	 has	 a	 more	
sinusoidal	 conformation	 creating	 a	more	 extensive	network	 (L-vessels).	Using	Aperio	
ImageScope	software,	vessels	were	manually	tracked	using	the	specific	structure	of	H-	
and	L-vessels	to	discriminate	between	the	two	different	sub-types.	The	first	parameter	
measured	was	the	area	of	bone	marrow	occupied	by	H-	and	L-vessels.	There	was	no	
difference	 in	 the	 area	 occupied	 by	 L-vessels	 between	 the	 two	 ages	 (p=0.7320),	
however	 for	 the	H-vessels	 the	difference	was	not	 significant	 (p=0.0603)(figure	4.10B	
and	C).	When	considering	the	surface	occupied	by	the	two	vessel	sub-types	within	the	
age	 groups,	 a	 significant	 difference	 was	 detected	 only	 in	 the	 young	 animal	 group	
(p=0.0328,	p=0.3073	for	the	mature	mice)	(figure	4.10D	and	E).	However,	irrespective	
of	age,	these	comparisons	were	significant	when	the	area	occupied	by	H-	and	L-vessels	
was	normalised	to	the	area	of	bone	analysed	(p=0.0082	6-week	old,	p=0.0359	12-week	
old).	 These	 data	 highlight	 that	 the	 H-vessels	 occupied	most	 of	 the	 area	 analysed	 in	
both	age.	No	changes	were	detected	when	H-	and	L-vessel	area	were	compared	in	the	
two	age	groups	(6-week	old	vs	12-week	old;	p=0.4211	vs	p=0.3209)(figure	4.11).		
These	results	suggest	that	the	total	area	of	bone	analysed	was	the	same	in	each	age	
group,	 the	 surface	 occupied	 by	 H-vessels	 slightly	 decrease	 with	 age	 and	 that	
irrespective	of	age,	the	percentage	of	area	occupied	by	H-vessels	is	greater	than	that	
occupied	by	L-vessels.	
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Figure	4.10	Quantification	of	area	of	bones	occupied	by	H-	and	L-vessels	
A)	Schematic	 illustration	of	areas	of	bone	marrow	occupied	by	H-	and	L-vessels.	 (B)	and	 (C)	 show	the	
area	of	bones	occupied	by	the	two	vessels	sub-types	in	the	different	ages.	(D)	and	(E)	display	how	the	
vessels	 sub-types	 are	 distributed	 within	 the	 two	 ages	 analysed.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	
animals/group,	 9	 bones	 analysed	 6-week	 old	 and	 10	 bones	 analysed	 12	 week-old),	 Student	 t-test,	
*p<0.05	and	ns	is	non-significant.	 	
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A)	and	(B)	show	the	percentage	of	area	of	the	bone	marrow	occupied	by	H-	and	L-	vessels,	while	(C)	and	
(D)	define	 the	proportion	of	bone	marrow	occupied	by	 the	 two	vessels	 sub-types	within	 the	different	
ages.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals/group,	 9	 bones	 analysed	 6-week	 old	 and	 10	 bones	
analysed	12	week-old),	Student	t-test,	*p<0.05,	**	p<0.01	and	ns	is	not	significant.		 	
Figure	4.11	Percentage	of	bone	marrow	occupied	by	H-	and	L-vessels
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4.5.3.2.2	Reorganisation	of	the	vascular	bed	with	aging	
Bone	turnover	decreases	during	aging	and	Kusumbe	et	al.	stated	that	the	expression	of	
the	vessel	subtype	that	couples	angiogenesis	and	osteogenesis	is	reduced	in	aged	mice	
(11-	 and	 70-week	 old	 compared	 to	 4-week	 old)	 [97].	 To	 verify	 how	 this	 particular	
component	of	the	microvascular	niche	changes	with	age,	the	number	and	length	of	H-	
and	L-vessels	were	measured	and	compared	between	the	two	age	groups.	
Unexpectedly,	 12-week	 old	 animals	 had	 a	 significantly	 higher	 total	 number	 of	
vessels/mm2	 when	 compared	 with	 young	 animals	 (p=0.0179).	 The	 vessels	 were	
analysed	 separately	 as	 H-	 and	 L-vessels,	 there	 was	 no	 difference	 in	 the	 number	 of	
column	 like	 (H)	 vessels	 of	 the	metaphysis	 between	 the	 two	 ages	 (p=0.2893).	 The	 L-
vessels	located	in	the	diaphysis	of	the	bone	appeared	to	be	more	numerous	in	mature	
animals	 but	 this	 did	 not	 reach	 statistical	 significance	 (p=0.0734)(figure	 4.12).	
Irrespective	 of	 age,	 H-vessels	 were	 significantly	 fewer	 than	 L-vessels	 p-value	 were	
0.0340	and	0.0003	for	the	6-	and	12-week	old	animals	respectively.		
As	explained	in	the	previous	section,	there	were	some	differences	in	the	area	occupied	
by	 the	different	vessels	 in	mature	and	aged	mice.	To	understand	 if	 the	difference	 in	
the	 number	 of	 vessels/mm2	was	 due	 to	 these	 changes,	 the	 number	 of	 vessels	were	
normalised	 against	 the	 surface	 occupied	 by	 the	 vessel	 subtype	 analysed	 and	 not	
against	 the	 total	 bone	 area	 (figure	 4.13).	 Regardless	 of	 age,	 the	 number	 of	 H-
vessels/mm2	was	significantly	 lower	than	the	number	of	L-vessels/mm2	counted	with	
Aperio	 ImageScope	 with	 a	 p-value	 <0.0001	 for	 both	 young	 and	 mature	 mice.	
Surprisingly	the	number	of	both	H-	and	L-vessels/mm2	increased	significantly	with	age,	
p=0.0082	and	p=0.0359	respectively	(figure	4.13).	Vessel	 length	differed	between	the	
two	vessel	 sub-types,	with	a	 visible	greater	elongation	of	 the	vessels	present	on	 the	
metaphysis	of	the	bone	compared	to	the	ones	found	 in	the	diaphysis	of	both	groups	
(p<0.0001).	 While	 the	 L-vessels	 maintained	 their	 length	 during	 the	 aging	 process	
(p=0.5361),	 the	 length	 of	 H-vessels	 was	 considerably	 reduced	 in	 12-week	 old	 when	
compared	with	6-week	old	animals	(p=0.0052)(figure	4.14).	
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A)	Illustration	of	the	area	used	in	this	analysis.	(B)	Total	number	of	vessels	counted	in	both	ages.	(C)	and	
(D)	show	the	number	of	H-	and	L-vessels/mm2	of	total	area	of	bone	in	the	different	ages.	(E)	and	(F)	are	
the	 number	 of	 H-	 and	 L-vessels	 in	 young	 and	 mature	 animal.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	
animals/group,	 9	 bones	 analysed	 6-week	 old	 and	 10	 bones	 analysed	 12	 week-old),	 Student	 t-test,	
*p<0.05,		***	p<0.001	and	ns	is	not	significant.	
Figure	4.12	Number	of	H-	and	L-vessels	quantified	in	the	total	area	of	bone	marrow	
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Figure	4.13	Quantification	of	the	number	of	H-	and	L-vessels	
A)	 Representative	 images	 of	 the	 H-vessels	 (yellow)	 and	 L-vessels	 (red)	manually	 tracked	 with	 Aperio	
ImageScope	software.	 (B)	and	 (C)	 show	the	number	of	H-	and	L-vessels/mm2	of	area	occupied	by	 the	
vessel	sub-type	considered	in	the	different	ages.	(E)	and	(F)	are	the	number	of	H-	and	L-vessels	in	young	
and	mature	animal.	Scale	bar	250µm.	Graphs	show	mean	±	SEM	(n=5	animals/group,	9	bones	analysed	
6-week	old	and	10	bones	analysed	12	week-old),	Student	t-test,	*p<0.05,	**	p<0.01	and	****	p<0.0001.	 	
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A)	and	 (B)	average	 length	of	H-	and	L-	vessels	of	6-	and	12-week	old	animals	 respectively.	 (C)	and	 (D)	
comparisons	of	H-	and	L-vessels	average	length	between	the	two	ages	analysed.	Graphs	show	mean	±	
SEM	(n=5	animals/group,	9	bones	analysed	6-week	old	and	10	bones	analysed	12	week-old),	Student	t-
test,	**	p<0.01	and	****	p<0.0001.	
	
The	 data	 indicate	 that	 even	 though	mature	 animals	 appear	 to	 have	more	 vessels	 in	
their	microenvironment,	the	vessels	in	the	metaphysis	shorten	with	age	reflecting	the	
reduced	osteogenesis	in	aging	animals.	
	 	
Figure	4.14	Average	length	of	the	two	vessels	sub-types	
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4.5.3.3	Ageing	results	in	decreased	CD31	expression	
In	 addition	 to	 the	 characteristic	 elongated	 column	 like	 shape,	 the	 H-vessels	 are	
characterised	 by	 expressing	 high	 levels	 of	 the	 platelet	 endothelial	 cell	 adhesion	
molecule	(PECAM-1),	known	as	cluster	of	differentiation	31	(CD31)	[97].	
To	quantify	the	changes	in	expression	of	this	marker	with	age,	three	non-consecutive	
sections	 of	 tibiae	 were	 stained	 both	 for	 Endomucin	 and	 CD31	 using	 the	 protocol	
described	 in	 section	 4.4.5.2	 and	 the	 tissue	 slides	 were	 then	 imaged	 using	 a	 Zeiss	
LSM880	AiryScan	Confocal	microscope.		As	for	the	images	acquired	using	the	inverted	
widefield	 fluorescence	 microscope	 Leica	 AF6000,	 the	 image	 obtained	 using	 the	
confocal	microscope	demonstrated	no	difference	in	the	size	of	the	bone	marrow	area	
analysed	 between	 the	 two	 groups	 studied	 (p=0.2754).	 The	 trend	 of	 an	 increased	
Endomucin	 expression	 in	 the	 mature	 animals	 compared	 to	 the	 young	 ones	 was	
maintained,	even	though	in	this	case	it	did	not	reach	the	significance	level	(p=0.1839)	
(figure	 4.15A	and	B).	 	 The	overall	 expression	of	 CD31	 and	 the	percentage	of	 vessels	
expressing	 both	 endothelial	 markers	 were	 significantly	 higher	 in	 the	 6-week	 old	
compared	 to	 the	 12-week	 old	 animals,	 p=0.0278	 and	 p=0.0081	 respectively	 (figure	
4.15C	and	D).	
The	number	of	CD31+	vessels/mm2	in	the	total	bone	marrow	surface	analysed	was	not	
different	between	the	two	age	groups	(p=0.4530).	Unexpectedly,	mature	animals	had	
significantly	more	CD31+	 vessels/mm2	 than	 young	 animals	when	we	 considered	only	
the	area	occupied	by	this	sub-type	of	vessels	(p=0.0025).	Even	though	the	number	of	
CD31+	was	increased	in	the	12-week	old	mice,	these	vessels	were	significantly	shorter	
compared	to	the	6-week	old	group	(p=0.0137),	explaining	why	the	overall	expression	
of	this	marker	was	reduced	with	aging	(figure	4.16).	
CD31	 quantification	 highlighted	 the	 overall	 decreased	 expression	 of	 CD31	 and	 in	
particular	CD31+Endomucin+	vessels.	This	vessel	subtype	was	 increased	 in	aged	mice,	
but	 the	 microvasculature	 positive	 for	 CD31	 in	 mature	 mice	 did	 not	 exhibit	 the	
characteristic	column-like	shape,	appearing	much	shorter	than	the	vessels	detected	in	
young	animals.	
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A)	Area	of	bone	marrow	analysed	 in	the	two	different	ages.	B)	and	(C)	show	the	overall	expression	of	
Endomucin	and	CD31	respectively	while	(D)	displays	the	percentage	of	Endomucin+	vessels	that	are	also	
expressing	CD31.	Graphs	show	mean	±	SEM	(n=5	animals	and	3	bones	analysed/group),	Student	t-test,	*	
p<0.05,	**	p<0.01	and	ns	is	not	significant.	
	 	
Figure	4.16	Quantification	of	immunofluorescent	staining	against	CD31	
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Figure	4.17	Quantification	of	CD31+	vessels	
A)	Shows	the	number	of	CD31+	vessels/mm2	in	the	total	area	of	bone	while	(B)	shows	this	quantification	
normalised	 to	 the	area	of	bone	marrow	occupied	by	 this	vessel	 sub-type.	 (C)	 is	 the	average	 length	of	
CD31+	 vessels	 of	 young	 and	 mature	 animals.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals	 and	 3	 bones	
analysed/group),	Student	t-test,	*	p<0.05	and	**	p<0.01.	 	
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4.5.3.4	Aged	animals	have	less	expression	of	CD34	
To	further	characterise	the	perivascular	niche,	the	 immature	vasculature	was	stained	
for	the	endothelial	marker	CD34	using	the	protocol	described	in	section	4.4.5.2.	
Quantification	 of	 the	 double	 staining	 of	 Endomucin	 and	 CD34	was	 performed	 in	 an	
area	 of	 approximately	 2.5mm2	 for	 both	 age	 groups,	 2.67±0.19	 and	 2.53±0.21	 for	 6-
week	 and	 12-week	 old	 respectively	 (p=0.6294).	 There	 was	 trend	 of	 increased	
Endomucin	 expression	 in	 the	 mature	 animals	 compared	 to	 the	 young	 animals,	
however	 this	 did	 not	 reach	 statistical	 significance	 (p=0.1367).	 The	overall	 expression	
pattern	of	CD34	and	percentage	of	Endomucin+	and	CD34+	vessels	were	comparable	to	
CD31	 expression,	with	 a	 significantly	 higher	 lever	 in	 6-week	 old	mice,	p=0.0470	 and	
p=0.0125	respectively	(figure	4.19).	
Between	 the	 two	 groups	 analysed	 there	was	 no	 difference	 in	 the	 number	 of	 CD34+	
vessels/mm2	counted	in	the	total	area	of	bone	marrow	analysed	(p=0.2722).	however	
in	 the	 area	 containing	 CD34+	 vessels,	 the	mature	 animals	 had	 a	 significantly	 higher	
number	of	CD34+	vessels/mm2	(p=0.0007)	and	similar	to	the	CD31+	vessels,	these	were	
considerably	shorter	than	in	the	young	animals	(p=0.0003)	(figure	4.20).	
Aged	mice	demonstrated	loss	of	CD34+	expression	and	this	is	due	to	the	reorganisation	
of	the	vasculature,	with	a	higher	number	of	short	vessels	compared	to	young	animals.	
This	 change	 in	 the	 shape	 of	 the	 CD34+	 vessels	 could	 contribute	 to	 the	 dormancy	
promoting	microenvironment	of	the	mature	animals.		
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A)	Area	of	bone	marrow	analysed	 in	the	two	different	ages.	B)	and	(C)	show	the	overall	expression	of	
Endomucin	and	CD34	respectively	while	(D)displays	the	percentage	of	Endomucin+	vessels	that	are	also	
expressing	CD34.	Graphs	show	mean	±	SEM	(n=5	animals	and	3	bones	analysed/group),		Student	t-test,	
*	p<0.05	and	ns	is	not	significant.	
	 	
Figure	4.19	Quantification	of	immunofluorescent	staining	against	CD34	
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Figure	4.20	Quantification	of	CD34+	vessels	
A)	 Represents	 the	 number	 of	 CD34+	 vessels/mm2	 in	 the	 total	 area	 of	 bone	 while	 (B)	 shows	 this	
quantification	 normalised	 to	 the	 area	 of	 bone	 marrow	 occupied	 by	 this	 vessel	 sub-type.	 (C)	 is	 the	
average	length	of	CD34+	vessels	of	young	and	mature	animals.	Graphs	show	mean	±	SEM	(n=5	animals	
and	3	bones	analysed/group),	Student	t-test,	***	p<0.001.	 	
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4.5.3.5	Arterial	component	of	the	bone	microenvironment	does	not	change	with	age	
It	has	been	reported	that	alpha-smooth	muscle	actin	 (α-SMA)	covered	arteries	enter	
the	 bone	 through	 the	 cortical	 bone.	 The	 bone	 diaphysis	 contains	 a	 few	 large	 un-
branched	 whereas	 surrounding	 the	 growth	 plate	 region	 these	 structure	 are	 more	
branched	[97].	
To	 detect	 the	 arterial	 component	 of	 the	 bone	 microenvironment,	 the	
immunofluorescent	 protocol	 described	 in	 section	 2.14.3	 was	 performed	 using	 an	
antibody	against	α-SMA.	
The	 area	 of	 bone	marrow	 imaged	with	 the	 Zeiss	 AiryScan	 confocal	microscope	was	
2.19±0.19mm2	 and	 1.90±0.10mm2	 in	 young	 and	 mature	 animals,	 respectively	
(p=0.3072).	 Regardless	 of	 age,	 only	 few	 α-SMA+	 vessels/mm2	 were	 detected	 in	 the	
bone	 marrow	 (1.27±0.41	 and	 1.38±0.63,	 young	 and	 mature	 animals	 respectively,	
p=0.8934)	and	therefore	the	overall	expression	of	this	marker	was	very	low	0.07±0.02	
in	6-week	old	and	0.04±0.00	in	12-week	old	mice	(p=0.2781)	(figure	4.22).			
As	 shown	 in	 figure	 4.21,	 the	majority	 of	 α-SMA+	 vessels	 were	 detected	 outside	 the	
bone	marrow	 in	 the	muscle	 surrounding	 the	bone.	For	 this	 reason	 the	analysis	were	
repeated	 to	 include	 the	 entire	 region	 imaged	 with	 the	 confocal	 microscope	
(3.88±0.11mm2	and	3.93±0.38mm2,	young	and	mature	animals	respectively,	p=0.8925).	
Even	including	the	tissue	adjacent	the	bone,	the	level	of	α-SMA	expression	remained	
barely	 detectable,	 0.16±0.05	 in	 6-week	 old	 and	 0.18±0.06	 in	 12-week	 old	 mice	
(p=0.7757).	 As	 expected,	 the	 number	 of	 α-SMA+	 vessels/mm2	 slightly	 increased	 for	
both	ages	analysed,	2.49±0.75	 in	young	and	3.34±1.34	 in	mature	animals	 (p=0.6112)	
(figure	4.22).			
Taken	 together,	 this	 data	 underline	 that,	 irrespective	 of	 age,	 the	 bone	
microvasculature	does	not	contain	many	small	arteries.	
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Figure	4.22	Quantification	of	immunofluorescent	staining	against	α-SMA	
Graphs	shows	the	area	of	bone	marrow	analysed	(A),	the	percentage	of	this	area	expressing	α-SMA	(B)	
and	 the	 number	 od	 α-SMA+	 vessels/mm2	 of	 area	 analysed	 (C).	 The	 same	 analyses	 were	 repeated	
including	 the	 total	 area	 imaged	 (D),	 (E)	 and	 (F).	Graphs	 show	mean	±	 SEM	 (n=5	animals	 and	3	bones	
analysed/group),	ns	is	not	significant	
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4.5.3.6	Dormancy-supporting	Thrombospondin-1	levels	are	increased	in	the	
microenvironment	of	mature	animals		
In	 studies	 using	 an	 ex	 vivo	 model	 system,	 Thrombospondin-1	 (TSP-1)	 has	 been	
suggested	to	be	involved	in	regulating	tumour	cell	dormancy	[8],	[35],	[107],	[109].	To	
verify	 whether	 there	 was	 a	 difference	 in	 expression	 of	 this	 marker	 between	 the	
tumour	 growth	 promoting	 (young)	 and	 the	 dormancy	 supporting	 (mature)	 bone	
microenvironment,	30µm	thick	sections	of	tibiae	were	stained	with	antibodies	specific	
for	Endomucin	and	TSP-1.	
Zeiss	LSM880	AiryScan	Confocal	microscope	was	used	to	acquire	the	image	of	the	bone	
marrow,	2.83±0.17mm2	for	young	and	2.93±0.12mm2	for	mature	animals	(p=0.6450).	
As	 shown	 in	 figure	 4.23,	 Thrombospondin-1	 is	 expressed	 in	 the	 proximity	 of	
Endomucin+	 vessels	 and	 its	 levels	 are	 significantly	 higher	 in	 12-week	 old	 animals	
compared	to	the	6-week	old	mice	(p=0.0061).	Moreover,	mature	animals	also	have	a	
higher	number	of	TSP-1	expressing	Megakaryocytes/mm2	compared	to	young	animals	
(p=0.0429	(figure	4.24).		
It	 is	 interesting	 to	 note	 that	 TSP-1	 expression	 appears	 to	 follow	 the	 trabecular	 and	
cortical	bone	structure	while	the	TSP-1+	megakaryocytes	are	distributed	evenly	in	the	
bone	marrow.	Taken	together,	these	results	show	that	mature	animals	present	higher	
levels	 of	 the	 dormancy-supporting	molecule	 TSP-1,	 compared	 to	 that	 of	 the	 tumour	
growth	promoting	microenvironment	of	young	animals.	
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Figure	4.24	Quantification	of	immunofluorescent	staining	against	Thrombospondin-1	
A)	Area	of	bone	marrow	analysed	in	the	two	different	ages.	B)	shows	the	overall	expression	of	TSP-1	in	
the	two	ages	analysed.	(C)	Number	of	megakaryocytes/mm2	stained	with	TSP-1	counted	in	bones	of	
young	and	mature	animals.	Graphs	show	mean	±	SEM	(n=5	animals	and	3	bones	analysed/group),	
Student	t-test,	*	p<0.05,	**	p<0.01	and	ns	is	not	significant.	 	
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4.5.4	DTC	in	bone	marrow	locate	next	to	components	of	the	perivascular	niche	
In	 addition	 to	 characterisation	 of	 the	 bone	microenvironment	 of	 young	 and	mature	
animal	 models,	 30µm	 thick	 tibia	 sections	 were	 stained	 with	 antibodies	 against	
different	components	of	the	perivascular	niche	(Endumucin	and	CD31,	CD34	or	TSP-1)	
and	 the	 stained	 slides	 were	 then	 screened	 with	 an	 inverted	 widefield	 fluorescence	
microscope	 Leica	 AF6000	 to	 detect	 single	 tumour	 cells	 within	 the	 bone	
microenvironment.	Histological	sections	in	which	DTC	were	present	were	imaged	using	
a	 Nikon	 A1	 confocal	 microscope	 with	 the	 help	 of	 Dr	 Russell	 Hughes	 (University	 of	
Sheffield,	UK).		
Due	 to	 the	 low	number	of	 tumour	cells	detected	 it	was	not	possible	 to	perform	any	
statistical	analysis,	however	it	was	interesting	to	note	that,	irrespective	of	age,	breast	
cancer	cells	disseminated	in	the	bone	microenvironment	in	close	proximity	to	the	bone	
microvasculature	network	(figure	4.25).	
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Figure	4.25	Representative	images	of	the	location	DTC	in	bone	microenvironment	
DTC	 were	 found	 in	 the	 microenvironment	 in	 close	 proximity	 of	 to	 (A)	 Endomucin+CD31+	 and	 (B)	
Endomucin+CD34+	vessels	 in	 the	metaphysis	area	of	 the	bone.	 (C)	DTC	were	also	 found	close	 to	areas	
rich	in	TSP-1	and	TSP-1	expressing	megakaryocytes.	Red	arrow=DTC	and	yellow	arrow=megakaryocytes.	
Scale	bar	100µm.		 	
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4.5.5	 Reorganisation	 of	 the	microvasculature	 and	 TSP-1	 expression	 in	 presence	 of	
tumours	
To	 investigate	 the	 structure	 of	 the	 microvasculature	 network	 in	 the	 presence	 of	
tumour	in	the	bone	microenvironment,	MDA-MB-231-NW-Luc2	cells	were	injected	i.c.	
in	 6-week	 old	 BALB/c	 nude	 mice	 and	 tumour	 growth	 was	 monitored	 with	 IVIS.	
Immunofluorescent	 staining	 of	 gelatine	 embedded	 long	 bones	 allowed	 qualitative	
assessment	 of	 the	 changes	 in	 the	 bone	 marrow	 vasculature	 in	 the	 presence	 of	
developing	tumours.	
The	 established	 microvasculature	 visualised	 with	 the	 antibody	 against	 CD31	 was	
considerably	reduced	in	bone	with	tumour	present	(figure	4.26),	in	contrast	the	newly	
formed	 vasculature	 positive	 for	 CD34	was	 highly	 expressed	 both	within	 the	 tumour	
and	 in	 the	 surrounding	 bone	 microenvironment	 (figure	 4.27).	 Endomucin+	 vessels	
maintain	their	characteristic	shape	in	the	tumour-free	microenvironment,	while	in	the	
tumour	this	structured	network	is	completely	lost	and	replaced	by	what	appears	to	be	
a	non-organised	arrangement.		
TSP-1	 is	thought	to	support	dormancy	therefore	 it	was	 interestingly	to	 investigate	 its	
pattern	of	expression	in	the	presence	of	developed	tumour	within	the	bone	marrow.	
As	show	in	figure	4.28,	TSP-1	is	expressed	even	in	bones	containing	bone	metastasis,	
but	inside	the	tumour	or	in	their	close	proximity	its	expression	is	substantially	reduced.	
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Representative	 image	of	a	30µm	thick	section	of	 tibia	 stained	with	antibodies	against	Endomucin	and	
CD31.	 CD31	 signal	 is	 overall	 reduced	 and	 completely	 lost	 inside	 the	 tumour.	 Blue=DAPI,	
green=Endomucin,	 red=CD31,	 white	 arrow=CD31+	 vessel	 and	 dotted	 white	 line=tumour.	 Scale	 bar	
200µm.	
	 	
Figure	4.26	Endomucin+CD31+	microvessels	in	presence	of	bone	metastasis	
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Representative	 image	 of	 30µm	 thick	 section	 of	 tibia	 stained	 with	 antibodies	 against	 Endomucin	 and	
CD34.	CD34	expression	is	abundant	inside	the	tumour	and	also	in	the	microenvironment	surrounding	it.	
Blue=DAPI,	green=Endomucin,	red=CD34	and	dotted	white	line=tumour.	Scale	bar	200µm.	
	
	
Figure	4.27	Endomucin+CD34+	microvessels	in	presence	of	bone	metastasis	
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Representative	 images	 of	 30µm	 thick	 section	 of	 tibia	 stained	with	 antibodies	 against	 Endomucin	 and	
TSP-1.	 (A)	Shows	an	age-matched	bone	without	 tumour	 in	 the	microenvironment	 to	 show	the	overall	
expression	of	TSP-1	in	the	bone	microenvironment.	Bones	with	small	tumour	is	shows	in	(B)	and	large	
tumour	in	(C).	Blue=DAPI,	green=Endomucin,	red=TSP-1	and	dotted	white	line=tumour.	Scale	bar	200µm.	
	
Figure	4.28	Expression	of	TSP-1	in	bones	with	and	without	tumour	
	 170	
4.6	Discussion	
The	main	aim	of	this	chapter	was	to	characterize	the	bone	microenvironment	of	young	
and	 mature	 animals	 with	 emphasis	 on	 the	 bone	 structure,	 cell	 components	 and	
different	vessel	 sub-types	 that	 form	 the	complex	microvascular	network.	 It	 is	 known	
that	 both	 the	 bone	 and	 the	perivascular	 components	 of	 the	metastatic	 niche	play	 a	
role	 in	 the	 fate	of	 the	breast	 cancer	cells	 that	 reach	 the	bone	microenvironment,	 so	
the	 focus	 of	 this	 chapter	 was	 to	 determine	 whether	 there	 were	 difference	 in	 the	
structures	that	form	the	metastatic	niche	of	6-week	old	animal	where	tumour	growth	
is	promoted	and	of	12-week	old	animals	in	which	dormancy	is	supported.	I	used	two-
photon	 microscopy	 to	 map	 the	 location	 of	 single	 tumour	 cells	 in	 the	 bone	
microenvironment	of	young	and	mature	mice,	micro	computed	tomography	to	assess	
the	 differences	 in	 the	 bone	 structure	 of	 these	 animals	 and	 immunofluorescent	
protocols	 to	 determine	 age	 related	 changes	 in	 the	 detection	 of	 osteoprogenitors,	
alteration	 in	 the	 presence	 and	 pattern	 of	 Endomucin+,	 CD31+,	 CD34+	 and	 αSMA+	
vessels	 and	 modification	 in	 the	 expression	 of	 the	 dormancy	 supporting	 molecule	
Thrombospondin-1.	 Intriguingly,	 the	 only	 component	 that	 was	 not	 altered	 in	 the	
groups	analysed	was	the	arterial	microvasculature	(αSMA+	vessels)	that	was	detected	
primarily	 outside	 of	 the	 bone	 marrow	 cavity.	 Mature	 animals	 have	 a	 lower	 bone	
turnover	and	this	was	reflected	in	the	less	dense	structure	of	the	trabecular	bone	and	
in	 the	 lower	 presence	 of	 osteoprogenitors	 when	 compared	 to	 young	 animals.	
Furthermore,	 the	microvasculature	 was	 significantly	 altered	 with	 the	 aging	 process,	
resulting	 in	 changes	 in	 both	 the	 numbers	 and	 length	 of	 the	 all	 the	 sub-types	 of	
microvessels	 analysed.	Not	 surprisingly,	 the	 overall	 expression	of	 Thrombospondin-1	
was	increased	in	the	12-week	old	animals	confirming	its	proposed	role	in	maintaining	
tumour	cell	dormancy.		
As	 previously	 described	 (chapter	 3),	 breast	 cancer	 cells	 prefer	 to	 locate	 in	 the	
trabecular	region	of	the	bone	in	close	proximity	to	the	nearest	bone	surface.	Between	
the	 two	 ages	 analysed	no	difference	was	 detected	 in	 the	overall	 number	 of	 tumour	
cells	 reaching	 the	 bone	 microenvironment,	 in	 their	 location	 and	 proximity	 to	 the	
nearest	bone	surface	or	distance	to	other	tumour	cells.	These	results	suggest	that	the	
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growth	of	bone	metastasis	is	influenced	by	the	condition	of	the	soil	in	which	they	seed.	
The	quantification	of	the	tumour	cells	in	young	vs	mature	animals	are	in	line	with	the	
findings	 of	 Wang	 et	 al.	 who	 studied	 the	 importance	 of	 bone	 turnover	 in	 the	
development	 of	 osteolytic	 lesions	 in	 both	 prostate	 and	 breast	 cancer	 [101].	 Even	
though	my	in	vivo	study	was	focused	of	the	early	stages	of	the	bone	metastasis	while	
Wang	 and	 colleagues	 investigated	 the	 later	 events	 when	 bone	 disease	 had	 already	
occurred,	both	studies	underline	that	there	are	no	differences	in	the	homing	of	breast	
cancer	cells	in	the	initial	stages	after	tumour	cell	injection,	5	days	in	my	in	vivo	and	1-7	
days	in	the	previously	published	study	[101].		
During	 the	 physiological	 process	 of	 bone	 resorption	 in	 a	mature	 animal,	 osteoclasts	
resorb	old	bone	and	osteoblasts	form	an	equal	amount	of	bone,	 in	contrast	 in	young	
animals	 the	 constant	 remodelling	of	 the	bone	matrix	 allows	 the	growth	of	 the	bone	
itself	[229].	This	process	releases	growth	factors	stored	in	the	bone	matrix	and	in	the	
presence	 of	 tumour	 cells	 these	 factors	 feed	 back	 to	 the	 malignant	 cells,	 creating	 a	
‘vicious	 cycle’	between	 tumour	 cells	 and	 the	microenvironment	 [9],	 [12]–[16],	 [113],	
[230].	 Young	 animals	 have	 a	 higher	 bone	 turnover	 compared	 to	 mature	 animals	 in	
which	 the	 bone	 remodelling	 process	 slows	 down.	 In	 young	 mice	 the	 intense	
remodelling	 process	 constantly	 degrades	 and	 rebuilds	 the	 thin	 trabeculae	 of	 the	
spongy	 bone,	 resulting	 in	 the	 less	 dense	mature	 trabecular	 structure	 found	 in	 aged	
mice.	 This	 situation	 is	 reflected	 in	 pre-	 and	 post-menopausal	 women,	 in	 which	 the	
bone	 turnover	 is	 altered	 by	 the	 reduced	 levels	 of	 reproductive	 hormones	 causing	 a	
differential	response	to	the	anti-resorptive	drugs	used	for	the	treatment	of	the	bone	
metastasis	[148],	[231].		
The	age-related	reduction	in	bone	turnover	was	reflected	by	alterations	of	the	number	
of	osteoprogenitors	detected	 in	bone.	Moreover,	 in	 young	animals	 the	Osterix+	 cells	
were	found	in	the	metaphysis	of	tibiae	and	lining	the	surface	of	the	trabecular	bone,	as	
well	as	on	compact	bone	towards	the	diaphysis.	In	contrast,	in	mature	animals	the	few	
cells	 detected	 were	 located	 only	 in	 the	 metaphysis	 area.	 Irrespective	 of	 age,	 the	
osteoprogenitors	were	more	abundant	in	the	border	with	the	growth	plate	area.	It	 is	
known	 that	osteogenesis	 and	angiogenesis	 are	 closely	 coupled	and	 the	 fact	 that	 the	
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osteoprogenitors	 reside	 mostly	 in	 area	 of	 the	 bone	 marrow	 which	 is	 highly	
vascularised	reinforce	this	concept	[88],	[97],	[221],	[232].	
It	is	proposed	that	a	particular	sub-type	of	vessel	expressing	high	levels	of	Endomucin	
and	CD31	 (H-vessels)	 couple	 these	processes	 [97].	 	 This	 specific	 category	of	vessel	 is	
located	 in	the	metaphysis	of	 long	bones	and	has	a	characteristic	straight	column-like	
shape	interconnected	by	loops	that	allows	to	discriminate	it	from	the	highly	branched	
sinusoidal	 network	 present	 in	 the	 diaphysis	 of	 bones	 which	 express	 low	 level	 of	
Endomucin	and	CD31	(L-vessels)	[97],	[221].	Irrespective	of	age,	the	H-vessels	occupied	
a	greater	portion	of	bone	marrow	compared	 to	 the	area	occupied	by	 L-vessels	even	
though	the	number	of	L-vessels/mm2	in	the	total	bone	was	higher	than	the	H-vessels.	
Overall	 the	mature	animals	had	more	vessels/mm2	but	 the	 length	of	 the	vessel	 sub-
type	that	couple	angiogenesis	with	osteogenesis	appeared	to	be	considerably	shorter	
than	 the	 H-vessels	 measured	 in	 the	 young	 animals,	 suggesting	 that	 not	 only	 the	
presence	of	this	particular	vessel	but	also	its	shape	contributes	to	its	specific	function.	
All	 these	 quantifications	 were	 performed	 using	 the	 characteristic	 shape	 of	 the	 two	
different	 vessel	 sub-types	 as	 discriminant	 between	 H-	 and	 L-vessels.	 Visual	
identification	used	to	classify	as	H-	or	L-vessels	was	not	always	easy	due	to	the	angle	of	
the	sections,	also	 the	L-vessels	appeared	elongated	 in	a	 few	bone	samples.	To	verify	
that	the	quantification	made	was	accurately	describing	changes	in	the	H-vessels	in	this	
chapter	I	also	performed	double	staining	of	two	endothelial	markers	highly	expressed	
by	this	vessels	sub-type,	Endomucin	and	CD31.	Kusumbe	and	colleagues	described	that	
H-vessels	are	 lost	when	comparing	 the	vasculature	of	young	animals	 (4-week	old)	 to	
the	 adult	 (11-week	old)	 and	aged	 (70-week	old)	mice	 [97],	 the	overall	 expression	of	
CD31	 in	 the	 bone	 marrow	 was	 reduced	 in	 aged	 animals	 and	 also	 the	 presence	 of	
Endomucin+CD31+	vessels	was	lower	in	12-week	old	compared	with	6-week	old	mice.	
Intriguingly,	the	lower	expression	of	CD31+	vessels	was	not	due	to	their	number	(which	
was	higher	in	mature	vs	young	animals)	but	to	their	average	length.	Also	the	H-vessels	
(Endomucin+CD31+)	appeared	to	increase	their	number/mm2	but	reduce	in	length	with	
aging.	
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Vessels	positive	for	the	endothelial	marker	CD34	were	another	important	component	
of	 the	 vessel	 sub-type	 analysed	 in	 this	 chapter.	 It	 has	 been	 shown	 that	 a	 high	
expression	of	CD34+	vessels	 in	primary	breast	 tumours	could	be	used	as	a	predictive	
marker	 of	 bone	 metastasis	 occurrence	 [233],	 [234].	 Furthermore,	 high	 expression	
levels	of	CD34	in	patient	tumour	samples	has	been	suggested	to	predict	the	behaviour	
and	 prognosis	 of	 the	 giant	 cell	 tumour	 of	 bone	 [235].	 The	 data	 described	 in	 this	
chapter	concerning	the	presence	of	CD34+	positive	vessels	support	the	theory	that	an	
increase	 in	 the	 level	of	 this	endothelial	marker	 results	 in	a	poorer	prognosis.	 In	 fact,	
the	tumour	growth	promoting	microenvironment	of	6-week	old	animals	have	a	higher	
overall	expression	of	CD34	compared	to	the	dormancy	supporting	microenvironment	
of	12-week	old	animals.	Similar	to	the	CD31+	vessels,	this	increase	in	the	level	of	CD34	
expression	was	due	to	the	length	of	the	vessels	stained	with	this	marker	and	not	their	
number,	which	was	greater	in	the	mature	mice	when	compared	to	the	young	ones.	
In	 this	 chapter	 I	 have	also	 investigated	 the	arterial	 component	of	 the	bone	marrow,	
staining	 the	 bone	microenvironment	with	 an	 antibody	 against	 alpha-smooth	muscle	
actin	 (α-SMA).	 	 Interestingly,	 this	marker	was	 the	only	marker	 analysed	 that	did	not	
change	 its	 expression	 between	 the	 different	 ages.	 Only	 a	 few	 α-SMA+	 vessels	 were	
detected	 in	 the	specimens	and	 the	majority	of	 these	were	observed	 in	 the	muscular	
tissue	 surrounding	 the	 bone	marrow	 and	 not	within	 the	 area	 normally	 colonised	 by	
tumour	 cells.	 Despite	 reports	 that	 α-SMA+	 vessels	 are	 connected	 with	 Endomucin	
positive	vessels	in	the	metaphysis	of	long	bones	[97],	[232],	[236],	this	association	was	
not	 observed	 in	 the	 bone	 specimens	 analysed,	 here	 probably	 because	 the	 sections	
used	 by	 our	 group	 are	 considerably	 thinner	 than	 those	 used	 by	 the	 Adams	 group	
(30µm	vs	300µm).	
A	 relative	 recent	 focus	 of	 investigation	 is	 the	 function	 of	 blood	 vessels	 in	 the	
maintenance	 of	 dormancy.	 Endothelial-derived	 Thrombospondin-1	 (TSP-1)	 is	 one	 of	
the	 factors	 that	 has	 been	 shown	 to	 play	 a	 key	 role	 in	 supporting	 human	 cells	
quiescence	[8],	[35],	[107],	[237].	Ghajar	et	al.	investigated	extensively,	the	correlation	
between	tumour	cell	dormancy	and	the	expression	of	TSP-1.	They	firstly	noticed	that	in	
vivo,	dormant	breast	cancer	cells	locate	in	close	proximity	to	microvasculature	both	in	
lungs	and	in	bone	marrow.	Then	human	umbilical	vein	endothelial	cells	(HUVEC)	were	
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cultured	with	lung	fibroblast	or	bone	marrow	mesenchymal	cells	and	different	breast	
cancer	cell	 lines	were	seeded	on	the	microvascular	network	formed	 in	vitro.	 	Tumour	
cells	 appeared	 to	 have	 a	 reduced	 rate	 of	 growth	 when	 in	 close	 proximity	 to	
microvessels	 than	 when	 in	 contact	 to	 stromal	 cells.	 This	 suggested	 that	 the	
microvasculature	may	 have	 an	 effect	 in	 inhibiting	 tumour	 growth.	Moreover,	 breast	
cancer	 cells	 seemed	 to	 maintain	 dormancy	 when	 surrounded	 by	 an	 established	
microvasculature	 however	 if	 located	 next	 to	 neovascular	 sprouting	 tips,	 tumour	
growth	 occurred.	 Proteomic	 and	 mass	 spectrometry	 analyses	 indicated	 that	 the	
established	microvasculature	expressed	high	levels	of	TSP-1	while	in	sprouting	vessels	
this	molecule	was	replaced	by	a	high	expression	of	periostin	and	transforming	growth	
factor	beta-1.	
The	 analyses	 described	 in	 this	 chapter	 confirm	 that	 TSP-1	 is	 expressed	 to	 a	 greater	
level	in	a	microenvironment	supporting	dormancy	(mature	animal	model)	compared	to	
microenvironment	in	which	tumour	growth	is	promoted	(young	animal	model).	It	was	
also	 interesting	 to	 observe	 that	 TSP-1	 was	 not	 only	 localised	 in	 the	 proximity	 of	
Endomucin+	 vessels	 but	 also	 expressed	 in	 Megakaryocytes.	 The	 number	 of	
Megakaryocytes/mm2	of	bone	marrow	was	greater	in	12-week	old	than	in	6-week	old	
animals	 and	 this	 has	 influenced	 the	 overall	 expression	 of	 the	 marker	 analysed,	
supporting	 the	 theory	 that	 these	 cells	might	 have	 a	 function	 in	 the	maintenance	 of	
tumour	cells	dormancy	in	the	bone	microenvironment	even	thought	the	mechanism(s)	
implicated	have	not	yet	been	elucidated	[110].	
The	 work	 described	 in	 this	 chapter	 has	 characterised	 some	 components	 of	 the	
metastatic	niche	in	young	and	mature	animals	models.	The	majority	of	in	vivo	studies	
on	 tumour	 growth	are	performed	 in	 young	animals	 and	 it	 is	 clear	 that	 this	model	 is	
very	different	from	the	mature	animals.	Taking	into	consideration	these	differences	it	
is	 important	 to	 plan	 and	 carry	 out	 research	 that	 could	 be	 better	 translated	 to	 the	
clinical	 setting	 in	which	 the	majority	of	 the	patients	are	elderly	women	with	a	 lower	
bone	 turnover.	 Ideally	 this	 study	 should	 have	 been	 carried	 out	 in	 old	 animals	 (30+	
week	old)	instead	of	using	12-week	old	animals	but	the	necessary	steps	to	process	the	
samples	for	the	immunofluorescent	staining	were	difficult	to	achieve	in	bones	with	a	
highly	fragile	bone	structure.	
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In	summary,	the	data	described	in	this	chapter	support	the	notion	that	components	of	
the	 tumour	 microenvironment,	 bone	 turnover	 and	 microvasculature	 are	 closely	
associated.	 Furthermore,	 I	 have	 demonstrated	 that	 the	 ageing	 process	 changes	 not	
only	 the	 bone	 structure	 and	 osteoprogenitor	 number	 but	 also	 the	 perivascular	
components	of	the	metastatic	niche.	The	microenvironment	of	mature	mice	is	known	
to	 support	 dormancy	 of	 tumour	 cells,	 and	 it	 was	 interesting	 to	 observe	 a	 large	
reduction	of	the	microvasculature	in	the	bones	of	these	animals	compared	to	the	level	
of	 vascularisation	 detected	 in	 the	 tumour	 growth-promoting	 microenvironment	 of	
young	 mice.	 These	 findings	 contribute	 to	 an	 improved	 characterisation	 of	 the	
metastatic	niche	and	in	particular	of	the	players	involved	in	supporting	dormancy.	This	
could	ultimately	 lead	 to	new	approaches	 in	 the	 treatment	of	 the	metastatic	 disease	
from	the	early	stages	of	the	tumour	cell	colonisation.	
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Chapter	5 		
Effect	of	ZOL	on	the	bone	microvasculature	
structure	
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5.1	Summary	
Bone	metastasis	 is	one	of	the	major	causes	of	cancer	death.	Unfortunately,	currently	
there	 is	 no	 cure	 for	 this	 secondary	 disease	 and	 the	 treatment	 are	 restricted	 to	
palliative	 care.	 Bisphosphonates,	 and	 in	 particular	 ZOL	 (ZOL),	 are	 often	 used	 in	 the	
treatment	 of	 cancer-induced	 bone	 disease.	 This	 drug	 is	 used	 for	 its	 anti-resorptive	
action	 slowing	down	 the	 formation	of	 bone	 lesions	 and	 eventually	 fractures	 and	 for	
the	management	of	bone	pain.		In	several	studies,	it	has	been	shown	that	ZOL	has	an	
anti-cancer	effect	 through	 the	modification	of	 the	bone	microenvironment,	 reducing	
the	 incidence	 of	 tumour	 relapse	 in	 animal	models.	 The	 changes	 induced	by	 ZOL	 are	
caused	by	alterations	to	the	physiological	presence	and	activity	of	the	osteoblast	and	
osteoclast	populations,	resident	in	the	bone	and	not	due	to	the	alteration	of	the	total	
number	 of	 malignant	 cells	 located	 in	 the	 secondary	 organ.	 In	 vivo	 studies	 have	
demonstrated	variable	efficiency	of	 this	anti-resorptive	drug	between	animal	models	
mimicking	 pre-	 and	 post-menopausal	 status	 [148].	 These	 findings	 suggest	 that	 the	
success	rate	of	 the	treatment	 is	 influenced	by	the	different	organisation	of	 the	bone	
marrow	between	the	two	statuses.	As	described	in	the	previous	chapter	of	this	thesis,	
young	 and	 mature	 animals	 have	 a	 substantially	 different	 organisation	 of	 the	 bone	
components,	 including	the	composition	and	architecture	of	the	different	vessels	sub-
types.		
The	hypothesis	to	be	tested	in	this	chapter,	 is	that	ZOL	treatment	alters	not	only	the	
bone	 structure	and	cell	populations	but	also	modifies	 the	 surrounding	microvascular	
network.	 The	 data	 presented	 show	 that	 a	 single	 dose	 of	 this	 anti-resorptive	 drug	
causes	major	changes	in	the	bone	structure,	extracellular	matrix	and	osteoprogenitors	
with	minimal	changes	to	the	vessel	organisation	in	animals	models	with	high	and	low	
bone	turnover.	
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5.2	Introduction	
In	the	latest	stages	of	bone	metastasis	the	tumour	cells	that	establish	in	the	bone	and	
escape	 the	dormancy	 state,	 start	 to	proliferate	and	develop	both	micro-	and	macro-
metastases	 in	 response	 to	 the	 signals	 generated	 by	 the	 bone	 microenvironment.	
Breast	 cancer	 cells	 are	 known	 to	 interact	 with	 osteoblasts	 and	 this	 cell	 population	
ultimately	 induces	 osteoclast	 bone	 resorption,	 resulting	 in	 bone	 lesions	 [14],	 [230],	
[238].	This	cancer-induced	bone	disease	is	the	cause	of	severe	morbidity	and	mortality	
in	cancer	patients.	Unfortunately,	there	is	no	way	to	predict	which	patient	will	develop	
bone	metastasis	and	when	the	secondary	disease	will	occur,	hence	 the	 treatment	of	
bone	 disease	 usually	 takes	 place	 when	 the	 metastasis	 is	 sufficiently	 big	 to	 cause	 a	
detectable	 lesion.	 The	goal	of	bone-targeted	 treatments	 is	 to	 improve	 the	quality	of	
life	of	cancer	patients	and	ultimately	increase	the	disease-free	and	overall	survival	[5].		
For	 the	 development	 of	 bone	 metastasis	 the	 interaction	 with	 the	 bone	
microenvironment	is	crucial,	therefore	to	effectively	inhibit	the	metastatic	process	it	is	
necessary	to	not	only	target	the	tumour	cells	but	also	the	microenvironment	hosting	
and	 supporting	 their	 proliferation.	 The	 therapies	 presently	 available	 are	 designed	 to	
target	 only	 one	 component	 of	 the	 metastatic	 niche,	 either	 the	 osteoblast	 and	
osteoclast	populations	or	the	microvasculature.		
Bisphosphonates,	 and	 particularly	 ZOL,	 are	 one	 of	 the	 most	 commonly	 used	 bone-
targeted	 therapeutic	 agents	 [5].	 Due	 to	 their	 structure,	 bisphosphonates	 have	 the	
ability	to	bind	divalent	metal	ions,	such	as	Ca2+.	This	ability	allows	binding	to	the	bone	
surface	 in	 particular	 in	 regions	 where	 bone	 remodelling	 is	 active,	 the	 agent	 is	 then	
released	 locally	 during	 bone	 resorption	 by	 osteoclasts.	 Uptake	 by	 the	 osteoclasts	
during	 bone	 remodelling,	 explains	 the	 high	 selectivity	 of	 the	 bisphosphonates	 for	
osteoclasts.	However,	with	repeated	administration	these	drugs	can	be	internalised	by	
other	bone	resident	cells,	such	as	osteoblasts	or	tumour	cells	[117].		
It	has	been	shown	that	this	potent	anti-resorptive	drug	targets	the	osteoblastic	niche	
and	this	modification	of	the	microenvironment	results	also	in	alteration	of	metastatic	
disease	 progression	 [30],	 [32],	 [126]–[128].	 Further	 more,	 alteration	 of	 the	 bone	
microenvironment	 also	 results	 in	 a	 reduction	 in	 the	 incidence	 of	 tumour	 relapse	 in	
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animal	models	 [129],	 [130].	 Even	 though	 imbalance	of	 the	bone	 turnover	 caused	by	
therapeutic	 administration	 of	 ZOL	 reduces	 the	 development	 of	 overt	 metastases,	 a	
successful	anti-tumour	effect	has	only	been	identified	in	combination	with	other	drugs,	
such	as	Doxorubicin	in	animal	models	[126].	
Intriguingly,	 the	 rapid	 changes	 in	 the	bone	marrow	 induced	by	ZOL	 treatment	affect	
both	osteoblasts	and	osteoclasts	and	this	results	in	a	modification	of	the	characteristic	
pattern	of	breast	cancer	cell	homing	 in	the	bone	microenvironment,	without	altering	
the	total	number	of	tumour	cells	detected	within	the	bone	[118].	This	variation	in	the	
location	 of	 tumour	 cells	 may	 represent	 adaptation	 to	 the	 newly	 organised	
microenvironment	after	treatment	with	ZOL.		
In	the	past	few	years	it	has	been	shown	that	the	effectiveness	of	ZOL	in	preventing	the	
development	of	overt	tumour	from	disseminated	tumour	cells	varies	between	animal	
models	 mimicking	 the	 pre-	 and	 post-menopausal	 status	 [148],	 [149].	 In	 animals	
undergoing	 ovariectomy	 to	 mimic	 the	 post-menopausal	 setting,	 ZOL	 is	 beneficial	
preventing	 the	 development	 of	 tumour	while	 this	 effect	 is	 not	 observed	 in	 the	 pre-
menopausal	 group.	 Also	 the	 overall	 number	 of	 tumour	 cells	 present	 in	 the	 bone	
marrow	 is	 not	 altered	 by	 the	 administration	 of	 the	 anti-resorptive	 drug.	 These	
fascinatingly	results	from	in	vivo	models	reflect	what	has	been	shown	in	clinical	trials.	
In	particular	the	AZURE	clinical	trial,	testing	whether	administration	of	ZOL	in	addition	
to	standard	adjuvant	therapy	improved	the	outcome	in	breast	cancer	patients	that	had	
no	 detectable	 distant	 metastasis	 when	 entering	 the	 study,	 revealed	 that	 the	 anti-
resorptive	 drug	 was	 beneficial	 in	 women	 that	 were	 postmenopausal	 for	 5	 years	 or	
longer	at	 the	start	of	 the	 treatment.	Post-menopausal	women	 in	 fact	not	only	had	a	
reduced	development	of	bone	metastasis	but	also	the	dissemination	to	other	sites	was	
prevented	 compared	 to	 the	 pre-menopausal	 breast	 cancer	 patients,	 where	
administration	 of	 ZOL	 prevented	 bone	 metastasis	 but	 appeared	 to	 increase	 the	
development	of	extraskeletal	metastasis	[141],	[142],	[146],	[147],	[239].	
Taken	 together,	 these	 data	 indicate	 that	 alterations	 of	 only	 the	 bone	 cellular	
populations	 is	 not	 sufficient	 to	 arrest	 the	 progression	 of	 the	 metastatic	 disease	
suggesting	that	further	studies	determining	the	mechanism	of	response	to	therapies,	
by	 the	 microenvironment	 are	 needed.	 As	 described	 in	 the	 previous	 chapter,	 the	
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perivascular	 component	 of	 the	 bone	 microenvironment	 displays	 a	 considerable	
difference	 between	 the	 young	 and	 mature	 animal	 models.	 This	 age-related	
modification	 of	 the	 fertile	 soil	 for	 the	 progression	 of	 the	 metastatic	 disease	 could	
partially	 explain	 the	 differential	 effectiveness	 of	 ZOL	 between	 pre-	 and	 post-
menopausal	status.	Therefore	in	this	chapter	I	investigated	whether	the	administration	
of	 a	 single	 clinically	 relevant	 dose	 of	 ZOL	 induced	 alterations	 of	 the	 microvascular	
component	of	the	metastatic	niche	in	young	and	mature	animal	models.		
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5.3	Aims	
The	aim	of	this	chapter	was	to	test	the	hypothesis	that:	
Therapeutic	 treatment	 with	 ZOL	 influences	 both	 the	 bone	 and	 the	 perivascular	
component	of	the	metastatic	niche.	
This	will	be	tested	by	the	following	objective	that	will	characterise	the	effects	of	ZOL	
on:	
• Bone	structure		
• Bone	microvasculature		
• Breast	cancer	bone	colonisation	
• Expression	of	dormancy-supporting	Thrombospondin		
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5.4	Materials	and	Methods	
Detailed	information	can	be	found	in	the	main	Material	and	Methods	Chapter	2.	
5.4.1	Breast	cancer	cell	line	
The	 triple	 negative	 breast	 cancer	 cell	 line	 MDA-MB-231-NW1-Luc2	 was	 cultured	 in	
DMEM	+	Pyruvate	medium	enriched	with	1%	penicillin/streptomycin	and	10%	 foetal	
bovine	serum	at	37°C	and	5%CO2.	As	explained	 in	detail	 in	section	2.3,	breast	cancer	
cells	were	trypsinized	once	confluent	and	labelled	with	the	membrane	fluorescent	dye	
Vybrant-CM-DiI.	
5.4.2	In	vivo	studies	
In	 vivo	 studies	 were	 performed	 to	 investigate	 the	 effect	 of	 ZOL	 on	 the	 principal	
components	of	the	metastatic	niche.	All	the	studies	here	described	were	executed	in	
conformity	with	Home	Office	guidelines	and	approval	under	 the	project	 licences	PPL	
70/8964	held	by	Professor	Nicola	Brown	(University	of	Sheffield,	UK)	and	PPL	70/8799	
held	by	Dr	Colby	Eaton	(University	of	Sheffield,	UK).	
To	assess	any	changes	in	the	bone	structure	and	perivascular	niche	caused	by	the	anti-
resorptive	agent	ZOL	(ZOL)	and	how	this	influences	the	colonisation	of	tumour	cells	to	
bone,	6-	and	12-week	old	female	BALB/c	nude	mice	(n=10/age	group)	were	injected	i.c.	
with	0.75x105	MDA-MB-231-NW1-Luc2	cells	labelled	with	the	membrane	dye	Vybrant-
CM-DiI.	Two	days	after	the	injection,	animals	were	injected	i.p.	with	100µg/Kg	freshly	
prepared	ZOL	(100µl/mouse)	or	PSB	control	(100µl/mouse).			On	day	five	animals	were	
culled	and	hind	limbs	were	collected	for	ex	vivo	analysis	(figure	5.1).		
5.4.2.1	Preparation	of	long	bones	for	ex	vivo	analysis	
On	 the	 day	 of	 cull,	 animals	 were	 injected	 i.p.	 with	 an	 overdose	 of	 Pentobarbital	
(50µl/mouse)	 and	 cervical	 dislocation	was	 performed	 to	 ensure	 death.	Dissection	 of	
the	 hind	 limbs	was	 executed	 by	meticulous	 removal	 of	 tissues	 surrounding	 the	 long	
bones	followed	by	careful	separation	of	tibiae	and	femora.	Subsequent	processing	of	
the	bone	are	described	in	the	Materials	and	Methods	chapter	and	summarised	in	the	
following	table	(table	5.1).	 	
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Table	5.1	Summary	of	the	bone	sample	preparations	for	the	different	analyses	performed.	
Sample	 Analysis	 Preparation	
Left	Femora	
• Two-photon	
microscopy	
• Bones	were	snap	frozen	in	liquid	nitrogen	
• Bones	 were	 then	 placed	 in	 modules	 and	
embedded	 in	 Bright	 Cryo-M-Bed	 and	 stored	 at	 -
80°C	
• On	day	of	analysis,	the	bone	marrow	was	exposed	
using	Bright	OTF	Cryostat	with	a	3020	microtome	
• Specimen	 was	 placed	 on	 a	 glass	 bottomed	 dish	
and	immobilised	with	a	coverslip	
Left	Tibiae	
• µCT	
• Histology	
• Bones	 were	 scanned	 during	 the	 incubation	 in	
4%PFA	prior	to	decalcification	(48-72hrs)	
• 4%	PFA	was	changed	to	0.5M	EDTA/0.5%	PFA	for	
2	 weeks	 (refreshed	 three	 time/week)	 prior	 to	
processing	and	paraffin	embedding	
• Blocks	were	sectioned	to	a	thickness	of	3µm	
Right	Tibia	
and	Femora	
• µCT	
• Immunofluorescent	
staining	
• Bones	 were	 scanned	 during	 the	 incubation	 in	
4%PFA	prior	to	decalcification	(4-6hrs)	
• 4%	PFA	was	changed	to	0.5M	EDTA	for	48hrs	
• Bones	 were	 immersed	 in	 CPT	 solution	 (20%	
Sucrose	 and	 2%	 Polyvinylpyrrolidone	 (PVP)	
prepared	in	PBS)	for	at	least	24hrs	at	4°C	
• Bones	 were	warmed	 up	 to	 60°C	 in	 a	 water	 bath	
for	45	min	 in	EMB	 (8%	gelatin	 from	porcine	 skin,	
20%	sucrose	and	2%	PVP	prepared	in	PBS)		
• Specimens	were	embedded	in	molds	and	stored	at	
-80°C	
• Tissue	 was	 cut	 with	 cryostat	 to	 a	 thickness	 of	
30μm	
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5.4.3	Two-photon	microscopy	
An	area	of	2104μm	×	2525μm	of	the	exposed	bone	marrow	surface	(70µm	depth)	was	
imaged	 using	 Zeiss	 LSM510	 NLO	 upright	 two-photon	 microscope,	 as	 described	 in	
section	2.10.2.	Chameleon	 two-photon	 laser	was	used	 to	visualise	 the	calcified	bone	
structure	 (900nm)	 and	HeNe	 laser	 to	 capture	 Vybrant-CM-DiI	 labelled	 breast	 cancer	
cells	(543nm).	The	reconstructed	three-dimensional	image	was	analysed	using	Volocity	
3D	 Image	 Analysis	 software	 version	 6.01	 and	 the	 parameters	 measured	 were	 the	
number	of	Vybrant-CM-DiI+	breast	 cancer	cells	 in	 two	different	ROIs,	distance	 to	 the	
nearest	bone	surface	and	to	the	closest	tumour	cell	as	described	in	section	2.10.3.		
5.4.4	Micro	Computed	tomography	
Trabecular	bone	volume,	trabecular	number	and	thickness	were	measured	using	CTAn	
software	on	the	images	captured	with	SkyScan	1272	during	the	incubation	time	in	4%	
PFA	and	reconstructed	with	NRecon	software.	The	µCT	analysis	 is	detailed	 in	section	
2.11.	
5.4.5	Toluidine	Blue	staining	
Paraffin	embedded	tibiae	were	sectioned	by	Mrs	Alyson	Evans	(University	of	Sheffield,	
UK)	at	a	thickness	of	3µm.	The	histological	sections	were	dewaxed	in	xylene	(2x5min)	
and	rehydrated	through	decreasing	concentration	of	alcohols	 (99%,	95%,	70%,	3	min	
each)	to	tap	water.	The	metachromatic	staining	to	identify	the	proteoglycan	rich	area	
of	the	growth	plate	cartilage	was	performed	by	incubating	the	tissue	slides	for	3	min	at	
ambient	temperature	with	toluidine	blue	solution	(Toluidine	Blue	O,	Sigma	Aldrich:	1%	
NaCl	 pH	 2.0-2.5),	 followed	 by	 rinsing	 under	 running	 water.	 Stained	 sections	 were	
subsequently	dehydrated	through	70%,	95%	and	99%	alcohol	to	xylene	and	cover	slips	
were	 applied	 with	 DPX.	 Images	 of	 the	 stained	 bones	 were	 captured	 using	 a	 20x	
objective	 of	 an	 OM-AFHM	 advanced	 histomorphometry	 microscope	 and	 Aperio	
ImageScope	software	was	used	to	identify	and	then	outiline	the	area	of	interest	(AOI)	
covering	 the	 proteoglycan-rich	 growth	 plate	 and	 the	 trabecular	 bone	 surface	
connected	 with	 the	 epiphysis.	 Analyses	 were	 performed	 on	 two	 non-serial	 sections	
and	cortical	bone	was	excluded	from	any	measurement.	
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5.4.5	Immunofluorescent	staining	of	the	components	of	the	metastatic	niche	
Bones	 used	 for	 immunofluorescence	 staining	 protocols	were	 prepared	 as	 explained	 in	 table	
5.1.	Tissue	sections	were	left	at	ambient	temperature	to	defrost	and	rehydrate	in	PBS	before	
the	start	of	the	immunostaining	protocols	summarised	in	table	5.2	and	antibodies	used	listed	
in	table	2.6	and	2.7.	 	
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Table	5.2.	Summary	of	immunoflourescent	protocols	used	to	visualise	components	of	the	metastatic	
niche	
Marker	 Protocol*	
Endomucin	
• Permeabilisation	 in	 0.3%	 Triton	 X-100	 for	 20	 min	 at	 ambient	
temperature	
• Incubation	 with	 primary	 antibody	 (1:100)	 for	 1hr	 at	 ambient	
temperature	or	overnight	at	4°C	
• Incubation	with	secondary	antibody	(1:200)	for	40min	at	ambient	
temperature	
• Nuclei	counterstaining	with	DAPI	and	coverslip	
Endomucin	and	
CD31/CD34	
• Permeabilisation	 in	 0.3%	 Triton	 X-100	 for	 20	 min	 at	 ambient	
temperature	
• Amplification	 of	 the	 signal	 blocking	 for	 15	 min	 at	 ambient	
temperature	 with	 Streptavidin	 solution	 followed	 by	 15	 min	 at	
ambient	temperature	with	Biotin	solution	
• Incubation	with	primary	antibody	(CD34	or	CD31;	1:100)	for	1hr	
at	ambient	temperature	
• Incubation	with	biotinylated	secondary	antibody	(anti-rat;	1:200)	
for	40min	at	ambient	temperature	
• Incubation	with	rat	IgG	for	30	min	at	ambient	temperature	
• Incubation	with	primary	antibody	 (Endomucin;	1:100)	 for	1hr	at	
ambient	temperature		
• Incubation	with	secondary	antibody	(1:200)	for	40min	at	ambient	
temperature	
• Incubation	 with	 fluorophore-conjugated	 Streptavidin	 for	 20min	
at	ambient	temperature	
• Nuclei	counterstaining	with	DAPI	and	coverslip	
Endomucin	and	
Osterix/TSP-1	
• Permeabilisation	 in	 0.3%	 Triton	 X-100	 for	 20	 min	 at	 ambient	
temperature	
• Amplification	 of	 the	 signal	 blocking	 for	 15	 min	 at	 ambient	
temperature	 with	 Streptavidin	 solution	 followed	 by	 15	 min	 at	
ambient	temperature	with	Biotin	solution	
• Incubation	 with	 primary	 antibodies	 (Endomucin	 1:100	 and	
Osterix	1:300	or	TSP-1	1:100)	for	1hr	at	ambient	temperature	
• Incubation	 with	 secondary	 antibodies	 (Alexafluor	 anti-rat	 1:200	
and	 biotinylated	 anti-rabbit	 1:200)	 for	 40min	 at	 ambient	
temperature	
• Incubation	 with	 fluorophore-conjugated	 Streptavidin	 for	 20min	
at	ambient	temperature	
• Nuclei	counterstaining	with	DAPI	and	coverslip	
*Each	step	is	followed	by	three	washes	in	PBS	 	
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Images	of	the	immunofluorescent	staining	against	the	endothelial	marker	Endomucin	
were	 captured	 using	 an	 inverted	 fluorescence	microscope	 (Leica	 AF6000)	 while	 the	
bone	 sections	 stained	 for	 multiple	 markers	 were	 imaged	 using	 the	 Zeiss	 LSM880	
AiryScan	 Confocal	 microscope.	 Aperio	 ImageScope	 software	 was	 used	 to	 manually	
track	the	distinctive	structure	of	H-	and	L-vessels	on	Endomucin	stained	slides	and	to	
trace	 the	 CD31	 and	 CD34	 positive	 vessels.	 Parameters	 considered	 in	 these	 analyses	
were	 the	 number	 and	 length	 of	 these	 microvessels	 and	 the	 area	 of	 bone	 marrow	
occupied	 by	 them.	 The	 overall	 expression	 of	 CD31,	 CD34,	 TSP-1	 and	 Osterix	 and	
CD31/Endomucin	 and	 CD34/Endomucin	 was	 measured	 using	 ImageJ	 software	 as	
explained	 in	 detail	 in	 section	 2.14.2-3.	 TSP-1	 expressing	 megakaryocytes	 were	
manually	 counted	 using	 the	 function	 ‘cell	 counter’	 of	 the	 software	 while	 Osterix+	
osteoprogenitors	were	quantify	using	 the	automatic	 function	 ‘3D	object	counter’.	All	
the	analyses	were	performed	on	three	non-serial	30µm	thick	section	to	minimise	the	
variations	due	to	the	angle	of	cut	with	the	cryostat.		
5.4.6	Statistical	analyses	
Statistical	analyses	were	performed	using	GraphPad	Prism	software	(versions	6.0	and	
7.0),	student	T-test	and	Two-way	ANOVA	with	Tukey	post	test	were	used	as	stated	in	
each	figure	legend	and	the		p-value	of	p<0.5	was	considered	significant.		
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5.5	Results	
The	current	treatments	for	breast	cancer	bone	metastasis	are	focused	on	treating	the	
advanced	 stages	 associated	 with	 lytic	 bone	 lesions.	 Moreover,	 most	 of	 the	 drugs	
currently	available	are	designed	to	target	one	of	the	multiple	components	of	the	bone	
microenvironment;	 bone	 structure	 in	 the	 case	 of	 the	 anti-resorptive	 agent	 ZOL.	 It	 is	
not	known	how	these	drugs	affect	the	other	components	of	the	metastatic	niche.	The	
aim	of	this	chapter	was	to	determine	the	response	to	therapeutic	modification	of	the	
microenvironment	with	ZOL	on	both	the	bone	and	the	perivascular	components	of	the	
metastatic	niche	and	on	breast	cancer	bone	colonisation.		
5.5.1.	ZOL	changes	the	bone	structure	
To	 investigate	 the	effect	of	a	 single	dose	of	ZOL	on	 the	bone	microenvironment	and	
breast	 cancer	 bone	 colonisation,	 Vybrant-CM-DiI	 labelled	 MDA-MB-231-NW1-Luc2	
cells	were	 injected	 i.c.	 in	 6-	 and	 12-week	 old	 BALB/c	 nude	 (n=10/group).	 	 Two	days	
after	tumour	cell	injection,	5	animals/group	were	treated	with	100µg/Kg	of	ZOL	while	
the	 remaining	 5	 mice/group	 received	 the	 vehicle	 control	 (PBS)(figure	 5.1).	 Animals	
were	culled	3	days	after	drug	administration	and	 long	bones	were	collected	for	 two-
photon	microscopy	(femora)	and	for	fluorescent	immunohistochemistry	and	histology	
(tibiae).		
	 	
	 189	
	
	
6-	 and	 12-week	 old	 female	 BALB/c	 nude	 female	 mice	 were	 injected	 via	 the	 intracardiac	 route	 with	
0.75x105	 Vybrant-CM-DiI	 labelled	 MDA-MB-231-NW1-Luc2	 cells	 (n=5	 mice/group).	 Two	 days	 after,	
animals	 were	 injected	 i.p.	 with	 100µg/Kg	 freshly	 prepared	 ZOL	 (100µl/mouse)	 or	 PSB	 control	
(100µl/mouse).			On	day	five,	animals	were	culled	and	hind	limbs	were	collected	for	ex	vivo	analysis.		
	
To	 determine	 whether	 the	 anti-resorptive	 agent	 caused	 any	 alteration	 in	 the	 bone	
structure	of	long	bones,	tibiae	were	analysed	with	µCT	as	described	in	section	2.11	(6-
week	old	mice	n=3	PBS	and	n=5	ZOL,	12-week	old	n=4	PBS	and	n=5	ZOL	(figure	5.2).		
As	expected,	 the	treatment	with	ZOL	 increased	the	bone	volume/	trabecular	volume	
ratio,	 significantly	 in	 the	 young	 (6-week	 old)	 animals	 and	 with	 a	 trend	 towards	
significance	 level	 in	 the	 mature	 animals	 (12-week	 old)(p=0.0372	 and	 p=0.0684	
respectively).	These	changes	in	the	trabecular	volume	were	caused	by	modification	of	
the	 trabeculae	 structure	 that	 resulted	 in	 slightly	 thinner	 but	 more	 numerous	
trabeculae.	Statistical	analysis	did	not	reach	significance	level	in	neither	of	the	ages	for	
both	 parameters	 analysed	 but	 the	 effects	 of	 ZOL	 on	 the	 bone	 structure	 was	 more	
pronounced	on	the	young	animals	compared	to	the	mature	ones	(trabecular	thickness	
p=0.1300	 and	 p=0.7599;	 trabecular	 number	 p=0.0989	 and	 p=0.1269	 for	 6-	 and	 12-
week	old	respectively)(figure	5.3).		
	 	
Figure	 5.1	 Outline	 for	 the	 in	 vivo	 studies	 evaluating	 the	 effect	 of	 ZOL	 on	 the	 bone	
microenvironment	
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These	 results	 showed	 that	 the	 imbalance	 on	 the	 forming	 and	 resorbing	 cell	
populations	caused	by	ZOL	results	in	bones	with	an	increased	trabecular	volume	in	the	
treated	animals	when	compared	to	the	control	group.		
	
	
Every	panel	shows	the	three-dimensional	reconstruction	of	the	trabecular	bone	analysed	and	the	open	
cross	section	of	the	entire	bone	scanned.	(A)	Tibia	of	6-week	old	animal	receiving	PBS	and	(B)	ZOL.	(C)	
and	(D)	are	tibia	of	12-week	old	animal	receiving	PBS	and	ZOL	respectively.	
	
	 	
Figure	5.2	Representative	images	of	reconstructed	bone	after	mCT	analysis	
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A)	Quantification	of	the	trabecular	bone	volume	after	ZOL	treatment	of	6-	and	(B)	12-week	old	BALB/c	
nude,	 (C)	 and	 (D)	 trabecular	 thickness	 and	 (E)	 and	 (F)	 trabecular	 number.	 6-week	 old	 n=5	 animals,	 3	
bones	analysed	PBS	and	n=5	animals	and	bones	analyse	ZOL,	12-week	old	n=5	animals,	4	bones	analysed	
PBS	and	n=5	animals	and	bones	analyse	ZOL.	Graphs	show	Mean	±	SEM,	Student	t-test,	*p<0.05	and	ns	
is	non-significant.		 	
Figure	5.3	Effect	of	a	single	dose	of	ZOL	on	bone	structure	of	young	and	mature	animal	models	
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5.5.1.1.	ZOL	causes	an	expansion	of	the	proteoglycan-rich	area	of	the	growth	plate	
According	to	the	literature,	a	single	dose	of	ZOL	decreases	the	number	of	osteoclasts,	
resulting	also	 in	 increased	endochondral	ossification	 that	 fails	 to	be	 resorbed	by	 the	
osteoclasts	[118].		
To	 detect	 changes	 in	 the	 proteoglycan	 rich	 area	 of	 the	 metaphysis,	 Toluidine	 blue	
staining	 was	 performed	 as	 described	 in	 section	 2.12.5.	 As	 shown	 in	 figure	 5.4,	 ZOL	
treated	animals	appear	to	have	an	excess	of	this	matrix	compared	to	the	control	mice	
even	 though,	 irrespective	 of	 age,	 the	 increase	 was	 not	 statistically	 significant	
(p=0.0585	in	6-week	old	mice	and	p=0.1175	in	12-week	old).	
The	decrease	 in	the	number	of	osteoclasts	 in	bones	treated	with	ZOL	resulted	 in	the	
accumulation	of	excess	of	proteoglycan	rich	matrix,	particularly	in	young	animals.			
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	(A)	Quantification	of	extracellular	matrix	visualised	with	Toluidine	Blue	staining	of	histological	sections	
of	tibiae.	(B)	Aperio	ImageScope	software	was	used	to	manually	draw	around	the	area	of	proteoglycan	
in	 the	epiphysis	and	 the	 trabecular	bone	directly	 connected	 to	 it	 (green	 line).	Fragments	of	bone	and	
cortical	 bone	 were	 excluded	 from	 the	 analysis.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	
analysed/group),	Student	t-test,	ns	is	non-significant.	
	 	
Figure	5.4	Quantification	of	the	proteoglycan-rich	area	of	bone	
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5.5.1.2	Alteration	of	the	bone	structure	is	reflected	in	the	osteoprogenitor	
population	
It	has	been	reported	that	the	increase	in	bone	volume	caused	by	ZOL	treatment	is	the	
result	 of	 decreased	 numbers	 of	 osteoclasts	 resorbing	 the	 calcified	 matrix	 and	
increased	osteoblasts	forming	the	bone	[118].		
Mesenchymal	precursor	cells	that	differentiate	into	osteoblasts	and	then	osteocytes	as	
express	Runx-2	 and	Osterix	 [240].	 Therefore	 I	 used	 the	expression	of	 this	 protein	 to	
investigate	 whether	 modification	 of	 the	 bone	 structure	 caused	 changes	 in	 the	
osteoprogenitors;	tibiae	were	stained	using	the	immunofluorescent	protocol	explained	
in	section	2.14.7	(figure	5.5	and	5.7).	Regardless	of	age,	there	was	no	difference	in	the	
area	 of	 bone	 marrow	 analysed	 for	 both	 treated	 and	 control	 animals	 (p=0.4717and	
p=0.5306	for	young	and	mature	animals	respectively)	(figure	5.5	and	5.6).	The	overall	
expression	 of	 the	 Osterix	marker	 was	measured	 using	 ImageJ	 software	 and	 in	 both	
ages	analysed	it	was	evident	that	a	single	administration	of	ZOL	caused	a	trend	in	the	
reduction	 in	Osterix	expression	compared	 to	 the	control	animals	 (p=0.0599	 in	young	
animals	and	p=0.0079	in	mature	mice,	figure	5.6	and	5.8).	Surprisingly,	mature	animals	
had	 a	 greater	 response	 to	 the	 drug	 treatment.	 In	 fact,	 both	 the	 overall	 number	 of	
Osterix+	 cells	 and	 the	number	 of	Osterix+	 cells/mm2	was	 significantly	 reduced	 in	 the	
ZOL	 treated	 group	 compared	 to	 the	 control	 (p=0.0364	 and	 p=0.0192	 respectively,	
figure	5.6	and	5.8),	while	no	changes	in	the	number	of	osteoprogenitors	were	detected	
in	young	animals	(p=0.4242	and	p=0.9283	respectively,	figure	5.6	and	5.8).	
The	changes	in	the	bone	structure	caused	by	a	single	dose	of	ZOL,	induced	a	reduction	
in	the	Osterix+	osteoprogenitors	detected	in	mature	animals	compared	to	the	control	
mice,	no	statistically	significant	differences	were	detected	in	young	mice.	This	change	
in	the	presence	of	Osterix+	cells	could	be	due	to	the	limited	sample	size	analysed	and	
further	investigations	are	required.	
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Immunofluorescent	 staining	 against	 Osterix	 and	 Endomucin	 performed	 on	 30µm	 tibia	 sections	 of	 6-
week	 old	 animals	 receiving	 PBS	 or	 ZOL.	 GP=growth	 plate,	 BM=bone	marrow,	 Green=Endomucin	 and	
red=Osterix.	Scale	bar	200µm.	
	 	
Figure	5.5	Representative	 image	of	the	effect	of	ZOL	 treatment	on	Osterix	expression	 in	6-week	old	
animals	
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Figure	5.6	Quantification	of	the	effect	of	ZOL	treatment	on	Osterix	expression	in	6-week	old	animals	
(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	Osterix.	(C)	Overall	
number	of	Osterix+	cells	and	(D)	Osterix+	cells/mm2.	Graphs	show	mean	±	SEM	(n=5	animals,	3	bones	
analysed/group),	Student	t-test,	ns	is	non-significant.		 	
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Immunofluorescent	 staining	 against	Osterix	 and	 Endomucin	 performed	 on	 30µm	 tibia	 sections	 of	 12-
week	 old	 animals	 receiving	 PBS	 or	 ZOL.	 GP=growth	 plate,	 BM=bone	marrow,	 Green=Endomucin	 and	
red=Osterix.	Scale	bar	200µm.	
	 	
Figure	 5.7	 Representative	 image	 of	 the	 effect	 of	 treatment	 on	 Osterix	 expression	 in	 12-week	 old	
animals	
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(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	Osterix.	(C)	Overall	
number	of	Osterix+	cells	and	(D)	Osterix+	cells/mm2.	Graphs	show	mean	±	SEM	(n=5	animals,	3	bones	
analysed/group),	Student	t-test,	*p<0.05,	**p<0.005,	ns	is	non-significant		
	 	
Figure	5.8	Quantification	of	the	effect	of	ZOL	treatment	on	Osterix	expression	in	12-week	old	animals	
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5.5.2	ZOL	treatment	affects	the	bone	microvasculature	
The	effect	of	ZOL	on	the	bone	microenvironment	has	always	been	focused	on	the	bone	
cell	 components	and	 there	 is	no	 comprehensive	analysis	of	 the	effect	of	 ZOL	on	 the	
perivascular	 component	 of	 the	 metastatic	 niche.	 Therefore,	 frozen	 sections	 of	 tibia	
and	 femora	were	stained	against	multiple	components	 (Endomucin,	CD31,	CD34	and	
TSP-1)	 of	 the	 perivascular	 niche	 as	 explained	 in	 detail	 in	 section	 2.13.1	 and	 all	 the	
analyses	were	performed	on	three	non-serial	sections	of	bone.		
5.5.2.1	Effect	of	ZOL	on	Endomucin	positive	vessels	of	young	and	mature	animals	
Using	 the	 immunofluorescent	 protocol	 with	 an	 antibody	 against	 the	 endothelial	
marker	Endomucin	it	is	possible	to	visualise	the	complex	microvasculature	network	of	
bone.	 The	 vessels	 positive	 for	 this	 marker	 are	 present	 both	 in	 the	 metaphysis	 (H-
vessels)	and	in	the	diaphysis	of	long	bones	(L-vessels).	
Irrespective	 of	 age,	 images	 captured	 using	 an	 inverted	 widefield	 fluorescence	
microscope	Leica	AF6000	consisted	of	an	area	of	2.5mm2	approximately.	No	difference	
was	 detected	 between	 control	 and	 ZOL	 treated	 animals	 (2.78±0.10	 and	 2.83±0.14,	
p=0.7753	 for	6-week	old;	2.30±0.12	and	2.57±0.12,	p=0.1807	 for	12-week	old)(figure	
5.9).	Moreover,	no	difference	in	the	area	of	bone	marrow	occupied	by	H-	and	L-vessels	
was	 detected	between	 treatment	 groups	 in	 the	 6-week	old	 animals	 (control	 vs.	 ZOL	
p=0.7107	and	p=0.9702	respectively).	In	mature	animals	ZOL	treatment	increased	the	
area	of	bone	marrow	occupied	by	L-vessels	(p=0.0225)	whereas	the	area	occupied	by	
H-vessels	 was	 not	 altered	 (p=0.4886)	 (figure	 5.10).	 Since	 the	 overall	 area	 of	 bone	
marrow	occupied	by	the	different	vessels	sub-types	was	changed	 in	 the	12-week	old	
mice	 treated	 with	 ZOL,	 it	 is	 not	 surprising	 that	 the	 area	 of	 bone	 marrow	 analysed	
occupied	by	H-vessels	was	 reduced	 in	 the	mature	 ZOL	 treated	 animals	 compared	 to	
the	 control	 while	 the	 area	 of	 L-vessels	 was	 enlarged	 (control	 vs.	 ZOL	 p=0.0316	 H-
vessels	and	p=0.0301	L-vessels)	(figure	5.11).		
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A)	 Representative	 images	 of	 the	H-vessels	 (yellow)	 and	 L-vessels	 (blue)	manually	 tracked	with	Aperio	
ImageScope	software.	Area	of	bone	marrow	analysed	is	drawn	in	green	and	quantification	in	6-	and	12-
week	old	is	shown	in	(B)	and	(C).	Graphs	show	mean	±	SEM	(n=5	animals,	4	bones	analysed	control	and	5	
bones	analysed	ZOL),	Student	t-test,	ns	is	non-significant		
	 	
Figure	5.9	Quantification	of	immunofluorescent	staining	against	Endomucin	
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	(A)	and	(B)	show	the	area	of	bones	occupied	by	H-vessels	in	6-	and	12-week	old	respectively.	(C)	and	(D)	
show	the	area	of	bones	occupied	by	L-vessels	in	6-	and	12-week	old	respectively.	Graphs	show	mean	±	
SEM	(n=5	animals,	4	bones	analysed	control	and	5	bones	analysed	ZOL),	Student	t-test,	*p<0.05	and	ns	
is	non-significant		 	
Figure	5.10	Area	of	bone	marrow	occupied	by	H-	and	L-vessels	
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Figure	5.11	Percentage	of	bone	marrow	occupied	by	H-	and	L-vessels	
A)	Schematic	illustration	of	the	area	occupied	by	H-	and	L-vessels.	(B)	and	(C)	show	the	percentage	area	
of	 the	bone	marrow	occupied	by	H-vessels	 in	6-	and	12-week	old	animals,	while	 (D)	and	 (E)	show	the	
percentage	area	of	the	bone	marrow	occupied	by	L-vessels	in	6-	and	12-week	old	animals,	Graphs	show	
mean	±	SEM	(n=5	animals,	4	bones	analysed	control	and	5	bones	analysed	ZOL),	Student	t-test,	*p<0.05	
and	ns	is	non-significant	 	
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The	next	parameter	analysed	was	the	overall	number	of	vessels	in	the	bone	marrow,	
manually	traced	with	Aperio	ImageScope	software.	Once	again	it	was	unexpected	that	
ZOL	treated	6-week	old	animals	did	not	show	any	difference	in	the	number	of	vessels	
in	 the	 total	 area	 of	 bone	 marrow	 analysed	 while	 12-week	 old	 mice	 displayed	 a	
significantly	 higher	 overall	 number	of	 vessels	 in	 the	 ZOL	 treated	 group	 compared	 to	
the	 control	 (p=0.9106	 and	 p=0.0010	 respectively,	 figure	 5.12).	 This	 increase	 in	 the	
number	 of	 vessels	 detected	 in	 the	 entire	 bone	marrow	was	 due	 to	 the	 significantly	
greater	 number	 of	 L-vessels	 present	 in	 the	 diaphysis	 of	 mature	 animals	 receiving	 a	
single	dose	of	ZOL	compared	to	animals	 in	the	control	group	(p=0.0035).	No	changes	
were	 detected	 in	 the	 number	 of	 H-vessels	 in	mature	mice	 (p=0.2763)	 or	 in	 H-	 or	 L-
vessels	number	in	6-week	old	mice	(p=0.4870	and	p=0.6574	respectively,	figure	5.12).		
Since	 the	 area	 of	 the	 bone	 marrow	 occupied	 by	 the	 L-vessels	 was	 enlarged	 in	 the	
animals	 treated	with	 the	anti-resorptive	drug	compared	 to	 the	animals	 receiving	 the	
vehicle,	next	the	number	of	vessels/mm2	was	normalised	against	the	surface	occupied	
by	 the	 subtype	analysed	 (and	not	against	 the	 total	bone	area).	 This	analysis	 showed	
that	 treatment	 with	 ZOL	 did	 not	 affect	 the	 number	 of	 vessels	 in	 young	 animals	
(p=0.4006	 and	 p=0.5964	 H-	 and	 L-vessels	 respectively),	 whilst	 this	 normalisation	
highlighted	 that	 ZOL	 increased	 the	 number	 of	 both	 H-	 (p=0.0326)	 and	 L-vessels	
(p=0.0016)	in	12-week	old	animals	when	compared	to	the	control	group	(figure	5.13).		
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Figure	5.12	Number	of	vessels	quantified	in	the	total	area	of	bone	marrow	
	
A)	and	(B)	total	number	of	vessels	counted	in	both	ages.	(C)	and	(D)	show	the	number	of	H-vessels/mm2	
of	total	area	of	bone	in	the	different	ages.	(E)	and	(F)	show	the	number	of	H-vessels/mm2	of	total	area	of	
bone	 in	 the	 different	 ages.	 Graphs	 show	mean	 ±	 SEM	 (n=5	 animals,	 4	 bones	 analysed	 control	 and	 5	
bones	analysed	ZOL),	Student	t-test,	**	p<0.01	and	ns	is	non-significant	
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(A)	and	(B)	show	the	number	of	H-	vessels/mm2	of	area	occupied	by	the	vessel	sub-type	 in	6-	and	12-
week	old	animals.	(C)	and	(D)	show	the	number	of	L-	vessels/mm2	of	area	occupied	by	the	vessel	sub-
type	in	6-	and	12-week	old	animals.	Graphs	show	mean	±	SEM	(n=5	animals,	4	bones	analysed	control	
and	5	bones	analysed	ZOL),	Student	t-test,	*p<0.05,	**	p<0.01	and	ns	is	non-significant		 	
Figure	5.13	Number	of	H-	and	L-vessels	quantified	in	the	area	of	bone	they	occupy	
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Irrespective	 of	 age,	 the	 H-vessels	 were	 longer	 than	 the	 L-vessels	 in	 both	 the	 PBS	
(p<0.0001	and	p=0.0877	6-	and	12-week	old	respectively)	and	the	ZOL	group	(p<0.0001	
for	 both	 6-	 and	 12-week	 old).	 However,	 it	 was	 interesting	 to	 notice	 that	 whereas	
treatment	with	ZOL	did	not	 cause	change	 in	 the	average	 length	of	H-	or	 L-vessels	 in	
young	 animals	 (p=0.4088	 and	 p=0.4357	H-	 and	 L-vessels	 respectively),	 the	 vessels	 in	
mature	 mice	 receiving	 a	 single	 dose	 of	 ZOL	 appear	 to	 be	 shorter	 compared	 to	 the	
control,	 even	 though	 this	 difference	 did	 not	 reach	 statistical	 significance	 for	 the	 H-
vessels	analysis	(p=0.0926	and	p=0.0004	H-	and	L-vessels	respectively)(figure	5.14).			
	
Figure	5.14	Average	length	of	the	H-	and	L-vessels	sub-types	
A)	and	(B)	average	length	of	H-vessels	of	6-	and	12-week	old	animals	respectively.	(C)	and	(D)	average	
length	of	L-vessels	of	6-	and	12-week	old	animals	respectively.	Graphs	show	mean	±	SEM	(n=5	animals,	4	
bones	analysed	control	and	5	bones	analysed	ZOL),		Student	t-test,	***	p<0.001	and	ns	is	non-significant	
	
	 	
	 207	
These	data	indicate	that	regardless	of	age	or	ZOL	treatment,	there	was	no	difference	in	
the	total	area	of	bone	analysed.	Unexpectedly,	ZOL	treatment	caused	changes	 in	the	
organisation	 of	 the	 microvasculature	 in	 mature	 but	 not	 young	 animals,	 which	
corresponded	to	the	ZOL-induced	change	 in	bone	structure.	 In	 fact,	 it	appears	that	a	
single	dose	of	ZOL	is	sufficient	to	modify	the	distribution	of	the	different	vessels	sub-
types	in	mature	animals,	increasing	the	area	containing	L-vessels	at	the	expense	of	the	
area	of	bone	marrow	occupied	by	H-vessels.	Moreover,	ZOL	causes	an	increase	in	the	
number	 of	 vessels	 in	 the	 mature	 animals	 even	 though	 these	 vessels	 appear	 to	 be	
shorter	that	the	ones	detected	in	the	control	animals.		
5.5.2.2	ZOL	treatment	does	not	cause	alteration	in	CD31	vessels	
CD31	 is	 a	marker	 associated	with	 established,	mature	microvasculature	 in	 the	 bone	
microenvironment	 and	 this	 marker	 decrease	 with	 the	 aging	 process	 [97].	 To	
investigate	whether	ZOL	treatment	changes	the	expression	of	the	endothelial	marker	
CD31,	frozen	sections	of	tibia	and	femur	were	stained	for	both	Endomucin	and	CD31	
using	the	immunofluorescent	protocol	described	in	section	2.13.1	(figure	5.15).		
The	 first	 parameter	 analysed	was	 the	 area	 of	 bone	marrow,	 imaged	 using	 the	 Zeiss	
LSM880	AiryScan	Confocal	microscope	 (figure	5.16).	Regardless	of	age,	no	difference	
was	discovered	between	treated	and	control	groups	(p=0.7304	for	6-week	old	animals	
and	p=0.2638	 for	 the	12-week	old	 animals).	 Treatment	with	 ZOL	did	not	modify	 the	
expression	of	Endomucin	when	compared	 to	 the	control	group	 in	neither	of	 the	age	
groups	 (p=0.9407	 and	p=0.8770	 6-	 and	 12-week	old	mice	 respectively)	 (figure	 5.16).	
Moreover,	 the	 overall	 expression	 of	 CD31	 and	 the	 percentage	 of	 vessels	 expressing	
both	 endothelial	 markers	 were	 not	 altered	 between	 drug-	 and	 PBS-treated	 groups	
(CD31:	 p=0.3151	 and	 p=0.3981	 6-	 and	 12-week	 old	 mice	 respectively;	
CD31/Endomucin:	p=0.93559	and	p=0.5123)	(figure	5.16).		
	 	
	 208	
	
Figure	5.15	Representative	image	of	the	effect	of	ZOL	treatment	on	CD31+	vessels	
Immunofluorescent	staining	against	CD31	and	Endomucin	performed	on	30µm	tibia	section	of	6-week	
old	 (A)	and	12-week	old	 (B)	animals	receiving	PBS	or	ZOL.	Green=Endomucin	and	red=CD31.	Scale	bar	
200µm.	
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Figure	5.16	Quantification	of	immunofluorescent	staining	against	CD31	
A)	 and	 (B)	 Area	 of	 bone	 marrow	 analysed	 in	 the	 two	 different	 ages.	 C)	 and	 (D)	 show	 the	 overall	
expression	of	Endomucin	in	6-	and	12-week	old	animals	respectively	while	in	(E)	and	(F)	the	expression	
of	CD31	is	shown.	(G)	Percentage	of	Endomucin+	vessels	that	also	express	CD31	in	6-	and	12-week	old	
animals	(H).	Graphs	show	mean	±	SEM	(n=5	animals,	3	bones	analysed/group),	Student	t-test,	ns	is	non-
significant	
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As	 expected,	 no	 differences	 were	 detected	 in	 the	 number	 of	 CD31+	 vessels/mm2	
counted	in	the	total	bone	marrow	surface	analysed,	nor	in	the	area	solely	occupied	by	
this	vessel	sub-type,	 in	animals	treated	with	ZOL,	compared	to	animals	receiving	PBS	
(total	bone	marrow:	p=0.95781	and	p=0.7835	6-	 and	12-week	old	mice	 respectively;	
area	 occupied	 by	 CD31+	 vessels:	 p=0.6842	 and	 p=0.8110)(figure	 5.14).	 The	 average	
length	of	this	vessel	sub-type	was	not	modified	by	the	single	dose	of	ZOL	in	the	6-week	
old	animals	 (p=0.2811)	and	unexpectedly	there	was	also	no	response	 in	the	12-week	
old	animals	(p=0.6585)(figure	5.17).	
These	results	show	that	 the	number	of	CD31	expressing	vessels	was	unaffected	by	a	
single	 dose	 of	 the	 anti-resorptive	 agent	 Zolendronic	 acid	 compared	 to	 the	 control	
group.	This	was	in	contrast	to	the	ZOL-induced	changes	in	bone	microarchitecture	and	
total	vessel	observed	at	the	same	time	point.	
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A)	and	(B)	show	the	number	of	CD31+	vessels/mm2	of	total	bone	in	6-	and	12-week	old.	(C)	and	(D)	show	
the	number	of	CD31+vessels/mm2	of	area	occupied	by	the	vessel	sub-type	in	6-	and	12-week	old	animals.	
(E)	and	(F)	display	the	average	length	of	CD31+	vessels.	Graphs	show	mean	±	SEM,	(n=5	animals,	3	bones	
analysed/group),	Student	t-test,	ns	is	non-significant		
	 	
Figure	5.17	Number	and	average	length	of	CD31+	vessels	measured	with	Aperio	ImageScope	
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5.5.2.3	Newly	formed	CD34+	vessels	are	not	influenced	by	the	ZOL	treatment	
To	 detect	 changes	 in	 the	 newly	 formed	 microvasculature	 of	 the	 bone	
microenvironment,	tibia	sections	were	stained	using	the	immunofluorescent	protocol	
described	in	section	2.13.1,	with	antibodies	against	CD34.		
The	 quantification	 of	 tissue	 slides	 stained	 for	 Endomucin	 and	 CD34	 was	 performed	
using	 ImageJ	 and	 Aperio	 ImageScope	 softwares	 on	 images	 captured	 with	 the	 Zeiss	
LSM880	AiryScan	Confocal	microscope.	The	area	analysed	was	approximately	2.0	mm2	
for	the	young	animals	(2.05±0.39	for	the	PBS	group	and	1.97±0.31	for	the	ZOL	treated	
animals)	and	2.5mm2	for	the	mature	animals	(2.76±0.24	PBS	group	and	2.44±0.08	ZOL	
group,	 figure	5.18	and	5.19).	Regardless	of	age,	 the	overall	expression	of	Endomucin	
was	not	affected	by	the	single	dose	of	ZOL	(p=0.5977	and	p=0.3038	for	6-	and	12-week	
old	 respectively,	 figure	 5.18	 and	 5.19).	 Likewise,	 the	 expression	 of	 CD34	 and	
percentage	of	Endomucin+	and	CD34+	vessels	were	comparable	between	groups	(CD34:	
p=0.9076	and	p=0.1120;	CD34/Endomucin:	p=0.4126	and	p=0.1017	for	6-	and	12-week	
old	 respectively,	 figure	 5.18	 and	 5.19).	 Irrespective	 of	 age	 and	 treatment,	 no	
differences	were	detected	in	the	number	or	length	of	CD34+	vessels	(number	of	CD34+	
vessels/mm2:	p=0.7206	and	p=0.6708;	length	of	CD34+	vessels:	p=0.2631and	p=0.3871	
for	6-	and	12-week	old	respectively,	figure	5.20).	
Taken	together,	these	data	show	that	a	single	dose	of	ZOL	does	not	alter	the	formation	
of	new	microvessels	within	the	bone	microenvironment	within	the	5-day	time	frame.			
	 	
	 213	
	
Figure	5.18	Effect	of	ZOL	treatment	on	CD34+	vessels	of	young	animals	
A)	 Immunofluorescent	 staining	 against	 CD34	 and	 Endomucin	 performed	 on	 30µm	 tibia	 section	 of	 6-
week	 old	 animals	 receiving	 PBS	 or	 ZOL.	 Green=Endomucin	 and	 red=CD34.	 (B)	 Area	 of	 bone	marrow	
analysed.	(C)	Shows	the	overall	expression	of	Endomucin	while	in	(D)	and	(E)	the	expression	of	CD34	and	
the	percentage	of	Endomucin+	vessels	that	are	also	expressing	CD31	is	shown.	Graphs	show	mean	±	SEM,	
(n=5	animals,	3	bones	analysed/group),		Student	t-test,	ns	is	non-significant.	Scale	bar	200µm.	
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Figure	5.19	Effect	of	ZOL	treatment	on	CD34+	vessels	of	mature	animals	
A)	 Immunofluorescent	 staining	 against	 CD34	 and	 Endomucin	 performed	on	30µm	 tibia	 section	of	 12-
week	 old	 animals	 receiving	 PBS	 or	 ZOL.	 Green=Endomucin	 and	 red=CD34.	 (B)	 Area	 of	 bone	marrow	
analysed.	(C)	Shows	the	overall	expression	of	Endomucin	while	in	(D)	and	(E)	the	expression	of	CD34	and	
the	percentage	of	Endomucin+	vessels	that	are	also	expressing	CD31	is	shown.	Graphs	show	mean	±	SEM,	
Student	t-test,	(n=5	animals,	3	bones	analysed/group),	ns	is	non-significant.	Scale	bar	200µm.	
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A)	and	(B)	show	the	number	of	CD34+	vessels/mm2	of	total	bone	in	6-	and	12-week	old.	(C)	and	(D)	show	
the	number	of	CD34+vessels/mm2	of	area	occupied	by	the	vessel	sub-type	in	6-	and	12-week	old	animals.	
(E)	and	(F)	display	the	average	length	of	CD34+	vessels.	Graphs	show	mean	±	SEM,	(n=5	animals,	3	bones	
analysed/group),	Student	t-test,	ns	is	non-significant		
	 	
Figure	5.20	Number	and	average	length	of	CD34+	vessels	
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5.5.3	 ZOL	 treatment	 and	 the	 homing	 of	 breast	 cancer	 cells	 in	 the	 bone	
microenvironment	
To	 establish	 whether	 treatment	 with	 a	 single	 dose	 of	 ZOL	 altered	 the	 pattern	 of	
homing	 of	 breast	 cancer	 cells	 to	 the	 metastatic	 niche,	 two-photon	 microscopy	 on	
femora	 was	 performed	 to	 determine	 if	 there	 were	 variation	 in	 the	 number	 and/or	
location	of	the	tumour	cells	between	the	control	and	the	treated	group.	MDA-MB-231-
NW1-Luc2	breast	 cancer	 cells	were	 labelled	with	 the	membrane	dye	Vybrant-CM-DiI	
were	 injected	 i.c.	 in	 immunocompromised	mice,	 two	days	post	 injection	 the	animals	
were	treated	with	ZOL	or	control	and	culled	five	days	after.	Hind	limbs	were	collected	
for	ex	vivo	analyses.	
As	previously	discussed	in	section	3.5.6,	the	concentration	of	the	lipophilic	dye	used	to	
label	the	tumour	cells	caused	a	cytotoxic	effect	reducing	considerably	the	numbers	of	
bones	in	which	we	could	detect	tumour	cells.	In	the	6-week	old	group	only	two	bones	
out	of	 the	 three	analysed	 for	 the	 control	 group	and	one	out	of	 three	of	 the	 treated	
group	contained	tumour	cells	in	the	trabecular	region	of	the	bone	(ROI1),	no	cells	were	
detected	 in	 the	 growth	 plate	 area	 (ROI2).	 The	 injection	 in	 the	 12-week	 old	 animals	
were	more	successful,	with	four	femora	out	of	five	in	the	control	group	and	two	out	of	
four	 of	 the	 ZOL	 group	 having	 detectable	 tumour	 cells	 in	 ROI1,	 while	 only	 one	
bone/group	 had	 detectable	 tumour	 cells	 in	 ROI2.	 As	 shown	 in	 figure	 5.21,	 no	
difference	in	the	number	of	cells	located	in	the	bone	marrow	was	found	between	the	
different	groups	(p=0.7835	and	p=0.5436	for	ROI1	of	6-	and	12-week	old	respectively).	
The	 low	 number	 of	 cells	 homing	 to	 the	 bone,	 limited	 the	 analysis	 that	 could	 be	
performed.		
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Graph	shows	the	number	of	MDA-MB-231-NW1-Luc2	cells	detected	in	bone	in	6-	(A)	and	12-week	old	
mice	 (B)	 5	 days	 after	 i.c.	 injection	 of	 	 0.75x105	 tumour	 cells.	 Graphs	 show	 mean	 ±	 SEM,	 (n=5	
animals/group,	6-week	old	3	bones	analysed	control	and	2	bones	analysed	ZOL,	12-week	old	5	bones	
analysed	control	and	4	bones	analysed	ZOL).	Ns	is	non-significant.	
	
Figure	5.21	Homing	of	MDA-MD-231-NW1-Luc2	cells	to	bone	in	young	and	mature	animals	after	the	
treatment	with	ZOL	
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5.5.4	ZOL	modification	of	expression	of	TSP-1	
To	 investigate	 whether	 the	 administration	 of	 a	 single	 dose	 of	 ZOL	 altered	 the	
expression	 of	 the	 dormancy-supporting	 Thrombospondin,	 30µm	 thick	 sections	 of	
tibiae	 were	 stained	 against	 Endomucin	 and	 TSP-1	 following	 the	 immunofluorescent	
protocol	described	in	section	2.13.1.	
Images	of	the	bone	marrow	were	acquired	using	the	Zeiss	LSM880	AiryScan	Confocal	
microscope	and	an	area	of	approximately	2.0mm2	was	analysed	for	the	young	animals	
(1.907±0.4540	 PBS	 control	 and	 1.764±0.5102	 ZOL	 treated	 animals,	 p=0.8439)	 and	
2.8mm2	for	the	mature	mice	(2.885±0.1328	PBS	control	and	2.793±0.3182	ZOL	treated	
animals,	 p=0.8035)(figure	5.22	and	5.23).	 Interestingly,	 ZOL	 increased	 the	expression	
of	 TSP-1	 in	 6-week	 old	 mice	 even	 though	 this	 change	 was	 did	 not	 reach	 statistical	
significance	(p=0.0762),	but	no	alterations	were	detected	 in	the	12-week	old	animals	
(p=0.2929)(figure	5.22	and	5.23).	Moreover,	there	was	no	difference	in	the	number	of	
megakaryocytes	 counted	 with	 ImageJ	 software	 between	 animals	 receiving	 the	 anti-
resorptive	drug	or	the	vehicle	control	(p=0.9164	and	p=0.3780	for	young	and	mature	
animals)	 and	 there	 were	 no	 changes	 between	 the	 groups	 when	 the	 number	 of	
megakaryocytes	 was	 normalised	 on	 the	 area	 analysed	 (p=0.5402	 and	 p=0.2295	 for	
young	and	mature	animals)(figure	5.22	and	5.23).	
The	data	here	presented	suggest	that	ZOL	does	not	affect	the	expression	of	TSP-1	or	
the	number	of	Megakaryocytes	located	in	the	bone	marrow.	
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Figure	5.22	Effect	of	ZOL	treatment	on	TSP-1	expression	in	6-week	old	animal	
	
	(A)	Immunofluorescent	staining	against	TSP	and	Endomucin	performed	on	30µm	tibia	section	of	6-week	
old	 animals	 receiving	 PBS	 or	 ZOL.	 (A)	 Area	 of	 bone	 marrow	 analysed.	 (B)	 Percentage	 area	 of	 bone	
marrow	expressing	TSP=1.	 (D)	number	of	Megakaryocytes/mm2	and	overall	number	(D).	Graphs	show	
mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	 analysed/group),	 Student	 t-test,	 ns	 is	 non-significant.	
Green=Endomucin	and	red=TSP-1.	Scale	bar	200µm.	
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Figure	5.23	Effect	of	ZOL	treatment	on	TSP-1	expression	in	12-week	old	animal	
(A)	 Immunofluorescent	 staining	 against	 TSP	 and	 Endomucin	 performed	 on	 30µm	 tibia	 section	 of	 12-
week	old	animals	receiving	PBS	or	ZOL.	(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	
marrow	expressing	TSP=1.	(D)	Number	of	Megakaryocytes/mm2	and	overall	number	(D).	Graphs	show	
mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	 analysed/group),	 Student	 t-test,	 ns	 is	 non-significant.	
Green=Endomucin	and	red=TSP-1.	Scale	bar	200µm.	
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5.6	Discussion	
The	main	objective	of	 the	work	described	 in	 this	chapter	was	to	 investigate	whether	
the	 administration	 of	 a	 single,	 clinical	 relevant,	 dose	 of	 ZOL	 affects	 the	 bone	
microenvironment,	with	 particular	 attention	 given	 to	 the	 perivascular	 component	 of	
the	 niche,	 comparing	 young	 and	 mature	 animal	 models.	 Differences	 in	 the	 bone	
structure	between	animals	treated	with	ZOL	and	animals	receiving	the	vehicle	control	
were	 measured	 using	 µCT.	 Changes	 in	 the	 number	 of	 osteoprogenitors	 and	
megakaryocytes	detected	and	in	the	pattern	of	expression	of	Endomucin+,	CD31+	and	
CD34+	 vessels	 and	 the	 dormancy	 supporting	 molecule	 Thrombospondin-1	 were	
assessed	 on	 tissue	 sections	 stained	 with	 specific	 antibodies	 immunofluorescent	
protocols.	As	anticipated,	young	animals	displayed	a	considerable	change	in	the	bone	
structure,	 while	 the	 effect	 of	 the	 anti-resorptive	 drug	 on	 the	 structure	 of	 mature	
animals	was	less	extensive.	Surprisingly,	the	alterations	in	the	bone	structure	of	young	
animals	did	not	result	in	corresponding	alterations	of	the	microvascular	component	of	
the	niche.	In	fact,	none	of	the	microvasculature	markers	investigated	were	altered	by	
ZOL	 treatment	 in	 the	 young	 animals,	 while,	 unexpectedly,	 the	 organisation	 of	
Endomucin+	vessels	was	modified	in	the	mature	animals.		
It	 is	known	that	the	treatment	with	ZOL	causes	a	reduction	in	number	and	activity	of	
both	bone-resorbing	osteoclasts	and	bone-forming	osteoblasts	during	the	early	days	of	
administration.	 These	 effects	 were	 detected	 as	 early	 as	 three	 days	 after	 the	
administration	of	a	single	dose	of	ZOL	and	the	modification	of	the	bone	cell	population	
resulted	 in	 an	 increase	 in	 the	 trabecular	 volume	 in	 6-week	 old	 mice	 [118].	 	 In	
agreement	 with	 this,	 in	 the	 current	 study	 I	 found	 that	 the	 bone	 of	 young	 animals	
treated	 with	 ZOL	 had	 a	 significant	 increase	 in	 trabecular	 volume	 compared	 to	 the	
control	group.	Even	though	an	increase	was	also	present	in	the	mature	animal	model,	
the	changes	in	the	bone	structure	did	not	reach	a	statistical	significance,	probably	due	
to	the	lower	level	of	bone	turnover	in	this	group.	
The	increased	trabecular	volume	could	have	been	influenced	by	the	expansion	of	the	
proteoglycan-rich	 extra-cellular	 matrix	 detected	 by	 Toliudine	 blue	 staining.	 In	 the	
physiological	bone	development,	 the	 chondrocytes	 residing	 in	 the	growth	plate	area	
produce	high	amounts	of	this	matrix	and	this	process	is	followed	by	the	remodelling	of	
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ossificated	 matrix	 by	 osteoblasts	 and	 osteoclasts	 [241].	 	 Furthermore,	 the	
reorganization	 of	 the	 growth	 plate	 area	 of	 the	 bone	 resulted	 in	 a	 considerable	
decrease	in	the	presence	of	osteropreogenitor	cells	(figure	5.5-8).	It	was	interesting	to	
notice	that	the	number	of	Osterix+	cells	/mm2	was	affected	by	treatment	with	ZOL	only	
in	 the	 mature	 animals.	 Intriguingly,	 it	 has	 been	 shown	 that	 ZOL	 also	 modifies	 the	
number	 of	 HSCs	 and	 promotes	 differentiation	 towards	 lymphoid	 progenitors	 and	
expansion	 of	 myeloids	 progenitors	 in	 both	 immunocompetent	 and	
immunocompromised	 animal	 models	 after	 a	 short	 period	 of	 time	 (3-5	 days	 after	
administration	of	a	single	clinically	relevant	dose	of	ZOL)	[134].		
The	 accumulation	 of	 extra-cellular	 matrix	 and	 the	 redistribution	 of	 the	
osteoprogenitors	in	the	modified	microenvironment	suggest	that	ZOL	treatment	could	
influence	 the	 structure	 of	 the	 microvasculature	 in	 the	 metaphysis	 of	 the	 bone	 and	
therefore	 affect	 homing	 of	 tumour	 cells	 to	 the	 bone	microenvironment.	 The	 major	
physical	 effect	 of	 ZOL	 treatment	on	 the	bone	marrow	 structure	 and	enlargement	of	
the	proteoglycan-rich	area	were	detected	 in	young	animals,	while	 in	mature	animals	
these	 changes	 were	 marginal.	 It	 was	 expected	 therefore	 to	 detect	 substantial	
modification	 of	 the	 microvascular	 structure	 of	 the	 6-week	 old	 animals	 and	 only	 a	
minimal	change,	if	any,	in	the	12-week	old	mice.	Surprisingly,	analysing	the	expression	
and	 pattern	 of	 the	 Endomucin+	 vessels	 revealed	 contrasting	 data.	 The	
microvasculature	 of	 young	 animals	 was	 not	 altered	 by	 ZOL,	 while	 most	 of	 the	
parameters	analysed	for	the	mature	animals	were	significantly	different	between	the	
treated	and	control	group.	The	area	of	bone	marrow	analysed	has	been	identified	to	
be	evenly	distributed	between	H-	and	L-vessel	content,	while	in	12-week	old	mice	the	
L-vessels	component	of	the	microvasculature	occupied	most	of	the	bone	marrow	area.	
Moreover,	 the	 administration	 of	 ZOL	 caused	 an	 increase	 in	 the	 total	 number	 of	
vessels/mm2	 and	 in	 particular	 the	 number	 of	 L-vessels	 was	 greater	 in	 ZOL	 treated	
animals	compared	with	the	animals	receiving	the	control	vehicle.	In	both	age	group	of	
mice	the	average	length	of	H-	and	L-vessels	decreased	after	the	single	dose	of	ZOL,	but	
only	in	the	mature	animals	was	this	modification	statistically	significant.		
Since	 the	 Endomucin+	 microvasculature	 network	 is	 highly	 interconnected	 with	 the	
CD31+	 and	CD34+	 vessels,	 it	was	predicted	 that	 ZOL	 treatment	 also	 influenced	 these	
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vessel	sub-types.	Surprisingly,	irrespective	of	age,	the	CD31+	and	CD34+	vessels	in	bone	
were	not	affected	by	the	treatment	with	the	anti-resorptive	drug,	despite	the	effects	
on	bone	structure	and	growth	plate	area.	
It	 has	 already	 been	 suggested	 that	 ZOL	 has	 an	 anti-angiogenic	 activity,	 but	most	 of	
these	 studies	 have	 investigated	 this	 action	 of	 ZOL.	 Independent	 in	 vitro	 studies	
performed	by	Wood	et	al.	and	Misso	et	al.	described	the	inhibitory	effect	of	ZOL	in	the	
proliferation,	migration	and	tubule	formation	of	HUVEC	cells	[135],	[136].	Furthermore,	
both	 groups	 demonstrated	 that	 ZOL	 has	 an	 anti-angiogenic	 effect	 in	 vivo.	 Wood’s	
group	observed	 reduction	of	angiogenesis	 in	 implants	with	or	without	growth	 factor	
(VEGF	 and	 basic	 fibroblast	 growth	 factor	 (bFGF))	 in	 animals	 treated	 with	 repeated	
administration	of	ZOL,	while	Misso’s	group	detected	a	reduction	 in	angiogenesis	 in	a	
matrigel	 plug	 assay.	Moreover,	 the	 anti-angiogenic	 effect	 of	 ZOL	was	 investigated	 in	
the	clinical	setting.	It	has	been	reported	that	intermittent	treatment	(once	weekly	for	4	
weeks)	 with	 low-dose	 (1mg)	 ZOL,	 caused	 a	 reduction	 in	 VEGF-circulating	 levels	 that	
persisted	even	after	the	treatment	with	ZOL	returned	to	the	normal	administration	of	
4mg	ZOL/monthly	 [138].	 	These	studies	 therefore	demonstrated	the	action	of	ZOL	 in	
interfering	 either	 directly	 or	 indirectly	 with	 pathways	 involving	 angiogenesis	 though	
not	in	bone.	
It	 has	 been	 suggested	 that	 ZOL	 inhibits	 the	 differentiation	 of	 endothelial	 progenitor	
cells	 (EPC)	 when	 administered	 at	 low	 concentrations,	 while	 at	 higher	 doses	 it	 also	
induces	 apoptosis	 in	 the	 differentiated	 EPC	 [137].	 	 Ottewell	et	 al.	 described	 that,	 in	
subcutaneous	tumours,	administration	of	ZOL	alone	was	not	sufficient	to	suppress	the	
formation	of	new	vasculature	positive	 for	 the	endothelial	marker	CD34,	but	 that	 the	
combination	therapy	of	ZOL	and	Doxorubicin	(DOX)	inhibited	the	angiogenic	process	in	
the	subcutaneous	tumours	[131].	Furthermore,	 it	has	been	shown	that	repeated	ZOL	
treatment	 (once	a	week	 for	6	weeks)	alone	does	not	affect	presence	 the	CD31+	and	
CD34+	vessels	 in	mammary	gland	tumours,	whilst	this	changes	 in	both	these	markers	
were	 detected	when	 ZOL	was	 administered	 following	 DOX	 treatment.	 However,	 the	
effect	on	the	bone	microvasculature	was	not	investigated	[132].		
Regarding	 the	 effect	 of	 ZOL	 on	 the	microvasculature	 in	 bone,	 there	 are	 few	 studies	
reported	 in	the	current	 literature,	but	they	reflect	the	alteration	on	the	shape	of	the	
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microvessels	that	has	been	described	in	this	chapter.	Soki	and	colleagues	reported	that	
ZOL	treatment	modifies	the	microvasculature	network	 in	bone	of	 immunocompetent	
young	and	adult	male	mice.	These	vessels	appeared	fragmented	and	more	numerous	
but	 the	 total	 volume	 of	 vasculature	 in	 bone	 was	 not	 altered	 by	 the	 administration	
twice	weekly	for	4	weeks	of	200µg/kg	of	the	anti-resorptive	drug	[119].	Data	published	
in	2017	by	Ubellacker	and	colleagues	 indicated	modification	of	 the	microvasculature	
network	in	bone	in	response	to	ZOL;	vessels	appeared	to	have	lost	the	characteristical	
sinusoidal	 pattern	 and	 Endomucin+	 vessels	 were	 shorter	 after	 administration	 of	 a	
single	dose	of	ZOL	in	young	(6/7-weeks	old)	animals	[134].			
The	 anti-angiogenic	 effect	 of	 bisphosphonates,	 and	 in	 particular	 ZOL,	 has	 been	
reported	 also	 from	 clinical	 data	 and	 it	 has	 been	 suggested	 that	 this	 could	 possibly	
increase	the	anti-tumour	action	of	ZOL	both	through	the	inhibition	of	bone-resorbing	
osteoclasts	and	the	anti-angiogenic	effects,	resulting	in	a	reduction	of	tumour	growth	
[127].		The	anti-tumour	effect	of	ZOL	treatment	has	been	extensively	studied,	both	in	
vitro,	 in	vivo	and	in	the	clinical	settings	[120].	Although	treatment	with	ZOL	has	been	
reported	 to	 reduce	 the	 tumour	 burden	 both	 inside	 and	 outside	 the	 bone	
microenvironment,	a	combination	therapy	with	repeated	dosing	of	DOX	and	ZOL	was	
much	more	effective	in	tumour	bearing	mice	[126],	[127],	[131],	[132].	When	treating	
ER+	tumours,	ZOL	administration	has	not	been	shown	to	be	effective	in	the	reduction	
of	the	tumour	growth	in	soft	tissue,	however	it	reduced	the	dissemination	of	tumour	
cells	 to	 bone	 and	 the	 development	 of	 bone	 metastasis	 in	 an	 in	 vivo	 model	 [231].	
Although,	due	to	the	cytotoxic	effect	of	the	lipophilic	dye	used	in	this	chapter,	 it	was	
not	possible	 to	compare	the	number	of	 tumour	cells	 located	 in	 the	bone	marrow,	 in	
groups	of	animals	receiving	the	vehicle	control	or	ZOL,	an	 in	vivo	study	performed	in	
our	 laboratory	 demonstrated	 that	 for	 triple	 negative	 breast	 cancer	 cells	 ZOL	
administration	did	not	alter	the	overall	number	of	cells	in	the	bone,	but	their	location	
within	 the	bone	marrow	was	 altered	quantified	by	 two-photon	microscopy	 [118].	 In	
similar	study	of	prostate	cancer	bone	metastasis,	Wang	and	colleagues	described	that	
ZOL	administration	prevent	 tumour	growth	but	did	not	 affect	 the	overall	 number	of	
cancer	 cells	 homing	 to	 the	 bone	 microenvironment	 [242].	 Since	 tumour	 growth	 in	
bone	is	prevented	or	slowed	down	without	detecting	changes	in	the	overall	number	of	
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cancer	cells	seeding	in	the	fertile	bone	microenvironment,	could	indicate	that	tumour	
cells	remain	dormant	in	the	bone	for	longer	period	of	time.	As	described	in	chapter	4,	
Thrombospondin-1	 is	 one	 of	 the	 molecules	 suggested	 to	 support	 tumour	 cells	
dormancy	[35]	and	in	the	in	vivo	study	presented	in	this	Chapter	the	level	of	TSP-1	in	
bone	appeared	to	be	increased	by	ZOL	treatment	in	young	animals.		
One	peculiarity	of	the	anti-tumour	effect	of	ZOL	treatment	is	that	it	has	been	shown	to	
have	 a	 differential	 effect	 between	 pre-	 and	 post-menopausal	 status.	 Animals	
mimicking	the	post-menopausal	(ovariectomy)	status	benefit	from	ZOL	administration	
compared	to	animals	mimicking	the	pre-menopausal	(sham)	status.	It	has	been	shown	
that	 ZOL	 prevented	 tumour	 growth	 in	 ovariectomised	 animals	 despite	 disseminated	
tumour	 cells	were	 detected	 in	 the	 tumour	microenvironment	 [243].	 The	 variance	 in	
the	success	of	ZOL	treatment	in	the	early	stages	of	breast	cancer	was	also	identified	in	
the	 clinical	 trial	 AZURE,	 where	 it	 has	 been	 reported	 that	 patients	 with	 established	
menopause	showed	improvement	in	the	disease-free	and	overall	survival	compared	to	
patients	in	pre-menopausal	settings	[146],	[147],	[244].	An	important	point	highlighted	
by	the	AZURE	trial	was	that	there	were	no	differences	 in	response	between	ER+	and	
ER-	tumours,	 indicating	that	the	microenvironment	plays	a	key	role.	The	mechanisms	
driving	these	differential	effects	remain	to	be	established.	To	elucidate	to	what	extent	
the	 bone	 microenvironment	 components	 are	 involved,	 an	 interesting	 clinical	 trial,	
ZOLMENO,	 is	 ongoing	 which	 will	 compare	 the	 bone	 microenvironment	 in	 pre-	 and	
post-menopausal	breast	cancer	patient	before	and	after	a	single	dose	of	ZOL.	
Taken	together,	the	data	presented	in	this	chapter	describe	the	differentials	effect	of	
ZOL	 on	 the	 bone	 microenvironment	 of	 young	 and	 mature	 animal	 models.	 ZOL	
treatment	modifies	the	bone	structure	of	young	animals	to	a	greater	extent,	while	the	
organisation	of	the	microvasculature	network	of	the	bone	microenvironment	is	altered	
in	the	mature	animals.	Further	 investigation	 is	needed	to	better	understand	why	the	
beneficial	effect	of	ZOL	treatment	 in	early	breast	cancer	 is	 restricted	to	women	with	
established	menopause.		
The	data	presented	 in	 the	current	Chapter	 suggests	 that	 changes	 in	 the	perivascular	
niche	 is	 a	 promising	 research	 area	 to	 pursue	 to	 improve	 the	 knowledge	 on	 the	
potential	 mechanisms	 of	 action	 and	 may	 identify	 how	 the	 anti-resorptive	 drug	 has	
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differential	response,	with	the	ultimately	aim	of	improving	therapies	for	breast	cancer	
bone	metastasis	by	targeting	multiple	components	of	the	metastatic	niche.	
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Chapter	6 	
Therapeutic	modification	of	the	
microvasculature	and	its	effect	on	the	bone	
metastatic	niche	
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6.1	Summary	
Angiogenesis	is	a	fundamental	process	required	for	the	development	and	progression	
of	 tumours	 and	 therefore	 pathways	 involved	 in	 regulating	 angiogenesis	 have	 been	
explored	 as	 targets	 in	 the	 development	 of	 new	 anti-tumour	 therapies.	 Anti-VEGF	
therapies,	 such	 as	 anti-VEFG	 antibodies	 (e.g.	 Bevacizumab)	 VEGF	 tyrosine	 kinase	
receptor	 inhibitors	 (Cabozantinib	 and	 Cediranib),	 have	 proven	 successful	 in	 the	
treatment	of	a	range	of	solid	tumours,	including	breast	cancer.	Cediranib	in	particular	
is	one	promising	candidate	drug	for	the	treatment	of	breast	cancer	and	it	is	the	focus	
of	 multiple	 clinical	 studies	 investigating	 its	 potential	 therapeutic	 effect	 in	 different	
stages	of	cancer	development.	Currently,	research	is	focusing	also	on	the	upstream	the	
VEGF	pathway	targeting	HIF-1α.	Deferoxamine	mesylate	(DFM)	is	an	iron	chelator	that	
has	been	shown	to	be	an	effective	HIF-1α	enhancer.					
The	anti-	and	pro-angiogenic	effect	of	these	drugs	has	been	extensively	evaluated	both	
in	vitro	and	in	vivo,	however	their	actions	on	multiple	components	of	the	bone	marrow	
microenvironment	have	not	been	 fully	elucidated.	 It	 is	 known	 that	angiogenesis	 and	
osteogenesis	are	tightly	associated	and	the	hypothesis	 to	be	tested	 in	this	chapter	 is	
that	 pharmacological	 induced	 decrease	 (Cediranib)	 or	 increase	 (Deferoxamine	
mesylate)	of	the	microvascular	activity	resulted	in	a	modification	of	the	bone	structure,	
in	particular	 in	the	trabecular	region	of	bone	where	breast	cancer	cells	preferentially	
home.		
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6.2	Introduction	
The	microenvironment	 in	which	metastasis	 occur	 is	 complex	 containing	multiple	 cell	
populations	involved	in	the	maintenance	of	the	dormancy	of	DTC	or	in	the	progression	
of	overt	tumours.	Currently	several	therapies	strategies	are	available	for	the	treatment	
of	 advanced	 breast	 cancer,	 hormone	 receptor	 positive	 cancers	 usually	 receive	
endocrine	 treatments	 while	 in	 the	 case	 of	 oestrogen-negative	 receptor	 (or	 when	
endocrine	 treatments	 has	 failed)	 chemotherapy	 is	 the	 most	 common	 option,	
bisphosphonates	have	proved	to	be	effective	in	both	ER+	and	ER-	breast	cancers	[112],	
[245].	 Increasingly	 interest	 in	other	possible	targets	 in	the	microenvironment	has	 led	
to	 the	 development	 of	 anti-angiogenic	 therapies,	 including	 the	 anti-VEGF	
(Bevacizumab)	 and	 VEGF	 tyrosine	 kinase	 receptor	 inhibitor	 (Cabozantinib	 and	
Cediranib)	 [111],	 [246].	 The	 FDA	 approval	 for	 Bevacizumab	 was	 revoked	 for	 the	
treatment	 of	 breast	 cancer	 patients	 due	 to	 its	 side	 effects	 while	 Cabozantinib	 and	
Cediranib	 are	 being	 evaluated	 in	multiple	 clinical	 trials	 investigating	 the	 response	 to	
the	 agents	 both	 alone	 or	 in	 combination	 with	 other	 therapies	 for	 the	 treatment	 of	
breast	cancer	(see	table	1.2).		
Cediranib	has	been	 shown	 to	be	a	promising	 therapeutic	agent	 for	 the	 treatment	of	
breast	 cancer.	 Experimental	 in	 vivo	 studies	 reported	 that	 the	 VEGF	 tyrosine	 kinase	
receptor	 inhibitor	even	at	small	doses	(0.75mg/kg/daily)	 is	effective	 in	the	treatment	
of	 subcutaneous	 tumours	 of	 different	 cancers	 such	 as	 prostate,	 breast,	 ovary,	 lung,	
colon	 [168].	 Moreover,	 several	 studies	 reported	 the	 highly	 potent	 anti-angiogenic	
effect	that	Cediranib	has	on	the	tumour	microenvironment	[168],	 [171],	 [173],	 [174].	
Clinical	 trials	 and	 in	 vivo	 studies	 investigating	 the	 effects	 of	 progression	 or	 reducing	
growth	 rate	 of	 overt	 tumours	 and	 the	 changes	 that	 these	 drugs	 cause	 on	 the	
established	 tumour	 microenvironment	 and	 in	 most	 cases	 subcutaneous	 models	 are	
used.	 As	 previously	 mentioned,	 tumour	 cells	 interact	 with	 the	 surrounding	
microenvironment	 and	 this	 cross-talk	 influences	 the	 tumour	 growth,	 therefore	 it	 is	
important	 to	 investigate	whether	 the	 response	 to	 drugs	 is	 reflected	 by	 a	 change	 in	
several	 components	 of	 the	 niche.	 In	 chapter	 4	 it	 is	 described	 how	 changes	 in	 bone	
structure	 as	 well	 as	 the	 microvasculature	 forms	 a	 bone	 microenvironment	 that	
promotes	 tumour	growth	 (young	animals)	or	 support	dormancy	 (mature	animals).	 In	
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this	 chapter,	 Cediranib	 was	 used	 in	 in	 vivo	models	 to	 investigate	whether	 the	 anti-
angiogenic	 effect	 identified	 in	 the	 tumour	 is	 also	 reflected	 in	 the	 bone	
microenvironment,	prior	to	the	injection	of	breast	cancer	cells	and	subsequently	if	any	
modulation	resulted	in	a	modification	of	the	pattern	of	homing	of	tumour	cells	in	bone.		
The	 microvascular	 activity	 was	 also	 increased	 by	 administration	 of	 Deferoxamine	
mesylate	 (DFM)	 to	 investigate	 whether	 changes	 in	 the	 bone	 microvasculature	 alter	
other	 components	 of	 the	 niche,	 such	 as	 the	 bone	 and	 extracellular	matrix,	 and	 the	
homing	of	breast	cancer	cells	to	bone.	This	drug	is	commonly	used	as	an	iron	chelator	
but	it	has	the	ability	to	expand	the	vascular	network	through	enhancement	of	hypoxia	
inducible	factor	1	alpha	(Hif-1α),	recently	described	both	in	vivo	and	in	vitro	[97],	[184],	
[185].	 Seeing	 that	 angiogenesis	 and	 osteogenesis	 are	 tightly	 connected	 it	 is	 not	
surprising	 that	 the	pro-angiogenic	effect	of	DFM	 is	 reflected	 in	a	modification	of	 the	
bone	structure	in	several	animal	models	[97],	[186]–[192].	DFM	has	also	been	reported	
to	 increase	 the	 number	 of	 HSCs	 homing	 to	 the	 bone	 marrow	 after	 transplantation	
[196].	Furthermore,	enhanced	invasion	and	migration	of	breast	cancer	cells	has	been	
demonstrated	after	in	vitro	treatment	with	DFM	[194],	[195].	In	the	current	chapter	it	
was	investigated	whether	treatment	with	Cediranib	or	DFM	in	our	animal	model	would	
alter	 the	 bone	 and	microvascular	 components	 of	 the	 niche	 as	 reported	 in	 literature	
and	whether	this	potential	change	affects	the	homing	of	breast	cancer	cells	to	bone.	
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6.3	Aims	
The	aim	of	this	chapter	was	to	test	the	hypothesis	that:	
Therapeutic	modification	of	the	perivascular	niche	resulted	in	modification	of	the	bone	
component	and	ultimately	in	alteration	of	the	homing	of	breast	cancer	cells	to	bone.		
	
This	 will	 be	 tested	 by	 the	 following	 objectives	 that	 will	 characterise	 the	 effect	 of	
Cediranib	 (reducing	 microvascular	 activity)	 or	 Deferoxamine	 mesylate	 (increasing	
microvascular	activity)	on:	
• Bone	structure	and	number	of	osteoprogenitors	
• Bone	microvasculature	structure	and	content	of	different	vessel	sub-types	
• Expression	of	dormancy-supporting	Thrombospondin		
• Breast	cancer	bone	colonisation	
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6.4	Materials	and	methods	
Summary	of	the	methods	used	in	this	chapter	is	found	in	table	6.1	below	and	methods	
not	described	in	the	next	section	can	be	found	in	the	Materials	and	Methods	chapter	
of	this	thesis.	
Table	6.1	Summary	of	material	and	methods	of	Chapter	6	
Method	 Analysis	 Equipment	
Two-photon	
microscopy	
• Number	of	tumour	cells	homing	to	
the	bone	microenvironment	
• Location	of	tumour	cells	within	the	
bone	marrow	
• Distance	to	the	nearest	bone	
surface	
• Distance	to	the	nearest	cancer	cell	
• Two-photon	Zeiss	LSM510	NLO	
• Chameleon	900nm	(bone	
structure)	
• HeNe	543	(Vybrant-CM-DiI)	
• Hene	633	(Vybrant-DiD)	
• Volocity	3D	Image	Analysis	
software	
Micro	Computed	
Tomography	
• Trabecular	bone	volume	(BV/TV	%)	
• Trabecular	number	(Tb.	N.	in	mm-1)	
• Trabecular	thickness	(Tb.	Th.	In	mm)	
• SkyScan	1272	scanner	
• NRecon	software	
• CTAn	software	
Toluidine	Blue	
staining	
• Area	of	the	extracellular	matrix	rich	
in	proteoglycan	–	growth	plate	
• OM-AFHM	advanced	
histomorphometry	microscope		
• Aperio	ImageScope	software	
Osterix/Endomucin	
immunofluorescent	
staining	
• Area	of	bone	marrow	expressing	
Osterix	
• Number	of	osteoprogenitors	in	the	
bone	marrow	
• Zeiss	LSM880	AiryScan	Confocal	
microscope	
• ImageJ	software	
Endomucin	
immunofluorescent	
staining	
• Area	of	bone	marrow	occupied	by	
H-	and	L-vessels	
• Number	of	H-	and	L-vessels	
• Average	length	of	H-	and	L-vessels	
• Leica	AF6000	inverted	
fluorescence	microscope		
• Zeiss	LSM880	AiryScan	Confocal	
microscope		
• Aperio	ImageScope	software	
CD31/Endomucin	
immunofluorescent	
staining	
• Area	of	bone	marrow	expressing	
CD31	
• Area	of	bone	marrow	expressing	
Endomucin	
• Percentage	of	Endomucin	vessels	
expressing	also	CD31		
• Number	of	CD31+	vessels	
• Average	length	of	CD31+	vessels	
• Zeiss	LSM880	AiryScan	Confocal	
microscope		
• ImageJ	software	
• Aperio	ImageScope	software	
CD34/Endomucin	
immunofluorescent	
staining	
• Area	of	bone	marrow	expressing	
CD34	
• Area	of	bone	marrow	expressing	
Endomucin	
• Percentage	of	Endomucin	vessels	
expressing	also	CD34	
• Number	of	CD34+	vessels	
• Average	length	of	CD34+	vessels	
• Zeiss	LSM880	AiryScan	Confocal	
microscope		
• ImageJ	software	
• Aperio	ImageScope	software	
TSP-1/Endomucin	
immunofluorescent	
staining	
• Area	of	bone	marrow	expressing	
TSP-1	
• Number	of	Megakaryocytes	
(expressing	TSP-1)	
• Zeiss	LSM880	AiryScan	Confocal	
microscope		
• ImageJ	software	
• Aperio	ImageScope	software	
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6.4.1	In	vivo	studies	
Animal	 studies	 were	 performed	 in	 accordance	with	 local	 guidelines	 and	with	 Home	
Office	 approval	 under	 the	 project	 licence	 70/8964	 held	 by	 Professor	 Nicola	 Brown,	
University	of	Sheffield,	UK.			
To	 investigate	 the	 effect	 of	 the	 reduction	 of	 microvascular	 activity	 of	 the	 bone	
microenvironment,	 6-week	 old	 female	 BALB/c	 nude	 received	 3mg/kg/daily	 (5	
days/week)	 of	 VEGF	 tyrosine-kinase	 inhibitor	 Cediranib	 through	 oral	 gavage	 while	
control	 animals	 were	 administered	 with	 the	 control	 1%	 Tween-80	 (made	 in	
PBS)(n=10/group).	On	day	 21,	 5	 animals/group	were	 culled	 and	hind	 limbs	 collected	
for	 ex	 vivo	 analyses.	 The	 remaining	 5	 animals/group	were	 injected	 i.c.	 with	 0.5x105	
MDA-MB-231-NW1-Luc2	breast	 cancer	 cells	 labelled	with	 the	 lipophilic	 dye	Vybrant-
CM-DiI.	After	seven	days	animals	were	culled	and	hind	limbs	collected	(figure	6.1).	
To	 detect	 whether	 increased	 microvascular	 activity	 would	 modify	 the	 bone	
microenvironment,	 6-week	 old	 female	 BALB/c	 nude	 were	 injected	 i.p	 daily	 (5	
days/week)	 with	 15mg/ml	 (100µl)	 of	 Deferoxamine	 mesylate	 (DFM)	 or	 PBS	 control	
(n=13/group).	On	day	21,	3	animals/group	were	culled	and	hind	limbs	were	collected	
to	check	the	effect	of	DFM	on	the	bone	structure	by	µCT.	No	changes	were	detected,	
therefore	the	animals	were	treated	for	additional	three	weeks	with	either	DFM	or	PBS	
and	 on	 day	 42,	 5	 animals/group	 were	 culled	 and	 hind	 limbs	 collected	 for	 ex	 vivo	
analyses.	The	remaining	5	animals/group	were	injected	i.c.	with	0.5x105	MDA-MB-231-
NW1-Luc2	 breast	 cancer	 cells	 labelled	 with	 the	 lipophilic	 dye	 Vybrant-CM-DiI.	 After	
seven	days	animals	were	culled	and	hind	 limbs	collected	for	analyses	of	tumour	cells	
homing	to	bone	(figure	6.1).		
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Experimental	outline.	A)	6-week	old	female	BALB/c	nude	mice	were	dosed	orally	with	Cediranib	3mg/kg	
5	days/week)	or	vehicle	control.	After	three	weeks	of	treatment	5	mice/group	were	culled	to	detect	the	
effect	of	Cediranib	on	bone	microenvironment	while	the	remaining	5mice/group	were	injected	i.c.	with	
0.5x105	MDA-MB-231-NW1-Luc2	 cells	 labelled	with	 Vybrant-CM-DiI).	 Animals	 were	 culled	 seven	 days	
after	 the	 injection	 and	 tibiae	 and	 femora	 were	 collected	 for	 ex-vivo	 analysis.	 B)	 6-week	 old	 female	
BALB/c	 nude	mice	 were	 injected	 i.p.	 with	 15mg/ml	 (100µl)	 of	 Deferoxamine	mesylate	 (DFM)	 or	 PBS	
control	5days/week	 for	 three	weeks	 (n=13/group).	After	 three	weeks	of	 treatment	3mice/group	were	
culled	to	detect	the	effect	of	DFM	on	bone	structure.	Since	no	difference	was	detected,	animals	were	
treated	 for	 an	 additional	 three	weeks.	 After	 the	 six	 weeks	 of	 treatment	 5mice/group	were	 culled	 to	
investigate	 the	 effect	 of	DFM	on	 the	bone	microenvironment	while	 the	 remaining	 5mice/group	were	
injected	 i.c.	 with	 0.5x105	 MDA-MB-231-NW1-Luc2	 cells	 labelled	 with	 Vybrant-CM-DiI).	 Animals	 were	
culled	seven	days	after	the	injection	and	tibiae	and	femora	were	collected	for	ex-vivo	analysis.	
	 	
Figure	 6.1	 Outline	 of	 the	 in	 vivo	 studies	 evaluating	 the	 effect	 of	 Cediranib	 and	 DFM	 on	 the	 bone	
microenvironment	
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6.4.2	Processing	of	bone	samples	
On	the	day	of	cull	hind	limbs	were	dissected,	muscle	tissue	surrounding	the	bones	was	
carefully	removed	and	femora	and	tibiae	separated.		
Left	femora	were	snap	frozen	in	liquid	nitrogen	and	processed	as	explained	in	section	
2.10.1	 to	perform	 two-photon	microscopy	 analyses,	 left	 tibiae	were	 fixed	 in	 4%	PFA	
followed	 by	 decalcification	 in	 0.5M	 EDTA/0.5%	 PFA	 for	 histological	 analyses	 (see	
section	 2.9.1)	 and	 right	 legs	 (both	 femur	 and	 tibia)	 were	 fixed	 in	 4%	 PFA	 for	 4hr,	
decalcified	 in	 0.5M	 EDTA	 for	 48hr,	 embedded	 in	 gelatine	 and	 stored	 at	 -80°C	 until	
immunofluorescent	staining	was	performed	(see	section	2.9.2).	
6.4.3	Two-photon	microscopy	
Two-photon	 microscopy	 was	 used	 to	 visualise	 tumour	 cells	 seeded	 in	 the	 bone	
microenvironment.	The	upright	 two-photon	microscope	Zeiss	 LSM510	NLO	was	used	
to	 image	 the	 exposed	 surface	 of	 the	 bone	marrow	of	 calcified	 femora	 using	 second	
harmonic	 generation	 to	 detect	 the	 bone	 structure	 (Chameleon	 laser,	 900nm)	 and	
HeNe	laser	(543nm)	to	visualise	Vybrant-CM-DiL	labelled	breast	cancer	cells	within	the	
bone	marrow.	A	tile	scan	of	2104μm	x	2525μm	and	70µm	depth	was	captured.		
Three-dimensional	 images	 of	 the	 bones	 scanned,	 were	 reconstructed	 and	 analysed	
using	Volocity	3D	Image	Analysis	software.	The	parameters	analysed	were	the	number	
of	 tumour	 cells	 and	 their	 distance	 to	 the	 nearest	 bone	 surface	 and	 to	 the	 nearest	
cancer	 cell.	 The	 quantifications	 were	 all	 performed	 in	 two	 different	 ROIs,	 the	
trabecular	region	of	the	bone	and	the	growth	plate	area	(see	section	2.10).		
6.4.4	µCT	
During	the	incubation	time	in	4%	PFA,	tibiae	were	scanned	using	the	SkyScan	1272	to	
detect	 changes	 in	 the	 bone	 structure	 caused	 by	 the	 drug	 administered.	 NRecon	
software	was	used	to	reconstruct	the	 images	captured	with	the	SkyScan	and	the	VOI	
was	manually	drawn	using	CTAn.	Trabecular	bone	volume	(expressed	as	bone	volume	
per	 tissue	 volume,	 BV/TV	 in	 %),	 trabecular	 number	 (Tb.N	 in	 mm-1)	 and	 trabecular	
thickness	were	measured	in	1mm	of	bone	length	(growth	plate	used	as	the	reference	
point	and	0.5mm	offset)(see	section	2.11).	
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6.4.5	Toluidine	Blue	staining	
To	identify	any	alteration	in	the	extracellular	matrix	in	the	growth	plate	area,	toluidine	
staining	 was	 performed	 on	 histological	 sections	 of	 two	 non-consecutive	 levels	 of	
paraffin	embedded	tibiae.	Dewaxed	and	hydrated	bone	slides	were	incubated	for	3min	
at	 ambient	 temperature	 with	 the	 toluidine	 blue	 solution	 and	 rinsed	 under	 running	
water	followed	by	dehydration	and	cover	slipping.		
Proteoglycan-rich	areas	were	quantified	by	manually	drawing	the	area	of	interest	using	
Aperio	 ImageScope	 software.	Any	 trabecular	bone	not	 connected	with	 the	epiphysis	
and	the	cortical,	bone	were	excluded	from	the	analysis	(see	section	2.14.1).	
6.4.6	Immunofluorescent	staining	
Gelatine	 embedded	 30µm	 sections	 of	 tibia	 were	 stained	 with	 antibodies	 against	
Osterix,	Endomucin,	CD31,	CD34	and	TSP-1	using	the	protocol	for	immunofluorescent	
staining	described	in	section	2.13.	
Aperio	 ImageScope	 software	 was	 used	 to	 quantify	 the	 number	 and	 length	 of	
Endomucin+,	CD31+	and	CD34+	vessels	while	ImageJ	software	was	used	to	measure	the	
overall	expression	of	 the	Osterix,	Endomucin,	CD31,	CD34	and	TSP-1,	 the	percentage	
of	 Endomucin+	 vessels	 positive	 both	 for	 CD31	 or	 CD34	 and	 the	 number	 of	
osteoprogenitors	(Osterix+)	and	megakaryocytes	(TSP-1+)	(see	section	2.14.2-4).	
6.4.7	Statistical	analysis	
Statistical	analyses	were	performed	using	GraphPad	Prism	software	(versions	6.0	and	
7.0).	 T-test	 and	 Two-way	 ANOVA	with	 Tukey	 post	 test	 were	 used	 as	 stated	 in	 each	
figure	legend	and	p-value	of	<0.05	was	considered	significant.	
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6.5	Results	
Traditional	treatments	for	bone	metastasis	mostly	target	the	bone	component	on	the	
microenvironment	and	 in	particular	 the	osteoclast	population.	Currently,	 researchers	
are	 focusing	 their	 attention	 on	 characterisation	 of	 the	 multiple	 components	 of	 the	
metastatic	 niche	 and	 this	 increased	 knowledge	 may	 allow	 the	 development	 of	
therapies	 targeting	 other	 cell	 types,	 such	 as	 osteoblasts,	 endothelial	 cells,	 immune	
cells.	However,	 it	 is	still	not	clear	whether	modifications	of	one	of	the	overlap	niches	
will	 alter	 the	 cell	populations	 in	 the	other	niche(s).	 In	 this	 chapter	 I	 investigated	 the	
response	of	the	microenvironment	and	the	subsequent	homing	of	breast	cancer	cell	to	
bone	in	response	to	therapies	targeting	microvascular	activity;	either	reduced	activity	
by	Cediranib	or	increased	activity	with	Deferoxamine	mesylate	(DFM).	
6.5.1	Cediranib	treatment	to	decrease	the	microvascular	activity	
Even	though	Cediranib	has	been	suggested	to	have	a	direct	anti-tumour	effect	and	to	
significantly	reduce	the	presence	of	the	vasculature	within	tumours	[168],	[171],	[173],	
[174],	little	is	known	about	the	effect	of	this	drug	on	the	components	of	the	niche.	The	
alterations	of	 the	bone	microenvironment	caused	by	administration	of	Cediranib	are	
described	in	the	following	sections.	
6.5.1.1	Effect	of	Cediranib	on	bone	structure	
To	 assess	 whether	 the	 administration	 of	 Cediranib	 affected	 the	 bone	 structure,	
animals	were	treated	daily	(5	days/week)	for	three	weeks	by	oral	gavage	with	3mg/kg	
of	Cediranib	or	 vehicle	 control,	 culled	and	 the	 tibiae	 collected	 for	µCT	analyses	 (n=3	
control	and	n=5	Cediranib).	
The	 first	parameter	analysed	was	 the	 trabecular	bone	volume.	Administration	of	 the	
VEGF	 inhibitor	 at	 this	 dose	 did	 not	 affect	 the	 trabecular	 bone	 of	 treated	 animals	
compared	to	the	controls	(p=0.6085)	(figure	6.2).	Trabecular	thickness	and	trabecular	
number	 were	 also	 not	 altered	 by	 drug	 administration	 (p=0.8376	 and	 p=0.3285,	
respectively,	figure	6.2).	
These	results	show	that,	at	the	dosage	used	in	this	in	vivo	study,	Cediranib	treatment	
did	 not	 modify	 the	 calcified	 bone	 structure	 of	 the	 tibia,	 the	 bone	 most	 frequently	
colonised	by	tumour	cells.	
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Figure	6.2	Effect	of	a	Cediranib	treatment	on	bone	structure	
Three-dimensional	 reconstruction	 of	 the	 trabecular	 bone	 analysed	 and	 the	 open	 cross	 section	 of	 the	
entire	bone	scanned.	(A)	Tibia	of	animals	receiving	vehicle	control	and	(B)	Cediranib.	(C)	Quantification	
of	 the	 trabecular	 bone	 volume	 after	 Cediranib	 treatment.	 (D)	 Trabecular	 thickness	 and	 (E)	 trabecular	
number.	Graphs	show	Mean	±	SEM	(n=5	animals/group,	3	bones	analysed	control	and	5	bones	analysed	
Cediranib),	Student	t-test,	ns	is	not-significant.		 	
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6.5.1.1.1	Changes	in	the	extracellular	matrix		
It	has	been	reported	that	repeated	oral	administration	(28	days)	of	Cediranib	causes	an	
expansion	 of	 the	 extracellular	 matrix	 of	 the	 epiphysis	 area	 of	 the	 bone	 when	
administered	in	rats	at	a	dose	of	5mg/kg/day	[168].	
To	 detect	 whether	 the	 dose	 used	 in	 the	 in	 vivo	 study	 here	 described	 (3mg/kg	 5	
days/week	for	3	weeks)	altered	content	of	the	extracellular	matrix	of	the	growth	plate	
area,	histological	sections	of	tibiae	were	stained	with	Toluidine	blue	(n=4	control	and	
n=5	Cediranib).	The	area	of	 the	proteoglycan-rich	matrix	was	measured	using	Aperio	
ImageScope	software;	 trabecular	bone	not	connected	with	the	epiphysis	and	cortical	
bone	were	excluded	by	the	analysis.	
As	 shown	 in	 figure	 6.3,	 Cediranib	 treatment	 did	 not	 alter	 the	 area	 of	 the	 epiphysis	
proteoglycan-rich	matrix	compared	to	the	vehicle	control	(p=0.3969).	
	
	(A)	Extracellular	matrix	visualised	with	Toluidine	Blue	staining	of	histological	sections	of	tibiae	areas	rich	
in	 of	 proteoglycan	 of	 the	 epiphysis	 and	 the	 trabecular	 bone	 directly	 connected	 to	 it	 (green	 line).	
Fragments	of	disconnected	bone	and	cortical	bone	were	excluded	from	the	analysis.	(B)	Quantification	
of	the	proteoglycan	rich	area.	Graph	shows	mean	±	SEM	n=5	animals/group,	4	bones	analysed	control	
and	5	bones	analysed	Cediranib),	Student	t-test,	ns	is	non-significant.	Scale	bar	250µm	and	100µm.	 	
Figure	6.3	Visualisation	of	the	proteoglycan-rich	area	of	bone	
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6.5.1.1.2	Effect	of	Cediranib	on	the	osteoprogenitor	population	
To	 investigate	 whether	 the	 treatment	 with	 Cediranib	 causes	 an	 alteration	 in	 the	
number	of	osteoprogenitors	in	the	bone	marrow,	30µm	thick	gelatine	embedded	tibia	
sections	were	stained	with	antibodies	against	Endomucin	and	Osterix	(figure	6.4).		
	
Immunofluorescent	staining	against	Osterix	and	Endomucin	performed	on	30µm	tibia	section	of	animals	
receiving	 vehicle	 control	 or	 Cediranib	 treatment	 for	 three	weeks.	Green=Endomucin,	 red=Osterix	 and	
yellow=Endomucin	and	Osterix.	Scale	bar	200µm.		
	 	
Figure	6.4	Representative	image	of	the	effect	of	Cediranib	treatment	on	Osterix+	cells	
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The	 images	were	 captured	with	 Zeiss	 LSM880	AiryScan	 Confocal	microscope	 and	 an	
area	of	approximately	2.6mm2	was	imaged	for	both	groups	(2.58±0.04	and	2.67±0.21	
control	and	Cediranib	respectively,	p=0.7184,	n=3/group)(figure	6.5).	Within	this	area	
the	 overall	 expression	 of	 Osterix	 was	 measured	 with	 ImageJ	 software,	 Cediranib	
caused	a	slightly	reduction	of	the	overall	expression	of	Osterix	even	though	this	change	
did	 not	 reach	 statistical	 significance	 (p=0.0746)(figure	 6.5).	 No	 differences	 were	
detected	 in	 the	 overall	 number	 and	 number	 of	Osterix+	cells/mm2	 between	 the	 two	
groups	analysed,	p=0.2355	and	p=0.8711	respectively	(figure	6.5).	
Taken	 together,	 this	 data	 show	 that	 3mg/kg	 5	 days/week	 for	 3	 weeks	 of	 Cediranib	
does	not	affect	the	presence	of	Osterix+	progenitors	in	the	bone	marrow.	
	
(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	Osterix.	(C)	Overall	
number	of	Osterix+	cells	and	(D)	Osterix+	cells/mm2.	Graphs	show	mean	±	SEM	(n=5	animals,	3	bones	
analysed/group),	Student	t-test,	ns	is	not-significant.		
	 	
Figure	6.5	Quantifications	of	the	effect	of	Cediranib	treatment	on	Osterix	expression	
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6.5.1.2	Effect	of	Cediranib	treatment	on	bone	microvasculature	
Cediranib	 is	 a	 VEGF-tyrosine	 kinase	 inhibitor	 and	 it	 has	 been	 shown	 to	 reduce	 the	
microvascular	activity	and	the	number	of	vessels	in	tumours	[168],	[171],	[173],	[174].	
To	my	 knowledge	 this	 is	 the	 first	 study	 investigating	 the	 effect	 of	 Cediranib	 on	 the	
bone	microvasculature	 to	 determine	 if	 this	 drug	modifies	 the	 different	 vessels	 sub-
types	in	the	absence	of	tumour.	
6.5.1.2.1	Endomucin+	vessels	
To	 observe	 whether	 Cediranib	 treatment	 changed	 the	 extensive	 microvascular	
network	of	 the	bone	microenvironment,	 gelatine	 sections	of	 tibia	were	 stained	with	
the	immunofluorescent	protocol	described	in	section	2.13	with	an	antibody	against	the	
endothelial	marker	Endomucin.	
Zeiss	LSM880	AiryScan	Confocal	microscope	was	used	to	image	the	bones	and	Aperio	
ImageScope	was	used	to	quantify	the	number	of	H-	and	L-vessels,	their	length	and	the	
area	of	bone	marrow	occupied	by	the	different	vessel	sub-type.	The	total	area	of	bone	
marrow	 analysed	 was	 approximately	 2.7mm2	 (2.67±0.13	 and	 2.79±0.06	 control	 and	
Cediranib	 respectively,	 p=0.4678,	 n=3/group)(figure	 6.6).	 In	 the	 area	 analysed,	
Endomucin+	vessels	can	be	divided	in	two	different	vessel	sub-types,	H-	and	L-vessels.	
The	 first	 type	 of	 vessels	 (H-vessels)	 has	 a	 characteristic	 column-like	 shape	 and	 its	
located	in	the	metaphysis	of	bones	while	the	second	type	of	vessels	(L-vessels)	is	more	
sinusoidal	 and	 is	 found	 towards	 the	 diaphysis	 of	 long	 bones.	 The	 first	 analysis	
performed	on	the	Endomucin	stained	section	was	to	determine	if	Cediranib	treatment	
caused	an	alteration	in	the	area	of	bone	marrow	occupied	by	the	two	vessel	sub-types.	
In	 the	 area	 of	 bone	 marrow	 analysed,	 there	 was	 an	 even	 distribution	 of	 H-	 and	 L-
vessels	 in	 the	 control	 group	 (48.90±4.44	 and	 51.1±4.437,	 p=0.7443)	 while	 animals	
treated	with	 cediranib	display	a	 slight	 increment	 in	 the	portion	of	bone	occupied	by	
the	 L-vessel	 sub-type	 (44.61±3.06	 and	 55.39±3.06,	 p=0.0675).	 However,	 when	
comparing	 between	 treatment	 groups	 there	 was	 no	 statistical	 difference	 in	 the	
proportion	of	bone	occupied	by	H-	(p=0.4705)	and	L-vessels	(p=0.4705)(figure	6.6).		
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A)	 Representative	 images	 of	 the	 total	 area	 of	 bone	marrow	 analysed	 (green),	 H-vessels	 (blue)	 and	 L-
vessels	 (red)	 manually	 tracked	 with	 Aperio	 ImageScope	 software.	 Area	 of	 bone	 marrow	 analysed	 is	
drawn	in	green	and	its	quantification	is	shown	in	(B).	(C)	and	(D)	show	the	percentage	of	area	of	bones	
occupied	by	H-	and	L-vessels	in	control	and	Cediranib	treated	animals	respectively.	(E)	and	(F)	show	the	
area	 of	 bones	 occupied	 by	 H-	 and	 L-vessels	 in	 the	 different	 groups.	 Graphs	 show	mean	 ±	 SEM	 (n=5	
animals,	3	bones	analysed/group),	Student	t-test,	ns	is	not-significant.		
	 	
Figure	6.6	Quantification	of	immunofluorescent	staining	against	Endomucin	
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The	 second	parameter	 analysed	was	 the	 number	 of	 vessels	within	 the	 area	 of	 bone	
marrow	analysed.	As	expected,	Cediranib	treatment	caused	a	significant	reduction	 in	
the	total	number	of	vessels/mm2	compared	to	the	control	group	(p=0.0378)(figure	6.7).	
However,	when	analysed	separately,	the	number	of	H-	and	L-vessel/mm2	of	the	total	
area	of	bone	marrow	analysed	was	not	significantly	different	between	the	treatments	
group	 (p=0.2671	 and	 p=0.4096	 respectively)(figure	 6.6).	 The	 number	 of	 H-vessels	
normalised	 to	 the	 area	 of	 bone	 marrow	 that	 they	 occupy	 was	 not	 affected	 by	 the	
Cediranib	treatment	(p=0.2193)	while	this	analysis	performed	on	the	L-vessel	sub-type	
revealed	 a	 decrease	 in	 the	 number	 of	 these	 vessels	 compared	 to	 the	 control	
(p=0.0222)(figure	 6.7).	 In	 tibiae	 from	 the	 control	 animals	 there	 was	 a	 significantly	
higher	number	of	L-vessels	compared	to	H-vessels	(p=0.0012),	but	this	pattern	was	lost	
in	 animals	 treated	 with	 Cediranib,	 resulting	 in	 a	 more	 even	 distribution	 of	 the	 two	
vessel	 sub-types	 (p=0.2977)(figure	 6.8).	 Interestingly,	 administration	 of	 Cediranib	
resulted	in	an	elongation	of	the	H-vessels	compared	to	controls	(p=0.0344)	while	the	
average	length	of	L-vessels	was	unchanged	(p=0.3821)(figure	6.8).		
Taken	 together,	 the	 data	 presented	 here	 describe	 how	 treatment	 with	 the	 VEGF-
tyrosine	kinase	inhibitor	affects	the	microvasculature	in	bone.	Cediranib	increases	the	
area	of	bone	marrow	occupied	by	L-vessels.	Moreover,	the	TKI	induces	a	reduction	in	
the	number	of	vessels,	but	 it	 increases	 the	average	 length	of	column-like	vessels	 (H)	
compared	to	controls.	
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A)	 Total	 number	 of	 vessels	 counted	 in	 both	 groups.	 (B)	 and	 (C)	 show	 the	 number	 of	 H-	 and	 L-
vessels/mm2	 of	 total	 area	 of	 bone.	 (D)	 and	 (E)	 show	 the	 number	 H-	 and	 L-vessels/mm2	 of	 the	 area	
occupied	 by	 the	 different	 vessel	 sub-types.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	
analysed/group),	Student	t-test,	*	p<0.05	and	ns	is	not-significant.	
	 	
Figure	6.7	Number	of	vessels	quantified	in	bone	marrow	
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(A)	and	(B)	show	the	number	of	H	and	L-	vessels/mm2	in	control	and	Cediranib	group	respectively.	 (C)	
and	(D)	show	the	length	of	H-	and	L-	vessels	between	different	groups.	Graphs	show	mean	±	SEM	(n=5	
animals,	3	bones	analysed/group),	Student	t-test,	*p<0.05,	**	p<0.01	and	ns	is	not-significant.		 	
Figure	6.8	Number	of	H-	and	L-vessels	in	different	groups	and	their	length	
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6.5.1.2.2	CD31+	vessels	
To	 define	 whether	 the	 treatment	 with	 Cediranib	 would	 result	 in	 a	 change	 in	 the	
established	 microvasculature	 present	 in	 the	 bone	 microenvironment,	 bone	 sections	
were	 stained	 with	 antibodies	 against	 Endomucin	 and	 CD31	 (see	 section	 2.13)	 and	
imaged	with	Zeiss	LSM880	AiryScan	Confocal	microscope	(figure	6.9).	
	
Immunofluorescent	 staining	 against	 CD31	 and	 Endomucin	 performed	 on	 30µm	 tibia	 section	 from	
animals	receiving	vehicle	control	or	Cediranib	treatment	for	three	weeks.	Green=Endomucin,	red=CD31	
and	yellow=Endomucin	and	CD31.	Scale	bar	200µm.		
	 	
Figure	6.9	Representative	image	of	the	effect	of	Cediranib	treatment	on	CD31+	vessels	
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An	area	of	approximately	2.5mm2	was	 imaged	and	analysed	with	 ImageJ	and	Aperio	
ImageScope	 software	 (2.407±0.0968	 and	 2.540±0.2751	 control	 and	 Cediranib	
respectively,	p=0.4678,	n=3/group)(figure	6.10).	Animals	treated	with	Cediranib	had	a	
significant	reduction	in	the	expression	of	Endomucin	compared	to	controls	(p=0.0208),	
while	 no	 difference	 was	 detected	 in	 the	 expression	 of	 CD31	 (p=0.1038)	 and	 in	 the	
percentage	 of	 Endomucin+CD31+	 between	 the	 two	 groups	 (p=0.4209)(figure	 6.10).	
Furthermore,	 the	 administration	 of	 the	 drug	 did	 not	 change	 the	 number	 of	 CD31+	
vessels/mm2	of	total	bone	of	CD31+	vessels/mm2	of	bone	occupied	by	this	vessel	sub-
type	 (p=0.6468	 and	 p=0.3225	 respectively)(figure	 6.11).	 As	 well	 as	 the	 number,	 the	
average	 length	 of	 the	 established	 vessels	 was	 not	 modified	 by	 the	 treatment	 with	
Cediranib	(p=0.1315)(figure	6.11).		
These	 results	 show	 that	 the	 established	 vasculature	 (positive	 for	 the	 endothelial	
marker	 CD31+)	 was	 not	 altered	 in	 its	 overall	 expression	 and	 structure	 by	 treatment	
with	Cediranib.	
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A)	 Area	 of	 bone	 marrow	 analysed	 in	 the	 two	 different	 groups.	 B)	 Shows	 the	 overall	 expression	 of	
Endomucin	 while	 (C)	 is	 the	 expression	 of	 CD31.	 (D)	 Percentage	 of	 Endomucin+	 vessels	 that	 are	 also	
expressing	 CD31	 in	 the	 different	 groups	 (H).	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	
analysed/group),	Student	t-test,	*p<0.05	and	ns	is	not-significant.	
	 	
Figure	6.10	Quantification	of	immunofluorescent	staining	against	CD31	
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A)	Show	the	number	of	CD31+	vessels/mm2	of	total	bone	and	illustration	of	the	area	considered	for	this	
analysis.	(B)	Show	the	number	of	CD31+vessels/mm2	of	area	occupied	by	the	vessel	sub-	and	illustration	
of	the	area	considered	for	this	analysis.	(C)	Displays	the	average	length	of	CD31+	vessels.	Graphs	show	
mean	±	SEM	(n=5	animals,	3	bones	analysed/group),	Student	t-test,	ns	is	not-significant.		
	 	
Figure	6.11	Number	and	average	length	of	CD31+	vessels	
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6.5.1.2.3	CD34+	vessels	
One	 important	 component	 of	 the	 perivascular	 niche	 is	 the	 newly	 formed	 vessels,	
which	are	CD34+.	To	investigate	if	Cediranib	caused	an	alteration	in	the	structure	of	the	
neo	vessels	immunofluorescent	staining,	using	antibodies	against	both	Endomucin	and	
CD34	was	performed	on	three	non-consecutive	gelatine	embedded	sections	tibia	(n=3	
tibia/group)(figure	6.12),	as	described	in	section	2.14.	
	
Immunofluorescent	 staining	 against	 CD34	 and	 Endomucin	 performed	 on	 30µm	 tibia	 sections	 from	
animals	receiving	vehicle	control	or	Cediranib	treatment	for	three	weeks.	Green=Endomucin,	red=CD34	
and	yellow=Endomucin	and	CD34.	Scale	bar	200µm.		
	
	 	
Figure	6.12	Representative	image	of	the	effect	of	Cediranib	treatment	on	CD34+	vessels	
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ImageJ	 and	 Aperio	 ImageScope	 software	 were	 used	 to	 analyse	 the	 area	 of	 bone	
marrow	captured	with	Zeiss	LSM880	AiryScan	Confocal	microscope.	The	area	of	bone	
marrow	varied	between	the	bones	analysed	but	no	statistical	difference	was	detected	
when	 comparing	 to	 the	 Cediranib	 to	 the	 control	 group	 (2.62±0.13	 and	 2.09±0.61	
control	 and	 Cediranib	 respectively,	 p=0.4678,	 n=3/group)(figure	 6.13).	 Endomucin	
expression	 was	 similar	 in	 both	 treatment	 groups	 (p=0.4331)	 whereas	 the	 CD34	
expression	 was	 significantly	 higher	 in	 the	 Cediranib	 group	 compared	 to	 the	 control	
(p=0.0377)(figure	 6.13).	 However,	 there	 was	 no	 difference	 in	 the	 presence	 of	
Endomucin+CD34+	 vessels	 between	 the	 groups	 analysed	 (p=0.6902)(figure	 6.13).	 As	
shown	 in	 figure	 6.14,	 there	 was	 a	 trend	 towards	 an	 increase	 in	 the	 number	 of	
CD34+vessels/mm2	in	the	total	bone	and	the	number	of	CD34+vessels/mm2	in	the	area	
occupied	by	this	vessel	sub-type	of	the	Cediranib	group,	none	of	these	trends	reached	
the	 statistical	 significance	 when	 compared	 to	 controls	 (p=0.1983	 and	 p=0.1987	
respectively).	As	for	the	CD31+vessels,	there	was	no	difference	detected	between	the	
average	 lengths	 of	 the	 CD34+vessels	 of	 the	 two	 treatment	 groups	 (p=0.4162)(figure	
6.14).	
Surprisingly,	 treatment	 with	 Cediranib	 had	 only	 marginal	 effect	 on	 newly	 formed	
vasculature	 in	 bone.	 The	 only	 parameter	 that	was	modified	 by	 Cediranib	 treatment	
was	 the	overall	expression	of	CD34.	 It	was	expected	 that	vascular	activity	 in	animals	
treated	with	the	VEGF-tyrosine	kinase	inhibitor	should	be	reduced,	while	in	this	in	vivo	
study	 the	 opposite	 result	 was	 obtained,	 with	 a	 small	 increase	 in	 the	 newly	 formed	
vascular	network	in	treated	animals.	
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A)	 Area	 of	 bone	 marrow	 analysed	 in	 the	 two	 different	 groups.	 B)	 Shows	 the	 overall	 expression	 of	
Endomucin	 while	 (C)	 is	 the	 expression	 of	 CD34.	 (D)	 Percentage	 of	 Endomucin+	 vessels	 that	 are	 also	
expressing	 CD34	 in	 the	 different	 groups	 (H).	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals,	 3	 bones	
analysed/group),	Student	t-test,	*p<0.05	and	ns	is	not-significant.	
	 	
Figure	6.	13	Quantification	of	immunofluorescent	staining	against	CD34	
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A)	Number	of	CD34+	vessels/mm2	of	total	bone	and	illustration	of	the	area	considered	for	this	analysis.	
(B)	 Number	 of	 CD34+vessels/mm2	 of	 area	 occupied	 by	 the	 vessel	 sub-	 and	 illustration	 of	 the	 area	
considered	for	this	analysis.	(C)	Displays	the	average	length	of	CD34+	vessels.	Graphs	show	mean	±	SEM	
(n=5	animals,	3	bones	analysed/group),	Student	t-test,	ns	is	not-significant.		
	 	
Figure	6.14	Number	and	average	length	of	CD34+	vessels	
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6.5.1.3	Effect	of	Cediranib	treatment	on	TSP-1	expression	
TSP-1	has	been	suggested	to	be	involved	in	the	support	of	dormancy	of	breast	cancer	
cells,	 as	 outlined	 in	 Chapter	 4.	 To	 investigate	 whether	 treatment	 with	 Cediranib	
influences	the	expression	of	TSP-1	and/or	the	number	of	megakaryocytes	in	the	bone	
microenvironment,	 immunofluorescent	 protocol	 against	 TSP-1	 was	 performed	 on	
30µm	sections	of	gelatine	embedded	tibia	(n=3/group)(figure	6.15).	
	
Immunofluorescent	 staining	 against	 TSP-1	 and	 Endomucin	 performed	 on	 30µm	 tibia	 sections	 from	
animals	 receiving	 vehicle	 control	 or	 Cediranib	 treatment	 for	 three	 weeks.	 Green=Endomucin	 and	
red=TSP-1.	Scale	bar	200µm.	
	 	
Figure	6.15	Representative	image	of	the	effect	of	Cediranib	treatment	on	TSP-1	expression	
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As	shown	in	figure	6.16,	there	was	no	difference	in	the	size	of	the	area	of	bone	marrow	
analysed	 between	 the	 two	 treatment	 groups	 (2.65±0.13mm2	 and	 2.89±0.19mm2	
control	 and	 Cediranib	 respectively,	 p=0.3527,	 n=3/group)(figure	 6.16).	 Interestingly,	
Cediranib	 treatment	 reduced	 the	 overall	 expression	 of	 TSP-1	 in	 the	 area	 of	 bone	
microenvironment	 analysed	 (p=0.0364)	 while	 the	 number	 of	 megakaryocytes/mm2	
was	not	altered	(p=0.1434)(figure	6.16).	
Taken	 together,	 these	 data	 demonstrated	 that	 Cediranib	 treatment	 reduces	 the	
intensity	 of	 expression	 of	 the	 dormancy-supporting	 TSP-1	 without	 modifying	 the	
number	of	megakaryocytes	counted	within	the	bone	marrow.	
	
(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	TSP-1.	(C)	Number	of	
Megakaryocytes/mm2.	Graphs	show	mean	±	SEM	(n=5	animals,	3	bones	analysed/group),	Student	t-test,	
*p<0.05	and	ns	is	not-significant.		
	 	
Figure	6.16	Quantification	of	the	effect	of	Cediranib	treatment	on	TSP-1	expression	
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6.5.1.4	Effect	of	Cediranib	treatment	on	breast	cancer	cell	homing	to	bone	
An	 ultimate	 aim	 of	 this	 chapter	 was	 to	 determine	 whether	 Cediranib	 treatment	
affected	 the	metastatic	 niche	 in	 bone	 to	 an	 extent	 that	modified	 breast	 cancer	 cell	
colonisation	of	the	bone	microenvironment.	To	achieve	this,	MDA-MB-231-NW1-Luc2	
cells	 labelled	 with	 the	 lipophilic	 dye	 Vybrant-CM-DiI	 were	 injected	 i.c.	 into	 BALB/c	
nude	mice	which	had	previously	treated	for	three	weeks	(5	days/week)	with	3mg/kg	of	
Cediranib	or	vehicle	control.	Femora	were	collected	7	days	after	tumour	cell	injection	
and	 analysed	 by	 two-photon	microscopy	 to	map	 the	 number	 and	 location	 of	 breast	
cancer	cells	within	the	bone	microenvironment.	
The	analyses	with	Volocity	3D	Image	software	were	performed	in	two	different	ROIs,	
the	trabecular	region	of	bone	(ROI1)	and	growth	plate	area	(ROI2)(n=6	control	and	n=7	
Cediranib).	 No	 difference	 was	 detected	 in	 ROI1	 (p=0.2593)	 or	 in	 ROI2	 (p=0.7172)	
between	 the	 treatment	 groups	 (figure	 6.17).	 Irrespective	 of	 treatment	 and	 ROI	
quantified,	 breast	 cancer	 cells	 located	 in	 close	 proximity	 to	 the	 bone	 surface	
(36.17±8.266µm	 and	 45.9±5.38µm	 p=0.3315	 ROI1,	 34.39±14.06µm	 and	
16.77±8.642µm	 p=0.3759	 ROI2,	 control	 and	 Cediranib	 respectively)(figure	 6.17).	
Distances	 to	 the	 nearest	 tumour	 cells	 were	 quantified	 only	 in	 ROI1	 as	 statistical	
analyses	were	not	possible	in	ROI2	due	to	the	low	number	of	femora	containing	cancer	
cells	in	this	area	of	bone.	Breast	cancer	cells	in	ROI1	locate	far	away	from	other	tumour	
cells	 (385.8±122.5	 vs.	 254.3±42.25,	 control	 vs.	 Cediranib	 respectively)	 and	 no	
difference	 was	 observed	 between	 treatment	 groups	 (p=0.2731)(figure	 6.17).	
Irrespective	of	treatment,	tumour	cells	locate	closer	to	the	bone	surface	than	to	other	
cancer	cells	(p=0.0017	control	and	p=0.0391	Cediranib)(figure	6.17).	
Taken	together	these	data	show	that	Cediranib	treatment	does	not	alter	the	pattern	of	
homing	of	breast	cancer	cells	to	bone,	resulting	in	a	preferential	homing	and	in	close	
proximity	to	the	trabecular	region	of	the	bone	when	compared	to	the	growth	plate.	
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Example	 images	of	 two-photon	 scans	of	 	 (A)	 control	 and	 (B)	Cediranib	 treated	animals	 showing	bone	
(white)	and	Vybrant-CM-DiI+	cells	(pink	and	pink	arrows).	C)	Graph	shows	the	number	of	MDA-MB-231-
NW1-Luc2	 cells	 detected	 in	 the	 two	 groups.	 (D)	 Distances	 of	 the	 tumour	 cells	 to	 the	 nearest	 bone	
surface.	 (E)	Distances	 to	 the	nearest	 bone	 surface	 and	 the	nearest	 tumour	 cell	 in	ROI1.	Graphs	 show	
Mean	±	SEM	(n=5	animals/group,	6	bones	analysed	control	and	7	bones	analysed	cediranib),	Two-way	
ANOVA	and	Tukey	post	test,	*p<0.05,	**p≤0.005	and	ns	is	not–significant.	
CONTROL	 CEDIRANIB	
Figure	6.17	Homing	of	breast	cancer	cells	in	animals	treated	with	Cediranib	
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6.5.2	Deferoxamine	mesylate	treatment	to	increase	the	microvascular	activity	
DFM	 increases	either	 the	angiogenic	and/or	osteogenic	processes	 in	a	wide	range	of	
animal	 models	 [97],	 [186]–[190],	 [192],	 [193].	 The	 treatment	 efficacy	 on	 the	 bone	
microvasculature	 has	 been	 quantified	 using	 qPCR	 [97]	 or	 µCT	 following	 vascular	
perfusion	 [187],	 [189],	 [190],	 [193]	but	quantitative	analyses	on	 the	 structure	of	 the	
vessels	 have	 not	 been	 previously	 reported.	 Moreover,	 the	 implications	 of	 these	
changes	 on	 the	 homing	of	 breast	 cancer	 cell	 to	 bone	have	not	 yet	 been	 elucidated.	
Therefore,	 studies	 described	 in	 the	 following	 sections	 aimed	 to	 fill	 this	 gap	 in	 our	
current	knowledge.		
6.5.2.1	Effect	of	DFM	on	bone	structure	
It	has	been	reported	that	DFM	treatment	affects	both	bone	mass	and	osteoprogenitor	
numbers	in	bones	of	aged	mice	(approximately	40-week	old),	reversingg	the	reduction	
of	these	two	components,	due	to	the	ageing	process	[97].	
	To	test	whether	treatment	with	DFM	modified	the	bone	structure	of	young	animals,	6-
week	old	BALB/c	nude	mice	received	15mg/ml	 (100µl)	of	DFM	daily	 for	5	days/week	
for	 3	 weeks	 (n=3/group)	 and	 tibiae	 were	 collected	 to	 perform	 µCT	 analyses	 as	
described	in	section	2.11.	
A	three	week	course	of	treatment	with	this	dose	of	DFM	was	not	sufficient	to	induce	
changes	 in	 the	 bone	 structure	 of	 young	 mice.	 There	 were	 no	 differences	 in	 the	
trabecular	 bone	 volume	 (p=0.7035),	 trabecular	 thickness	 (p=0.5602)	 or	 trabecular	
number	 (p=0.8788)	 of	 animals	 treated	 with	 DFM	 compared	 to	 the	 control.	 Animals	
were	therefore	treated	with	DFM	for	additional	three	weeks	(n=10/group)	(figure	6.18).		
Surprisingly,	at	 the	end	of	 the	six	weeks	of	administration	of	DFM,	no	changes	were	
detected	 in	 the	 bone	 structure	 of	 treated	 animals	 compared	 to	 controls	 (p=0.6816	
trabecular	 bone	 volume,	 p=0.2867	 trabecular	 thickness	 and	 p=0.4242	 trabecular	
number)(figure	6.19).	
Results	described	 in	 this	 section	 show	 that	 treatment	with	15mg/ml	 (100µl)	 of	DMF	
daily	 for	 5	days/week	 for	 3	or	 6	weeks	does	not	 affect	 the	 structure	of	 the	bone	of	
young	animals.		
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Three-dimensional	 reconstruction	 of	 the	 trabecular	 bone	 analysed	 and	 the	 open	 cross	 section	 of	 the	
entire	bone	scanned.	Tibia	of	animals	receiving	(A)	vehicle	control	and	(B)	DFM.	(C)	Quantification	of	the	
trabecular	bone	volume	after	Cediranib	treatment.	(D)	Trabecular	thickness	and	(E)	trabecular	number.	
Graphs	show	Mean	±	SEM	(n=3	animals/group,	4	bones	analysed	control	and	5	bones	analysed	DFM),	
Student	t-test,	ns	is	not-significant.	
	
Figure	6.18	Effect	of	3	weeks	of	DFM	treatment	on	bone	structure	
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Three-dimensional	 reconstruction	 of	 the	 trabecular	 bone	 analysed	 and	 the	 open	 cross	 section	 of	 the	
entire	bone	scanned.	Tibia	of	animals	receiving	(A)	vehicle	control	and	(B)	DFM.	(C)	Quantification	of	the	
trabecular	bone	volume	after	Cediranib	treatment.	(D)	Trabecular	thickness	and	(E)	trabecular	number.	
Graphs	show	Mean	±	SEM	(n=5	animals/group,	8	bones	analysed	control	and	7	bones	analysed	DFM),	
Student	t-test,	ns	is	not-significant.	
	 	
Figure	6.19	Effect	of	6	weeks	of	DFM	treatment	on	bone	structure	
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6.5.2.1.1	Changes	in	the	extracellular	matrix		
To	detect	whether	DFM	treatment	modified	 the	extracellular	matrix	 rich	area	of	 the	
epiphysis,	 Toluidine	 blue	 staining	was	 performed	 on	 histological	 sections	 of	 tibia	 as	
described	in	section	2.12.4.	
There	was	no	difference	in	the	area	of	the	proteoglycan	rich	region	between	treatment	
groups	(p=0.5214)(figure	6.20).	
	
	
Figure	6.20	Visualisation	of	the	proteoglycan-rich	area	of	bone	
	(A)	Extracellular	matrix	visualised	with	Toluidine	Blue	staining	of	histological	sections	of	tibiae;	area	rich	
in	proteoglycan	of	the	epiphysis	and	the	trabecular	bone	directly	connected	to	it	(green	line).	Fragments	
of	 bone	 disconnected	 and	 cortical	 bone	 were	 excluded	 from	 the	 analysis.	 (B)	 Quantification	 of	 the	
proteoglycan	rich	area	(n=5	animals	and	4	bones	analysed/group).	Graph	shows	mean	±	SEM,	Student	t-
test,	ns	is	non-significant.	Scale	bar	250µm.	 	
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6.5.2.1.2	Effect	of	DFM	on	the	osteoprogenitor	population	
When	aged	mice	(approximately	70-week	old)	are	treated	with	DFM	in	addition	to	an	
increase	in	bone	volume,	the	number	of	osteoprogenitors	also	increase	[97].	To	detect	
whether	 such	 changes	 occur	 also	 in	 young	 animals,	 30µm	 thick	 gelatine	 embedded	
tibiae	 section	 were	 stained	 Endomucin	 and	 Osterix	 using	 the	 immunofluorescent	
protocol	described	in	section	2.14	(figure	6.21).		
Zeiss	AiryScan	confocal	microscopy	was	used	 to	 image	 the	bone	marrow	area	of	 the	
bones	stained	(2.553±0.0778mm2	control	and	2.206±0.1556mm2	DFM,	p=0.1168)	and	
ImageJ	 was	 used	 to	 quantify	 the	 expression	 of	 Osterix	 in	 the	 samples	 analysed	
(n=3/group).	 The	overall	 expression	of	Osterix	 in	 the	 area	of	 bone	marrow	analysed	
was	not	affected	by	the	DFM	treatment	(p=0.4380)(figure	6.21).	Likewise,	no	changes	
were	 observed	 between	 treatment	 groups	 in	 the	 overall	 number	 of	 Osterix+	 cells	
(p=0.3033)	or	in	the	number	of	Osterix+	cells/mm2	(p=0.4788)(figure	6.21).	
Data	 here	 presented	 indicate	 that	 expression	 of	 Osterix	 in	 our	 animal	model	 is	 not	
affected	by	treatment	with	DFM.	
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Immunofluorescent	staining	against	Osterix	and	Endomucin	performed	on	30µm	tibia	section	of	animals	
receiving	vehicle	control	or	DFM	treatment	for	three	weeks.	Green=Endomucin	and	red=Osterix	(A)	Area	
of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	Osterix.	(C)	Overall	number	
of	 Osterix+	 cells	 and	 (D)	 Osterix+	 cells/mm2.	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals	 and	 3	 bones	
analysed/group),	Student	t-test,	ns	is	not-significant.	Scale	bar	200µm.	 	
Figure	6.21	Effect	of	DFM	treatment	on	Osterix+	cells	
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6.5.2.2	Effect	of	DFM	treatment	on	bone	microvasculature	
6.5.2.2.1	Endomucin+	vessels	
Endomucin	 is	 an	endothelial	marker	expressed	 in	 the	microvasculature	of	 the	entire	
bone	 marrow.	 Changes	 in	 the	 percentage	 of	 expression	 of	 this	 marker	 have	 been	
studied	using	the	immunofluorescent	protocol	described	in	section	2.13.	Images	were	
captured	using	the	Zeiss	AiryScan	confocal	microscope	and	Aperio	ImageScope	used	to	
quantify	the	number	of	H-	and	L-vessels,	their	length	and	the	portion	of	bone	marrow	
area	occupied	by	these	different	vessel	sub-types.	
The	 area	 of	 bone	 marrow	 analysed	 was	 2.341±0.0712mm2	 control	 and	
2.194±0.185mm2	for	 the	DFM	group	(p=0.4986)(figure	6.22).	 Interestingly,	 in	animals	
treated	with	DFM	there	appears	to	be	a	reorganisation	of	the	microvascular	network,	
resulting	 in	 a	 increase	 in	 the	 area	 of	 bone	 marrow	 occupied	 by	 H-vessels	 and	 a	
reduction	 in	 the	area	occupied	by	L-vessels	compared	 to	 the	controls,	but	 this	 trend	
did	 not	 reach	 statistical	 significance	 (p=0.0957	 and	 p=0.0976	 for	 H-	 and	 L-vessels	
respectively)(figure	6.22).		
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A)	 Representative	 images	 of	 the	 total	 area	 of	 bone	marrow	 analysed	 (green),	 H-vessels	 (blue)	 and	 L-
vessels	 (red)	 manually	 tracked	 with	 Aperio	 ImageScope	 software.	 Area	 of	 bone	 marrow	 analysed	 is	
drawn	 in	green	and	 its	quantification	 is	 shown	 in	 (B).	 (C)	 and	 (D)	 show	 the	percentage	area	of	bones	
occupied	 by	 H-	 and	 L-vessels	 in	 control	 and	 DFM	 treated	 animals	 respectively.	 (E)	 and	 (F)	 show	 the	
percentage	 area	of	 bones	occupied	by	H-	 and	 L-vessels	 in	 the	different	 groups.	Graphs	 show	mean	±	
SEM	(n=5	animals	and	3	bones	analysed/group),	Student	t-test,	ns	is	not-significant.		
	 	
Figure	 6.22	 Quantification	 of	 immunofluorescent	 staining	 against	 Endomucin	 after	 treatment	 with	
DFM	
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The	 total	 number	 of	 vessels/mm2	 of	 bone	 was	 not	 affected	 by	 DFM	 treatment	
(p=0.3838).	 Surprisingly,	 the	changes	 in	 the	organisation	of	 the	vascular	network	did	
not	alter	the	total	number	of	vessels/mm2	or	the	number	of	H-	and	L-vessels/mm2	in	
the	 total	bone	analysed	 (p=0.8233	and	p=0.4199	respectively)(figure	6.23).	However,	
the	ratio	between	H-	and	L-vessels	 in	animals	 treated	with	DFM	was	altered,	control	
animals	had	a	significant	higher	number	of	L-vessels	 than	H-vessels	 (p=0.0235)	while	
treated	animals	lost	this	characteristic,	exhibiting	a	more	even	distribution	of	the	two	
vessels	 sub-types	 (p=0.1653)(figure	 6.23).	 The	 characteristic	 higher	 number	 of	 L-
vessels	 compared	 to	 H-vessels	 was	 restored	 when	 the	 vessel	 sub-types	 were	
normalised	 to	 the	 area	 of	 bone	 marrow	 that	 they	 covered,	 with	 no	 difference	
observed	between	treatment	groups	in	the	number	of	H-	and	L-vessels/mm2	of	bone	
marrow	 area	 occupied	 by	 the	 vessel	 sub-type	 (p=0.1298	 and	 p=0.5076	
respectively)(figure	 6.23).	 Irrespective	 of	 treatments	 L-vessels/mm2	 were	 more	
abundant	than	H-vessels/mm2	(p=0.0073	control	and	p=0.0070	DFM)(figure	6.24).	
No	 differences	 were	 detected	 between	 DFM	 treated	 and	 control	 animals	 in	 the	
average	vessel	 length	 (µm)	of	 the	vessels	analysed	 (p=0.6356	control	and	p=0.52936	
DFM)(figure	6.24).	
Taken	together	these	results	shows	that	DFM	treatment	only	marginally	modifies	bone	
the	microvasculature.	The	H-vessels,	characteristic	of	the	bone	metaphysis,	appears	to	
be	 extended	 towards	 the	 bone	 diaphysis	 area	 in	 DFM	 treated	 animals	 compared	 to	
controls.	Surprisingly,	this	change	altered	the	ratio	between	H-	and	L-vessel	number	of	
the	 total	 bone	 analysed,	 loosing	 the	 characteristic	 ratio	 in	 favour	 of	 L-vessels	 when	
compared	to	H-vessels.		
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A)	 Total	 number	 of	 vessels	 counted	 in	 both	 groups.	 (B)	 and	 (C)	 show	 the	 number	 of	 H-	 and	 L-
vessels/mm2	of	total	area	of	bone	analysed.	(D)	and	(E)	show	the	number	H-	and	L-vessels/mm2	of	the	
area	occupied	by	 the	different	vessel	 sub-types.	Graphs	 show	mean	±	SEM	(n=5	animals	and	3	bones	
analysed/group),	Student	t-test,	*	p<0.05	and	ns	is	not-significant.	
	 	
Figure	6.23	Number	of	vessels	quantified	in	bone	marrow	after	DFM	treatment	
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(A)	and	(B)	show	the	number	of	H	and	L-	vessels/mm2	bone	area	analysed	 in	control	and	DFM	groups	
respectively.	(C)	and	(D)	show	the	length	of	H-	and	L-	vessels	between	the	different	groups.	Graphs	show	
mean	 ±	 SEM	 (n=5	 animals	 and	 3	 bones	 analysed/group),	 Student	 t-test,	 **	 p<0.01	 and	 ns	 is	 not-
significant.		 	
Figure	6.24	Number	of	H-	and	L-vessels	in	different	groups	and	their	length	
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6.5.2.2.2	CD31+	vessels	
The	 HIF-1α	 enhancer	 DFM	 has	 been	 reported	 to	 increase	 the	 area	 of	 established	
vasculature	in	aged	mice	[97].	To	visualise	modification	of	the	microvascular	network	
and	perform	quantitative	 analyses	 on	 these	 changes,	 30µm	 thick	 section	of	 gelatine	
embedded	 tibiae	were	 stained	with	 specific	 antibodies	 against	 both	 Endomucin	 and	
CD31	and	analysed	using	the	resultant	immunofluorescence	(figure	6.25).		
	
Immunofluorescent	staining	against	CD31	and	Endomucin	performed	on	30µm	tibia	section	of	animals	
receiving	 vehicle	 control	 or	 DFM	 treatment	 for	 three	 weeks.	 Green=Endomucin,	 red=CD31	 and	
yellow=Endomucin	and	CD31.	Scale	bar	200µm.		
	 	
Figure	6.25	Representative	image	of	the	effect	of	DFM	treatment	on	CD31+	vessels	
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An	area	of	 approximately	2.5mm2	 (2.68±0.11	 control	 and	2.44±0.34	DFM,	p=0.5396)	
was	 imaged	 using	 Zeiss	 AiryScan	 confocal	microscopy	 and	 analyses	were	 performed	
using	ImageJ	and	Aperio	ImageScope	software.	Within	the	area	analysed,	no	difference	
was	 detected	 in	 the	 overall	 expression	 of	 the	 endothelial	 cell	 marker	 Endomucin	
between	 treatment	 groups	 (p=0.3121)(figure	 6.26).	 As	 expected,	 the	 overall	
percentage	 expression	 of	 CD31	 and	 Endomucin+CD31+	 vasculature	were	 significantly	
increased	by	treatment	with	DFM	(p=0.0055	and	p=0.0018,	respectively)(figure	6.26).	
The	 number	 of	 CD31+	 vessels	 in	 the	 total	 area	 of	 bone	 analysed	 was	 significantly	
increased	after	administration	of	DFM	compared	to	control	(p=0.0392).	However	when	
the	number	of	vessels/mm2	was	normalised	 to	 the	area	occupied	by	 this	vessel	 sub-
type	this	was	not	significant	(p=0.2789)(figure	6.27).	In	contrast,	the	average	length	of	
the	 CD31+	 vessels	 was	 significantly	 reduced	 in	 DFM	 treated	 animals	 compared	 to	
controls	(p=0.0282)(figure	6.27).	
In	 summary,	 DFM	 treatment	 alters	 the	 overall	 expression	 of	 CD31	 and	
Endomucin+CD31+	vasculature.	The	increased	number	of	CD31+	vessels	counted	within	
the	bone	marrow	were	 significantly	 shorter	 compared	 to	 the	 control	 group	and	had	
not	been	quantified	in	previous	studies.	
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A)	 Area	 of	 bone	 marrow	 analysed	 in	 the	 two	 different	 groups.	 B)	 Shows	 the	 overall	 expression	 of	
Endomucin	while	(C)	is	the	expression	of	CD31+	vessels.	(D)	Percentage	of	Endomucin+	vessels	that	also	
express	 CD31	 in	 the	 different	 groups	 (H).	 Graphs	 show	 mean	 ±	 SEM	 (n=5	 animals	 and	 3	 bones	
analysed/group),	Student	t-test,	**p<0.01	and	ns	is	not-significant.	
	 	
Figure	6.26	Quantification	of	immunofluorescent	staining	against	CD31	
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A)	 Shows	 the	 number	 of	 CD31+	 vessels/mm2	 of	 total	 bone	 and	 illustration	 of	 the	 area	 used	 for	 this	
analysis.	(B)	Show	the	number	of	CD31+vessels/mm2	of	area	occupied	by	the	vessels	and	an	image	of	the	
area	used	for	this	analysis.	(C)	Displays	the	average	length	of	CD31+	vessels.	Graphs	show	mean	±	SEM	
(n=5	animals	and	3	bones	analysed/group),	Student	t-test,	ns	is	not-significant.		
	
Figure	6.27	Number	and	average	length	of	CD31+	vessels	after	treatment	with	DFM	
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6.5.2.2.3	CD34+	vessels	
To	 investigate	 whether	 treatment	 with	 DFM	 modified	 the	 development	 of	 new	
vasculature,	tibia	sections	were	stained	with	antibodies	against	Endomucin	and	CD34	
using	the	protocol	described	in	section	2.13	(figure	6.28).	
	
	
Immunofluorescent	 staining	 against	 CD34	 and	 Endomucin	 performed	 on	 30µm	 tibia	 sections	 from	
animals	receiving	vehicle	control	or	DFM	treatment	for	three	weeks.	Green=Endomucin,	red=CD34	and	
yellow=Endomucin	and	CD34.	Scale	bar	200µm.		
	 	
Figure	6.28	Representative	image	of	the	effect	of	DFM	treatment	on	CD34+	vessels	
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A	Zeiss	AiryScan	confocal	microscope	was	used	to	image	the	bone	marrow	area	of	the	
stained	 samples	 (2.023±0.3207mm2	 control	 and	 2.311±0.1479	mm2	 DFM,	 p=04615),	
within	 this	 area	 no	 difference	was	 detected	 in	 the	 overall	 percentage	 expression	 of	
Endomucin	 between	 treatment	 groups	 (p=0.2876)(figure	 6.29).	 As	 anticipated,	 the	
overall	 percentage	 expression	 of	 CD34	 in	 animals	 treated	 with	 DFM	 was	 increased	
compared	 to	 control,	 but	 this	 did	 not	 reach	 statistical	 significance	 (p=0.0679).	
Moreover,	 DFM	 administration	 caused	 a	 significant	 increase	 in	 the	 percentage	 of	
Endomucin+CD34+	vasculature	(p=0.0005)(figure	6.29).	
	
	
A)	Area	of	bone	marrow	analysed	in	the	two	different	groups.	B)	Overall	expression	of	Endomucin	while	
(C)	is	the	expression	of	CD34.	(D)	Percentage	of	Endomucin+	vessels	that	are	also	expressing	CD34	in	the	
different	groups	 (H).	Graphs	show	mean	±	SEM	(n=5	animals	and	3	bones	analysed/group),	Student	t-
test,	***p<0.001	and	ns	is	not-significant.	
	 	
Figure	6.29	Quantification	of	immunofluorescent	staining	against	CD34	
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To	 examine	 whether	 the	 increase	 of	 percentage	 expression	 of	 CD34	 was	 due	 to	 a	
change	in	the	number	of	CD34+	vessels	or	in	their	structure,	the	number	and	length	of	
this	 vessel	 sub-type	 were	 measured	 by	 manually	 tracking	 using	 Aperio	 ImageScope	
software.	DFM	treatment	did	not	affect	the	number	of	CD34+	vessels/mm2	of	the	total	
surface	 of	 bone	 (p=0.2584).	 However,	 when	 the	 number	 of	 CD34+	vessels/mm2	was	
quantified	only	 in	the	area	occupied	by	these	vessels	there	was	a	significant	 increase	
compared	to	controls	(p=0.0270)(figure	6.30).	Furthermore,	the	more	abundant	CD34+	
vessels	appeared	shorter	in	the	animals	receiving	DFM	compared	to	the	vehicle	control,	
but	this	trend	did	not	reach	statistical	significance	(p=0.0837)(figure	6.30).	
The	 results	presented	 in	 this	 section	describe	 the	effect	of	DFM	treatment	on	newly	
formed	vasculature	 in	bone	as	 identified	by	CD34.	DFM	not	only	 increase	the	overall	
percentage	 expression	 of	 CD34	 but	 also	 affected	 the	 number	 of	 CD34+	 vessels	
detected	 in	 the	 bone	 microenvironment.	 However,	 the	 increased	 number	 of	 CD34+	
vessels	appeared	shorter	after	administration	of	DFM	when	compared	to	control.	
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A)	Shows	the	number	of	CD34+	vessels/mm2	of	total	bone	and	illustration	of	the	area	used	for	analysis.	
(B)	Show	the	number	of	CD34+vessels/mm2	of	area	occupied	by	the	vessel	sub-type	and	illustration	of	
the	area	used	for	 this	analysis.	 (C)	Displays	the	average	 length	of	CD34+	vessels.	Graphs	show	mean	±	
SEM	(n=5	animals	and	3	bones	analysed/group),	Student	t-test,	*p<0.05	and	ns	is	not-significant.		
	 	
Figure	6.30	Number	and	average	length	of	CD34+	vessels	after	treatment	with	DFM	
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6.5.2.3	Effect	of	DFM	treatment	on	TSP-1	expression	
A	 high	 expression	 of	 TSP-1	 and	 high	 number	 of	 megakaryocytes	 are	 detected	 in	 a	
dormancy-supporting	 microenvironment	 [35],	 [110].	 Sections	 of	 tibia	 were	 stained	
with	 an	 antibody	 against	 TSP-1	 to	 evaluate	 the	 effect	 of	 DFM	 treatment	 on	 TSP-1	
expression	in	regions	surrounding	the	microvasculature	and	in	megakaryocytes	(figure	
6.31).	
	
	
Immunofluorescent	 staining	 against	 TSP-1	 (red)	 and	 Endomucin	 (green)	 performed	 on	 30µm	 tibia	
section	of	animals	receiving	vehicle	control	or	DFM	treatment	for	three	weeks.	Scale	bar	200µm.		
	
	 	
Figure	6.31	Effect	of	DFM	treatment	on	TSP-1	expression	
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The	 area	 imaged	 with	 Zeiss	 AiryScan	 confocal	 microscope	 was	 similar	 between	
treatment	 groups	 (p=0.6321,	 2.52±0.33mm2	 and	 2.35±0.12mm2	 control	 and	 DFM,	
respectively).	In	this	area	of	bone	marrow	analysed,	no	changes	were	observed	in	the	
overall	 percentage	 expression	 of	 TSP-1	 (p=0.9070)	 or	 in	 the	 number	 of	
megakaryocytes/mm2	(p=0.4005)(figure	6.32).	
These	 results	 suggest	 that	 the	DFM	 treatment	 schedule	 used	 in	 this	 study	 does	 not	
influence	 the	 overall	 expression	 of	 the	 dormancy-supporting	 marker	 TSP-1	 and	 the	
number	of	megakaryocytes	present	in	the	bone	microenvironment.	
	
(A)	Area	of	bone	marrow	analysed.	(B)	Percentage	area	of	bone	marrow	expressing	TSP=1.	(C)	Number	
of	Megakaryocytes/mm2.	Graphs	show	mean	±	SEM	(n=5	animals	and	3	bones	analysed/group),	Student	
t-test,	ns	is	not-significant.		
	 	
Figure	6.32	Quantification	of	the	effect	of	DFM	treatment	on	TSP-1	expression	
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6.5.2.4	Effect	of	DFM	treatment	on	breast	cancer	cell	homing	to	bone	
To	 assess	whether	 the	 changes	 in	 the	microvasculature	 caused	 by	 administration	 of	
DFM	resulted	in	alteration	of	the	homing	of	breast	cancer	cells	to	bone,	BALB/c	nude	
mice	 treated	 for	 six	weeks	with	 i.p	 injection	 (5	days/week)	with	15mg/ml	 (100µl)	 of	
DFM	 or	 PBS	 control	 were	 injected	 i.c.	 with	 0.5x105	 MDA-MB-231-NW1-Luc2	 breast	
cancer	 cells	 labelled	 with	 the	 lipophilic	 dye	 Vybrant-CM-DiI	 and	 seven	 days	 later,	
femora	 were	 collected	 for	 two-photon	 microscopy.	 Specimens	 were	 prepared	 and	
analysed	as	described	in	section	2.10.	
The	number	of	tumour	cells	homing	to	the	trabecular	region	of	bone	(ROI1)	or	growth	
plate	 area	 (ROI2)	 was	 not	 influenced	 by	 the	 treatment	 with	 DFM	 (p=0.6557	 and	
p=0.6332	respectively)	(figure	6.33).	Furthermore,	the	preferential	pattern	of	homing	
towards	ROI1	compared	to	ROI2	was	maintained	in	both	treatment	groups,	but	did	not	
reach	 significance	 level	 (80.38±18.9	 and	 33.34±18.45	 cells/mm3	 ROI1	 and	 ROI2,	
p=0.1052	 control;	 68.93±14.87	 and	49.74±29.03	 cells/mm3	ROI1	 and	ROI2,	p=0.5724	
DFM)(figure	6.33).	Irrespective	of	the	area	of	bone	colonised	and	treatment	received,	
breast	cancer	cells	located	in	close	proximity	to	the	nearest	bone	surface.	The	average	
distance	 to	 the	 nearest	 bone	 surface	 in	 ROI1	 was	 39.04±11.03µm	 in	 the	 control	
animals	and	36.62±4.98µm	in	DFM	treated	(p=0.8564)	and	these	values	reduced	even	
more	 in	 ROI2	with	 2.08±1.09µm	and	6.14±4.69µm	 for	 control	 and	DFM	 respectively	
(p=0.5023)(figure	 6.33).	 As	 expected,	 tumour	 cells	 colonising	 the	 bone	
microenvironment	did	not	home	close	to	other	cancer	cells	(134.5±9.24µm	control	and	
254.1±87.66µm	 DFM,	 p=0.2117	 ROI;	 206.10±112.90µm	 control	 and	 46.22±40.59µm	
DFM,	p=0.3615	ROI2)(figure	6.33).	
Taken	together,	the	data	indicate	that	DFM	does	not	affect	the	pattern	of	homing	of	
breast	cancer	cells	to	bone.	Irrespective	of	treatment,	tumour	cells	prefer	to	locate	in	
the	 trabecular	 region	of	bone	compared	 to	 the	growth	plate	area	and	 they	 locate	 in	
close	 proximity	 to	 the	 bone	 surface	 and	maintain	 a	 clear	 distance	 from	 the	 nearest	
cancer	cell.	
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(A)	and	(B)	are	examples	of	two-photon	scans	of	control	and	DFM	treated	animals	showing	bone	(white)	
and	Vybrant-CM-DiI+	cells	 (pink	 and	pink	 arrows).	 C)	Graph	 shows	 the	number	of	MDA-MB-231-NW1-
Luc2	cells	detected	in	the	two	groups	at	both	ROIa.	(D)	Distances	of	the	tumour	cells	to	the	nearest	bone	
surface.	 (E)	Distances	 to	 the	nearest	 bone	 surface	 and	 the	nearest	 tumour	 cell	 in	ROI1.	Graphs	 show	
Mean	 ±	 SEM	 (n=5	 animals/group,	 6	 bones	 analysed	 control	 and	 5	 bones	 analysed	 DFM),	 Two-way	
ANOVA	and	Tukey	post	test,	*p<0.05	and	ns	is	not-significant.	 	
Figure	6.33	Homing	of	breast	cancer	cells	in	animals	treated	with	DFM	
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6.6	Discussion	
The	 main	 aim	 of	 this	 chapter	 was	 to	 investigate	 whether	 alteration	 of	 the	
microvascular	 activity	 using	 pharmacological	 agents	 would	 result	 in	 changes	 in	 the	
bone	microenvironment	and/or	 in	the	homing	of	breast	cancer	cells	to	bone.	 I	 found	
that	the	microvascular	activity	in	bone	was	reduced	by	administration	of	Cediranib	and	
increased	 by	 treatment	 with	 DFM,	 as	 would	 have	 been	 predicted	 from	 previous	
studies.		
Components	of	the	bone	microenvironment	investigated	in	this	chapter	were	the	bone	
structure	 (trabecular	 bone	 volume,	 trabecular	 thickness	 and	 trabecular	 number)	
analysed	by	µCT,	the	proteoglycan-rich	extracellular	matrix	assessed	by	Toluidine	blue	
staining	 and	 osteroprogenitor	 number	 investigated	 by	 immunofluorescent	 staining.	
Immunofluorescent	 protocols	 were	 also	 used	 to	 determine	 the	 effects	 on	 different	
vessel	sub-types	(Endomucin+,	CD31+	and	CD34+	vessels)	and	on	the	expression	of	the	
dormancy	 supporting	 molecule	 TSP-1.	 The	 number	 and	 location	 of	 Vybrant-CM-DiI	
labelled	breast	cancer	cells	homing	to	the	bone	microenvironment	were	analysed	by	
two-photon	microscopy.		
Cediranib	 treatment	did	not	alter	 the	bone	components	of	 the	niche	and	has	only	a	
marginal	 effect	 on	 the	microvascular	 network,	 consequently	 it	 was	 expected	 to	 not	
observe	 a	 change	 in	 the	 pattern	 of	 homing	 of	 breast	 cancer	 cells	 to	 bone.	 No	
modification	 of	 bone	 structure	 was	 observed	 in	 animals	 treated	 with	 DFM,	 while	
several	changes	were	detected	in	the	microvasculature	of	these	animals.	Even	though	
one	important	component	of	the	metastatic	niche	was	altered	by	the	administration	of	
DFM	(the	perivascular	niche),	this	modification	did	not	affect	the	characteristic	pattern	
of	homing	of	 tumour	cells	 to	bone.	However,	 this	change	could	potentially	 influence	
the	later	stages	of	metastasis	development.	
The	 efficacy	 of	 Cediranib	 as	 pan-VEGF	 tyrosine	 kinase	 inhibitor	 has	 been	 broadly	
studied	[168],	[247],	[248],	showing	an	anti-tumour	effect	against	a	range	of	tumours	
[168]–[170],	[249].		Wedge	and	colleagues	reported	that	a	dose	of	0.75mg/kg/day	for	
21	 days,	 treatment	 starting	 when	 tumours	 were	 0.2cm3	 was	 effective	 in	 inhibiting	
subcutaneous	tumour	growth	in	xenograft	models	of	lung,	colon,	ovary,	prostate	and	
breast	 cancer.	 Moreover	 between	 91-100%	 tumour	 growth	 inhibition	 across	 the	
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different	 tumours	 analysed,	 was	 achieved	 by	 increasing	 the	 dosage	 to	 6mg/kg/day	
[168].	The	anti-tumour	effect	of	Cediranib	was	coupled	with	a	dramatic	 reduction	 in	
the	tumour-associated	vasculature	reflecting	the	in	vitro	studies	of	inhibition	of	vessel	
sprouting	following	treatment	with	Cediranib	[168].		
In	the	clinical	setting	Cediranib	has	been	shown	to	be	well	tolerated	and	to	have	anti-
tumour	 effects,	 reducing	 the	 growth	 of	 solid	 tumour	 both	 as	 monotherapy	 or	 in	
combination	 with	 other	 treatments	 [165],	 [176]–[178],	 [250],	 [251].	 Some	 of	 these	
clinical	 trials	 are	 focused	 on	 the	 treatment	 of	 different	 sub-types	 of	 breast	 cancer,	
locally	advanced	and	inflammatory	[165],	hormone-sensitive	[176]	and	triple-negative	
breast	cancer	[178].	The	effect	on	breast	cancer	varied	in	the	different	clinical	studies;	
limited	activity	was	observed	 in	 triple-negative	breast	cancer	patients	 treated	with	a	
combination	of	Cediranib	and	the	PARP	 inhibitor	Olaparib	[178],	while	an	 increase	 in	
progression	 free	 survival	 was	 registered	 for	 patients	 with	 hormone-sensitive	 breast	
cancer	 treated	 with	 Cediranib	 and	 Fulvestrant	 [176].	 The	 clinical	 data	 on	 hormone-
sensitive	breast	cancer	reflect	what	was	reported	from	previous	 in	vivo	 studies[252].	
Cediranib	 inhibited	 the	 progression	 of	MCF-7	 implanted	mammary	 fat	 pad	 tumours	
and	 the	 efficacy	 of	 the	 drug	 was	 increased	 in	 tumour	 developed	 from	MCF-7	 cells	
overexpressing	VEGF	[252].		
Even	though	the	anti-angiogenic	and	anti-tumour	action	of	Cediranib	has	been	widely	
studied,	 little	 is	 know	 about	 the	 effect	 of	 this	 drug	 outside	 the	 tumour	
microenvironment.	 It	 is	 know	 that	 VEGF	 signalling	 is	 important	 for	 the	 coupling	 of	
angiogenesis	and	osteogenesis	 [253]	 therefore,	 it	was	not	 surprising	 	 that	 treatment	
with	Cediranib	resulted	 in	an	expansion	of	the	hypertrophic	chondrocyte	zone	of	the	
growth	plate	area	of	long	bones	in	rats	[168].	This	effect	was	observed	with	a	range	of	
doses	(1.5-6mg/kg/day)	with	the	treatment	being	used	for	28	days.	The	animal	model	
used	in	the	study	presented	in	this	chapter	received	a	dose	of	3mg/kg	5	days/week	for	
21	 days	 and	 no	 effect	 was	 seen	 on	 the	 bone	 structure	 (µCT),	 osteoprogenitors	
presence	 (immunofluorescent	 staining	 against	 Osterix)	 or	 growth	 plate	 extension	
(toluidine	 blue	 staining).	 The	 difference	 between	 the	 data	 reported	 in	 the	 literature	
and	my	study	may	be	due	to	the	shorter	period	of	administration	of	Cediranib	and	that	
the	 dosing	 was	 not	 continuous	 for	 the	 21	 days	 of	 treatment	 (5	 days/week).	
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Furthermore,	 I	 only	 used	 a	 small	 number	 of	 animals	 in	 this	 study	 that	 resulted	 in	
variable	data,	which	could	be	another	reason	accounting	for	the	discrepancy	between	
data	found	in	literature	and	the	results	here	described.		
There	 is	 also	 little	 known	 about	 the	 effect	 of	 Cediranib	 on	 the	 microvasculature	
network	 in	 bone.	 The	 few	 published	 studies	 consider	 the	 vasculature	mainly	 in	 the	
context	 of	 prostate	 cancer	 bone	metastasis.	 It	 has	 been	 shown	 that	 daily	 gavage	 of	
5mg/kg	of	Cediranib	treatment	reduced	the	intraosseous	growth	and	associated	bone	
response	of	platelet-derived	growth	factor	D	(PDGF	D)	overexpressing	prostate	cancer	
cells	injected	intratibially	in	5-week	old	SCID	mice,	and	this	effect	was	enhanced	when	
administered	in	combination	with	docetaxel	[254].	An	in	vivo	model	of	prostate	cancer	
bone	and	brain	metastasis	showed	an	increase	in	overall	survival	after	the	treatment	
with	6	mg/kg/daily	for	5	weeks	of	Cediranib,	while	this	result	was	not	achieved	using	
the	agent	as	a	preventive	 treatment	 [171].	Beneficial	effect	of	Cediranib	on	prostate	
cancer	bone	metastasis	has	also	been	recorded	in	the	clinical	setting	where	Cediranib	
administered	as	monotherapy	increased	the	progression-free	survival	[251].	Moreover,	
bone	metastasis	were	inhibited	in	both	the	preventive	and	the	treatment	(for	3	weeks)	
settings	using	Cediranib	(6mg/kg/day),	while	brain	metastasis	were	inhibited	only	with	
continuous	dosing	[171].	These	data	suggest	that	treatment	with	Cediranib,	maintains	
the	dormant	state	of	 tumour	cells	 that	 reach	the	bone	microenvironment	even	after	
the	end	of	the	treatment.	This	is	in	contrast	with	the	lower	level	of	TSP-1	detected	in	
treated	animals	 in	our	study,	however	it	was	in	 line	with	the	two-photon	microscopy	
results	 indicating	 that	 pre-treatment	 with	 Cediranib	 does	 not	 alter	 the	 number	 of	
breast	 cancer	 cells	 reaching	 the	 bone	 microenvironment.	 Further	 investigations	 are	
required	 to	 understand	 the	 fate	 of	 the	 tumour	 cells	 located	 in	 the	 bone	metastatic	
niches.	Another	 aspect	 that	 needs	 clarification	 is	 the	 increase	expression	of	 CD34	 in	
animals	 treated	 with	 Cediranib	 compared	 to	 controls,	 but	 this	 data	 can	 not	 be	
compared	to	any	other	data	found	in	literature	because	vascular	density	has	mostly	be	
reported	 in	 the	 tumour	microenvironment	 or	 tumour	 bearing	 animals	 and	 not	 in	 a	
non-tumour	bearing	model.		
The	HIF-1α	enhancer	Deferoxamine	mesylate	(DFM)	is	used	in	the	clinical	setting	as	an	
iron	chelator	in	the	case	of	iron	overdose	due	to	multiple	blood	transfusions	or	genetic	
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condition	 such	 thalassemia	 and	 aluminium	 toxicity	 in	 people	 in	 dialysis.	 HIF-1	 α	 is	
involved	 in	 physiological	 and	 pathological	 angiogenesis,	 such	 as	 wound	 healing	 and	
tumour	 angiogenesis	 [255],	 [256].	 For	 this	 reason	DFM	has	been	 studied	 in	 the	pre-
clinical	 settings	 for	 its	 pro-angiogenic	 properties.	 In	 vitro	 studies	 showed	 that	
treatment	with	 0-100µM	DFM	significantly	 increased	 the	 tubule	 formation	by	CD34-
positive	cells	isolated	from	the	bone	marrow	of	6-	to	8-week-old	male	nude	mice[184],	
human	aortic	endothelial	cells	[185]	and	human	umbilical	vein	endothelial	cells	[257].	
Moreover,	this	pro-angiogenic	property	has	also	been	reported	in	vivo;	DFM	has	been	
tested	for	its	efficacy	to	restore	blood	flow	after	hind	limb	ischemia	in	mice	[184],	[185]	
and	for	wound	healing	properties	in	diabetic	rats	[257].	Angiogenesis	and	osteogenesis	
are	tightly	coupled	processes,	therefore	the	action	of	DFM	on	the	bone	structure	has	
also	 been	 investigated.	 Kusumbe	 and	 colleagues	 reported	 that	 treatment	with	 DFM	
15mg/ml/mouse	every	other	day	for	4-6	weeks	in	aged	mice	resulted	in	an	expansion	
of	 H-vessels	 and	 an	 increase	 in	 bone	 volume	 [97],	 [221].	 Li	 et	 al.	 showed	 that	
administration	 of	 DFM	 activated	 HIF	 and	 the	 downstream	 expression	 of	 VEGF	 was	
amplified,	 leading	 to	 increased	 angiogenesis	 and	 bone	 repair	 of	 steroid-induced	
osteonecrosis	 in	the	femoral	head	of	rabbits	[186].	Donneys	and	colleagues	reported	
the	 dual	 action	 of	 DFM	 as	 a	 pro-angiogenic	 and	 osteogenic	 drug	 using	 a	 rat	 in	 vivo	
model	of	mandibular	distraction.	Treatment	with	DFM	resulted	 in	an	 increased	bone	
volume	measured	by	µCT	and	an	improved	vascular	response	visualised	with	injection	
of	Microfil	 [193].	Moreover,	 the	mandibular	 fracture	model	was	used	 also	 to	detect	
the	 effect	 of	 DFM	 on	 the	 osteocytes	 after	 radiotherapy,	 and	 these	 in	 vivo	 studies	
determined	that	DFM	had	the	ability	to	reverse	the	anti-angiogenic	effects	of	radiation	
[190],	[192].		
The	data	 reported	 in	 this	 Chapter	 are	 in	 agreement	with	 the	 literature.	 The	 animals	
treated	 with	 DFM	 had	 an	 increased	 expression	 of	 the	 CD31	 (mature)	 and	 CD34	
(immature,	proliferating)	endothelial	markers	and	the	H-vessel	network	was	expanded	
compared	 to	 that	 of	 the	 control	 animals	 [97].	 However,	 in	 our	 animal	 model	 no	
difference	 in	 the	 bone	 structure	 or	 osteoprogenitor	 number	was	 detected	 between	
the	 two	 groups.	 Matsumoto	 and	 colleagues	 reported	 that	 administering	 DFM	 to	
mitigate	 the	 reduction	 of	 osteogenesis	 caused	 by	 unloading,	 successfully	 stimulated	
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the	 bone	 microvasculature	 but	 this	 effect	 was	 not	 associated	 with	 a	 complete	
restoration	of	the	bone	structure	[187],	suggesting	that	this	was	due	to	an	inadequate	
dosage	of	DFM.	In	my	in	vivo	study	the	lack	of	modification	of	the	bone	structure	could	
be	in	part	due		to	the	dose	used	or	to	the	low	number	of	samples	analysed.		
It	has	been	shown	that	treatment	with	5-100µM	of	DFM	for	7	days	induced	apoptosis	
and	 arrested	 the	 growth	 of	 tumour-associated	 macrophages,	 mesenchymal	 stromal	
cells	[258],	and	acute	myeloid	leukaemia	cells	[259].	In	vivo	DFM	treatment	showed	an	
increase	 in	 the	 survival	 and	 decrease	 in	 tumour	 size	 of	 acute	 myeloid	 leukaemia	
models,	 however	 Duarte	 and	 colleagues	 observed	 higher	 number	 of	 HSCs	 in	 the	
trabecular	region	of	bone	of	treated	mice	and	an	improvement	of	HSCs	homing	to	the	
bone	marrow	[196].		The	increased	homing	of	HSCs	to	the	bone	niche	should	be	taken	
into	consideration	in	the	treatment	of	breast	cancer	patients	since	the	mechanism	of	
homing	of	breast	cancer	cells	is	thought	to	be	similar	to	the	one	utilised	by	the	HSCs.	
Moreover,	 in	 vitro	 studies	 reported	 an	 enhanced	 DFM-mediated	 migration	 and	
invasion	 in	MDA-MB-231	breast	cancer	cells	 [194].	The	pre-treatment	setting	used	 in	
my	 in	 vivo	 study	 did	 not	 alter	 the	 homing	 of	 cancer	 cells	 to	 bone	 compared	 to	 the	
control	 animals,	 but	 further	 analyses	 are	needed	 to	understand	whether	 continuous	
administration	 of	 DFM	 could	 increase	 the	 tumour	 cells	 able	 to	 seed	 in	 the	 bone	
microenvironment	or	modify	the	tumour	progression.		
Collectively,	 my	 data	 did	 not	 show	 substantial	 changes	 in	 either	 the	 bone	 or	 the	
microvasculature	 structure.	 Moreover,	 these	 analyses	 were	 focused	 on	 changes	
caused	by	the	pharmaceutical	agent	on	the	capillaries	network,	alteration	of	arteries	
and	 veins	 have	 not	 been	 investigated.	 Further	 analyses	 are	 needed	 to	 understand	
whether	 treatment	 with	 these	 drugs	 would	 be	 beneficial	 in	 the	 treatment	 of	
metastatic	breast	cancer.		
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Chapter	7 	
Discussion	
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7.1	Discussion	
Advanced	 breast	 cancer	 is	 associated	 with	 high	 mortality	 and	 development	 of	
secondary	 disease.	 Breast	 cancer	 preferentially	 colonises	 the	 skeleton,	 resulting	 in	 a	
considerable	decrease	in	patient	quality	of	life.	To	date,	treatments	are	focused	on	the	
latest	 stages	 of	 bone	 metastasis	 when	 there	 are	 already	 established	 lesions	 and	
therapeutic	 interventions	 are	 only	 palliative.	 	 The	 metastatic	 process	 consists	 of	
several	 steps,	 which	 are	 all	 influenced	 by	 the	 cross	 talk	 between	 cancer	 cells	 and	
different	components	of	the	bone	microenvironment.	Thus,	a	better	understanding	of	
the	 response	 of	 the	microenvironment	 to	 the	 therapeutic	 approaches	may	 improve	
the	 treatments	 for	 the	secondary	disease.	 It	has	become	clear	 that,	when	arriving	 in	
bone,	 breast	 cancer	 cells	 locate	 in	 a	 putative	metastatic	 niche,	 which	 is	 thought	 to	
comprise	of	 the	overlapping	HSCs,	endosteal,	and	perivascular	niches	 [34],	 [39]–[41].	
Interactions	of	the	components	of	these	niches	and	tumour	cells	have	therefore	been	
increasingly	 investigated	 for	 the	 development	 of	 new	 therapeutic	 treatments	 that	
target	both	cancer	cells	and	the	microenvironment.	Current	standard	of	care	for	breast	
cancer	bone	metastasis	 involves	the	use	of	anti-resorptive	agents,	such	as	Zoledronic	
acid	(ZOL),	moreover	novel	agents,	such	as	TKI	inhibitors	(i.e.	Cediranib),	are	achieving	
promising	 results	 in	 pre-clinical	 and	 clinical	 settings	 indicating	 that	 targeting	 the	
tumour	microvasculature	 could	 be	 an	 effective	 approach.	 A	 better	 understanding	 of	
the	early	stages	of	the	metastatic	process	would	allow	the	development	of	therapies	
targeting	the	DTCs	in	bone	before	the	establishment	of	cancer-induced	bone	disease,	
thus	improving	the	patients’	quality	of	life	and	overall	survival.				
Work	presented	in	this	thesis	has	utilised	in	vivo	models	and	novel	methodologies	to	(i)	
investigate	 the	 homing	 of	 breast	 cancer	 cells	 to	 bone,	 (ii)	 characterise	 the	
microenvironment	in	which	tumour	cells	seed	and	(iii)	determine	the	response	of	both	
the	microenvironment	and	the	homing	of	breast	cancer	cells	to	therapeutic	agents.	
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Homing	of	breast	cancer	cells	to	the	bone	microenvironment	
The	recent	technological	advances	both	in	cell	labelling	and	imaging	allows	research	to	
focus	 investigations	 on	 the	 early	 steps	 of	 bone	 colonisation	 [25].	 Two-photon	
microscopy	 has	 been	 used	 to	 visualise	 single	 tumour	 cells	 colonizing	 the	 bone	 in	
myeloma	 [260],	 prostate	 cancer	 [24],	 [26]	 and	breast	 cancer	 [118]	models,	 however	
the	majority	of	published	studies	focus	only	on	one	cancer	cell	 line	and	one	route	of	
injection.	 The	 work	 presented	 in	 Chapter	 3	 of	 this	 thesis	 represents	 a	 more	
comprehensive	 investigation	 involving	 several	 breast	 cancer	 cell	 lines	 and	 route	 of	
injections.	 Wang	 et	 al.	 described	 the	 homing	 of	 prostate	 cancer	 cells	 to	 the	 bone	
microenvironment	 indicating	 that	 Vybrant-DiD	 labelled	 PC3	 cells	 colonise	 the	
osteoblast-rich	 area	 of	 the	 bone	with	 a	 preferential	 pattern	 of	 homing	 towards	 the	
lateral	bone	surface	[26].	The	current	investigations	did	not	discriminate	between	the	
lateral	 and	medial	 sides	 of	 the	 bone	 to	 allow	 the	 determination	 of	 whether	 breast	
cancer	cells	 locate	 in	area	where	both	osteoblasts	and	vessels	 reside,	with	 the	 latter	
component	of	 the	metastatic	niche	being	equally	present	on	both	sides	of	 the	bone.	
Therefore,	 the	 regions	 of	 interested	 were	 divided	 into	 the	 trabecular	 bone	 region	
(ROI1)	 rich	 in	 osteoblasts,	 osteoclasts	 and	 vessels,	 and	 the	 growth	plate	 area	 (ROI2)	
consisting	principally	of	chondrocytes	and	extracellular	matrix	with	no	vascularisation.	
	As	hypothesized,	breast	cancer	cells	were	mainly	 located	 in	ROI1	compared	to	ROI2,	
irrespective	of	ER	status,	 route	of	 injection	or	 lipophilic	membrane	dye	used	to	 label	
the	cells.			Intriguingly,	only	a	small	number	(<100	cells/bone)	of	the	breast	cancer	cells	
injected	 in	 the	 animal	 models	 (1x105/mouse)	 could	 be	 detected	 the	 bone	
microenvironment.	 Valkenburg	 et	 al.	 using	 the	 intracardiac	 route	 of	 administration	
1x106	MDA-MB-231	cells	to	immunocompromised	mice,	harvested	the	bone	marrow	3	
and	5	days	post	 injection	 [261].	Bone	marrow	was	centrifugated	and	 red	blood	cells	
lysed,	 marrow	 solution	 was	 then	 washed	 in	 PBS	 and	 resuspended	 in	 a	 solution	
containing	 3x106	 cells.	 Samples	 were	 later	 stained	 with	 an	 antibody	 against	 human	
leukocyte	antigen	(HLA)	and	the	number	of	cells	positive	for	this	marker	was	counted	
using	an	automatic	slide	scanner.	The	results	obtained	from	day	3	post	injection	were	
comparable	 with	 those	 presented	 in	 Chapter	 3	 using	 the	 two-photon	 microscopy	
technology	 with	 <50	 breast	 cancer	 cells	 detected.	 At	 5	 days	 post	 injection	
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approximately	 500	MDA-MB-231	 cells/3x106	 bone	marrow	 cells	 were	 detected;	 this	
value	 is	considerably	higher	than	I	observed,	however	still	 indicates	that	only	a	small	
number	 of	 the	 tumour	 cells	 injected	 (1x106)	 home	 to	 and	 survives	 in	 the	 bone	
microenvironment	 [261].	 It	 has	 been	 shown	 in	 several	 studies	 that	 the	 presence	 of	
high	number	of	DTC	 in	bone	marrow	aspirates	 is	associated	with	a	poor	prognosis	 in	
breast	 cancer	 [262]–[265].	 However	 the	 study	 of	 sufficient	 numbers	 of	 patients	
samples	 is	 not	 always	 achievable	 therefore	 to	 improve	 the	 knowledge	 of	 the	 early	
steps	of	the	metastatic	process	model	systems	are	required.		
Previous	 work	 has	 highlighted	 that	 tumour	 cells	 and	 HSCs	 may	 use	 the	 same	
mechanism(s)	to	home	to	bone	and	are	thought	to	localise	to	the	same	region	of	bone.	
Moreover,	a	theory	has	been	proposed	that	assumes	the	presence	of	a	niche(s)	which	
has	the	capacity	to	retain	HSCs,	their	progenitors	and	other	cells	compatible	with	that	
specific	microenvironmental	 niche,	 including	 tumour	 cells	 [16],	 [26],	 [36],	 [78],	 [79].	
This	 hypothesis	 of	 the	 ‘equivalent’	 niche,	 introduces	 the	 concept	 of	 cellular	
competition	for	the	limited	space	available	within	the	niche	[41],	[165].	Shiozawa	and	
colleagues	 elegantly	 demonstrated	 that	 prostate	 cancer	 cells	 locate	 in	 the	 same	
niche(s)	occupied	by	HSCs.	In	their	experiments,	treatment	with	the	CXCR4	antagonist	
AMD3100	resulted	in	a	mobilization	of	HSCs	in	the	circulation,	and	in	a	higher	number	
of	 prostate	 cancer	 cells	 (detected	by	 PCR)	 homing	 to	 the	bone	marrow	 [36].	Others	
studies	have	quantified	 the	homing	of	prostate	 cancer	 cells	 to	bone	after	 treatment	
with	AMD3100	using	 two-photon	microscopy,	but	did	not	detect	any	 changes	 in	 the	
number	of	cancer	cells	in	the	bone	microenvironment	between	treatment	and	control	
groups	[26].	Price	et	al.	used	intra-vital	microscopy	to	detect	the	homing	of	ER+ve	and	
ER-ve	breast	cancer	cells	to	the	calvaria	of	immunocompromised	mice	after	treatment	
with	 ADM3100,	with	 no	 differences	 identified	 between	 treatment	 groups.	 However,	
the	 parameter	 measured	 was	 ‘bone	 trafficking’	 rather	 that	 true	 cancer	 cell	 homing	
since	the	 images	were	taken	 immediatelly	after	 injection	of	the	cancer	cells,	and	not	
following	seeding	in	the	bone	marrow	[266].	The	use	of	calvarial	bone	marrow	as	site	
of	homing	was	probably	chosen	due	to	the	deep-tissue	imaging	limitation	of	the	intra-
vital	microscopy;	 however	 overt	 metastasis	 rarely	 develop	 in	 calvaria	 in	 preclinical	
models,	 in	 contrast	 to	 the	 long	 bones,	 a	 common	metastatic	 site	 in	 both	 preclinical	
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models	 and	patients.	 To	my	knowledge	 the	work	described	 in	Chapter	3,	 represents	
the	 first	 time	 that	 cancer	 cells	 competition	 for	 the	 HSC	 niche,	 after	 treatment	with	
AMD3100,	has	been	studied	in	long	bones	in	a	xenograft	model	of	breast	cancer.	The	
modification	 of	 the	 bone	 marrow	 using	 AMD3100	 resulted	 in	 a	 higher	 number	 of	
breast	cancer	cells	successfully	homing	to	the	bone	marrow	compared	with	the	control	
group,	supporting	the	theory	of	an	 ‘equivalent	niche’	 [41],	 [165]	and	competition	for	
the	space	in	the	nice(s)	between	HSCs	and	tumour	cells	as	sugested	by	Shiozawa	[36].		
Simply	arriving	 in	bone	 is	not	 sufficient	 for	 tumour	cells	 to	 result	 in	overt	 secondary	
tumour	 [2],	 [16],	 [205],	 [206],	 [214],	 [217].	 Once	 tumour	 cells	 reach	 the	 bone	
microenvironment,	they	have	to	interact	with	the	microenvironment	in	order	to	both	
receive	and	respond	to	signals	which	enable	their	survival	and	proliferation	[87],	[218].	
Despite	 the	 two-photon	 microscopy	 allowing	 high	 resolution	 imaging,	 this	 is	 not	
sufficiently	sensitive	to	visualise	the	components	of	the	bone	microenvironment	likely	
to	play	a	key	role	in	the	fate	of	the	tumour	cells	seeded	in	the	bone	marrow.	Hence,	in	
Chapters	4-6	of	 this	 thesis	 I	 combined	the	 two-photon	microscopy	with	 fluorescence	
microscopy	 and	 histology	 to	 allow	 enhanced	 visualisation	 of	 the	 components	 of	 the	
bone	microenvironment,	with	a	particular	focus	of	characterisation	of	the	perivascular	
niche,	which	has	been	less	well	described.		
Characterisation	of	the	metastatic	niche	in	young	and	mature	mice	
Previous	studies	have	highlighted	that	is	the	condition	of	the	microenvironment	where	
tumour	 cells	 seed	and	will	determine	whether	 the	DTC	present	 in	bone	will	develop	
into	overt	metastasis	[101].	In	a	previous	study	from	our	laboratory	no	differences	in	
the	 number	 of	 breast	 cancer	 cells	 homing	 to	 the	 bones	 of	 young	 (6-week	 old)	 or	
mature	 mice	 (16-week	 old)	 were	 identified,	 however	 young	 animals	 developed	 a	
significantly	 higher	 number	 of	 tumours	 in	 bone	 indicating	 that	 the	 fertile	
microenvironment	 into	which	the	breast	cancer	cells	 located	was	a	key	player	 in	 the	
progression	 of	 the	metastatic	 disease	 [101].	 Thus,	 in	 Chapter	 4	 of	 this	 thesis	 I	 have	
characterised	the	bone	microenvironment	of	both	young	and	mature	murine	models.	
	In	 younger	 animals,	 bone	 turnover	 is	 higher	 when	 compared	 to	 mature	 animals,	
resulting	in	a	less	dense	mature	trabecular	structure	in	mature	mice	accompanied	by	a	
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reduced	number	of	osteoprogenitors	 (Osterix+	cells).	Osteoprogenitors	are	 located	 in	
close	proximity	to	the	trabeculae	 in	the	metaphysis	of	tibiae,	an	area	of	bone	that	 is	
particularly	 well	 vascularised,	 reinforcing	 the	 concept	 that	 osteogenesis	 and	
angiogenesis	 are	 closely	 coupled	 [88],	 [97],	 [221],	 [232],	 [267].	 Visualisation	 of	 the	
three-dimensional	 structure	 of	 the	 bone	 marrow	 microvasculature	 and	 the	
surrounding	cellular	component	was	challenging,	until	an	innovative	methodology	was	
described	by	Kusumbe	and	colleagues	in	2014	[97].	This	new	technique	allows	imaging	
of	thick	sections	(30µm)	of	decalcified	bones,	which	are	only	fixed	for	a	short	period	of	
time	 (4h)	 and	 do	 not	 require	 antigen	 retrieval	 methodologies	 likely	 to	 damage	 the	
tissue.	 Even	 though,	 Kusumbe	 et	 al.	 described	 the	 structural	 organization	 of	 the	
microvasculature,	particularly	H-	and	L-vessels	 in	 the	bone	marrow,	 their	 loss	during	
the	 ageing	 process	 and	 changes	 in	 the	 osteoprogenitors	 numbers	 in	 detail,	 the	
analyses	were	largely	qualitative	with	only	partial	quantification	performed	using	flow	
cytometry	 or	 qPCR	 [97].	Using	 an	 optimised	 version	 of	 Kusumbe’s	 protocol	 allowing	
use	of	the	equipment	available	at	the	University	of	Sheffield,	I	was	able	to	visualise	the	
complex	network	of	the	bone	marrow	microvasculature	and	for	the	first	time	quantify	
the	 differences	 in	 the	 structure	 of	 the	 vessels,	 the	 area	 of	 bone	 occupied	 and	 the	
number	and	length,	in	young	and	mature	mice.	Moreover,	in	my	work	I	used	CD31	and	
Endomucin	 to	 quantify	 mature	 likely	 quiescent	 vessels	 in	 addition	 to	 identifying	
changes	in	the	newly	formed	microvasculature	positive	for	the	marker	CD34,	that	has	
not	been	previously	described.	
Previous	 in	vivo	work	observed	that	the	microvasculature	not	only	plays	a	role	in	the	
delivery	of	oxygen	and	nutrients	but	also	in	the	homing	of	HSCs	and	DTCs;	intriguingly	
after	bone	marrow	transplantation,	hematopoietic	stem	cells	progenitors	locate	in	the	
trabecular	 region	 of	 bone	where	 the	 vascular	 and	 endosteal	 niches	 are	 overlapping	
[98],	[99].	 	 In	vitro	studies	have	demonstrated	that	breast	cancer	cells	 locate	 in	close	
proximity	to	the	vessels,	furthermore	it	has	been	observed	that	the	tumour	cells	that	
home	next	to	the	established	microvasculature	remain	in	the	dormant	state	while	cells	
seeded	in	the	vicinity	of	a	sprouting	microvasculature	undergo	proliferation.	Moreover,	
this	 study	 reported	 that	 different	 state	 of	 the	 microvasculature	 development	 (i.e.	
quiescent	 vs.	 sprouting)	 influences	 the	 expression	of	 the	 inhibitory	 Thrombospondin	
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(TSP-1)	 or	 growth	 promoting	 (periostin	 and	 TGF-β1)	 signalling	 [35].	 Moreover,	 a	
further	 study	performed	 IHC	on	microarrays	 containing	 core	biopsy	 from	100	breast	
cancer	patients	and	observed	that	TSP-1	expression	was	low	in	invasive	breast	cancer	
with	 increased	 expression	 in	 adjacent	 and	 normal	 tissue	 [268].	 In	 the	 current	 study	
TSP-1	 expression	was	 higher	 in	 the	 dormancy	 supporting	 (mature)	 compared	 to	 the	
tumour-promoting	 (young)	 animal	 model,	 supporting	 the	 role	 for	 TSP-1	 as	 key	
regulator	of	tumour	cell	dormancy.	
TSP-1	 is	 highly	 expressed	 in	 areas	 surrounding	 the	 established	 vessels	 but	 this	
molecule	 is	also	expressed	by	megakaryocytes.	Megakaryocytes	have	been	shown	to	
maintain	HSC	quiescence	and	promote	their	expansion	following	chemotherapy	via	the	
secretion	of	platelet	factor	4	(PF4)	[108],	[269].	Furthermore,	it	has	been	shown	in	 in	
vitro	 studies	 that	 osteoclast	 formation	 and	 activity	 is	 inhibited	 by	 co-culture	 with	
megakaryocytes,	 however	 further	 investigations	 are	 required	 to	 determine	 the	
mechanism(s)	involved	in	this	inhibition	[270].	Giving	the	high	level	of	expression	TSP-1,	
the	 regulation	of	HSC	dormancy	and	 the	 inhibitory	action	on	osteoclast	 activity,	 it	 is	
not	 surprising	 that	 in	 vivo	 studies	 using	 genetically	 engineered	 mice	 lacking	 in	
megakaryocytes,	 developed	 a	 bigger	 burden	 of	 metastases,	 suggesting	 that	
megakaryocytes	 may	 have	 a	 protective	 role	 against	 metastases,	 even	 though	 the	
potential	mechanism(s)	 of	 action	 has	 not	 been	 fully	 elucidated	 [110].	 In	my	 study	 I	
detected	 a	 higher	 number	 of	 megakaryocytes	 in	 the	 bone	 marrow	 of	 mature	
compared	 to	young	animals,	which	may	also	be	 involved	 in	 the	maintenance	of	DTC	
dormancy	in	the	bone	marrow.		
By	 using	 confocal	 microscopy	 I	 visualised	 single	 tumour	 cells	 in	 close	 proximity	 of	
different	vessel	sub-types	in	the	bone	marrow,	an	area	where	TSP-1	is	highly	expressed	
and	 there	 are	megakaryocytes.	However,	 due	 to	 the	 low	number	of	 cells	 homing	 to	
bone	 and	 the	 inadequate	 equipment	 available,	 it	 was	 not	 possible	 to	 perform	
quantitative	analyses.	To	better	understand	the	 interaction	between	cancer	cells	and	
the	 components	 of	 the	 surrounding	 niche,	 it	 would	 be	 interesting	 to	 establish	 the	
location	of	single	tumour	cells	 in	relation	to	the	vessel	sub-types	present	in	the	bone	
microenvironment,	 the	 TSP-1	 expressing	 region	 and	 the	 megakaryocytes.	 This	
challenging	task	require	access	to	a	confocal	microscope	capable	of	imaging	the	entire	
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surface	of	the	bone	(tile	scan),	and	allows	penetrate	deep	into	the	tissue,	to	obtain	the	
three-dimensional	structure	of	the	components	analysed	(z-stack)	with	multiple	colour	
detectors.		
Effect	of	ZOL	on	the	bone	microvasculature	structure	
Although	Bisphosphonates	(BPs),	 in	particular	Zoledronic	acid	(ZOL),	are	the	standard	
treatment	of	care	in	metastatic	breast	cancer,	comprehensive	data	on	the	effect	of	the	
anti-resorptive	 agents	 on	 components	 of	 the	 bone	 other	 that	 osteoclasts	 and	
osteoblasts,	 including	 the	bone	microvasculature	are	not	available.	This	 is	 somewhat	
surprising	in	light	of	the	close	association	between	osteogenesis	and	angiogenesis	[97].	
The	anti-angiogenic	 response	 to	ZOL	was	 reported	by	Wood	et	al.	 in	2002;	 the	anti-
resorptive	 agent	 caused	a	 reduction	 in	 the	proliferation	of	HUVEC	 cells	 in	 vitro	 (0.3-
30µM	 for	 24h),	 ex	 vivo	 exposure	 for	 24h	 to	 50µM	 ZOL	 induced	 a	 reduction	 in	
angiogenesis	 of	 rat	 aortic	 ring	 and	 in	 vivo	 chicken	 egg	 chorioallantoic	 membrane	
angiogenesis	was	reduced	with	100µM	of	ZOL	and	with	complete	inhibition	using	1mM	
ZOL	 [136].	Misso	 and	 colleagues	observed	 that	 ZOL	 administration	 (0.31-160µM)	 for	
24h	inhibited	the	tubule	formation	of	HUVEC	cells	in	a	dose-dependent	manner	in	vitro,	
moreover	they	also	showed	that	 in	vivo	administration	of	100µM	of	ZOL	reduced	the	
formation	of	vessels	in	matrigel	plugs	and	ZOL	treatment	(20µg/mouse	trice/week	for	
3	weeks)	significantly	reduced	the	number	of	newly	formed	vessels	CD34+	in	xenograft	
model	 of	 breast	 cancer	 [135].	 Furthermore,	 in	 vitro	 administration	 of	 ZOL	 at	 low	
concentration	(1-5µM)	inhibited	the	differentiation	of	endothelial	progenitors,	caused	
their	apoptosis	at	higher	doses	(>10µM),	inhibited	tubule	formation	at	a	dose	as	little	
as	 1µM	 and	 reduced	 the	 expression	 of	 VEGFR-2	 [137].	 Moreover,	 the	 ZOL-induced	
reduction	of	VEGF	has	also	been	reported	in	the	clinical	setting;	26	patients	with	solid	
tumour	 and	 bone	 metastasis	 received	 1mg/week	 of	 ZOL	 for	 4	 weeks	 and	 then	
continued	 with	 4	 cycles	 of	 the	 standard	 dosing	 regime	 (4mg	 every	 28	 days).	 This	
repeated	 administration	 of	 low	 doses	 of	 ZOL	 resulted	 in	 a	 significant	 reduction	 of	
circulating	VEGF,	7	days	after	the	first	treatment	and	this	effect	persisted	even	at	the	
last	time	point	analysed	[138].	All	 these	data	 indicate	that	ZOL	has	a	direct	effect	on	
the	angiogenesis	process,	which	results	in	an	indirect	anti-tumour	effect.		
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Given	 the	data	 suggesting	 an	anti-angiogenic	 effect	 and	 the	 fact	 that	 ZOL	 is	 used	 to	
treat	 skeletal	 disease,	 it	 seems	 somewhat	 surprising	 that	 the	 effect	 on	 the	 bone	
microvasculature	 has	 not	 been	 extensively	 investigated.	 This	 may	 be	 due	 to	 the	
difficulties	 in	obtaining	patient	samples	and,	until	recently,	 it	has	been	challenging	to	
visualise	the	bone	microvasculature	even	in	pre-clinical	settings.	Soki	et	al.	investigated	
the	changes	in	the	bone	microvasculature	in	response	to	ZOL	by	injecting	radiopaque	
silicone	 rubber	 agent	 Microfil™	 followed	 by	 µCT	 analysis	 and	 reported	 that	
administration	twice	weekly	for	4	weeks	of	200µg/kg	ZOL,	resulted	in	a	higher	number	
of	shorter	vessels	in	bone	of	immunocompetent	young	(4-week	old)	and	mature	male	
mice	(16-week	old),	however	the	total	bone	volume	occupied	by	the	microvasculature	
was	 not	 altered	 by	 the	 anti-resorptive	 drug	 [119].	 Although	 visualising	 the	 three-
dimensional	microvasculature	structure	is	feasible	using	Microfil™,	this	technique	does	
not	allow	the	discrimination	between	different	vessel	sub-types.	Therefore,	in	Chapter	
5	of	this	thesis,	I	have	investigated	the	effect	of	a	single	dose	of	ZOL	on	young	(6-week	
old)	and	mature	animals	(12-week	old),	focusing	in	particular	on	the	effect	of	the	anti-
resorptive	drug	on	the	capillary	components	of	bone	microvasculature	using	confocal	
microscopy.	Using	 immunofluorescent	protocols	 I	 observed	 that,	 irrespective	of	 age,	
the	vessel	sub-types	positive	for	the	markers	CD31	(mature	and	quiescent)	and	CD34	
(immature)	 were	 not	 affected	 by	 ZOL	 treatment.	 In	 contrast,	 the	 organisation	 of	
Endomucin+	 vessels	 in	 12-week	old	 animals	was	 altered	 resulting	 in	 fragmented	 and	
more	 numerous	 vessels,	 as	 observed	 by	 Soki	 and	 colleagues	 [119].	 Given	 that	 the	
greater	 effect	 on	 the	 bone	 structure	 were	 observed	 in	 young	 animals	 and	 that	
osteogenesis	 and	 angiogenesis	 are	 tightly	 coupled,	 it	 was	 expected	 that	 greater	
changes	 in	 the	microvasculature	of	young	animals	would	be	detected	and	not	 in	 the	
mature	animals.	The	reason	there	is	a	differential	effect	in	the	two	ages	analysed	is	not	
clear,	 however	 it	 somewhat	 reflects	 the	 effect	 of	 ZOL	 on	 pre-	 and	 post-menopausal	
women	with	early	breast	cancer.	Ottewell	and	colleagues	used	pre-clinical	models	to	
assess	the	effect	of	ZOL	treatment	in	animals	that	mimicked	pre-	(sham	operated	12-
week	old	mice)	and	post-menopausal	status	(ovarectomised	(OVX)	12-week	old	mice).	
MDA-MB-231	breast	cancer	cells	were	injected	in	the	left	ventricle	of	mature	animals	
and	the	ZOL	treatment	(100	µg/kg	once	a	week)	cominced	four	days	after	tumour	cell	
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inoculation,	 when	 there	 were	 no	 metastases	 established.	 OVX	 increased	 tumour	
growth	 in	bone,	 and	which	was	 inhibited	by	 ZOL	 administration.	 ZOL	 treatment	was	
not	 effective	 in	 preventing	 the	 development	 of	 overt	 bone	 metastasis	 of	 sham-
operated	 animals	 [216].	 Intriguingly,	 a	 differential	 response	 to	 ZOL	 treatment	 was	
recorded	 also	 in	 the	 clinical	 setting.	 A	meta-analysis	 performed	 by	 the	 Early	 Breast	
Cancer	Trials	Collaborative	Group	(EBCTCG)	collected	the	results	from	26	randomised	
trials	involving	18,766	women	and	showed	that	treatment	with	bisphosphonates	(BPs)	
had	a	beneficial	effect	only	 in	postmenopausal	women.	The	clinical	outcomes	for	the	
overall	 population	 (pre-	 and	 post-menopausal)	 was	 often	 ‘borderline’	 beneficial,	
however	 in	post-menopausal	women,	BP	treatment	 improved	the	time	until	 the	 first	
overall	 recurrence,	 recurrence	 in	 bone,	 distant	 recurrence	 at	 any	 site	 and	 breast	
cancer	mortality	[145].		
In	my	study,	detecting	changes	in	the	homing	of	breast	cancer	cells	in	animals	treated	
with	ZOL	was	not	possible	due	to	technical	limitations,	however	it	has	been	shown	that	
a	single	dose	of	ZOL	(100	µg/kg)	alters	the	pattern	of	seeding	of	breast	cancer	cells	to	
bone.	 Previous	 in	 vivo	 study	 from	 our	 laboratory	 found	 that	 the	 overall	 number	 of	
cancer	 cells	 homing	 to	 bone	 was	 not	 affected	 by	 ZOL	 but	 were	 evenly	 distributed	
between	the	growth	plate	and	the	trabecular	region	of	bone,	losing	their	preferential	
pattern	of	seeding	[118].	I	observed	that	tumour	cells	located	in	close	proximity	to	the	
microvasculature	 in	 bone	 and	 the	 fact	 that	 the	 vessels	 were	 fragmented	 after	 ZOL	
treatment	could	potentially	explain	why	the	tumour	cells	switch	their	homing	towards	
the	growth	plate	rather	than	homing	to	the	trabecular	bone.	
Therapeutic	 modification	 of	 the	 microvasculature	 and	 its	 effect	 on	 the	 bone	
metastatic	niche	
Targeting	 angiogenesis	 to	 inhibit	 tumour	 growth	 and	 progression	 is	 a	 well-accepted	
concept.	 After	 the	 ground	 breaking	 observation	 of	 Folkman	 and	 colleagues	 in	 the	
1970s	 [150],	 several	 approaches	 targeting	 the	 angiogenic	 process	 have	 been	
developed	 [151]–[153],	 [159]–[161].	 Novel	 tyrosine	 kinase	 inhibitors	 (TKI)	 such	 as	
Cediranib	 have	 shown	 promising	 results	 with	 their	 anti-angiogenic	 and	 anti-tumour	
efficacy	 [164]–[170],	 [247],	 however	 only	 little	 is	 known	 about	 effects	 on	 the	 bone	
microenvironment.	 Previous	 work	 reported	 an	 alteration	 in	 structure	 of	 the	 growth	
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plate	 area	 in	 rats	 treated	 with	 the	 TKI	 daily	 for	 28	 days	 [168].	 Yin	 and	 colleagues	
observed	 a	 reduction	 in	 metastatic	 growth	 in	 bone	 with	 the	 administration	 of	
Cediranib	 in	 both	 treatment	 and	 preventative	 settings	 [171].	 The	work	 presented	 in	
Chapter	6	of	this	thesis	investigates	for	the	first	time,	the	effect	of	this	TKI	on	the	bone	
microvasculature.	 Given	 that	 the	 osteoblastic	 and	 perivascular	 niches	 are	 tightly	
coupled	and	breast	cancer	cells	home	in	close	proximity	to	vessels	and	bone	surface,	I	
tested	the	ability	of	two	agents	to	modulate	the	microvasculature	in	vivo,	cediranib	to	
decrease	the	angiogenic	process	and	DFM	to	increase	it,	and	detect	any	changes	in	the	
bone	 structure	 and	 in	 the	 homing	 of	 breast	 cancer	 cells	 to	 the	 modified	
microenvironment.	 In	my	study	the	bone	structure	was	not	altered	and	the	effect	of	
cediranib	on	the	bone	microvasculature	was	marginal,	the	treatment	resulted	in	longer	
H-vessels	 and	 fewer	 L-vessels	 when	 compared	 to	 the	 control	 animals.	 Since	 these	
changes	 did	 not	 cause	 major	 alterations	 of	 the	 bone	 metastatic	 niche,	 this	 likely	
explains	why	no	differences	in	the	homing	of	breast	cancer	cells	to	bone	was	observed.	
The	marginal	effect	obtained	could	have	been	due	to	the	dose	used,	furthermore,	due	
to	 the	 invasiveness	of	 the	 gavage	administration	and	 the	 fact	 that	 technical	 support	
was	not	available	during	the	weekend,	 the	TKI	was	administered	5	days/week	rather	
than	 7days/week	 used	 in	 other	 studies.	 Further	 experiments	 using	 different	 dose	
ranges	 and	 timing	 of	 administration	 are	 required	 to	 better	 understand	 the	 effect	 of	
cediranib	on	the	bone	microenvironment.	 	 In	clinical	trials,	cediranib	 is	mostly	tested	
as	part	of	combination	therapy,	rather	than	as	single	agent,	and	this	should	be	tested	
in	our	pre-clinical	model.	Moreover,	the	data	showed	in	Chapter	6	reports	a	decreased	
expression	 of	 the	 dormancy-supporting	 molecule	 TSP-1,	 this	 could	 indicate	 that	
tumour	 cells	 arriving	 in	 bone	 could	 proliferate	 and	 result	 in	 a	 higher	 rate	 of	 overt	
metastasis	 when	 receiving	 Cediranib.	 Thus,	 a	 tumour	 growth	 study	 is	 needed	 to	
understand	this	aspect	of	TKI	treatment.		
In	 Chapter	 6	 of	 this	 thesis	 I	 have	 also	 used	 Deferoxamine	 mesylate	 (DFM)	 to	
investigate	whether	the	expansion	of	the	perivascular	niche	 increased	the	homing	of	
breast	cancer	cells	to	bone	 in	vivo.	This	iron	chelator	has	been	shown	to	increase	the	
angiogenesis	 in	 response	 to	 hindlimb	 ischemia	 [184],	 [185]	 and	 the	 pro-angiogenic	
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models	 [97],	 [186]–[192].	Deciding	on	 the	dose	 to	use	 in	my	 in	 vivo	 study	was	quite	
challenging	since	most	studies	in	literature	used	rats	[187],	[189],	[190],	[192]	and/or	
use	the	in	vivo	models	to	detect	the	healing	property	of	the	drugs	while	we	were	trying	
to	 manipulate	 the	 microenvironment	 without	 any	 previous	 alteration	 of	 the	 bone	
structure	such	as	fracture,	ischemia	or	loading.		Kusumbe	and	colleagues	used	DFM	on	
naïve	mice	and	described	that	the	administration	of	15mg/ml	per	mouse	every	other	
day	 for	4-6	weeks	altered	both	the	bone	structure	and	the	microvasculature	of	aged	
mice	 (60-65	 weeks	 old)	 [97].	 Although	 in	 my	 work	 I	 used	 a	 comparable	 dose	 to	
Kusumbe’s	 study	 (animals	 treated	 5days/week	 for	 6	 weeks	 with	 15mg/ml	 DFM)	 no	
changes	in	the	bone	structure	were	detected,	while	the	expression	of	both	CD31	and	
CD34	were	 increased	 in	 animals	 treated	with	DFM,	however	 these	 vessels	 appeared	
shorter	than	in	control	animals.	Also	the	homing	of	breast	cancer	cells	to	bone	was	not	
altered,	 indicating	that	a	marginal	change	 in	the	microvasculature	was	 insufficient	to	
modify	the	early	steps	of	breast	cancer	bone	colonisation.	A	different	range	of	doses	
and	 older	 mice	 should	 be	 used	 in	 the	 future	 to	 detect	 if	 DFM	 cause	 an	 enhanced	
expansion	 of	 the	 perivascular	 niche	 and	 consequently	 the	 homing	 of	 breast	 cancer	
cells	to	bone	is	affected	by	this	alteration	of	the	niche.	
	 	
	 299	
7.2	Future	work	
Listed	below	is	the	proposed	future	work	to	follow-up	the	work	presented	in	this	thesis:	
• Establish	protocols	to	visualise	other	components	of	the	perivascular	niche	(e.g.	
PDGFRβ+	mesenchymal	cells,	arteries	and	veins)		
• Investigate	whether,	within	the	trabecular	region	of	bone	(ROI1),	breast	cancer	
cells	 locate	 in	proximity	 to	a	particular	vessel	 sub-type	and	establish	whether	
there	are	differences	dependent	on	sub-types	of	breast	cancer	
• Perform	quantitative	analysis	on	the	 location	of	cancer	cells	 in	relation	to	the	
bone	microvasculature	
• Obtain	histological	sample	from	clinical	trials/patients	to	explore	whether	DTC	
locate	in	the	immediacy	of	endosteal	and	vascular	niche(s)	
• Investigate	 the	effect	of	modulating	 the	microvascular	 activity	using	different	
dose	ranges	of	Cediranib	and	DFM,	different	animal	models	(i.e.	older/younger	
animals,	 immunocompetent	 mice)	 and	 consider	 both	 ER+ve	 and	 –ve	 breast	
cancer	subtypes	
• Assess	 whether	 the	 treatment	 with	 Cediranib	 and	 DFM	 affects	 the	
development	of	metastasis	from	disseminated	tumour	cells	or	inhibit/promote	
the	growth	of	established	micro-metastasis	
• Determine	 the	 response	 of	 the	 bone	 microenvironment	 to	 Cediranib	 in	
combination	with	other	 therapies	 (i.e.	bisphosphonates,	 chemotherapy,	PARP	
inhibitors	etc.)		
• Establish	 the	effect	of	 increasing/decreasing	 the	microvascular	activity	on	 the	
dissemination	of	tumour	cells	in	the	presence	of	a	primary	tumour	
	
7.3	Conclusion	
The	 work	 presented	 in	 this	 thesis	 provide	 the	 first	 detailed	 characterisation	 of	 the	
homing	of	several	sub-types	of	breast	cancer	cells	administered	with	different	routes	
of	injections	to	the	bone	microenvironment,	visualisation	of	several	components	of	the	
perivascular	niche	that	contribute	to	the	fate	of	the	DTC	in	bone,	short	term	effects	of	
ZOL	 treatment	 in	 the	 bone	 microenvironment	 of	 both	 young	 and	 mature	 animal	
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models	 and	 effects	 in	 bone	 of	 agents	 targeting	 the	microvasculature.	 I	 demonstrate	
that	 irrespective	 of	 ER/HER	 status	 and	 route	 of	 administration,	 breast	 cancer	 cells	
prefer	to	 locate	in	the	trabecular	region	of	bone	compared	to	the	growth	plate	area.	
Moreover,	 I	 have	 shown	 that	 mobilization	 of	 HSCs	 in	 the	 circulation	 results	 in	 the	
homing	 of	more	 breast	 cancer	 cell	 to	 the	 niche(s),	 suggesting	 that	 tumour	 cells	 and	
HSCs	compete	for	the	space	available	in	the	bone	marrow	niche(s).	It	has	been	shown	
that	 the	 homing	 of	 tumour	 cells	 to	 the	 bone	 microenvironment	 does	 not	 change	
between	young	and	mature	animal	models,	however	young	animals	are	more	likely	to	
develop	overt	metastasis	compared	to	mature	animals.	In	this	thesis	I	have	therefore	
characterised	 the	 bone	 structure	 and	microvasculature	 of	 these	 two	 animal	models,	
highlighting	 the	 differences	 between	 the	 tumour-promoting	 (young)	 and	 the	
dormancy-supporting	(mature)	animal	models.	Bisphosphonates,	in	particular	ZOL,	are	
the	standard	of	care	 in	bone	metastatic	cancer,	however	 it	has	been	shown	that	the	
administration	of	ZOL	at	 the	early	 stages	of	breast	cancer	 is	beneficial	only	 for	post-
menopausal	women.	My	work	contributes	to	the	characterisation	of	the	effect	of	ZOL	
treatment	on	the	bone	microenvironment	in	young	and	mature	animals,	in	particular	I	
have	investigated	the	alteration	on	the	bone	microvasculature	that	could	be	involved	
in	the	differential	response	of	pre-	or	post-menopausal	patients.	I	have	also	examined	
the	 response	 of	 the	 bone	 microenvironment	 to	 agents	 targeting	 the	 angiogenic	
process.	
Further	 work	 is	 required	 to	 elucidate	 the	 function	 of	 the	 perivascular	 niche	 on	 the	
metastatic	process	and	the	mechanism(s)	of	cross-talk	between	different	components	
of	 the	niche(s).	However,	 the	work	presented	here	 suggests	 that	 breast	 cancer	 cells	
home	to	particular	regions	of	bone	where	the	HSCs,	endosteal	and	perivascular	niches	
overlap	 and	 that	 new	 therapeutic	 approaches	 should	 take	 into	 consideration	 the	
interconnection	 between	 niche(s)	 to	 target	 in	 a	 more	 effective	 way	 the	 metastatic	
disease.		
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